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Abstract  
Asthma is an economically important disease, with exacerbations causing significant 
morbidity and morality. Viral infections cause ~80% of asthma exacerbations; the 
majority of which are attributed to rhinovirus infection. How rhinovirus infection leads to 
an acute asthma exacerbation is incompletely understood. The up-regulation of pro-
inflammatory cytokines/chemokines from rhinovirus infected bronchial epithelial cells 
and an impaired ability of rhinovirus infected asthmatic bronchial epithelial cells to 
produce type I interferon-β and type III interferon-λs, are believed to contribute. This 
study aimed to investigate differences in the signalling requirements of rhinovirus-
induced pro-inflammatory cytokines/chemokines from those of IFN-β/IFN-λ. The viral 
pattern recognition receptors, signalling intermediates and transcription factors required 
by rhinovirus to induce pro-inflammatory cytokine/chemokine and IFN-β/IFN-λ 
expression were explored using short interfering RNA, constitutive activation/over-
expression of signalling molecules and IFN-β promoter reporter mapping experiments. 
The viral pattern recognition receptors RIG-I, MDA5 and TLR3 were required for 
rhinovirus-induced pro-inflammatory cytokines IL-8/CXCL8, ENA-78/CXCL5, IL-6 
RANTES/CCL5, IP-10/CXCL10 and IFN-β expression. Only MDA5 and TLR3 are 
required for rhinovirus-induced IFN-λ expression. Whilst having common signalling 
intermediates, the adaptor protein TRAF6, the kinases JNK2 and PI3Kα and the 
transcription factor NF-κB p65 were not required for rhinovirus-induced IFN-β/λ 
expression, but were required for rhinovirus induction of some/all of the pro-
inflammatory cytokines measured. IRF3 was the only transcription factor identified to be 
commonly required for rhinovirus-induced expression of IFN-β and IFN-λs. These 
findings support the hypothesis that the induction of IFN-β/λ and pro-inflammatory 
cytokines/chemokines, by rhinovirus, requires one or more distinct signalling molecules, 
and/or transcription factors. TRAF6, JNK2, PI3Kα and NF-κB p65 are potential novel 
therapeutic targets for rhinovirus-induced asthma exacerbations, the inhibition of which 
may suppress the detrimental actions of pro-inflammatory cytokines/chemokines without 
inhibiting IFN-β/λ production in asthmatic bronchial epithelial cells.   
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1.1 Asthma and Asthma Exacerbations 
1.1.1 Epidemiology of Asthma 
The worldwide prevalence of asthma in both children and adults has increased over the 
last four decades [1] [2] [3]. With 400 million predicted to be affected by 2025 [4] asthma 
presents a major healthcare and economic burden. Large international studies have 
found higher rates of prevalence in westernised countries, and a higher prevalence in 
children, with the UK having the highest prevalence of childhood asthma (36.8%) [5]. 
The cost of childhood asthma in the EU was estimated at EUR 3 billion in 2004 [6], and 
in the UK the estimated total cost of asthma is greater than £2,000 million per year [7]. 
This is associated with direct medical costs such as hospital care, clinic visits and drug 
therapy, and indirect economic costs such as lost work and school days, lost 
productivity, sick benefit and premature retirement, positively correlated with asthma 
severity [8].  
1.1.2 Definition and Diagnosis 
The definition of asthma is based upon a combination of pathological, physiological and 
clinical characteristics presented by asthmatic subjects. The dominant pathological 
feature is chronic airway inflammation, which is associated with increased airway 
hyperresponsiveness (AHR). AHR can be defined as an exaggerated bronchoconstrictor 
response to a range of provocative agents. Increased AHR, results in recurrent episodes 
of the clinical symptoms of wheeze, cough, breathlessness and chest tightness 
particularly in the evening and early morning. These recurrent episodes are associated 
with the physiological characteristic of variable airflow obstruction that is often reversible 
either spontaneously or with treatment with a short acting β2-agonist [9].  
Asthma diagnosis is based upon a history of wheezing, cough and breathlessness, and 
supported by the presence of variable and reversible airflow obstruction. Lung function 
tests measuring forced expiratory flow in one second (FEV1) and forced vital capacity 
(FVC) are used, as are measures of peak flow variability and AHR. Airway inflammation 
can be assessed by measurement of sputum eosinophilic or neutrophilic inflammation 
[10] and exhaled nitric oxide or carbon monoxide may be used to indirectly measure 
airway inflammation [11] [12]. Allergic asthmatics encompass ~80% of all asthma 
patients [13] and are identified by skin-prick testing with allergens, or alternatively serum 
IgE levels. Asthma is classified as mild intermittent, mild persistent, moderate persistent 
or severe persistent according to the severity and frequency of clinical features (i.e. 
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degree of airflow limitation, variability in lung function) before treatment and the 
requirement for, and response to treatment regimens.  
1.1.3 Causes of Asthma Exacerbations 
Exacerbations of asthma symptoms have been associated with several factors including 
allergen exposure, such as house-dust mites, animal dander or pollen [14] [15] [16], air 
pollution [17] [18], cigarette smoke [19], chemical exposure [20], exercise [21], drugs 
[22], bacterial [23] [24] and viral [25] [26] respiratory infections. Air pollution, virus 
infections and allergens have also been shown to act synergistically in asthma 
exacerbations. The combination of sensitisation and exposure to allergen, with the 
presence of viral infection, increases the risk of hospitalisation due to acute asthma in 
both adults and children [27] [28]. High exposure to nitrogen dioxide has been correlated 
with increased severity of asthma symptoms following viral infection [29], and increased 
asthma symptoms have been related to thunderstorms [30], which are postulated to 
disperse pollen grains. Of the many potential triggers of asthma exacerbations, 
respiratory viruses and in particular rhinoviruses (RV) are most frequently associated 
with asthma exacerbations in both adults [31] and children [32].  
1.1.4 Treatment of Asthma Exacerbations 
Current treatment for asthma exacerbations includes inhaled bronchodilators and 
systemic/oral steroids. Steroids provide an anti-inflammatory effect by a variety of 
mechanisms, including reducing the transcription of inflammatory genes [33]. In vitro, 
steroids have shown beneficial effects on RV-associated inflammatory responses [34] 
[35] [36] [37]. However, in a study of asthmatic patients experimentally infected with RV, 
steroid treatment did not significantly reduce airway inflammation [38], and using inhaled 
steroids alone to treat adults with persistent asthma only reduces the frequency of 
exacerbations by ~45% [39]. Doubling the dose of steroids has also shown no 
therapeutic benefit in preventing asthma exacerbations in adults [40]. Studies have 
shown inhaled steroids to reduce the risk of emergency treatment for virus induced 
asthma exacerbations in children [41] [42]. However, reports are conflicting, with some 
studies in children, reporting maintenance low-dose steroids not to reduce the proportion 
of hospital admissions due to virus induced wheeze [43] [44]. Moderate doses of inhaled 
steroids have also been reported not to reduce exacerbation frequency, severity or 
duration associated with virus infection in children [45]. Combining steroids with long 
acting β2 agonists (LABA) enhances the anti-inflammatory properties of steroids [46] 
[47]. The maintenance of asthma symptoms with combination therapy has shown 
promise in reducing the frequency of asthma exacerbations of mixed aetiology [48] [49]. 
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Further, studies using maintenance combination therapy with an “as needed” increase in 
combination therapy have shown some benefit in reducing exacerbation risk (of all 
aetiologies) compared to maintenance therapy alone [49] [50], but do not completely 
remove the number of exacerbations. Clinical studies to determine whether combination 
therapy can reduce asthma exacerbations caused by the most frequent trigger, RV 
infection, are yet to be performed. 
The above data demonstrates that current treatments are still only partially effective. 
There is a need for new, more specific and effective therapies to effectively treat and/or 
prevent virally induced acute asthma exacerbations. A better understanding of the 
cellular and molecular mechanisms involved in the pathogenesis of RV-induced asthma 
exacerbations will help identify new drug targets, and facilitate the development of new 
treatments for acute exacerbations of asthma.   
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1.2 Role of Respiratory Viruses in Asthma 
Exacerbations 
1.2.1 Clinical Features of Asthma Exacerbations 
In a 4 month study of naturally occurring RV infections, asthmatic and non-asthmatic 
cohabiting couples had the same frequency, severity and duration of RV related upper 
respiratory tract symptoms [51]. However, RV infections in asthmatics were more 
frequently associated with lower respiratory symptoms (wheeze, cough, shortness of 
breath, chest tightness), which were more severe and longer lasting than those in non-
asthmatics. Asthmatic patients also had greater reductions in lung function upon RV 
infection compared to non-asthmatics [51]. It was postulated that the increased severity 
and prolonged duration of chest symptoms and reduction in lung function could be due 
to increased virus loads and/or a delayed clearance of the virus; however this study did 
not investigate the host immune response during infection.  
1.2.2 Human Rhinovirus is a Major Cause of Asthma 
Exacerbations  
Initial studies associating viral infections with asthma exacerbations were done using 
standard virology methods such as serologic testing or viral culturing of samples, 
producing low rates of virus detection [52]. Recent studies using RT-PCR to detect virus 
have revealed a much greater role for virus infections in asthma exacerbations, with RV 
infections identified as the most common trigger in adults and children. To a lesser 
extent, the respiratory viruses, enteroviruses, influenza viruses, respiratory syncytial 
virus (RSV), adenoviruses, coronaviruses and parainfluenza viruses are also associated 
with exacerbations of asthma in children [25] and adults [26] [31] [53]. A community 
based longitudinal study by Johnston et al [32] using standard techniques and RT-PCR 
to detect viruses, reported the detection of upper respiratory viral infections in 80-85% of 
exacerbations of asthma in school children (aged 9-11 years), with 66% of these 
identified as RVs. In more severe cases of children hospitalised with asthma 
exacerbation, RVs are detected in the majority of cases, with detection rates of 47% 
[25], and 82% [54] and in 61% of children (>3 years) hospitalised with wheezing illness 
[55]. Studies of wheezing episodes in hospitalised infants (<2 years of age) have shown 
a predominant association with RSV infection [56] [57] [58]. However, recent community 
based studies of respiratory tract illness, in the first year of life, have shown a 
predominant association with picornavirus infection [59] and RV infection [60], indicating 
RVs to be associated with respiratory illness in children of all age groups.  
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Fewer studies of respiratory virus association with exacerbations in asthmatic adults 
have been performed. A community based longitudinal study of adults by Nicholson et al 
[31] reported viral infections in 44% of exacerbations of which 64% were RVs. Studies of 
asthmatic adults attending an emergency department with acute exacerbation of asthma 
detected a viral respiratory tract infection in 76% [61], 55% [26], and 78% [53] of cases, 
the majority of which were RVs [26] [53]. Hence RV is also highly associated with 
asthma exacerbations in adults. 
RV infections occur thoughout the year with peak periods of infection in mid-to-late 
spring and early autumn when RVs comprise >75% of circulating viruses [62] [63]. In 
keeping with this, Johnston et al [41] showed a correlation between the September peak 
in children hospitalised with asthma exacerbation and detection of respiratory viral 
infection, with picornaviruses detected in the majority (62%) of cases and >80% 
identified as RV. Taken together these studies clearly demonstrate the critical role of 
respiratory viral infections, and in particular RV infections in the exacerbation of asthma 
in both children and adults; however the cellular and molecular mechanisms by which 
RVs cause exacerbations remains unknown.  
1.2.3 Lifecycle of Human Rhinovirus 
RVs are the largest subgroup of the Picornaviridae family of viruses, with more than 100 
serotypes identified. RVs are small (25-30nm diameter), non-enveloped viruses 
composed of an icosahedral (20 faced) capsid formed from 60 copies of each of four 
viral proteins (VP1-4) [64]. The virion is composed of three external structural proteins 
(VP1-3) and an internal structural protein (VP4). Depressions in the capsid occur at 
each vertex formed by the interaction of five VP1 proteins [64] creating a star-like 
structure. The depressions represent the most conserved regions of the RV structure 
[65] [66] and are the sites at which RV interacts with its host cell receptor [67]. The most 
exposed regions of the capsid are hyper-variable, and are responsible for the antigenic 
diversity of RV serotypes [65]. The capsid contains a genome of single-stranded positive 
sense RNA (~7kb in length) [68]. The 5’ and 3’ ends of the genome contain untranslated 
regions (∼620 bases and ∼50 bases respectively) with a poly-A tail at the 3’ end and a 
covalently linked virus protein (VPg) at the 5’ end [68]. The 5’ untranslated region forms 
a cloverleaf structure (thus containing regions of double stranded (ds) RNA) and 
contains internal ribosome binding sites required for mRNA CAP-independent 
translation of the viral genome [69]. The RV genome is divided into region P1 encoding 
the capsid proteins VP1-4 and the P2 and P3 regions which encode non-structural 
proteins including two viral proteases (2A and 3C), VPg and RNA-dependent RNA 
polymerase. 
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RV serotypes are divided into major or minor groups based upon their interactions with 
cell surface receptors. Major group RVs (~90 serotypes) enter host cells by binding to 
intercellular adhesion molecule 1 (ICAM-1) [70] [71] and minor group RVs (~10 
serotypes) by binding to low-density lipoprotein receptor (LDLR) [72] [73]. Major and 
minor group RVs require low pH for efficient un-coating and release of viral genome 
RNA, and their infection of cells is blocked in the presence of an agent which prevents 
endosomal acidification, or raises endosomal pH [74] [75] [76]. Replication takes place 
throughout the host cell cytoplasm, the first step of which requires the infecting virion 
positive sense parental ssRNA to act as mRNA, and bind to host cell ribosomes. The 
genome is then translated as a single poly-protein and cleaved into the required 
individual proteins by RV 3C protease, including viral RNA polymerase. The positive 
sense parental ssRNA genome can then also act as a template for the synthesis of 
negative sense RNA, transcribed by viral RNA polymerase, and in turn is used as a 
template for the synthesis of progeny viral genomes. The large number of viral proteins 
and progeny viral RNA genomes produced aggregate and mature into fully formed 
virions. RVs replicate within 6h with up to 100,000 infective virions produced per cell 
[69]. A summary of the Rhinovirus life cycle is shown in Figure 1.1. 
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Figure 1.1 Summary of the Rhinovirus life cycle.  
RV enters host cell and un-coats (1). Positive sense parental ssRNA is translated by host cell 
ribosomes (2), and cleaved by viral proteases (3) into individual proteins (4). Viral RNA 
polymerase transcribes positive sense parental ssRNA (5) into negative sense RNA (6), which is 
then transcribed into positive sense progeny ssRNA (7). Viral proteins and progeny viral ssRNA 
aggregate into fully formed new virions (8). 
 
1.2.4 Secreted Mediators and Cell Surface Molecules Associated 
with Asthma Exacerbations 
Much of the data concerning the host response to and immunology against RV infection 
is derived from in vitro models of RV infection in respiratory cells and natural or 
experimental infection of mild asthmatic patients. Results of these studies with RV show 
an up-regulation of several pro-inflammatory cytokines/chemokines, growth factors, and 
adhesion molecules from bronchial epithelium and enhanced mucin production.   
Studies have shown induction of mRNA and/or protein of the neutrophil attracting 
chemokines CXCL8 (IL-8) [77] [78] [79] [80] [81] [82] [83] and CXCL5 (ENA-78) [84] 
following experimental RV infection of respiratory cell lines, or normal primary human 
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bronchial epithelial cells. Increased CXCL8 protein is also observed in nasal washings 
[85] [86] and induced sputum [87] [88] from RV experimentally infected or naturally 
infected asthmatics, and CXCL8 and CXCL5 proteins are elevated in the sputum or 
nasal aspirates of patients with naturally occurring exacerbations [89] [84]. The severity 
of cold symptoms in experimental RV infected non-asthmatics has also been correlated 
with CXCL8 concentration in nasal washings [90], implicating CXCL8 in the 
pathogenesis of RV infection. 
The T-cell and eosinophil attracting chemokine CCL5 (RANTES) and the T-cell and 
natural killer (NK) cell attracting chemokine CXCL10 (IP10) mRNA/protein are increased 
in a bronchial epithelial cell line upon RV infection [79] [91] and CCL5 mRNA/protein is 
increased in primary bronchial epithelial cells following experimental RV infection [83]. 
Increased CCL5 mRNA or protein has been detected in nasal aspirates or induced 
sputum of patients with natural virus-induced asthma exacerbations [92] [53] and 
CXCL10 protein was detected in nasal washes of symptomatic volunteers 
experimentally infected with RV, with CXCL10 positively correlated with symptom 
severity [91]. Serum CXCL10 has also recently been reported to be a novel biomarker of 
RV-induced asthma exacerbations [93]. Expression of the eosinophil chemoattractants 
MIP-1α and eotaxin/eotaxin-2 are also increased upon RV infection of an epithelial cell 
line [79], and elevated MIP-1α mRNA and protein are detected in nasal aspirates or 
induced sputum of patients with natural virus-induced asthma exacerbations [92] [53].    
The cytokine IL-6 stimulates the production of acute phase proteins, B-cell 
differentiation, immunoglobulin secretion and T-cell activation [94]. RV-induction of IL-6 
mRNA and/or protein has been observed in respiratory cell lines [77] [78] [80] [95] and 
IL-6 protein is increased in nasal washings [86] and induced sputum of RV 
experimentally infected asthmatic volunteers [87]. IL-6 concentration in nasal washings 
from experimental RV infected non-asthmatics has also been correlated with severity of 
cold symptoms [95] implicating IL-6 in the pathogenesis of RV infection. IL-11 is also 
increased in RV infected epithelial cells [96], and is involved in the activation of B-cells 
via a T-cell dependent mechanism [97]. IL-11 is elevated in nasal aspirates of children 
with upper respiratory tract infection, and greatest in those with wheezing [96].  
The haematopoietic growth factor GM-CSF stimulates the proliferation of granulocytes, 
monocytes and eosinophils and is increased in RV infected epithelial cell lines [77] [78] 
and normal primary human bronchial epithelial cells [83]. RV infected bronchial epithelial 
cells also show increased production of the angiogenic growth factor VEGF, and 
fibroblast growth factor FGF-2 [98], and RV infection has been demonstrated to induce 
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the secretion of mucins MUC5AC and MUC5B, in cultured normal human airway surface 
epithelium cells [99] [100] and sub-mucosal gland cells [100]. 
Expression of the cell surface receptor ICAM-1 and the cell adhesion molecule, VCAM-1 
are increased upon RV infection of epithelial cell lines and normal primary bronchial 
epithelial cells [101] [102]. Increased ICAM-1 expression has also been demonstrated 
on nasal epithelium [103] and in bronchial biopsies from RV experimentally infected 
volunteers [104]. In addition to its role in major group RV epithelial cell entry, ICAM-1 
has a role in recruitment of eosinophils, lymphocytes [105] [106] and neutrophils [107] to 
the airways. VCAM-1 has a role in T-cell, B-cell, eosinophil, monocyte and basophil, 
recruitment into the airways [108] [109], and its expression on the endothelium may 
cause retention and accumulation of these cells. 
Collectively these studies implicate the increased expression of secreted mediators and 
adhesion molecules in the pathogenesis of RV infection in asthmatic subjects, with 
enhanced inflammatory cell recruitment into the airway, increased bronchovascular 
volume and permeability, and increased mucus production leading to enhanced 
inflammation, airway oedema and airway mucus plugging.  
1.2.5 Cellular Features of Asthma Exacerbations 
Consistent with RV-induction of pro-inflammatory cytokines/chemokines and adhesion 
molecules, RV experimental infection studies in asthmatic adults have shown increased 
neutrophil numbers in sputum [87] and BAL fluid [110] and increased lymphocytes and 
eosinophils in bronchial mucosal biopsies [111]. Increased neutrophils in these studies, 
correlated with increased CXCL8 nasal concentration [110], and elevation of 
submucosal lymphocytes [111] and the eosinophil activation marker, eosinophil cationic 
protein in sputum samples [87] correlated with increased AHR. Eosinophil inflammation 
in asthmatic subjects also persists for longer than in non-asthmatics [111].  
A natural infection study in children reported increased neutrophils and elevation of the 
neutrophil activation marker neutrophil myeloperoxidase in nasal aspirates during virus-
induced asthma exacerbations [112]. Increased neutrophil myeloperoxidase correlated 
with both CXCL8 levels and symptom severity in this study. Natural infection studies in 
children hospitalised with acute asthma exacerbation, also show increased inflammatory 
cell numbers and markers of neutrophil and eosinophil activation in sputum samples 
[89]. Similarly, bronchial biopsy specimens from adults hospitalised with severe 
exacerbation show neutrophilia and eosinophilia in bronchial mucosa [113], and reduced 
lung function
 
in adults is associated with increased neutrophils and eosinophils in 
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sputum, prior to bronchodilator use, and
 
with increased sputum neutrophils post-
bronchodilator use [114], suggesting airway neutrophilia to have a role in airflow 
limitation in asthmatic subjects. 
A study comparing naturally infected asthmatics and non-asthmatics has shown 
qualitatively similar sputum cell findings, but greater sputum total inflammatory cell, and 
neutrophil numbers in asthmatic subjects [88]. Increased neutrophils in this study were 
correlated with level of sputum CXCL8 [88]. Further, the severity of virus-induced 
asthma exacerbation in adults has been correlated with increased neutrophil 
numbers/degranulation and epithelial cell necrosis [61], and rapid onset fatal asthma is 
frequently associated with a neutrophil infiltrate [115]. In contrast, higher levels of 
eosinophils have been reported in non-virus induced asthma exacerbations, than in 
virus-induced exacerbations [61], and slower onset exacerbations associated with a 
predominant eosinophil infiltrate [116]. 
Collectively, these studies emphasise the importance of pro-inflammatory 
cytokine/chemokine release and ICAM-1 and VCAM-1 up-regulation in the development 
of asthma exacerbations, and implicate neutrophil inflammation to be at least partially 
responsible for virus-induced asthma exacerbations. Inflammatory cell infiltration into the 
lower airway of asthmatic subjects may therefore be the first step in the inflammatory 
cascade, leading to enhancement of existing lower airway inflammation and resulting in 
impaired lung function, increased bronchial responsiveness and exacerbation of asthma 
symptoms.  
1.2.6 Deficient Type I IFN and Type III IFNs in Asthma 
Exacerbations  
The 13 interferon (IFN)-α species and a single IFN-β gene are produced and secreted 
by virus-infected or dsRNA stimulated cells and are collectively termed type I IFNs. 
These proteins mediate the production of antiviral proteins by activation of the janus 
kinase (JAK) and signal transducer and activator of transcription (STAT) signalling 
pathway, through binding to a common cell surface receptor IFN-α receptor (IFNAR) on 
infected cells and neighbouring cells. Antiviral actions of type I IFNs include growth 
arrest, induction of apoptosis, and the expression of a large number of antiviral proteins 
including PKR, OAS, ADAR1, RNAseL, ISG56, Viperin and Mx GTPase proteins, which 
act to inhibit viral replication by different mechanisms [117] [118] [119] [120] [121]. The 
single type II IFN gene (IFN-γ) is also required for an effective innate immune response 
against viruses and is produced by activated T-cells and NK cells [122]. The recently 
described type III IFNs, include IFN-λ1 (IL-29) and IFN-λ2/3 (IL-28A/B). Significant 
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homology exists between IFN-λ1 and IFN-λ2/3 (80%) and between IFN-λ2 and IFN-λ3 
(96%), but limited homology (20%) with type I IFNs [123]. They are induced upon viral 
infection, signal through a unique IFN-λ receptor, composed of IFN-28Rα and IL-10Rβ 
and similarly to type I IFNs, can induce IFN-stimulated genes (ISGs) via JAK/STAT 
signalling pathways and induce anti-proliferative and antiviral responses in vitro [123] 
[124].  
 
There is increasing evidence that asthmatic bronchial epithelial cells (BECs) respond 
differently to RV infection compared to normal BECs. Adult asthmatic BECs infected 
with RV, have significantly more viral replication/virus release and show a progressive 
increase in cell lysis, which is not observed in BECs of non-asthmatics [125]. This 
suggested deficiency in innate response was confirmed by a reduced ability of asthmatic 
BECs to induce apoptosis in response to viral infection [125]. Reduced apoptosis and 
increased viral replication in asthmatic BECs was linked to a deficiency of IFN-β 
mRNA/protein production in RV-infected asthmatic bronchial epithelial cells [125]. RV-
infected adult asthmatic BECs also have an impaired ability to induce IFN- 
mRNA/protein, which is inversely correlated with RV replication, severity of cold 
symptoms, airway inflammation and lung function impairment [126]. These studies are 
supported by a recent study of RV infected differentiated adult asthmatic BECs in air-
liquid culture, showing deficient IFN-β/λ expression [127], and have been extended to a 
preliminary study of asthmatic BECs from children, which also show deficient IFN-β/λ 
expression in response to RV infection (M. Edwards unpublished observation). 
Additionally, recent studies of RSV infected asthmatic PBMCs from adults and children 
have shown deficient IFN-α2 production [128] [129], and bacterial lipopolysaccharide 
(LPS) stimulated macrophages from asthmatics have shown reduced IFN-λ secretion 
[126], suggesting that deficient IFN production in asthmatics is not specific to BECs or to 
RV infection.   
 
This data suggests that a deficient innate antiviral response in the cells of asthmatic 
patients contributes to higher RV replication levels, and thus higher pro-inflammatory 
mediators and the pathogenesis of respiratory symptoms seen in RV-induced 
exacerbations. The mechanisms by which IFN deficiency occurs are currently unknown. 
Polymorphisms in the genes encoding IFNs is perhaps unlikely, due to more than one 
IFN being deficient and their differing chromosomal locations. A deficiency may be due 
to an inadequate development of IFN responses in early life, or a deficiency in the 
signalling intermediates required for the induction of IFNs in asthmatic cells, or 
alternatively may be a consequence of the disease itself.  
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To begin to explore the later possibility a better understanding of the mechanism by 
which RV infection induces IFN-β/λ in normal BEC is first required. In this respect, virus-
induced triggering of host cell signalling, and therefore the secretion of IFNs (and pro-
inflammatory cytokines/chemokines) is thought to be initiated by the production of a 
double-stranded (ds) RNA intermediate during viral replication. This is supported by 
many studies showing a role for replicating virus in the up-regulation of several 
mediators, which is not observed with UV-inactivated virus [81] [83] [101]. The focus of 
the remainder of this introduction will therefore focus upon current knowledge of the 
signalling mechanisms by which virus (dsRNA) induces IFN and pro-inflammatory 
cytokine/chemokine expression.  
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1.3  Signalling Pathways involved in Virus-induced 
Interferon and Pro-inflammatory Cytokine Gene 
Expression  
The signalling pathways identified in the literature to be involved in virus-induced 
interferon (IFN) and pro-inflammatory cytokine expression will be described in this 
section. A diagrammatic summary of these signalling pathways is shown in Figure 1.6. 
Much of this current knowledge has been obtained from studies primarily focusing on 
viruses and cell lines/primary cells that are not relevant to human virus infection. 
Although valuable, with respect to furthering our knowledge of virus-induced cell 
signalling, there is a need to confirm the findings of these studies in human systems with 
clinically relevant viruses, if the targeting of these signalling pathways is to become a 
viable future therapeutic strategy for human diseases.  
1.3.1 Transcriptional Regulation of Interferon and Pro-
inflammatory Cytokine Genes  
While many of the upstream pathways leading to transcriptional activation are still being 
elucidated, the transcriptional regulation of IFN-β has been well studied for decades. 
Transcription factors identified in the literature to be required for virus-induced IFN and 
pro-inflammatory cytokines are described in this section, including how they are 
activated upon virus infection, and evidence of their requirement in virus-induced IFN 
and pro-inflammatory cytokine expression. The transcription factors required for RV-
induced pro-inflammatory cytokine expression are quite well explored. In contrast, 
transcription factors required for RV induction of type I IFN-β and type III IFN-λ 
expression are unknown. 
1.3.1.1 IRF Family 
The interferon regulatory factor (IRF) family of transcription factors comprises nine 
members (IRF1-IRF9). Each has a conserved N-terminal DNA-binding domain (DBD), 
that mediates their binding to a consensus IRF recognition sequence (5’-AANNGAAA-3’) 
[130] termed the IRF sequence or the IFN-stimulated regulatory element (ISRE), and 
found within the promoters of IFN-αs, IFN-β and many IFN-simulated genes (ISG). The 
C-terminal regions of IRFs (except IRF1 and IRF2) have an IRF-association domain 
(IAD), which is responsible for homo- and hetero-dimeric interactions with other family 
members. All IRFs are ubiquitously expressed except IRF4, IRF5 and IRF8, which are 
restricted to B-cells and dendritic cells [131] [132]. The expression of IRF1 [133] [134] 
[135] and IRF2 [135] is increased by virus or IFN treatment. IRF3 is constitutively 
expressed and unlike IRF1 and IRF2 is not an ISG [136]. IRF7 is critically dependent 
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upon type I IFN signalling for its induction [137] [138], except in some lymphoid cells and 
in pDCs [139] where IRF7 is constitutively expressed.    
IRF1 was identified as an IFN-β-promoter binding factor [134], and shown to induce type 
I IFN promoter activation and endogenous production when over-expressed in monkey 
and mouse cell lines [140] [141] [135]. Further, expression of IRF1 antisense RNA 
inhibits polyIC-induced IFN-β mRNA/protein production in a human fibroblast cell line 
[142], and IRF1 deficient murine embryonic fibroblasts (MEFs) lack type I IFN induction 
in response to polyIC-stimulation [143].  In contrast, a role for IRF1 in virus-induced type 
I IFN has been questioned, with IRF1 deficient MEFs showing comparable Newcastle 
disease virus (NDV)-induced type I IFN production to wild-type MEFs [143] and IRF1 
binding to the endogenous IFN-β promoter not detected following sendai virus (SV) 
infection of HeLa cells [144]. This suggests the existence of both IRF1-dependent and 
IRF1-independent pathways for induction of type I IFNs. 
IRF2 binds to the same regulatory element in the IFN-β promoter as IRF1 [135]. IRF2 
functions as a repressor, with IRF2 over-expression inhibiting the type I IFN transcription 
induced by over-expression of IRF1 in mouse cell lines [141] [135]. Consistent with this, 
IRF2 deficient MEFs show an up-regulation of type I IFN induction by NDV virus 
compared to wild-type controls [143].  
IRF3 resides in the cytosol in an inactive form and is activated upon virus infection or 
polyIC-stimulation of cells, and undergoes phosphorylation, dimerisation and nuclear 
translocation [145] [146] [147]. Mutagenesis studies show the transcriptional activation 
of IRF3 to be controlled by C-terminal phosphorylation on serine 396 [148] and serine 
386, with phosphorylation of serine 386 a critical determinant for IRF3 activation [149]. 
Homo- or hetero-dimerisation is proposed to occur by the interaction of IRF3 
phosphorylated serine residues with a hydrophobic pocket (within the IAD) of another 
IRF3 or IRF7 [150]. The dimeric form of IRF3 translocates to the nucleus and binds to 
the ISRE within the promoters of type I IFN genes and ISGs including some chemokine 
genes, to stimulate their transcription. Consistent with this, NDV [151], Encephalo-
myocarditis virus (EMCV) and vesicular stomatitis virus (VSV) [139] induced IFN-α/β 
expression is inhibited in MEFs from IRF3 gene knockout mice. Studies have also 
shown IRF3 over-expression to enhance NDV-induced endogenous IFN-α/β expression 
[146] [147] and IFN-α and IFN-β promoter reporter activation [146] [147] [152]. 
Conversely, NDV-induced IFN-α/β endogenous expression [147] and NDV [146] and 
SV-induced [153] IFN-β promoter reporter activation is inhibited by dominant negative 
IRF3. Further, promoters of the chemokines CCL5 and CXCL10 contain IRF binding 
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sites [154] [155] [91], and a role for IRFs in their transcription has been demonstrated by 
mutation or truncation of the IRF binding site, inhibiting their activation by polyIC or virus 
infection [155] [91]. Other ISGs that IRF3 has a role in the transcription of include 
ISG15, ISG54 and ISG56 [156] [157]. The importance of IRF3 in viral infection is 
illustrated by EMCV infected IRF3 deficient mice having a reduced survival rate [151], 
and influenza A [158] infection demonstrated to prevent type I IFN induction by targeting 
the function of IRF3.  
Type I IFN production is required prior to the induction of IRF7 expression [137] [159] 
[138]. The rapid first phase induction of type I IFN is therefore proposed not to be 
dependent on IRF7, but instead on IRF3, which is constitutively expressed and activated 
upon virus infection. Following initial production of type I IFN, the binding of type I IFN 
protein to the cell surface receptor IFNAR1, induces activation of the JAK-STAT 
signalling pathway leading to activation of the hetero-trimeric transcription factor 
complex interferon stimulated gene factor 3 (ISGF3). This complex consists of IRF9, 
Stat1 and Stat2, and is responsible for induction of the IRF7 gene [137] [138]. Once 
expressed, IRF7 protein resides in the cytoplasm and is transcriptionally activated by 
virus-induced serine phosphorylation within its C-terminal region [160], allowing its 
homo- or hetero-dimerisation with IRF3, and its nuclear translocation. Dimeric IRF7 
binds to the ISRE within the promoters of type I IFN genes and consistent with this, 
studies have shown a role for IRF7 in the second phase of type I IFN production [137] 
[138]. A diagrammatic representation of the mechanism of IRF7 gene transcription 
following virus infection is shown in Figure 1.2.  
Similarly to studies in IRF3 gene knockout mice, MEFs from IRF7 gene knockout mice 
show reduced NDV [151], EMCV and VSV [139] induced IFN-β expression. Consistent 
with a role for both IRF3 and IRF7 in virus-induced IFN-β induction, virus-induced IFN-β 
is abolished in IRF3/IRF7 double knockout MEFs [151] [139]. Additionally, unlike IRF3 
deficient MEFs, IRF7 deficient MEFs have abolished EMCV or VSV-induced IFN-α 
expression, indicating that IRF7 (and not IRF3) is essential for IFN-α induction. In 
support of this, studies have also shown enhanced NDV-induced IFN-α promoter 
activation upon IRF7 over-expression [138], and mutation of the IRF-binding site in the 
IFN-α promoter, to prevent IRF7 binding, and abolished NDV-induced IFN-α promoter 
activation [138].  
 
                                                                                                                      Chapter 1: Background 
 36 
 
IRF3
(constitutive)
p-IRF3
IFN-β
IFN-α4
IFN
AR
1
JAK/STAT
IFN-β
IFN-α4
ISGF3
IRF7
IRF7
Virus
IRF3 & IRF7
p-IRF3 & p-IRF7
IFN-β
all IFN-αs
All type I IFNsA B C
 
 
Figure 1.2 Induction of Type I IFNs by IRF3 and IRF7. Adapted from [161]. 
A: Viral infection induces the activation of IRF3 by phosphorylation, leading to nuclear 
translocation and induction of IFN-β/IFN-α4. B: Secreted IFN-β/IFN-α4 bind to the type I IFN 
receptor (IFNAR1) and activate the JAK-STAT signalling pathway, leading to activation and 
nuclear translocation of the transcription factor ISGF3. ISGF3 mediates induction of the IRF7 
gene. C: Further infection, activates both IRF3 and IRF7 by phosphorylation, leading to induction 
of all type I IFN genes. 
1.3.1.2 NF-κB Family 
The nuclear factor-κB (NF-κB) or Rel family has five members: RelA (p65), RelB, c-Rel, 
p50 and p52, characterised by their Rel homology domain (RHD), mediating their 
dimerisation, DNA-binding and interaction with inhibitory IκB proteins. The RHD also 
contains a nuclear localisation sequence (NLS).  
RelA (p65), RelB and c-Rel are synthesized directly as mature proteins; whereas p50 
and p52 are generated from larger precursors of 105 (p105) and 100kDa (p100) 
respectively by 26S proteasome mediated proteolysis. The canonical NF-κB pathway is 
essential for activating innate immunity, and is triggered by a plethora of substances 
including pro-inflammatory cytokines, bacterial lipopolysaccharide (LPS), viruses/viral 
proteins, dsRNA, and physical and chemical stresses [162] [163]. The non-canonical 
NF-κB pathway preferentially involves p52-RelB hetero-dimers, and is important for the 
regulation of adaptive immunity and lymphoid organogenesis. This pathway occurs in 
certain cell types and responds to limited stimuli including lymphotoxin β (LTβ), B-cell 
activating factor (BAFF) and CD40 ligand [164].  
NF-κB regulates the transcription of many genes including those involved in innate and 
adaptive immunity, inflammation, anti-apoptosis, proliferation, stress responses and 
cellular differentiation and development [162] [163]. Studies of asthmatic individuals 
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have shown increased p65 protein expression in PBMCs [165] and increased NF-κB 
DNA-binding in cells extracted from sputum and bronchial biopsies [166], suggesting 
that NF-κB activation is increased in asthmatic individuals. Coupled with the knowledge 
that the expression of many pro-inflammatory mediators is enhanced in asthmatic 
patients upon RV infection, NF-κB is believed to play an important role in the 
pathogenesis of RV-induced asthma exacerbations. 
The importance of NF-κB in IFN-β expression has been demonstrated using MEFs 
deficient in the NF-κB up-stream activating kinase, IκB kinase beta (IKK-β), showing 
impaired NF-κB DNA-binding activity and IFN-β expression in response to polyIC 
treatment or VSV infection [167]. Over-expression of the NF-κB inhibitory protein IκBα in 
HEK293 cells also inhibits NF-κB DNA-binding and inhibits SV-induced endogenous 
IFN-β production and promoter activation [168]. However, a recent study, and the first 
study to use NF-κB deficient mice to assess the role of NF-κB in virus-induced type I 
IFN, has questioned a critical role for NF-κB in virus-induced type I IFN production, with 
SV and NDV-induced type I IFN production in NF-κB deficient MEFs and conventional 
dendritic cells (cDCs) reduced, but still robustly produced, and not significantly different 
to levels in wild-type cells [169]. Poliovirus cleaves NF-κB to prevent its activation [170], 
and the NS1 protein of influenza A virus prevents activation of NF-κB [171], 
demonstrating the importance of NF-κB in the innate antiviral response, and thus its 
targeting by viral proteases. 
RV-induced pro-inflammatory cytokine/chemokine expression is well studied at the 
transcriptional level. CXCL8 and IL-6 mRNA/protein is induced, and CXCL8 and IL-6-
promoter reporter constructs are activated, in response to RV infection of airway 
epithelial cells [82] [95] [77], with activation of both promoters abolished by NF-κB site 
removal [82] [95] [37]. These studies also showed NF-κB p65/p50 to preferentially bind 
to the CXCL8 NF-κB sequence, and p65, p50 and p52 to bind to the IL-6 NF-κB 
sequence following RV infection. The CXCL10 promoter also contains an NF-κB binding 
site and its truncation inhibits RV-induced CXCL10-promoter reporter activation [91]. 
The CCL5 promoter contains an NF-κB binding site [172] [155] that specifically binds to 
p65/50 [155], and mutation of which inhibits its activation by polyIC in BEAS-2B cells 
[155]. The CXCL5 promoter also contains an NF-κB binding site and is required for 
CXCL5 transcription in response to pro-inflammatory stimuli [173] [174]. The 
transcription factors required for CCL5 and CXCL5 induction in response to RV infection 
are unknown. 
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1.3.1.3 ATF-2 and c-Jun 
The activator protein 1 (AP-1) family of transcription factors consists of dimers 
composed of Jun (c-Jun, JunB, JunD) and Fos (c-Fos, FosB, Fra-1, Fra-2) protein 
groups [175]. AP-1 protein levels are controlled at the transcriptional level, with 
transcriptional regulation of c-Fos and c-Jun proteins best understood, and rapidly up-
regulated by many stimuli including growth factors, cytokines and chemokines [176]. 
Despite being induced, most cell types contain c-Jun protein prior to its induction by 
stimuli. Members of the AP-1 family hetero-dimerise with members of the ATF/CREB 
transcription factor family including CREB and ATF1-4 [177], which are constitutively 
expressed. Hetero-dimers of ATF-2/c-Jun are constitutively nuclear and are activated by 
the mitogen activated protein kinases (MAPK) c-Jun N-terminal kinase (JNK)-1, JNK2 
and p38. Like NF-κB, JNK and p38 activity is stimulated by pro-inflammatory cytokines, 
LPS and environmental stress [178] [179]. MAPKs, and therefore ATF-2/c-Jun, are 
important mediators of cellular responses including cell proliferation, apoptosis, 
oncogenesis, and cytokine biosynthesis [180] [179]. ATF-2/c-Jun are also implicated in 
type I IFN production, with polyIC stimulated or VSV infected MEFs deficient in ATF-2/c-
Jun activating kinase JNK2, showing reduced induction of IFN-β expression, and faster 
VSV genomic RNA accumulation [167], suggesting an impairment of the antiviral 
response in these cells. PolyIC or influenza A induced IFN-β promoter reporter 
activation is inhibited in canine kidney cells, using dominant negative JNK or dominant 
negative c-Jun [181], supporting a role for JNK and c-Jun in IFN production. AP-1 family 
members are also implicated in the transcription of CCL5 [172] and CXCL8 [182], which 
contain an AP-1 binding site within their promoters. LPS and RSV-induced CCL5 
promoter reporter activation is reduced upon AP-1 binding site mutation in macrophages 
and A549 cells respectively [183] [184]. However, RSV-induced CCL5 transcription was 
only abolished following IRF site mutation [184], and mutation of IRF and NF-κB binding 
sites in the CCL5 promoter has been shown to be sufficient to abolish polyIC-induced 
CCL5 promoter activation in BEAS-2B cells [155], suggesting that AP-1 may not be 
essential for CCL5 transcription. Further, the AP-1 binding site is dispensable for CXCL8 
promoter activation in RV infected BEAS-2B cells [37], and mutation of the NF-κB 
binding site alone has been shown to be sufficient to abolish RV induced CXCL8 
promoter activation in BEAS-2B and A549 cells [82] [37]. AP-1 may therefore also not 
be essential for CXCL8 transcription, although a cell type specific role for AP-1 in 
CXCL8 (and CCL5) transcription cannot be discounted.  
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1.3.1.4 Structure of the Interferon-beta promoter 
The IFN-β promoter contains four positive regulatory domains (PRDs), namely PRDI, 
PRDII, PRDIII and PRDIV, which lie within a region of DNA localised to the first 104bp 
immediately up-stream of the start site of transcription, termed the enhancer region. The 
transcription factors NF-κB, IRF1, IRF3, IRF7 and ATF-2/c-Jun, bind to specific PRD 
regions of the IFN-β promoter. NF-κB binds to PRDII [185] [186] [187], IRF1 to PRDI 
[187], IRF3 [188] [144] and IRF7 [144] to PRDI-III and ATF2/c-Jun to PRDIV [189] [190]. 
Mutation of PRDI [191], PRDII [185] [191] or PRDIV [189] in the IFN-β promoter, 
reduces transcription factor binding and the level of virus induction. Dominant negative 
IRF3 [144] [147] and IRF7 [144] have also been shown to reduce virus-induced IFN-β 
promoter activation. 
 
Which of the five NF-κB rel proteins are required for PRDII transcriptional activation and 
virus-induced activation of the IFN-β promoter has been extensively studied. Studies in 
HEK293 [192] or HeLa cells [186] show PRDII-dependent reporter constructs to be 
weakly activated by expression of p50 (~2-4 fold) [192] [186], weakly activated (~4 fold) 
[192] or not activated by c-Rel [186], efficiently activated by p65 (~18 fold; [192]) with 
increasing PRDII activation with p65 dose [186], strongly activated by p65/p50 (~25 fold; 
[192]) and p65/c-rel (~20 fold; [192]) with increasing PRDII activation with dose of both 
hetero-dimers [186]. Thus, p65, p50 and c-Rel are the most strongly implicated in 
binding to PRDII in response to virus. SV infection of MG63 cells, and EMSA analysis of 
whole cell extracts using a PRDII probe, identified the presence of p50, p65, p65/50 and 
p65/c-Rel, and p65/p50 to be the most abundant [186]. Similarly, Garoufalis et al [192] 
performed EMSA on a time-course of SV infection of HEK293 cells and identified the 
predominance of the same NF-κB subunits (p65, p50, c-Rel) binding to a PRDII probe. 
However, the interaction of these sub-units with the intact IFN-β promoter was not 
proven in these studies. 
 
In the context of the intact IFN-β promoter and its activation by virus infection, site 
directed mutagenesis of PRDII within the IFN-β promoter, and assessment of NF-κB 
subunit binding, revealed only the binding of p65/p50 to be sufficient to confer virus-
inducibility on the promoter [186], implicating p65/p50 to be the crucial subunit in virus 
induction of the IFN-β promoter. Further work by Wathelet et al [144] established 
p50/p65 to bind to the endogenous IFN-β promoter following virus infection and also 
ATF-2/c-Jun, IRF3/IRF7 but not IRF1.  
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Despite their involvement in virus-induced IFN-β transcription, in the absence of virus 
infection, transfection studies show expression of p50, p65, c-Rel or p65/50 alone in 
HEK293 cells, not to activate the intact IFN-β promoter [192], or alternatively p65 alone 
to minimally induce IFN-β promoter activation [188] [145]. Additional transfection studies 
show IRF3 [188] or IRF1 [192] [188] expression alone, in HEK293 cells, not to stimulate 
IFN-β promoter reporter activity, or to minimally induce IFN-β promoter reporter activity 
[145], and ATF-2 expression in HeLa cells [190] and IRF7 expression in SAN cells [144], 
to minimally induce IFN-β promoter activation. In contrast, these transfection studies 
showed the co-expression of two transcription factors to enhance IFN-β promoter 
activation above that achieved with the expression of individual transcription factors 
alone [144] [145] [190] [188] [192]. The greatest induction of IFN-β promoter activation is 
achieved with co-expression of transcription factors, which bind to each of the PRD 
regions. Expression of ATF-2/c-Jun, IRF1 and p65/p50 strongly induced IFN-β promoter 
activation [186], with increasing activation with transcription factor dose [186] [187]. The 
co-expression of ATF-2/c-Jun, IRF3/IRF7 and p65/p50 has also been reported to 
synergistically activate the IFN-β promoter, and show a correlation between increasing 
transcription factor dose and degree of IFN-β activation [193]. Activation of the IFN-β 
promoter therefore appears to require cooperative interactions between transcription 
factors. In support of this, the insertion of sections of DNA between the PRD regions of 
the promoter, preventing protein-protein interactions between transcription factors, 
inhibited promoter activation by virus [187]. Furthermore, IRF1 and NF-κB have been 
shown to interact [194], and thus likely explains their enhanced IFN-β promoter 
activation when expressed together [192] [145], and an interaction between ATF2/c-Jun 
and NF-κB has been identified [190]. A chimeric fusion protein of IRF3-NF-κB is also 
able to further increase IFN-β promoter activation, than individual expression of IRF3 
and NF-κB together, indicating fusion to have bypassed their need for cooperative 
binding [188].  
 
The DNA-bending, high-mobility-group protein HMG I(Y) is implicated in facilitating 
transcription factor binding to the IFN-β promoter, and thus likely assists cooperative 
interactions between transcription factors. A HMG I(Y) binding site is located within 
PRDII [185], and two HMG I(Y) binding sites are located within PRDIV [190]. The 
presence of HMG I(Y) facilitates the binding of NF-κB p65/p50 to PRDII [185] and ATF-2 
to PRDIV [190]. The ability of HMG I(Y) to alter the conformation of the DNA helix [195] 
may explain its facilitated DNA binding of NF-κB and ATF-2/c-Jun. In turn, inhibition of 
HMG I(Y) binding to PRDII or PRDIV, inhibits p50/p65 [185] and ATF-2/c-Jun [190] 
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dependent activation of PRDII-element and PRDIV-element linked reporter constructs, 
respectively. Additionally, HMG I(Y) has been demonstrated to induce a conformational 
change to enable co-occupancy of PRDI and PRDII by IRF1 and NF-κB [187], indicating 
a critical role for HMG I(Y) in cooperative assembly of transcription factors on the IFN-β 
promoter as a whole. Hence, HMG I(Y) is required to enable synergistic activation of the 
IFN-β promoter to occur in response to co-transfection of transcription factors [187] 
[193], and mutation of HMG I(Y) binding sites inhibits virus-induced IFN-β promoter 
activation [185].  
 
Once bound to the IFN-β promoter, IRF3/IRF7 [144] [196], NF-κB p65 [197] [198] and 
ATF-2/c-Jun [199] [200] interact with different domains of the co-activator proteins 
CBP/p300, suggesting that CBP/p300 mediates interactions between transcription 
factors. Subsequently, in the absence of transcription factor interaction with CBP/p300 
synergistic activation of the IFN-β promoter is lost [198] [193]. 
 
In summary, the co-induction of the transcription factors ATF-2/c-Jun, IRF3/IRF7 and NF-
κB into their active forms upon virus infection, their interactions with each other and their 
simultaneous interaction with PRDs enables the formation of a multi-component 
transcriptional enhancer complex, required to initiate IFN-β transcription and termed the 
IFN-β enhanceosome. Recent crystal structural studies have provided a complete 
atomic model of the IFN-β enhanceosome at the protein-DNA interface [201]. This 
structure is shown below in Figure 1.3. HMG I(Y) is not included in this structure as it is 
believed to promote formation, but not to be present in the final enhanceosome 
assembly [201]. 
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Figure 1.3 Structure of the IFN-β enhanceosome (after Panne et al [201]. 
p50 is depicted in light blue and Rel A in dark blue. IRF3A and IRF3C are in green, and IRF7B 
and IRF7D in yellow. ATF-2 is in red and c-Jun in blue. The DNA sequence is coloured to show 
the core-binding sites of the corresponding coloured transcription factors.  
 
 
1.3.1.5 Structure of Interferon-lambda (IFN-λ) promoters 
The regulatory mechanism of type III IFN induction is less clearly understood. Studies of 
the regulatory elements up-stream of the IFN-λ1 and IFN-λ2/3 transcriptional start site, 
have identified an NF-κB binding site and multiple IRF binding sites, including an IRF1 
binding site [202] [203]. The requirement for these sites has been shown using a 
luciferase reporter linked to the regulatory elements of IFN-λ1, with reporter gene 
activation observed in mouse L292 cells upon NDV infection, and inhibited by mutating 
either the IRF or NF-κB binding site, or both IRF and NF-κB binding sites [202].  
Using NDV infected HeLa cells, NF-κB p50/p65 has been shown to bind the IFN-λ1 NF-
κB motif using EMSA [202], and using SV infected DCs, IRF3 to bind IFN-λ1 and IFN-
λ2/3 promoters at early time-points, and IRF1 and IRF7 to bind at later time-points post-
infection [203]. A role for IRF1, IRF3 and IRF7 in IFN-λ1 and IFN-λ2/3 induction is 
supported by their ectopic expression enhancing SV-induced IFN-λ1 and IFN-λ2/3 
promoter activation in HEK293 cells [203]. A role for IRF3 is further supported by 
constitutively active IRF3, in HeLa cells, inducing IFN-λ1 and IFN-λ2/3 expression, and 
confirmed with IRF3 deficient MEFs derived from IRF3 knockout mice, showing 
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abolished NDV-induced IFN-λ2 expression [202]. Additionally, it has been proposed that 
IRF7 is the predominant IRF regulating IFN-λ2/3 promoter activation, due to a greater 
enhancement of SV-induced IFN-λ2/3 promoter activation in HEK293 cells with IRF7 
ectopic expression, than with IRF1 or IRF3 ectopic expression [203]. However, whether 
this is a virus or cell type specific finding is unknown.    
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1.3.2 Pattern Recognition Receptors (PRRs) 
The upstream events controlling the activation of transcription factors required for type I 
IFN induction was largely unexplored prior to an explosion of interest in this area within 
the last 6 years. They consist of antiviral signalling pathways which are triggered by the 
detection of invading pathogens by evolutionarily conserved PRRs. PRRs sense 
conserved structures (pathogen-associated molecular patterns; PAMPs) in a broad 
range of pathogens and trigger innate immune responses by inducing the production of 
inflammatory cytokines/chemokines and IFNs, and therefore mediating recruitment of 
inflammatory cells required for host defence. Toll-like receptors (TLRs) constitute a class 
of membrane bound PRRs, and protein kinase R (PKR), retinoic acid-inducible gene-I 
(RIG-I) and melanoma differentiation-associated gene 5 (MDA5) function as cytoplasmic 
PRRs. The PAMPs that these PRRs recognise, the adaptor proteins to which they bind, 
and their importance in mediating transcription factor activation and IFN and pro-
inflammatory cytokine/chemokine expression, in response to virus infection is discussed 
in this section. 
1.3.2.1 Protein kinase R (PKR) 
PKR has been a focus of interest since the 1980s, and is a cytoplasmic dsRNA-binding 
serine/threonine protein kinase, comprised of an N-terminal dsRNA-binding domain 
(dsRBD) and a C-terminal kinase domain. PKR homo-dimers are activated by dsRNA 
ligation, and induce NF-κB activation by direct phosphorylation of the NF-κB inhibitor 
IκBα [204] or phosphorylation and activation of IκB kinase-alpha/beta (IKK-α/β) [205]. 
PKR also inhibits translation of host cell and virus RNA, and thus virus replication [206], 
by phosphorylating the eukaryotic translation initiation factor eIf2α. The role of PKR in 
virus-induced IFN is a matter of much debate. When challenged with NDV or polyIC, 
PKR knock-out mice can produce type I IFNs to a comparable level with wild-type mice 
[207], however, PKR deficient MEFs show markedly impaired NF-κB activation and type 
I IFN production in response to polyIC treatment [207] and do not produce type I IFNs in 
response to VSV [167]. The specificity of the standard PKR inhibitor 2-aminopurine has 
also been questioned [208], thus the requirement for PKR in type I IFN production is 
controversial. Although possibly involved in IFN-β induction through its activation of NF-
κB, further experiments to define the role of PKR in type I IFN induction using more 
specific inhibitors are required.  
 
A role for PKR in pro-inflammatory cytokine/chemokine expression is more clear, with 
PKR chemical inhibition and/or dominant negative PKR experiments, reducing polyIC 
and RV-induced CCL5, CXCL8 and IL-6 protein production in BEAS-2B cells [209], and 
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polyIC-induced CCL5 and CXCL8 protein in primary human bronchial epithelial cells 
[210]. 
1.3.2.2 TLR Family 
Thirteen mammalian TLRs (TLR1-13) have been identified to date, each consisting of an 
extracellular N-terminal domain containing multiple copies of a short motif known as the 
leucine rich repeat (LRR), a membrane spanning domain, and a C-terminal cytoplasmic 
signalling domain, termed the Toll/IL-1 receptor (TIR) domain. Ligand recognition by 
TLRs is mediated by their N-terminal ectodomains (ECD), with signalling originating 
from their intracellular TIR domains, which serve as platforms for the assembly of 
adaptor proteins, which also contain TIR domains and bind to TLRs through a TIR 
domain homotypic interaction [211]. Each TLR member recognises different pathogen 
components, TLR1, TLR2, TLR4, TLR5 and TLR6 primarily recognise bacterial 
components and TLR3, TLR7, TLR8 and TLR9 recognise viral nucleic acids. Ligands 
binding TLRs10-13 have not yet been identified. Different combinations of four TIR 
domain-containing adaptor proteins; myeloid differentiation factor 88 (MyD88), TIR 
domain-containing protein (TIRAP)/MyD88 adaptor like (MAL), TIR domain-containing 
adaptor inducing IFN-β (TRIF)/TIR domain-containing adaptor molecule 1 (TICAM1), 
and TRIF related adaptor molecule (TRAM)/TIR domain-containing adaptor molecule 2 
(TICAM2), are recruited to ligand bound (activated) TLRs. TLR cellular localisation, 
ligand and adaptor protein specificity is summarised in Figure 1.4.  
TLRs recognising viral nucleic acids are primarily localised to endocytic compartments, 
suggesting that they recognise viruses which traffic through the endosomal 
compartments during cellular entry or depend on the acidic environment of endosomes 
for their replication or assembly of viral particles. Upon TLR activation, all adaptor 
proteins couple to and activate downstream signalling pathways that lead to the 
activation of transcription factors, including NF-κB and ATF-2/c-Jun, and in turn the 
production of inflammatory cytokines and chemokines. TLRs recognising viral nucleic 
acids (TLR3, TLR7, TLR8, TLR9) additionally signal via pathways leading to the 
activation of interferon regulatory factor 3 (IRF3) and/or IRF7 and the induction of type I 
IFN production.   
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Figure 1.4 Toll-like receptor (TLR) localisation, pattern recognition specificity and 
associated adaptor protein(s). LPS= lipopolysaccharide; ds/ssRNA = double-stranded/single-
stranded RNA; CpG= cytidine-phosphate-guanosine; MyD88= myeloid differentiation factor 88; 
TRIF= TIR domain-containing adaptor inducing interferon-β; TRAM= TRIF related adaptor 
molecule; TIRAP= TIR domain-containing protein.  
1.3.2.3 Importance of TLR3 and TRIF in Interferon and Pro-
inflammatory Cytokine Gene Expression 
The majority of in vitro studies investigating the role of TLR3 in transcription factor 
activation and induction of IFNs have used various cell lines and polyIC to model virus 
infection. Stimulation of TLR3 expressing HEK293 cells with the TLR3 ligand polyIC, has 
been demonstrated to induce NF-κB activation [212] [213] [214] [215], and IRF-
dependent (ISRE) reporter construct activation [212] [216]. Activation of the MAPKs p38, 
JNK and ERK1/2 is also observed in polyIC treated BEAS-2B cells [212], implicating 
TLR3 in AP-1 activation. Consistent with the activation of these transcription factors, 
TLR3 expressing HEK293 cells simulated with polyIC, show IFN-β promoter activation 
[213] [214]. By contrast, in vitro studies inhibiting TLR3 function by expressing dominant 
negative TLR3, using TLR3 monoclonal blocking antibodies or TLR3 targeting siRNA, 
have shown inhibition of polyIC-induced NF-κB activation [212] [214] [217], ISRE 
reporter activation [217], p38 MAPK phosphorylation [217] and subsequently inhibition of 
IFN-β promoter activation [214] and IFN-β protein secretion [213] [214]. Ex-vivo studies 
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of polyIC-stimulated TLR3 deficient macrophages [215] [218] and lung fibroblasts [218] 
additionally show impaired NF-κB activation [215] [218] and type I IFN induction.  
The TLR3 adaptor protein TIR domain-containing adaptor inducing IFN-β (TRIF) [219] 
also known as TIR domain-containing adaptor molecule-1 (TICAM-1) [214] consists of 
an N-terminal proline-rich domain, a TIR domain and a C-terminal proline-rich domain 
[214]. TRIF binds to TLR3 via a TIR homotypic interaction, and has been shown in 
numerous studies to be required for TLR3-mediated signalling, by virus and/or polyIC, 
leading to the induction of the transcription factors NF-κB, IRF3 and AP-1 and 
production of IFN-β [212] [214] [218] [219] [220]. Consistent with these findings, studies 
have shown the over-expression of TRIF to activate NF-κB [214] [216] [219] [221] [222], 
AP-1 [214] and IRF3 [216] [223] [222] in HEK293 cells, and to induce IRF3 dimerisation 
in HeLa cells [214]. Hence, TRIF over-expression induces IFN-β promoter reporter 
activation [214] [216] [219] [221]. TRIF over-expression has also been shown to induce 
activation of IFN-λ1 and IFN-λ2/3 promoter reporter constructs in HEK293 cells [203], 
implicating the TLR3 pathway in IFN-λ induction. 
Viral evasion mechanisms targeting the TLR3 pathway have been identified, and 
strongly suggest that targeting TLR3 or associated adaptors has been evolutionary 
conserved giving the virus an advantage. For example Vaccinia virus encodes the 
proteins A46R and A52R; A46R targets TRIF to inhibit TRIF-induced IRF3 activation 
[224], and A52R targets tumour necrosis factor receptor-associated factor 6 (TRAF6), to 
block TLR3-mediated signalling to NF-κB activation [225]. Also NS3-4A, a protease 
produced by hepatitis C virus cleaves TRIF to prevent TLR3 signalling [226] [227] [228]. 
1.3.2.4 Importance of TLR7, 8 and 9 in Interferon and Pro-
inflammatory Cytokine Gene Expression 
TLR7 and TLR8 recognise single-stranded (ss) RNA in a range of microorganisms 
including viruses [229] and TLR9 recognises unmethylated CpG dsDNA [230] found in 
bacteria and DNA viruses. The recognition of ssRNA by TLR7 has been reported to 
require an acidic compartment [231] [232], and TLR8 mediated signalling has been 
shown to be sensitive to the lysosomal maturation inhibitor bafilomycin [233], indicating 
both to be endosomal receptors. TLR7 is predominantly expressed in lung, placenta, 
spinal cord and spleen, TLR8 in the lung and spleen [234] [235] and TLR9 in skeletal 
muscle and spleen [235]. B-cells and plasmacytoid dendritic cells (pDC) express TLR7 
and TLR9 [236] [237] [238], and TLR8 has been detected in monocytes, NK cells and T 
cells [236] [237]. TLR9 is expressed in bronchial epithelial cells [239] and nasal epithelial 
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cells [240], however, TLR7 and TLR8 expression was not detected in a study of small 
airway epithelial cells [241], or a study of human bronchial epithelial cells [242], and in 
nasal epithelial cells the expression of TLR7 and TLR8 was determined to be low and 
below that of the dsRNA receptor TLR3 [240]. TLR7, 8 and 9, signal downstream using 
the MyD88 adaptor, which possesses a C-terminal TIR domain and an N-terminal death 
domain. MyD88 recruits the serine/threonine kinase IL-1 receptor-associated kinase 
(IRAK) to the TLR through interaction of the death domains of both molecules. IRAK 
becomes activated and then associates with TRAF6, leading to the activation of NF-κB 
and MAPK signalling pathways. Ex-vivo studies of pDCs have reported a role for TLR7 
in IFN-α production in response to the ssRNA viruses’ influenza A and VSV [229], and a 
role for TLR9 in response to the DNA virus HSV [243] [244]. 
1.3.2.5 RNA Helicases 
The RNA helicase family of viral pattern recognition receptors includes RIG-I, MDA5 and 
Laboratory of Genetics and Physiology 2 (LGP2). RIG-I, MDA5 and LGP2 are localised 
to the cytoplasm and bind dsRNA [245] [246] [247] [248]; additionally RIG-I binds 5’-
triphosphate ssRNA/dsRNA [249] [250]. RIG-I and MDA5 are positive regulators of IFN 
and pro-inflammatory cytokine/chemokine induction, and LGP2 is a negative regulator, 
which competes with RIG-I for dsRNA binding [247], and also interacts with the RIG-I 
helicase domain to prevent RIG-I signalling [248].  
1.3.2.5.1 Structure and Function of RIG-I, MDA5 and Cardif 
RIG-I and MDA5 are members of the DExD/H-box family of proteins, characterised by a 
C-terminal DExD/H box RNA helicase domain (with ATPase activity) and two tandem N-
terminal caspase recruitment domains (CARDs). MDA5 and RIG-I share 35% and 23% 
amino acid similarity in their helicase and CARD domains respectively [245]. RIG-I and 
MDA5 are interferon responsive genes (ISG) [245] [251] [252] and are basally 
expressed in most tissues. 
Expression of the N-terminal CARD domains of RIG-I or MDA5 alone is sufficient to 
initiate signalling leading to NF-κB [245] [246], IRF3 [246] and IRF7 activation [246]. 
Studies have also shown expression of the CARDs of RIG-I and/or MDA5 alone, to 
induce IFN-β promoter activation [245], and endogenous IFN-β production [246].  
The C-terminal helicase domain of RIG-I and MDA5, have been demonstrated to bind to 
dsRNA using dsRNA pull-down assays [245] [246]. However, in contrast to the CARDs, 
expression of the C-terminal region of RIG-I alone inhibits polyIC [245], NDV [245] [246] 
and SV-induced [253] IRF-3 activation. Expression of the MDA5 C-terminal region alone 
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does not inhibit or augment NDV-induced IRF3 activation [246]. The MDA5 C-terminal 
region is therefore also incapable of inducing positive signalling [246]. These results 
support a hypothesis that the C-terminal region of RIG-I and MDA5 act as regulatory 
regions, containing a helicase domain that binds to dsRNA, but the C-terminal region 
alone does not induce signalling down-stream.  
The C-terminal regions of RIG-I and MDA5 have been suggested to prevent the CARDs 
of RIG-I and MDA5 respectively from transmitting down-stream signals in a non-
pathogenic environment. This is supported by a study showing full-length RIG-I or 
MDA5, in the absence of virus infection or polyIC, to fail to activate IRF3 and induce 
IFN-β promoter activation [246]. In contrast, in the presence of polyIC or NDV, 
expression of full-length RIG-I or MDA5 enhanced IRF3 activation and IFN-β promoter 
activation [246]. The region within the C-terminal of RIG-I responsible for preventing 
RIG-I CARD signalling in the absence of pathogenic stimuli has recently been 
determined and designated a repressor domain (RD) [248]. RD interacts with the RIG-I 
helicase domain and CARDs to prevent RIG-I signalling in the absence of virus infection 
[248]. During virus infection it is proposed that dsRNA binding to the RIG-I helicase 
domain, induces an ATP-dependent conformational change in the RIG-I structure, 
exposing the CARDs and converting RIG-I into an active signalling intermediate. In this 
respect, ATPase activity in the helicase domain of RIG-I has been shown to be required 
for signalling in response to viral infection [245] [246]. In contrast, the C-terminal region 
of MDA5 does not contain a RD [248], and so the mechanism by which the MDA5 C-
terminal prevents MDA5 CARD signalling in the absence of virus (or polyIC) is as yet 
undefined. The structure of RIG-I and MDA5 are shown in Figure 1.5.  
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Figure 1.5 Structure of Retinoic acid inducible gene-I (RIG-I) and Melanoma differentiation-
associated gene 5 (MDA5). 
 
The RIG-I and MDA5 adaptor protein CARD adaptor inducing IFN- (Cardif) [228] is 
ubiquitously expressed, and contains a N-terminal CARD domain similar to that of RIG-I, 
a proline-rich region in the middle and a hydrophobic C-terminal transmembrane-
domain, which targets Cardif to the mitochondrial membrane [254]. Cardif has been 
identified by three other independent research groups and named variously as IFN- 
promoter stimulator-1 (IPS-1) [255], mitochondrial antiviral signalling (MAVS) [254] and 
virus-induced signalling adaptor (VISA) [256]. The N-terminal CARD of Cardif interacts 
with both RIG-I [255] [256] and MDA5 [255] CARD domains. 
Consistent with a role for RIG-I and MDA5 in transcription factor activation, several 
studies have used HEK293 cells and shown Cardif over-expression to induce NF-κB, 
IRF3 [228] [254] [255] [256], IRF7 [254] [255] and JNK [254] activation. The later finding 
of Cardif induced JNK activation indirectly implicates Cardif in activation of the JNK 
down-stream transcription factors c-Jun and ATF2. Consistent with the activation of 
these transcription factors by Cardif, over-expression of Cardif induces IFN-β promoter 
reporter activation [228] [254] [255] [256], endogenous IFN-β mRNA/protein expression 
[228] [254] [255], and pro-inflammatory cytokine (CXCL8, CXCL10, IL-6, CCL5) 
production [228] [254] [255].  
Further to the ability of Cardif, like RIG-I and MDA5, to induce activation of transcription 
factors and type I IFN production, several studies have shown Cardif to be required for 
RIG-I and MDA5 signalling, and thus to function down-stream of RIG-I and MDA5. 
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Cardif specific targeting siRNA has been demonstrated to inhibit RIG-I and/or MDA5 
induced IRF3 [256], NF-κB [256] and IFN-β promoter [228] [254] [255] [256] activation, 
in HEK293 cells, following expression of RIG-I or MDA5 CARD domains [255] [256], 
stimulation of cells with polyIC [228] [254] [255] or infection with SV [256]. A reduction in 
endogenous IFN-β mRNA production in HEK293 cells co-transfected with polyIC and 
Cardif siRNA has also been demonstrated [255]. Collectively, this data suggests that 
Cardif is an essential component of the RIG-I and MDA5 pathways and is required for 
RIG-I and MDA5-mediated type I IFN induction. Thus, the RIG-I mediated antiviral 
response to HCV is evaded by HCV synthesis of the viral protease NS3-4A, which 
targets, cleaves and inactivates Cardif to prevent IFN-β induction [228] [257].  
1.3.2.5.2 Importance of RIG-I, MDA5 and Cardif in Interferon and Pro-
inflammatory Cytokine Gene Expression 
A number of ex-vivo and in vitro studies have demonstrated a role for RIG-I and/or 
MDA5, in signalling to transcription factor activation, type I IFN and pro-inflammatory 
cytokine production in response to infection with a number of different RNA viruses [245] 
[246] [254] [253] [257] [258] [259]. RIG-I and MDA5 have been shown to be required for 
virus-induced IRF3 and IRF7 activation [245] [246] [254] [253] and hence IFN-β 
production [246] [254] [253] [257]. RIG-I and MDA5 have also been shown to activate 
NF-κB [245] [246], and to be required for virus-induced pro-inflammatory cytokine 
(CCL5, CXCL10 and IL-6) production by in vitro and/or ex-vivo studies using cells from 
RIG-I or MDA5 knockout mice [245] [259] [258]. The importance of RIG-I and MDA5 in 
the anti-viral innate immune response is further demonstrated by the observation that 
over-expression of RIG-I or MDA5 in vitro offers a protective effect to cells challenged 
with EMCV or VSV, by suppressing viral cytopathic affect/viral replication to below that 
seen in control cells [245] [246].  
Consistent with a requirement for Cardif in RIG-I and MDA5 signalling, in vitro, ex-vivo 
and in vivo studies have shown a requirement for Cardif in virus-triggered signalling to 
IRF3, IRF7 and NF-κB activation [254] [255] [256] [260] [261], type I IFN induction [228] 
[254] [256] [260] [261], and pro-inflammatory cytokine (CCL5, CXCL10 and IL-6) 
production [228] [254] [260]. The importance of Cardif in the anti-viral innate immune 
response has also been demonstrated in vivo, with Cardif deficient mice, challenged 
with EMCV or VSV reported to have higher viral titres and a reduced survival rate [260] 
[261], and in vitro, with Cardif over-expression offering a protective effect to cells 
challenged with VSV [254] [255]. 
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Little investigation of a role for RNA helicases and Cardif in type III IFN production has 
been performed. Constitutively active RIG-I and Cardif over-expression has been 
demonstrated to induce endogenous IFN-λ1 and IFN-λ2/3 [202], and activation of IFN-
λ1 and IFN-λ2/3 promoter reporter constructs in HEK293 cells [203]. NDV-induced IFN-
λ2/3 expression has also been reported to be absent in RIG-I deficient MEFs [202]. 
These findings suggest a role for RIG-I and Cardif in IFN-λ induction.  
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1.3.3 Downstream signalling pathways activated by TLR3 and 
RNA Helicases 
1.3.3.1 The IKK-α/β Kinase Complex 
In un-stimulated cells, NF-κB-dimers remain within the cytoplasm via interaction with a 
family of inhibitory proteins known as IκBs. IκBs mask the nuclear localisation signal 
(NLS) of NF-κB and prevent its nuclear translocation. During viral infection IκB is 
phosphorylated, poly-ubiquitinated and subsequently degraded by the ubiquitin-
proteasome pathway. The exposed NLS enables NF-κB to translocate to the nucleus 
where it binds specific sequences (κB sites) in the promoter region of various target 
genes e.g. PRDII in the IFN-β promoter, to modulate their transcription. The IκB kinase 
(IKK)-complex, containing the kinases IKK-α, IKK-β and the scaffolding protein NF-κB 
essential modulator (NEMO) (also known as IKKγ) phosphorylates IκB proteins. MEFs 
deficient in IKK-β show impaired NF-κB DNA-binding activity and type I IFN mRNA 
induction when treated with polyIC or infected with VSV [167]. The same impairment 
was not seen with IKK-α deficient MEFs [167] indicating that IKK-β is required for 
efficient activation of the IKK-complex by polyIC and virus. IKK-complex activation itself 
is believed to depend on its phosphorylation, with IKK inactivated by protein 
phosphatase 2A treatment [262] or mutation of specific phosphorylation sites within the 
activation loop of IKK-α and IKK-β, preventing phosphorylation and resultant kinase 
activation [263] [264]. Consistent with IKK-complex activation requiring phosphorylation, 
a number of mitrogen-activate protein kinase kinase kinase (MAPKKK) family members 
have been demonstrated to phosphorylate IKK, including MAPK/ERK kinase kinase 1 
(MEKK1) [265], MEKK2 [266], MEKK3 [266] and transforming growth factor-β-activated 
kinase 1 (TAK1) [267]. In addition to these upstream kinases, when over-expressed, 
IKK-α and IKK-β alone can auto-phosphorylate and auto-activate [268] [269]. Elevated, 
IKK-β protein (but not IKK-α), phosphorylated IκBα and nuclear NF-κB p65 have been 
detected in PBMCs from asthmatic subjects compared to non-asthmatics [165], 
supporting a role for the NF-κB pathway in asthma pathogenesis. 
1.3.3.2 The IKKε/ι TBK-1 Kinase Complex 
The IκB kinase ε (IKKε) / TANK-binding kinase-1 (TBK-1) complex consists of these two 
kinases and the scaffold protein TRAF family member-associated NF-κB activator 
(TANK) which interacts with IKKε and TBK-1 [270] [271]. Several studies have shown 
the activation of TBK-1 and IKKε to be responsible for IRF3 [153] [216] [272] and IRF7 
activation [153], measured by phosphorylation, nuclear translocation or DNA-binding. 
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TBK-1 or IKKε expression also induces IRF3/IRF7 (PRDI-III) dependent reporter 
activation, IRF-dependent (ISRE)-reporter activation [216] and IRF7-dependent IFN-α4 
promoter activation [153]. siRNA targeting TBK-1 or IKKε inhibit VSV-induced IRF3 
phosphorylation [153], polyIC-induced ISRE-reporter activation [216], SV-induced 
IRF3/IRF7 (PRDI-III) dependent reporter activation [216] and VSV-induced IRF7-
dependent IFN-α4 promoter reporter activation [153], confirming a role for TBK-1 and 
IKKε in IRF3 and IRF7 activation. The IFN-β promoter is also activated by TBK-1 or IKKε 
over-expression and this signal is inhibited by dominant negative IRF3 [216], indicating 
TBK-1 and IKKε to mediate IFN-β promoter activation through their activation of IRF3. 
The relative importance of TBK-1 and IKKε for IRF3 activation and IFN-β expression has 
been assessed using TBK-1 and IKKε deficient MEFs. MEFs deficient in TBK-1 have 
reduced polyIC-induced IFN-β induction, but IKKε deficient MEFs have no impairment of 
IFN-β induction, and cells deficient in both TBK-1 and IKKε have no IFN-β induction 
[273]. This suggests that TBK-1 and IKKε may activate IRF3 in a redundant fashion, with 
IKKε appearing to have less importance than TBK-1 in IFN-β induction. An alternative 
study showed a complete absence of SV or NDV-induced IFN-β transcription in TBK-1 
deficient MEFs [272], suggesting TBK-1 to be crucial and functional redundancy 
between TBK-1 and IKKε to be stimulus specific. A physical interaction between both 
TBK-1 and IKKε and IRF3 [216] [274] and IRF7 [274] has been demonstrated, 
suggesting that TBK-1 and IKKε phosphorylate IRF3 and IRF7 directly. HEK293 cells 
expressing IKK-α or IKK-β do not result in IRF3 activation [153] [216] suggesting that the 
IKK-α/β complex does not activate IRF3. 
1.3.3.3 JNK2  
Stress-activated protein kinase/c-Jun amino-terminal kinase (SAPK/JNK) is a subgroup 
of the MAPK family. The JNK family consists of JNK1 and JNK2 which are ubiquitously 
expressed and JNK3 whose expression is largely restricted to the brain. JNKs are dual 
phosphorylated and activated by the MAPKKs, MKK4 (SEK1) [275] [276] or MKK7 
(SEK2) [277] [278]. In turn a number of upstream MAPKKKs have been identified as 
MKK4 and MKK7 activators, including members of the MEKK group (MEKK1-4), the 
mixed-lineage protein kinase group (MLK1-3), the apoptosis signal regulating kinase 
(ASK) group (ASK1 and ASK2), and TAK1. 
ATF-2 [279] [280] and c-Jun [281] [282] can interact with and be phosphorylated by JNK 
MAPKs to induce their transcriptional activity. The binding of JNK to ATF-2 [280] and c-
Jun [281] occurs at sites distinct from the sites of ATF-2 and c-Jun phosphorylation and 
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is essential for their transcriptional activation [281] [280], as is JNK-mediated 
phosphorylation of ATF-2 at Thr69 and Thr71 [279] [280] and c-Jun at Ser63 and Ser73 
[281] [282]. Catalytically inactive JNK inhibits ATF-2 [279] and c-Jun [282] transcriptional 
activation as does mutation of ATF-2 Thr69 and Thr71 residues [279] [280] or c-Jun 
Ser63 and Ser73 residues [283] [284]. Of the JNK isoforms, JNK2 binds c-Jun [285] 
[282] and ATF-2 [285] with greatest affinity, and has been demonstrated to 
phosphorylate c-Jun more efficiently than JNK1 [282].  
1.3.3.4 PI3K 
A role for the Class 1A PI3K isoform PI3Kα has been identified in TLR3-mediated 
(polyIC-induced) signalling to IRF3 activation [286]. The cytoplasmic domain of TLR3 
contains five tyrosine residues, which are phosphorylated upon polyIC stimulation [287]. 
PI3Kα interacts with tyrosine phosphorylated TLR3, and requires phosphorylated 
tyrosine residue 759 for its binding [286]. Mutation of tyrosine 759 and prevention of 
PI3Kα recruitment to TLR3, or a dominant negative form of the PI3Kα down-stream 
kinase protein kinase B (PKB, also known as Akt), does not inhibit IRF3 
dimerization/nuclear translocation in polyIC stimulated cells, but IRF3 fails to associate 
with co-activator protein CBP and the ISG56 promoter, preventing gene transcription 
[286]. Sarkar et al [286] attributed these findings to incomplete IRF3 phosphorylation in 
the absence of TLR3-associated PI3Kα activity, at an alternative site to the known TBK-
1 mediated IRF3 phosphorylation site (Ser396) [148]. Therefore in addition to the TBK-1 
pathway, the PI3Kα-Akt pathway plays an essential role in polyIC stimulated, TLR3-
mediated IRF3 activation, and is required for full phosphorylation and activation of IRF3.  
A role for PI3K in TLR3-induced NF-κB activation has been investigated using the TLR3 
ligand polyIC or viruses that have been demonstrated to trigger TLR3-mediated 
signalling. These studies have largely used chemical inhibitors that target all class 1A 
and 1B PI3K isoforms (α, β, δ and λ), and have reported conflicting results, with PI3K 
chemical inhibition reported not to inhibit polyIC-induced NF-κB dependent gene 
transcription [288], and differentially, to increase NF-κB activation in polyIC stimulated 
DCs and HEK293 cells [289]. In contrast, PI3K chemical inhibition has been shown to 
inhibit RSV-induced and RV-induced NF-κB dependent reporter construct activation in 
A549 cells [290], and 16HBE cells [291] respectively. PI3K chemical inhibition in BEAS-
2B cells and 16HBE cells has also been shown to inhibit polyIC and influenza A induced 
CXCL8 and CCL5 production [212], and RV-induced CXCL8 production [291] 
respectively, with the transcription of CXCL8 dependent upon NF-κB, and that of CCL5 
partly dependent on NF-κB. Additional experiments using a dominant negative form of 
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the Class 1A PI3K regulatory subunit (p85), have specifically determined Class 1A PI3K 
isoforms (α, β, δ) to be required for RV-induced NF-κB activation and CXCL8 production 
[291]. Collectively, these findings suggest a role for PI3K in TLR3-induced NF-κB 
activation and that this role is cell type and/or stimulus dependent.  
A role for PI3K in RNA helicase signalling is less explored. One report has reported no 
role for Class 1A and 1B PI3K isoforms in RIG-I-mediated signalling, with SV-infected 
HEK293 cells showing no inhibition of ISG56 transcription, in the presence of a PI3K 
chemical inhibitor [286]. Another using JEV to trigger RIG-I signalling in A549 cells, 
showed chemical inhibition of PI3K not to affect IRF3 activation [292]. Together these 
findings suggest that Class 1A and IB PI3K members are not required for RIG-I 
signalling to IRF3 activation. In contrast, Class 1A and 1B PI3K members have been 
implicated in RIG-I mediated NF-κB activation, with JEV infected A549 cells reported to 
show reduced NF-κB activation upon PI3K chemical inhibition [292]. 
1.3.4 Important Adaptor Proteins that are required for TLR3 and 
RNA Helicase mediated signalling pathways 
1.3.4.1 Role of TRAF6 in NF-κB and ATF-2 activation 
Tumour necrosis factor receptor-associated factor 6 (TRAF6) is an ubiquitin E3 ligase 
and has been determined to interact with the RIG-I/MDA5 adaptor protein Cardif [256] 
[254] [293] and the TLR3 adaptor protein TRIF [221] [222]. The mechanism by which 
TRAF6 E3 ligase activity is turned on following its binding to Cardif or TRIF is unclear, 
and is believed to be triggered by TRAF6 oligomerisation [294]. Activated TRAF6 
functions with an E2 enzyme complex termed TRAF6-regulated IKK activator 1 
(TRIKA1), containing ubiquitin conjugating enzyme UBC13 and the UBC-like protein 
UEV1A [295] to generate lysine-63-linked poly-ubiquitin chains on target proteins 
including TRAF6. TRIKA2 is a trimeric complex that consists of the protein kinase TAK1 
and the two adaptor proteins TAB1 and TAB2 [296]. The MAPKKK TAK1 is recruited to 
poly-ubiquitinated TRAF6 via TAB2, which contains a highly conserved novel zinc-finger 
domain that preferentially binds to lysine-63-linked poly-ubiquitin chains [297]. TRAF6 
activates TAK1 kinase activity by an unknown mechanism, although Lysine-63-linked 
TRAF6 auto-ubiquitination has been shown to be required for TRAF6-mediated 
activation of TAK1 [298]. The IKK-α/β complex may be recruited to the TRAF6-TAK1 
complex by the ubiquitin binding ability of NEMO [299] [295], and in turn, activated TAK1 
phosphorylates IKK-α/β [296] leading to NF-κB activation. Activated TAK1 also 
phosphorylates MAPKKs [296], which in turn phosphorylate and activate the MAPKs, 
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JNK1/2 and p38 [296] [300], leading to phosphorylation and activation of members of 
the AP-1 family of transcription factors.  
A number of studies have shown a role for TRAF6 in TRIF-induced NF-κB activation, 
although the extent of this role is debated. Sato et al [221] show mutation in all three 
TRAF6-binding motifs of TRIF to abolish TRIF-TRAF6 association and impair TRIF over-
expression-induced NF-κB-dependent reporter activation in HEK293 cells, indicating a 
requirement for TRAF6 in TRIF-mediated NF-κB activation. They suggest that residual 
NF-κB activity is attributed to the known ability of the C-terminal region of TRIF to 
mediate NF-κB activity independently to TRAF6, by interacting with receptor interacting 
protein (RIP)-1 [301], which can mediate TRIF-induced NF-κB activation [301] [302]. In 
contrast, Jiang et al [222] report a single mutation in the TRAF6 binding site of TRIF to 
abolish TRIF-TRAF6 interaction and TRIF over-expression-induced NF-κB-dependent 
reporter activation, and suggest that TLR3-mediated activation of NF-κB is solely 
dependent on TRAF6. Although these differences cannot be explained and may be due 
to different experimental conditions, a clear role for TRAF6 in TRIF-induced NF-κB is 
evident. Dominant negative TRAF6 has been reported to impair TRIF-induced NF-κB 
activation in HEK293 cells [222] [223]. TRAF6 deficient MEFs fail to phosphorylate the 
NF-κB inhibitory protein IκBα, when stimulated with polyIC [302], further confirming the 
requirement for TRAF6 in TLR3-mediated NF-κB activation. The TRAF6 downstream 
kinase, TAK1 is activated upon polyIC stimulation of TLR3 expressing HEK293 cells, 
and dominant negative TAK1 blocks polyIC-induced NF-κB activation [303]. Expression 
of kinase inactive IKK-β also inhibits TRIF-induced NF-κB activation in HEK293 cells 
[223]. Collectively this evidence suggests that TLR3 induces NF-κB activation be means 
of a TRIF-TRAF6-TAK1-IKK-β pathway.  
Studies have also determined TRAF6 to function downstream of, and to be required for 
Cardif-mediated NF-κB activation. Mutation of the TRAF6 binding-sites in Cardif, 
reduced Cardif over-expression induced NF-κB-dependent reporter activation in 
HEK293 cells [256]. TRAF6 deficient MEFs also show decreased Cardif-mediated NF-
κB-dependent reporter activation [256]. Dominant negative mutants of TAK1 [256] and 
IKK-β [256] [255] also inhibit Cardif-induced NF-κB-dependent reporter activation in 
HEK293 cells, indicating that Cardif mediates NF-κB activation through a TRAF6-TAK1-
IKK-β dependent pathway. Although Seth et al [254] reported no impairment of NF-κB 
activation by Cardif containing a single TRAF6 binding site mutation (in the proline rich 
N-terminal), the remaining TRAF6 binding-site in the C-terminal of Cardif may account 
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for their observed NF-κB activation. Kawai et al [255] show Cardif-induced NF-κB 
activation in TRAF6 deficient MEFs, questioning a role for TRAF6 in Cardif signalling to 
NF-κB. However, this finding may be explained by Cardif interaction with RIP1 and 
FADD [255] [293], with RIP1 or FADD over-expression shown to induce the expression 
of NF-κB target genes, and dominant negative FADD demonstrated to block Cardif-
mediated NF-κB-dependent reporter activation [255]. Studies have also shown a role for 
TRAF6 [302] or the TRAF6 downstream signalling intermediates TAK1 [304] [300] and 
IKK-β [37] [167] in the induction of NF-κB regulated pro-inflammatory cytokines. 
1.3.4.2 Role of TRAF3 in IRF3/IRF7 activation 
TRAF3 is suggested to function in a similar manner to TRAF6. TRAF3 has a RING-
domain, thus like TRAF6, TRAF3 oligomerisation may induce RING finger ubiquitin E3 
ligase activity and result in TRAF3 self poly-ubiquitination. An interaction between the 
IKKε/TBK-1 kinase complex scaffold protein TANK and TRAF3 has been demonstrated 
[305], suggesting that TANK may recruit IKKε/TBK-1 to TRAF3, as NEMO may recruit 
IKK-α/β to TRAF6. In turn, IKKε and TBK-1 have been shown to phosphorylate and 
activate IRF3/IRF7, which are required for IFN-β/λ expression. A complex of TRAF3-
TANK-IKKε/TBK-1 may therefore form and mediate IRF3/IRF7 activation. This is 
supported by TRAF3 or TANK alone weakly activating the IFN-β promoter, but together 
enhancing activation [306]. TANK also enhances TBK-1 and IKKε-induced IFN-β 
promoter activation [306]. Although mechanistically unclear, a role for TRAF3-TANK-
IKKε/TBK-1 has been established in RIG-I/MDA5 and TLR3-mediated IRF3/IRF7 
activation and is discussed below.  
Although the TLR3 adaptor protein TRIF associates with TBK-1 and IKKε [216] this 
interaction may not be direct, as TRIF can interact with TRAF3 [307] [308], and TRAF3 
with TANK/IKKε/TBK-1, suggesting that TRAF3 serves to link TRIF with downstream 
IKKε/TBK-1 kinases required for IRF3/IRF7 activation. In HEK293 cells, TRAF3 
enhances TRIF-induced IFN-β promoter activation, and TBK-1 and IKKε-induced IFN-β 
promoter activation [308], supporting the requirement for a TRIF-TRAF3-
TANK/IKKε/TBK-1 pathway to IRF3/7 activation. Expressed together, TRIF, TRAF3 and 
TANK strongly activate the IFN-β promoter in HEK293 cells, with the removal of any of 
these intermediates reducing IFN-β promoter activation [306]. TLR3-induced (polyIC 
stimulated) TRAF3 deficient macrophages have impaired IRF3 activation and IFN-β 
mRNA induction [308], implicating TRAF3 in TLR3-mediated IRF3 activation and 
subsequent IFN-β expression. Further to the formation of a TRIF-TRAF3-
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TANK/IKKε/TBK-1 complex, knowledge of an association between TRIF and IRF3 [219] 
and IRF7 [223], suggests that a larger TRIF-TRAF3-TANK/TBK-1/IKKε-IRF3/7 multi-
component protein complex may form, indicating TRAF3 to complex directly with IRF 
transcription factors. This is supported by Guo et al [306], who show TANK to form a 
signalling complex containing both TBK-1 and IRF3, and that this TANK-TBK1-IRF3 
complex bound to TRIF, with its presence increasing over time following polyIC 
stimulation of macrophages.  
The RIG-I and MDA5 adaptor protein Cardif interacts with TRAF3 [309] and TANK [306], 
suggesting that a complex containing Cardif-TRAF3-TANK/IKKε/TBK-1 may form. This 
is supported by Guo et al [306] who detected the formation of an endogenous Cardif-
TRAF3-TANK/TBK-1 complex over time in SV infected MEFs. TRAF3 deficient MEFs 
have defective type I IFN mRNA/protein induction in response to SV or VSV infection 
[308] [309], indicating the requirement of TRAF3 in the RIG-I pathway. This is further 
supported by the inability of Cardif to induce type I IFN promoter activation in TRAF3 
deficient MEFs [309].  
A role for TRAF3 has not yet been investigated in IFN-λ expression, however over-
expression of the TRAF3 downstream kinases, TBK-1 and IKKε induces activation of 
IFN-λ1 and IFN-λ2/3 promoter reporter constructs in HEK293 cells [203], and NDV-
induced IFN-λ2/3 expression is absent in TBK-1 deficient MEFs [202], implicating TBK-
1/IKKε in IFN-λ induction. These findings suggest a possible role for TRAF3 in IFN-λ 
induction through its interaction with the TANK/IKKε/TBK-1 complex. However, recent 
evidence suggests that a scaffold protein other than TANK, named NAK associated 
protein 1 (NAP1), can bind to TBK-1/IKKε [310], and is required for TLR3 and RIG-I 
induced IRF3 activation [311] [312]. As no interaction between NAP1 and TRAF3 has 
yet been reported, it is possible that a TRAF3 independent mechanism to IRF3 
activation also exists. 
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1.3.5 Evidence that signalling intermediates required for 
Interferon gene expression are distinct from those required 
for pro-inflammatory cytokine gene expression 
An NF-κB binding site it located in the promoters of the pro-inflammatory genes CXCL8 
and IL-6, and NF-κB shown to be required for their induction by RV [82] [95]. In contrast, 
studies in gene deficient mice have shown IRF3 and IRF7 to be essential for virus 
induced IFN-β expression [151] [139]. IRF3 and IRF7 also bind to the promoters of IFN-
λ1 and IFN-λ2/3 upon virus infection [203]. Signalling intermediates that lead to NF-κB 
activation but not IRF activation, or alternatively lead to IRF activation and not NF-κB 
activation, can therefore be considered to be distinct in their roles, with respect to pro-
inflammatory cytokine or IFN induction. There are few currently identified signalling 
intermediates that have distinct roles with respect to NF-κB and IRF activation, but those 
that do include TRAF6 and TRAF3.  
Current experimental evidence implicating TRAF6 in TLR3 and RIG-I/MDA5 signalling to 
NF-κB activation has been described in section 1.3.4.1. In contrast, TRIF-induced IRF3 
activation, in HEK293 cells, is not inhibited by dominant negative TRAF6 [222] [223] or 
expression of TRIF containing a mutated TRAF6 binding-site [222] [221], suggesting no 
role for TRAF6 in TRIF-mediated IRF3 activation. TLR3-mediated IRF3 activation is also 
not impaired in TRAF6 deficient MEFs [222] or by the TRAF6 downstream kinase TAK1 
in HEK293 cells [222]. Cardif-induced ISRE (IRF) dependent reporter activation is also 
not inhibited in TRAF6 deficient MEFs [256] suggesting TRAF6 not to required for RIG-I 
or MDA5 signalling to IRF3/7. Consistent with these findings, IFN-β promoter activation 
is unimpaired by the expression of TRIF or Cardif containing a mutated TRAF6 binding-
site [221] [254], and Cardif-induced IFN-β promoter activation is unimpaired in TRAF6 
deficient MEFs [255].  
Current experimental evidence implicating TRAF3 in TLR3 and RIG-I/MDA5 signalling to 
IRF3/IRF7 activation has been described in section 1.3.4.2. In contrast, TRAF3 deficient 
macrophages stimulated with polyIC, show no defect in NF-κB activation [308], 
suggesting that TRAF3 does not have a role in TLR3-mediated NF-κB activation. Cardif-
induced NF-κB activation is also not inhibited in TRAF3 deficient MEFs or by mutant 
TRAF3 in HEK293 cells [309], indicating no role for TRAF3 in RIG-I or MDA5 signalling 
to NF-κB. Mouse gene knockout studies and the use of kinase inactive mutants have 
also suggested that the TRAF3 downstream signalling kinases TBK-1 and IKKε, which 
are required for IRF3/IRF7 activation [153], are not required for TLR3 or RIG-I/MDA5 
signalling to NF-κB activation [273] [223] [272] [255]. However, over-expression studies 
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have implicated TBK-1 and IKKε in NF-κB activation [313] [270], demonstrated TBK-1 to 
phosphorylate IKK-β [314] and alternatively suggested TBK-1 to phosphorylate NF-κB 
p65 directly [315]. These findings suggest that a role for TBK-1 and IKKε in NF-κB 
activation may be cell type and/or stimuli specific, and may only lead to IRF3/IRF7 
activation in others.  
Further to these findings of differential roles for TRAF6 and TRAF3, a recent study is the 
first to report on a factor, termed phosphatase-1 (SHP-1), which acts to inhibit pro-
inflammatory cytokine induction and increase type I IFN production during the antiviral 
response, mediated by both TLR3 and RIG-I signalling pathways [316]. SHP-1 over-
expression has been shown to enhance TRIF-induced IRF3 and IRF7 activation, and 
TRIF and RIG-I-induced IFN-β transcription [316]. In contrast, SHP-1 deficient cells 
derived from gene knockout mice, and stimulated with polyIC show enhanced pro-
inflammatory cytokine induction and impaired IFN-β induction [316].  
These findings support the possibility that differences in the signalling molecules 
required for RV-induced IFN, from those required for RV-induced pro-inflammatory 
cytokine/chemokine expression in HBEC may exist. If so, the modulation of which may 
enable the enhancement of IFN and/or inhibition of pro-inflammatory 
cytokine/chemokine expression in asthmatic BECs, and thus represent potential new 
therapeutic targets for RV-induced asthma exacerbations.   
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Figure 1.6 Signalling pathways implicated in IFN-β and Pro-inflammatory cytokine 
production.
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1.4 Rational, Aim and Outline of the Thesis 
1.4.1 Rationale 
The rational of this study is based upon the requirement for new therapeutic targets for 
virus-induced asthma exacerbations, the majority of which are attributed to RV infection. 
In order to identify potential new drug targets, an understanding of how asthmatics and 
normal individuals differ in their response to RV infection is required. Accumulating 
evidence suggests that asthmatics and normals respond differently to RV infection, with 
asthmatic bronchial epithelial cells (BEC) having an impaired ability to produce IFN-β 
and IFN-λ, decreased apoptosis and greater viral loads. A deficient innate immune 
response to RV infection, resulting in increased viral loads and consequent up-
regulation of pro-inflammatory cytokines/chemokines in asthmatic BEC, is believed to 
contribute to the exacerbation of asthma symptoms. An understanding of the molecular 
mechanism by which RV induces IFN and pro-inflammatory cytokines/chemokines and 
determination of whether these mechanisms can be separated, may identify potential 
new therapeutic targets which can be modulated to increase IFN production or decrease 
pro-inflammatory cytokine/chemokine production. Also, understanding the mechanisms 
of RV-induced IFN-β/IFN-λ will also aid in understanding why asthmatics are deficient in 
IFN-β/IFN-λ. 
1.4.2 Specific Hypotheses 
Specific hypotheses to be tested in this study are: 
1. The double stranded (ds) RNA pattern recognition receptors (RIG-I, MDA5, TLR3), 
their downstream signalling adaptor proteins (TRIF, Cardif, TANK, TRAF3, TRAF6), 
kinases (TBK-1/IKKε, IKK-β, JNK), and transcription factors (ATF/c-Jun, NF-κB, IRF-3/7) 
are required for RV induced type I IFN-β and type III IFN-λ expression in normal human 
bronchial epithelial cells (HBEC). 
2. Whilst having common signalling intermediates, the induction of type I IFN-β / type III 
IFN-λ and pro-inflammatory cytokines/chemokines, by RV, requires one or more distinct 
signalling molecules, and/or transcription factors, allowing inhibition of pro-inflammatory 
cytokine/chemokine production that will not affect type I IFN-β and type III IFN-λ 
expression, and enhancement of type I IFN-β and type III IFN-λ expression, that will not 
cause elevated pro-inflammatory cytokine/chemokine expression.  
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1.4.3 Aims 
 
1. To better understand the cellular signalling pathways involved in RV-induced type I 
IFN-β, type III IFN-λ, and pro-inflammatory cytokine/chemokine gene expression in 
normal bronchial epithelial cells. 
2. To identify the key signalling molecules and transcription factors which are required 
by RV for type I IFN-β, type III IFN-λ and pro-inflammatory cytokine/chemokine gene 
expression in bronchial epithelial cells. 
3. To identify differences in signalling pathways, that induce type I IFN-β and type III 
IFN-λs from those that induce pro-inflammatory cytokine/chemokines. 
1.4.4 Outline 
Chapter 1 of this thesis provides a review of the literature concerning asthma 
exacerbation causes and treatments, the clinical and cellular features of virus-induced 
asthma exacerbations and current knowledge of the signalling pathways leading to IFN 
and pro-inflammatory cytokine/chemokine production. Chapter 3 focuses on the role of 
the viral dsRNA pattern recognition receptors TLR3, RIG-I and MDA5 in RV-induced IFN 
and pro-inflammatory cytokine/chemokine expression in normal HBEC. Chapter 4 
identifies RIG-I and MDA5 as ISGs and provides evidence that they may work in concert 
with TLR3. Chapter 5 identifies signalling intermediates important for RV-induced IFN 
and pro-inflammatory cytokine/chemokine expression in normal HBEC. Chapter 5 also 
provides evidence that some signalling intermediates required for IFN induction are 
distinct from pro-inflammatory cytokine/chemokine induction, and thus represent 
potential new therapeutic targets. Finally Chapter 6 investigates RV-induced 
transcriptional regulation of IFN-β, and provides evidence that RV-induced IFN-β and 
IFN-λ expression require a common transcription factor. This transcription factor should 
therefore be carefully studied in asthmatic tissues. Chapter 6 also identifies a 
transcription factor that is not required for RV-induced IFN but is required for RV-
induced pro-inflammatory cytokine/chemokine expression, and thus identifies another 
potential new therapeutic target for virus-induced asthma exacerbations. Finally the 
results and future directions are discussed in context of our current understanding of 
virus-induced asthma exacerbations. 
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2.1 Materials 
2.1.1 Buffers and reagents 
Table 2.1 Buffers and reagents used in this study in alphabetical order. 
Reagent Composition Application Supplier 
Agarose 
 
Agarose molecular grade powder Agarose gel 
electrophoresis 
Sigma Aldrich, 
Poole, UK 
Agarose gel loading 
dye (10X) 
1.5g ficoll, 0.02g bromophenol blue,  
0.02g xylene cyanole FF, in 10mL 
distilled H2O 
Agarose gel 
electrophoresis 
All chemicals 
from Sigma 
Aldrich 
Ampicillin 
(100mg/mL) 
Provided in 70% (v/v) ethanol 
 
E.coli culture Sigma Aldrich 
β-mercaptoethanol 
(β-Me) 
14.3M C2H605  RNA isolation Sigma Aldrich 
Bovine serum 
albumin powder 
(BSA) 
1% BSA in 0.15M NaCl pH 7.0 ELISA Sigma Aldrich 
DNA ladders: 123bp 
and 1Kb 
(1 µg/µL) 
Provided in 10mM Tris-HCl (pH 7.5), 
50mM NaCl and 0.1mM EDTA (123bp) 
/ 1mM EDTA (1Kb) 
Agarose gel 
electrophoresis 
Invitrogen,  
Paisley, UK 
Dulbecco’s-PBS 
(1X) (D-PBS) 
Phosphate buffered saline: 0.0014M 
KH2PO4, 0.008M Na2HP04-7H20, 
0.0026M KCl, 0.137M NaCl  
HeLa culture Invitrogen 
ELISA diluent buffer 0.2% (w/v) BSA in ELISA wash buffer ELISA Sigma Aldrich 
ELISA blocking 
solution 
1% (w/v) BSA in ELISA wash buffer  ELISA Sigma Aldrich 
ELISA wash buffer PBS, 0.05% tween20 ELISA Sigma Aldrich 
Invitrogen 
ELISA stop solution 2M H2SO4 ELISA Sigma Aldrich 
Lipofectamine 2000 
(LP2000) 
No information given by supplier Transfection Invitrogen 
LY-294002 Re-suspended in DMSO, stock 10mM PI3K inhibitor Sigma Aldrich 
Non-specific dsDNA 
oligonucleotide 
25bp oligonucleotide corresponding to 
the CCAAT enhancer binding protein 
(c/EBP) site within the human CXCL8 
promoter 
Transfection Invitrogen 
NuPAGE  
anti-oxidant 
No information given by supplier Western blot  Invitrogen 
PBS (per tablet) 0.01M phosphate buffer, 0.0027M KCl, 
0.137M NaCl, in 200mL distilled H2O 
(pH 7.4) 
Western blot 
ELISA  
Sigma Aldrich 
Quantitect probe 
PCR master mix 
HotStarTaq DNA polymerase, 
quantitect probe PCR buffer (Tris-HCl, 
KCl, (NH4)2SO4, 8mM MgCl2 pH 8.7) 
dNTP mix, ROX (passive reference 
dye) 
TaqMan RT 
PCR 
Qiagen, 
Crawley, UK 
Random primers Random hexadeoxynucleotides 
(0.5µg/mL) 
cDNA 
synthesis 
Promega, 
Madison, WI 
USA  
SeeBlue Plus2  
pre-stained standard 
Containing: Tris-HCl, formamide, 
sodium dodecyl sulphate, phenol red 
No quantities specified by 
manufacturer 
Agarose gel 
electrophoresis 
Invitrogen 
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Reagent Composition Application Supplier 
siRNA buffer (5X) Containing: 100mM KCl, 30mM 
HEPES (pH 7.5), 1mM MgCl2 
siRNA re-
suspension 
Dharmacon, 
Chicago, IL, 
USA 
Strepavidin-HRP 
(Horse Radish 
Peroxidise) 
Provided in phosphate buffered saline 
solution (pH 7.2) containing 0.01% 
Thimerosal and 40% glycerol 
ELISA Biosource Int., 
Camarillo, CA, 
USA 
T4 DNA ligase 100 units T4 DNA ligase in storge 
buffer: 10mM Tris-HCl (pH 7.4 at 
25°C), 50mM KCl, 1mM DTT, 0.1mM 
EDTA and 50% glycerol.  
Ligation Promega 
T4 DNA ligase (10X) 
reaction buffer 
300mM Tris-HCl, 100mM MgCl2, 
100mM DTT, 10mM ATP 
Ligation Promega 
TE buffer (1X), 
Molecular grade 
10mM Tris-HCl containing 1mM 
EDTA.Na2 
Plasmid, 
primer/probe  
re-suspension  
Promega 
3, 3’, 5, 5-
tetramethylbenzidine 
(TMB) 
1x TMB single solution 
No detailed components given by 
manufacturer 
ELISA Invitrogen 
Tris-acetate-EDTA 
buffer (TAE) (50X) 
2M tris-acetate solution containing 
50mM EDTA 
Agarose gel 
electrophoresis  
Invitrogen 
Tris-glycine SDS 
sample buffer (2X) 
0.5M Tris-HCl (pH 6.8), glycerol, 10% 
(w/v) SDS, 0.1% bromophenol blue in 
distilled water 
Western blot  Invitrogen 
Trypan blue 
 
0.4% trypan blue in 0.85% saline 
solution 
Cell viability  Invitrogen 
Tween20 
(polyoxyethylene-
sorbitan monlaurate) 
20 ethylene oxide units, 1 sorbitol unit, 
1 lauric acid unit 
Western blot 
ELISA 
Sigma Aldrich 
Western blot  
blocking solution 
10g w/v milk proteins in western blot 
washing solution 
Western blot Sigma Aldrich 
Western blot running 
buffer 
50mL NuPAGE MOPS SDS running 
buffer (20X) in 1L distilled water  
or 100mL Novex Tris-Gylcine SDS 
running buffer (10X) in 1L distilled 
water 
Western blot Invitrogen 
Western blot 
stripping buffer 
2% sodium dodecyl sulphate (SDS), 
62.5 mM Tris-HCL (pH 6.7), 100mM 2-
mercaptoethanol 
Western blot All chemicals 
from Sigma 
Aldrich 
Western blot 
transfer buffer 
For 1 gel: 50mL NuPAGE transfer 
buffer (20X) or *40mL Novex Tris-
Glycine transfer buffer (25X), 100mL 
methanol (10% v/v), 850mL or *860mL 
water, 1mL NuPAGE anti-oxidant. For 
2 gels 20% v/v 
Western blot Invitrogen 
Western blot  
washing solution 
0.1% tween-20 in PBS Western blot Sigma Aldrich 
Wortmannin Re-suspended in DMSO, stock 10mM PI3K inhibitor Sigma Aldrich 
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2.1.2 Commercially available kits 
  Table 2.2 Commercially available kits used in this study listed in alphabetical order. 
Name Components Application Supplier 
β-Galactosidase 
enzyme assay 
system 
5X reporter lysis buffer, assay 2X buffer, 
100U β-Galactosidase, 1M sodium 
carbonate 
β-Galactosidase 
protein 
measurement  
Promega 
ECL Advance 
western blotting 
detection kit 
Solution A: 50mL ECL advance solution 
containing tris buffer in 3.2% (v/v) ethanol. 
Solution B: 50mL proprietary substrate in 
tris buffer 
Western blotting GE 
Healthcare, 
Buckingham
-shire, UK  
ECL Plus western 
blotting detection 
kit 
Solution A: 100mL ECL plus substrate 
containing tris buffer  
Solution B: 2.5mL Acridan solution in 
Dioxane and Ethanol 
Western blotting GE 
Healthcare 
Human IFN-β 
ELISA Kit 
Antibody coated 96-well plate, enzyme 
labelled antibody, human IFN-β standard, 
washing solution 
dilution buffer, developer solution, 
reaction stop solution  
ELISA BioSource 
Luciferase assay 
system 
5X cell culture lysis reagent, 
luciferase assay buffer, lyophilized 
luciferase assay substrate 
Luciferase 
protein 
measurement 
Promega 
Maxiprep Kit Buffer P1, Buffer P2, Buffer P3 
Buffer QBT, Buffer QC 
Buffer QF, Qiagen-tip 500 
Large (and 
small scale) 
plasmid isolation 
Qiagen 
Ominscript RT 
(Reverse 
Transcription) Kit 
dATP, dCTP, dGTP, dTTP   
(10 mM each) in water, 
10X Buffer RT, Omniscript reverse 
transcriptase, RNase-free water 
cDNA synthesis Promega 
QIAquick Gel 
Extraction Kit 
Buffer QG, buffer PE, buffer EB, QIAquick 
spin columns, collection tubes 
PCR production 
gel extraction 
Qiagen 
QuickChange II 
site-directed 
mutagenesis kit 
10X reaction buffer, PfuUltra DNA 
polymerase, Dpn Ι restriction enzyme, 
control plasmid, control primers, 
quicksolution reagent, dNTP mix, XL10-
Gold cells 
Site-directed 
mutatgenesis 
Stratagene, 
La Jolla, CA, 
USA 
RNAase-free 
DNase set 
1500 units RNase-free DNase I, RNase-
free buffer RDD 
Total RNA 
isolation 
Qiagen 
RNeasy Mini Kit Buffer RLT, Buffer RW1 
Buffer RPE, RNase-free water 
RNeasy mini spin columns 
Collection tubes 
Total RNA 
isolation 
Qiagen 
TOPO TA cloning 
kit (with pCR 2.1- 
TOPO vector) 
Components of this kit used in this study 
include: pCR 2.1-TOPO (10ng/µL) in 50% 
glycerol, 50mM Tris-HCl (pH 7.4), 1mM 
EDTA, 1mM DTT, 0.1% trition X-100, 
100µg/mL BSA, phenol red; salt solution 
(1.2M NaCl, 0.06M MgCl2) 
Cloning TaqMan 
RT-PCR 
products  
Invitrogen 
  Refer to manufacturers’ component formulations for detailed component composition. 
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2.1.3 Media and media supplements 
Table 2.3 Media and media supplements used in this project listed in alphabetical order. 
Name Composition Application Supplier 
BEGM complete 
medium 
BEBM with BEGM single quot additives 
 
HBEC culture Lonza, 
Cleveland, 
USA 
BEGM single quot 
additives 
13g/L bovine pituitary extract, 5g/L insulin, 
50g/L gentamicin, 0.1mg/L retinoic acid, 
10g/L transferrin, 6.5mg/L triiodothyronine, 
0.5g/L hydrocortisone & epinephrine, 
0.5mg/L human epidermal growth factor 
HBEC culture Lonza 
Bronchial epithelium 
basal medium  
(BEBM) 
Refer to manufacturers’ media formulation 
 
HBEC culture Lonza 
Dulbeccos modified 
eagles medium 
(D-MEM) 
Refer to manufacturers’ media formulation HeLa culture Invitrogen 
Foetal bovine serum 
(FBS) 
Heat inactivated foetal bovine serum HeLa culture Invitrogen 
BEGM serum free 
medium 
BEGM complete medium, without 2mL 
bovine pituitary extract 
HBEC Lonza 
HeLa cell infection 
media  
20mL (4%) FCS, 10mL (2%) Hepes 
buffer, 5mL (1%) sodium bicarbonate in 
500mL D-MEM 
HeLa cell 
infection 
Invitrogen 
HEPES buffered 
saline solution  
30mM HEPES HBEC  
sub-culture 
Lonza 
HEPES buffered 
solution 
238.3g (1M) HEPES in 1L distilled water,  
pH 7.2-7.5 
HeLa culture Invitrogen 
LB agar 14g of agarose, in 1L LB media  E.coli culture Sigma- 
Aldrich 
Luria-Bertani media 
(LB) 
10g tryptone, 5g yeast extract, 5g NaCl, in 
1L distilled water, adjusted to pH 7.0  
E.coli culture Sigma- 
Aldrich  
NZY+ broth 10g NZ amine, 5g of yeast extract, 5g 
NaCl, in IL distilled water, adjusted to  
pH 7.5  
E.coli culture Sigma- 
Aldrich 
Optimem-1 medium Refer to manufacturers’ media formulation Transfection  Invitrogen 
Powdered blasticidin 
LB agar 
LB based agar medium supplemented 
with blasticidin 
No quantities given by supplier 
E.coli culture  InvivoGen, 
San Diego, 
CA, USA 
Powdered Terrific 
Broth (TB) medium  
TB based medium (tryptone, yeast extract, 
K2HPO4, KH2PO4, glycerol) supplemented 
with blasticidin 
No quantities given by supplier 
E.coli culture  InvivoGen 
Sodium bicarbonate  7.5% sodium bicarbonate solution HeLa culture Invitrogen 
Trypsin-EDTA (1X) 0.025% trypsin, 0.01% EDTA HBEC  
sub-culture 
Lonza 
Trypsin-EDTA (10X) 0.5% trypsin, 5.3mM EDTA HeLa  
sub-culture 
Invitrogen 
Trypsin neutralising 
solution (TNS) 
No information given by supplier HBEC  
sub-culture 
Lonza 
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2.1.4 Cells 
The human cervix carcinoma cell line HeLa was obtained from the European Collection 
of Cell Cultures (ECACC), and primary Human Bronchial Epithelial Cells (HBEC) 
obtained from Lonza (Cleveland, USA). Four different sources of HBECs were used 
throughout this study with each obtained from non-asthmatic, non-smoking, non-
alcoholic subjects. A summary of the individual characteristics of each HBEC source is 
shown in Table 2.4. HeLa and HBECs were provided in frozen cryo-vials and stored in 
liquid nitrogen until resuscitated in pre-warmed D-MEM and BEGM complete medium 
respectively (Table 2.3). Cells were grown in T75 tissue culture flasks (Nunc) in a 
humidified 37°C incubator with 5% CO2 (Table 2.11). Once resuscitated, HBECs were 
given the passage number 1 and were typically cultured and used in experiments until 
passage 4, beyond which point cell growth rate and transfection efficiency was reduced 
and cells were no longer used. 
 
Table 2.4 HBECs and their sources used in this project. 
 HBEC source number 
 4F0174 4F0872 4F1604 6F4181 
Age 18 Y 34 Y 27 Y 19 Y 
Sex F M M M 
Race C AA AA C 
Smoking N N N N 
Alcohol N N N Y 
Cell passage 1 1 1 1 
Viability-blue 
exclusion (%) 
79 89 83 96 
Cell count 
(cells/mL) 
675,000 650,000 955,000 607,500 
Doubling time (h) 38 20 21 26 
Population 
doubling 
19 15 15 15 
 
       Y=Years; M=Male; AA=African American; C=Caucasian; N=Non 
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2.1.5 Short interfering RNA (siRNA) 
All gene targeting siRNA were purchased from Dharmacon (Chicago, IL, USA), and are 
listed in Table 2.6. The non-targeting negative control siRNA (siCONTROL Non-
targeting #2), siGLO RISC-free siRNA (DY-547 labelled), RIG-I and Cardif siRNA were 
purchased as single siRNA duplexes. All other siRNA were purchased in the form of a 
SMARTpool consisting of a pool of four individual siRNA duplexes. All siRNA were 
provided in a dry pellet form and re-suspended at a concentration of 20µM, using 1X 
siRNA buffer (Table 2.1), in a sterile class II tissue culture hood (Table 2.11), aliquoted 
and stored at -20°C, in sterile 0.2mL PCR tubes (BioQuote Ltd., York, UK). siRNA were 
used at a final concentration of 100nM as recommended by Dharmacon.  
 
           Table 2.5 siRNA used in this project in alphabetical order. 
Name Accession number 
Activating transcription factor 2 (ATF-2) NM_001880 
CARD adaptor inducing IFN-β (Cardif) (duplex #1) NM_020746 
c-Jun N-terminal Kinase 2 (JNK2) NM_002752 
IκB kinase-ε (IKKε) XM_375834 
IκB kinase-β (IKK-β) NM_001556 
Interferon regulatory factor 7 (IRF7) NM_001572 
Interferon regulatory factor 1 (IRF1) NM_002198 
Interferon regulatory factor 3 (IRF3) NM_001571 
Jun oncogene (c-Jun) NM_002228 
Melanoma differentiation associated protein-5 (MDA5) NM_022168 
Nuclear factor-kappaB p65 sub-unit (NF-κB p65) NM_021975 
Phosphoinositide 3-kinease p110 sub-unit alpha (PI3Kα) NM_006218 
Retinoic acid inducible gene-I (RIG-I) (duplex #2) NM_014314 
siCONTROL Non-targeting #2 N/A 
siGLO RISC-Free N/A 
TANK Binding Kinase-1 (TBK-1) NM_013254 
TIR domain containing adaptor inducing IFN-β (TRIF) NM_182919 
TNF receptor associated factor 3 (TRAF3) NM_003300 
TNF receptor associated factor 3 (TRAF6) NM_004620 
Toll-like receptor 3 (TLR3) NM_003265 
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2.1.6 Antibodies  
2.1.6.1 Antibodies for Western Blotting 
Table 2.6 Antibodies used in western blotting and their working concentrations used in 
this project.  
Antibody Isotype Working 
concentration 
Supplier 
Anti-ATF-2 Rabbit IgG 200ng/mL Santa Cruz Biotechnology, 
Santa Cruz, CA, USA 
Anti-IRF3 Goat IgG 200ng/mL Santa Cruz 
Anti-MAVS  Rabbit IgG 1µg/mL Abcam, Cambridge, UK  
Anti-TRAF6 Mouse IgG1 200ng/mL Santa Cruz  
Anti-JNK2  Mouse IgG1 200ng/mL Santa Cruz  
Anti-TRAF3 Mouse IgG1 200ng/mL Santa Cruz  
Anti-RIG-I Mouse 1µg/mL T. Fujita, Tokyo Metropolitan 
Institute of Medical Science, 
Japan 
Anti-RIG-I Rabbit IgG 1µg/mL ProSci, Poway, CA, USA 
Anti-MDA5 Goat IgG 1µg/mL Santa Cruz 
Anti-β-Actin  Rabbit IgG 1µg/mL BioVision Inc., Mountain 
View, CA, USA 
Anti-TBK1 Goat IgG 200ng/mL Santa Cruz  
Anti-IKKε Goat IgG 200ng/mL Santa Cruz  
Anti-IKK-β Mouse IgG2a 400ng/mL Santa Cruz  
Anti-PI 3-kinase 
p110α 
Mouse IgG2a 400ng/mL Santa Cruz  
Anti-c-Jun  Rabbit IgG 200ng/mL Santa Cruz  
Anti-NF-κB p65 Rabbit IgG 200ng/mL Santa Cruz  
Anti-IRF1 Mouse IgG2a kappa 3µg/mL Stratech Scientific Ltd., 
Suffolk, UK 
Anti-TRIF Rabbit IgG 4µg/mL ProSci 
Anti-IRF7 Goat IgG 400ng/mL Santa Cruz 
Anti-α tubulin Mouse IgM 200ng/mL Santa Cruz 
Anti-TLR3 Mouse IgG1 2µg/mL Cambridge Bioscience, 
Cambridge, UK 
Anti-rabbit  Sheep IgG-HRP 200ng/mL AbD Serotec, Kidlington, UK 
Anti-goat Swine Ig’s-HRP 140ng/mL Biosource, Paisley, UK 
Anti-mouse Goat IgG-HRP 80ng/mL Santa Cruz 
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2.1.6.2 Antibodies for ELISA 
All antibodies for ELISA were purchased from R&D Systems (Abingdon, UK) in a 
lyophilized form and re-suspended, as per manufacturers’ recommendations; in D-PBS 
(Table 2.1) for monoclonal capture antibodies and 0.1% BSA in D-PBS (Table 2.1) for 
polyclonal detection antibodies. 
 
Table 2.7 Antibodies used in ELISA and their working concentrations used in this project. 
Antibody Isotype / Clone Working 
Concentration 
Capture antibody, anti-human IL-6 Mouse IgG1 / 6708 4µg/mL 
Detection antibody, anti-human IL-6 Biotinylated goat IgG 25ng/mL 
Capture antibody, anti-human IL-8 Mouse IgG1 / 6217 4µg/mL 
Detection antibody, anti-human IL-8 Biotinylated goat IgG 25ng/mL 
Capture antibody, anti-human CXCL5 Mouse IgG1 / 33170 4µg/mL 
Detection antibody, anti-human CXCL5 Biotinylated goat IgG 25ng/mL 
Capture antibody, anti-human CCL5 Mouse IgG1 / 21418 4µg/mL 
Detection antibody, anti-human CCL5 Biotinylated goat IgG 25ng/mL 
Capture antibody, anti-human IP10 Mouse IgG1 / clone 33036 4µg/mL 
Detection antibody, anti-human IP10 Biotinylated goat IgG 25ng/mL 
Capture antibody, anti-human IFN-λ1 Mouse IgG2A / clone 247801 1µg/mL 
Secondary antibody, anti-human IFN-λ1 Goat IgG 1µg/mL 
Detection antibody, anti-goat IgG Biotinylated donkey IgG 0.05µg/mL 
 
2.1.7 DNA oligonucleotides 
2.1.7.1 Primers and probes for Realtime RT-PCR 
All Realtime RT-PCR primers were purchased from Invitrogen (Paisley, UK) in a 
desalted, dry pellet form, and all probes purchased from Qiagen (Crawley, UK) in a 
HPLC purified, dry pellet form. All handing of primers and probes was preformed in a 
designated nuclease-free, TaqMan RT-PCR flow hood (Table 2.11). Primers and probes 
were re-suspended using sterile TE buffer (Table 2.1) at a stock concentration of 100µM 
and stored at -20°C. Primer and probe working stocks were prepared by diluting to 5µM 
in nuclease-free water (Promega, Madison, WI, USA) and stored at -20°C. Forward and 
reverse primer and probe sequences, and their optimised concentration (nM) for use in 
Realtime RT-PCR are shown in Table 2.8.  
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Table 2.8 TaqMan Realtime RT-PCR primers and probes and their optimal concentrations 
used in this project. 
Name Sequence (5’-3’) 
ATF-2 forward (900nM) GGAATCTCGACCGCAGTCA 
ATF-2 reverse (900nM) GCTGGAGAAGCCGGAGTTT 
ATF-2 probe TACAACAGCCAGCCACATCCACTACA 
Cardif forward (900nM) CATCAGGAGAAGGACACAGAACTG 
Cardif reverse (900nM) CCCACGGGATGGTGTGA 
Cardif probe AGTACCCACACAGCAGGTGCGACCTC 
CCL5 (RANTES) forward (900nM) GCATCTGCCTCCCCATATTC 
CCL5 (RANTES) reverse (900nM) CAGTGGGCGGGCAATG 
CCL5 (RANTES) probe TCGGACACCACACCCTGCTGCT 
c-Jun forward (300nM) GGATCAAGGCGGAGAGGAA 
c-Jun reverse (900nM) TTCCTTTTTCGGCACTTGGA 
c-Jun probe CGCATGAGGAACCGCATCGCT 
CXCL8 (IL-8) forward (900nM) CTGGCCGTGGCTCTCTTG 
CXCL8 (IL-8) reverse (900nM) CCTTGGCAAAACTGCACCTT 
CXCL8 (IL-8) probe CAGCCTTCCTGATTTCTGCAGCTCTGTGT 
CXCL10 (IP10) forward (900nM) CGATTCTGATTTGCTGCCTTATC 
CXCL10 (IP10) reverse (900nM) GCAGGTACAGCGTACGGTTCT 
CXCL10 (IP10) probe CTGACTCTAAGTGGCATTCAAGGAGTACCTCTCTC 
CXCL5 (ENA-78) forward (900nM) AGAGCTGCGTTGCGTTTGT 
CXCL5 (ENA-78) reverse (900nM) TGGCGAACACTTGCAGATTACT 
CXCL5 (ENA-78) probe ACAGACCACGCAAGGAGTTCATCCCA 
IL-6 forward (300nM) CCAGGAGCCCAGCTATGAAC 
IL-6 reverse (900nM) CCCAGGGAGAAGGCAACTG 
IL-6 probe CCTTCTCCACAAGCGCCTTCGGT 
IFN-β forward (300nM) CGCCGCATTGACCATCTA 
IFN-β reverse (900nM) TTAGCCAGGAGGTTCTCAACAATAGTCTCA 
IFN-β probe TCAGACAAGATTCATCTAGCACTGGCTGGA 
IFN-λ1 forward (300nM) GGACGCCTTGGAAGAGTCACT 
IFN-λ1 reverse (900nM) AGAAGCCTCAGGTCCCAATTC 
IFN-λ1 probe AGTTGCAGCTCTCCTGTCTTCCCCG 
IFN-λ2/3 forward (300nM) CTGCCACATAGCCCAGTTCA 
IFN-λ2/3 reverse (900nM) AGAAGCGACTCTTCTAAGGCATCTT 
IFN-λ2/3 probe TCTCCACAGGAGCTGCAGGCCTTTA 
IKK-β forward (900nM) CCTGCTGGCCATGGAGTACT 
IKK-β reverse (900nM) CGCAGACCACAGCAGTTCTC 
IKK-β probe AACTGGTTCAGGTACTTCCGGAGATCT 
IKKε forward (900nM) TGCCCTTCATCCCCTTTG 
IKKε reverse (900nM) TTCTCTGTGGTGATCCGGTACA 
IKKε probe TGGGCCACGGCGGAACAAG 
IRF1 forward (900nM) CTCCAGCACTGTCGCCATG 
IRF1 reverse (900nM) GCACAACTTCCACTGGGATGT 
IRF1 probe TGTCAGCAGCACTCTCCCCGACTG 
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Name Sequence (5’-3’) 
IRF3 forward (900nM) GCTCGTGATGGTCAAGGTTGT 
IRF3 reverse (900nM) CCTACCCGGGCCATTTCT 
IRF3 probe CCAAGGCCCTGAGGCACGTGG 
IRF7 forward (900nM) TCCCCACGCTATACCATCTACCT 
IRF7 reverse (900nM) ACAGCCAGGGTTCCAGCTT 
IRF7 probe CTTCGGGCAGGACCTGTCAGCTG 
JNK2 forward (300nM) GATATCTGGTCAGTGGGTTGCA 
JNK2 reverse (300nM) TGGTCAGTGCCTTGGAATATCA 
JNK2 probe ACAACCTTTCACCAGCTCTCCCAT 
MDA5 forward (900nM) GATTCAGGCACCATGGGAAGT 
MDA5 reverse (900nM) AGGCCTGAGCTGGAGTTCTG 
MDA5 probe GGGATGCTCTTGCTGCCACATTCTCTT 
NF-κB p65 forward (900nM) CGAACTGTTCCCCCTCATCTT 
NF-κB p65 reverse (900nM) CTTGGGCTGCTCAATGATCTC 
NF-κB p65 probe CCGGCAGAGCCAGCCCAGG 
PI3K forward (900nM) TCAGGCTTGAAGAGTGTCGAATT 
PI3K reverse (900nM) TAACTCTGACATGATGTCTGGGTTCT 
PI3K probe ATTCAACCACAGTGGCCTTTTTGCAGA 
RIG-I forward (900nM) CCAAGCCAAAGCAGTTTTCAAG 
RIG-I reverse (900nM) CACATGGATTCCCCAGTCATG 
RIG-I probe TTGAAAAAAGAGCAAAGATATTCTGTGCCCGAC 
Rhinovirus forward (900nM) GTGAAGAGCCSCRTGTGCT 
Rhinovirus reverse (900nM) GCTSCAGGGTTAAGGTTAGCC 
Rhinovirus probe TGAGTCCTCCGGCCCCTGAATG 
TBK-1 forward (900nM) GAAGCGGCAGAGTTAGGTGAA 
TBK-1 reverse (900nM) CTATTGTTCCCTGAGAACTGGAAAG 
TBK-1 probe TTTCAGACATACACACCAAATTGTTGAG 
TLR3 forward (900nM) AAATTAAAGAGTTTTCTCCAGGGTGTT 
TLR3 reverse (300nM) ATTCCGAATGCTTGTGTTTGC 
TLR3 probe TTTGGCCTCTTTCTGAACAATGTCCAGC 
TRAF3 forward (300nM) GCACTTGTCGCTGTTTTTTGTC 
TRAF3 reverse (300nM) CTGCTTAAACGGCCAAGGAA 
TRAF3 probe TCATGCGTGGAGAATATGATGCCCTG 
TRAF6 forward (900nM) GTCCAAATGAAGGTTGTTTGCA 
TRAF6 reverse (900nM) GAGCAAACTCACAATGTGCTTGA 
TRAF6 probe AAGATGGAACTGAGACATCTTGAGGATC 
TRIF forward (300nM) TGCACAGGCCCATCACTTC 
TRIF reverse (300nM) AGTTTGTGCTTCAGATACAAGAGCTT 
TRIF probe TAGCGCCTTCGACATTCTAGGTGCAGC 
18S forward (300nM) CGCCGCTAGAGGTGAAATTCT 
18S reverse (300nM) CATTCTTGGCAAATGCTTTCG 
18S probe ACCGGCGCAAGACGGACCAGA 
 
 
                                                                                                        Chapter 2: Materials & Methods 
 76 
 
2.1.7.2 Primers for Site Directed Mutagenesis 
PRD mutant primers required for site directed mutagenesis of the wild-type IFN-β 
promoter reporter construct, to create four new IFN-β promoter reporter constructs, each 
containing a different mutated enhancer element (PRDI, PRDII, PRDIII, PRDIV) were 
synthesised by Invitrogen and provided in a HPLC purified, dry pellet form. Primers were 
re-suspended using nuclease-free water at a stock concentration of 1µg/µL and stored 
at -20°C. 
 
Table 2.9 Forward and reverse primers encoding mutations (underlined) of each PRD 
region for use in site directed mutagenesis. 
Name Sequence (5’-3’) 
PRDI Forward AAACTGAAAGGGGGGAGTGAGGGTGGGAAATTCCTCTG 
PRDI Reverse CAGAGGAATTTCCCACCCTCACTCCCCCCTTTCAGTTT 
PRDII Forward GGGAGAAGTGAAAGTTTTAAATTCCTCTGAATAGAGAGAGGACC 
PRDII Reverse GGTCCTCTCTCTATTCAGAGGAATTTAAAACTTTCACTTCTCCC 
PRDIII Forward GTAAATGACATAGGAGGGCTGAGGGGGAGAAGTGAAAGTGGG 
PRDIII Reverse CCCACTTTAACTTCTCCCCCTCAGCCCTCCTATGTCATTTAC 
PRDIV Forward CTACTAAAATGTAAAGGCCATAGGAAAACTGAAAGGG 
PRDIV Reverse CCCTTTCAGTTTTCCTATGGCCTTTACATTTTAGTAG 
 
 
2.1.8 Plasmids and E. coli 
2.1.8.1 Plasmids 
The plasmids used in this study are listed in Table 2.10. They were either obtained 
commercially, non-commercially, or built in house. With the exception of InvivoGen 
purchased plasmids, all plasmids were grown in E.Coli XL1 blue cells (Stratagene) and 
all plasmid DNA prepared using a maxiprep method, aliquoted and stored at -80 °C at 
1µg/µL. All plasmids purchased from InvivoGen were provided in pre-transformed 
lyophilized E.Coli. Plasmids were re-suspended in LB medium (Table 2.3), streaked 
onto plates containing blasticidin LB agar (Table 2.3), and an individual colony grown in 
blasticidin TB medium (Table 2.3), according to manufacturers’ instructions. 
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Table 2.10 Plasmids used in this study. Plasmids were either obtained commercially, non-
commercially, or built in house.  
Plasmid Description Source 
pGL3-basic luciferase 
reporter gene vector 
Luciferase expression vector lacking eukaryotic 
promoter and enhancer sequences 
Promega 
∆RIG-I-pEFBOS Constitutively active RIG-I, encoding the RIG-I 
CARD domain only 
T. Fujita 
pEFBOS ∆RIG-I empty vector control T. Fujita 
pUNO1-sahTRIF∆ 
(∆TRIF) 
Super-activated human TRIF, encoding TRIF 
lacking the C-terminal 67aa 
InvivoGen, San 
Diego, CA, USA 
pUNO1.mcs (pUNO1) ∆TRIF empty vector control InvivoGen 
pCMVSPORT-β-gal  
(β-gal) 
Transfection efficiency control vector Invitrogen 
pUNO-hTRAF6-HA  
(pUNO-TRAF6) 
Human TRAF6 over-expression vector InvivoGen 
pUNO-hTRAF3a  
(pUNO-TRAF3) 
Human TRAF3 over-expression vector InvivoGen 
pUNO-mcs (pUNO) pUNO-TRAF6 and pUNO-TRAF3 empty vector 
control 
InvivoGen 
pNF-κB Luciferase  
(NF-κB Luc.) 
NF-κB dependent luciferase reporter (containing 
consensus NF-κB-binding sites) 
Clontech, Saint-
Germain-en-
Laye, France 
IRF3 Luciferase (IRF3 
Luc.) 
IRF3 dependent luciferase reporter (containing 
consensus IRF3-binding sites) 
T. Fujita 
IFN-β promoter reporter 
construct 
Wild-type IFN-β promoter luciferase reporter 
construct containing PRDI-IV enhancer elements 
(-125bp relative to the transcriptional start site) 
T. Fujita 
IFN-λ1 promoter 
reporter construct 
Wild-type IFN-λ1 promoter inserted into the MluΙ 
and XhoΙ restriction sites of the pGL3-basic 
luciferase reporter gene vector 
S. Kotenko, New 
Jersey Medical 
School, NJ, USA 
IFN-λ2/3 promoter 
reporter construct 
Wild-type IFN-λ2/3 promoter inserted into the 
MluΙ and XhoΙ restriction sites of the pGL3-basic 
luciferase reporter gene vector 
S. Kotenko 
-546bp CXCL8 promoter 
reporter construct 
A fragment of the CXCL8 promoter cloned into 
the pGL3-basic luciferase reporter gene vector          
(-546bp relative to the transcriptional start site)  
Built in house 
-651bp IL-6 promoter 
reporter construct 
Full-length IL-6 promoter cloned into the pGL3-
basic luciferase reporter gene vector                    
(-651bp relative to the transcriptional start site) 
Built in house 
Mutant PRD region 
(PRDI, PRDII, PRDIII, 
PRDIV) IFN-β promoter 
reporter constructs 
Four IFN-β promoter reporter constructs, each 
with a different mutated enhancer element (PRDI, 
PRDII, PRDIII or PRDIV), ligated into a pGL3-
basic luciferase gene vector  
Built in house 
TaqMan RT-PCR 
standard plasmids 
TaqMan RT-PCR products were each ligated into 
a pCR 2.1-TOPO vector (Table 2.2) 
Built in house 
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2.1.8.2 E.Coli  
E.Coli XL-1 blue competent cells (Stratagene) and XL10-GOLD ultra-competent cells 
(QuickChange II site-directed mutagenesis kit, Stratagene) were used in this study. The 
genotypes of the XL1-blue strain and XL10-GOLD strain (shown below) signify which 
genes within the E.Coli chromosome have been mutated or deleted (∆). The XL10-
GOLD strain has relatively the same gene mutations/deletions as the XL1-blue strain, 
and the Hte phenotype that increases transformation efficiency (approximately 20-30-
fold) and allows transformation of large plasmid DNA. The XL-10 Gold strain was used 
exclusively for transformations during site-directed mutagenesis experiments.  
XL1-blue strain genotype: recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F’ 
proAB laclqZ∆M15 Tn10 (Tetr)] 
XL10-GOLD strain genotype: Tetr ∆(mcrA)183 ∆(mcrCB-hsdSMR-mrr)173 endA1 
supE44 thi-1 recA1 gyrA96 relA1 lac Hte [F’ proAB laclqZ∆M15 Tn10 (Tetr) Amy Camr]   
2.1.9 Instruments 
Table 2.11 Instruments used in this project in alphabetical order. 
Name Application Company 
AutoLumat Plus LB953 Luciferase assay Berthold Technologies, Wildbad, 
Germany 
Centrifuge (Biofuge 
PrimoR, Heraeus) 
Maxi-prep  Kendro Laboratory Products Plc., 
Bishop’s Stortford, UK 
Centrifuge (Eppendorf 
5415D) 
RNeasy kit RNA isolation Eppendorf, Hamburg, Germany 
Centrifuge (Eppendorf 
5810R) 
Centrifugation of cultured cells Eppendorf, Hamburg, Germany 
Centrifuge (HERMLE 
Z252MK) 
Maxi-prep and mini-prep  Hermle, Gosheim, Germany 
Electrophoresis tank (wide 
mini sub cell)  
Agarose gel electrophoresis BioRad, Hemel Hempstead, 
Hertfordshire, UK 
EpiChemi Darkroom UV 
transilluminator system 
Visualisation of ethidium 
bromide stained DNA 
Ultra-Violet Products Inc., 
Upland, CA, USA 
GeneQuant DNA 
calculator 
Plasmid DNA quantification Amersham Biosciences, 
Buckinghamshire, UK 
Heating block (Techne 
DRI-block DB-2A) 
Western blot Jencons Scientific Ltd., Leighton 
Buzzard, UK 
HERA Category ΙΙ tissue 
culture hood 
All sterile cell work Kendro Lab. Products, Hanau, 
Germany 
Hotplate and stirrer 
(Jenway1000) 
Buffer and solution preparation Grant Instruments Ltd., 
Cambridge, UK 
Humidity cabinet (LEEC 
compact incubator) 
E.coli incubation  
β-galactosidase assay 
LEEC Ltd., Nottingham, UK 
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Name Application Company 
Incubator (NU 5500E air 
jacketed automatic CO2) 
Cell culture NuAire Inc., Plymouth, MN, USA 
Inverted microscope (Leica 
DME) 
Cell quantification Leica Microsystems, Wetzlar, 
Germany 
Meta 510 laser scanning 
microscope (LSM) 
Confocal microscopy Carl Zeiss Ltd, Welwyn Garden 
City, UK  
Novex XCell SureLock 
Mini-Cell (gel tank) 
Western blot Invitrogen, Paisley, UK 
Novex Xcell blot module Semi-wet western blot transfer Invitrogen 
Orbital incubator (S150 
shaking) 
E.coli incubation  
 
Stuart Scientific, Watford, UK 
Plate reader (Spectramax 
plus384)  
ELISA, β-galactosidase assay, 
plasmid DNA quantification 
Molecular devices Ltd., 
Wokingham, UK 
Power supply (CONSORT 
E844) 
Gel electrophoresis Topac, Hingham, MA, USA 
Realtime PCR system 
(ABI 7500) 
Taqman RT-PCR Applied Biosystems, Foster City, 
CA, USA 
RG II x-ray film processor Western blot Fujifilm Ltd., Bedford, UK 
Rotator (Micro4 heated) Western blot Hybaid Ltd., Middlesex, UK 
Shaker (R100 rotatest)  RV1B infection, western blot Luckham Ltd, Sussex, UK 
Sonicator  Western blot Ultrawave Ltd., Cardif, UK 
TaqMan RT-PCR hood 
(Bioair Instruments, Aura 
Mini) 
Handling of TaqMan RT-PCR 
primers and probes 
Wolf Laboratories Ltd., 
Pocklington, UK 
Trans-Blot SD cell Semi-dry western blot transfer BioRad 
UV cross-linker 
(Stratalinker 2400) 
UV inactivation of RV Stratagene, Amsterdam, NL 
Water bath (Grant) cDNA synthesis Grant Instruments Ltd, 
Cambridge, UK 
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2.1.10 Software 
Table 2.12 Software used in this project listed in alphabetical order. 
Name Application  Company 
ABI Prism 7500 SDS 
software v1.4.0 
Taqman RT-PCR data analysis Applied Biosystems 
AxioVision imaging 
software v4.6.3.0 
Fluoresecent cell imaging Carl Zeiss Microimaging Inc., 
NY, USA 
Clone Manager Suite 
software v6.0 
Alignment of DNA sequences Scientific and Educational 
Software, Cary, NC, USA 
GraphPad Prism 4 Statistical analysis of data GraphPad Software Inc. San 
Diego, CA, USA 
LabWorks Image 
software 4.5 
Ethidium bromide stained DNA 
photo acquisition 
Ultra-Violet Products Inc., 
Upland, CA, USA 
Chromas software DNA sequence analysis by 
electrophoretogram 
Griffith University, QLD, Aus. 
Softmax Pro v3.1.2 ELISA, β-galactosidase assay data 
acquisition and analysis 
Molecular Devices Corporation, 
Sunnyvale, CA, USA 
Primer Express v3.0 Primer and probe design Applied Biosystems 
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2.2 General Methods 
2.2.1   Tissue and virus culture  
All cell culture medium and media supplements used in this study are listed in Table 2.3. 
All tissue culture was performed in a designated “clean” (i.e. free of respiratory viruses) 
category ΙΙ tissue culture hood (Table 2.11) and all RV1B infections in a designated 
“virus” category ΙΙ tissue culture hood (Table 2.11). 
2.2.1.1 Maintenance of cells 
HeLa cells were cultured in D-MEM medium (Table 2.3). All media were supplemented 
with 10% heat inactivated foetal calf serum, 2.5% HEPES buffer solution, and 1% 
sodium bicarbonate solution (Table 2.3). Human primary bronchial epithelial cells 
(HBECs) were cultured in bronchial epithelial growth medium (BEGM) consisting of 
bronchial epithelial basal medium (BEBM), supplemented with single-quot additives 
(Table 2.3). Medium with the addition of supplements will be referred to as complete 
BEGM throughout this study. Medium was changed every 2-3 days during the culturing 
period. All cells were cultured in T75 tissue culture flasks (Nunc, Rochester, NY, USA), 
in a humid 37°C incubator with 5% CO2 (Table 2.11), and cells passaged when 80-90% 
confluent. 
2.2.1.2 HeLa cell sub-culture 
Cells were washed 2X with D-PBS (Table 2.1), and 3mL trypsin-EDTA (Table 2.3) 
diluted in D-PBS to 1x solution added and cells incubated at 37°C until cells were 
detached. Cells were re-suspended in 10mL pre-warmed complete D-MEM to inactivate 
the trypsin and one quarter of cells transferred to a new T75 tissue culture flask 
containing pre-warmed medium.       
2.2.1.3 HBEC sub-culture 
Cells were washed with 3mL HEPES buffered saline solution (Table 2.3), 2mL trypsin-
EDTA (Table 2.3) was added and cells incubated at 37°C until cells were detached. 4mL 
trypsin neutralising solution (TNS) was added (Table 2.3), and cells centrifuged at 540g 
(Table 2.11) for 6 min. Cells were re-suspended in 10mL complete BEGM (Table 2.3) 
and one third transferred into a new T75 tissue culture flask containing pre-warmed 
medium.  
2.2.1.4 Cell quantification 
Re-suspended cells (100-200µl) were removed from the cell suspension (section 2.2.1.2 
and 2.2.1.3) and an equal volume of 0.1% trypan blue (in D-PBS) added. A Neubauer 
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haemocytometer was filled with cell/trypan blue suspension (approx 5-10µl) and viewed 
under a light microscope (Table 2.11). Viable cells were counted, and cells per mL 
calculated. 
2.2.1.5 Resuscitation of frozen HeLa cells and HBECs 
Cells were thawed quickly in a 37°C water bath (Table 2.13) and transferred to a T75 
flask (Nunc) containing pre-warmed D-MEM (HeLa) or complete BEGM (HBECs). The 
cells were placed in a humid 37°C incubator with 5% CO2 (Table 2.11) overnight. The 
medium was changed the following day, and cells cultured as above. 
2.2.1.6 RV culture 
RV1B was cultured using confluent HeLa cell monolayers in T175 flasks (Nunc). Cells 
were washed with 2X 10mL HeLa cell infection medium (Table 2.3) and 5mL of virus 
stock added to cells with 7.5mL of infection medium. Flasks were gently agitated for 1h 
at room temperature, 12.5mL of infection medium added and incubated overnight at 
37°C with 5% CO2 (Table 2.11) or until approximately 90% cytopathic effect was 
observed. Cells were lysed by freeze/thawing (3X) and centrifuged at 4,000rpm for 
15min (Table 2.11) to pellet cell debris. The resulting RV inoculum was decanted and 
filtered through a 0.2µm filter (PALL Life Sciences, Portsmouth, UK) and then stored in 
2mL aliquots at -80°C.  
2.2.1.7 RV titration in HeLa cells 
HeLa cells were split, re-suspended in HeLa cell infection medium (Table 2.3), counted 
and further diluted in infection medium to give 0.5×105 cells/mL. 150µL of cells were 
placed in each well of a 96-well plate (Nunc). Undiluted RV inoculum was added, or 10-
fold dilutions of the RV inoculum were added to each well, and the plate incubated in a 
humid 37°C incubator with 5% CO2 (Table 2.11) for 4-5 days. Viral cytopathic effect 
(CPE) was determined using light microscopy (Table 2.11) and infected wells were 
counted at Day 4-5. Tissue culture infective dose 50% (TCID50)/mL value was 
determined by scoring the sum of positive wells and using the Spearman Karber formula 
[317]. 
2.2.1.8 Filtration of RV inoculum producing a virus free filtrate 
RV was removed from the inoculum by filtration through a 30kDa filter spin column 
(Millipore, Watford, UK). Filter spin columns were spun at 12,000rpm for 5 min (Table 
2.11), and filtrate collected.  
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2.2.1.9 UV inactivation of RV 
RV was inactivated by exposing 1mL of inoculum in a 6-well plate (Nunc) to UV light at 
1,200 mJ/cm2 (Table 2.11) for 30min on ice and filter sterilised with a 0.2µm filter (PALL 
Life Sciences). 
2.2.1.10 RV infection of HBECs 
HBEC were grown in 6 or 12 well tissue culture plates (Nunc) until 80% confluent and 
were then starved by culturing in BEBM (Table 2.3) overnight before incubating with RV 
inoculum (200µl/well for a 12-well plate; 500µL/well for a 6-well plate) for 1h with 
agitation at room temperature. This corresponds to a multiplicity of infection (MOI) of 1. 
Inoculum was removed and replaced with BEGM serum free medium (1mL/well for a 12-
well plate; 2mL/well for a 6-well plate) and incubated at 37°C with 5% CO2, before 
harvesting cell supernatants for ELISA or cells for protein and/or RNA analysis at 
required time points (0-48h). In some experiments, where RV replication was to be 
measured, after 1h agitation at room temperature the RV inoculum was removed, and 
the cell monolayer washed 3X in 0.5mL BEBM medium, to remove non-adhered RV 
prior to incubation at 37°C for required time points. 
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2.2.2   Protein analysis techniques 
All buffers and general reagents used in this study are listed in Table 2.1. A list of 
commercially purchased kits used is provided in Table 2.2. The antibodies used for 
western blot and ELISA are listed in Table 2.6 and Table 2.7 respectively. 
2.2.2.1 Firefly luciferase reporter gene assay 
The Luciferase Assay Kit (Promega) was used to assess luciferase (reporter) gene 
expression, according to manufacturers’ instructions. Supernatants were removed, and 
cells were washed with D-PBS (Table 2.1) and lysed in 100µL reporter lysis buffer 
(diluted 1/5 with distilled water, Table 2.2). Extracts were collected and centrifuged at 
12,000rpm for 2min (Table 2.12) to pellet cell debris and nuclei. Each sample (20µL) 
was used to quantify luciferase, using a luminometer (Table 2.11). Samples were 
measured for a 10sec, time interval, and expressed as relative light units (RLU). 
2.2.2.2 β-galactosidase reporter gene assay 
Samples were prepared as for luciferase measurements, and 50µL was added to a 96-
well plate (Nunc), and mixed with 50µL of assay 2X buffer (Table 2.2), until adequate 
colour development. Plates were read at 420nm on a microplate reader (Table 2.11) and 
data expressed as absorbance at 420nM (A420nM). RLU readings were normalised to β-
galactosidase assay readings by dividing RLU with A420nM. All reporter gene results were 
expressed as normalised RLU or fold induction over control treated cells.  
2.2.2.3 Enzyme linked immunoabsorbent assay (ELISA) for pro-
inflammatory cytokines 
ELISAs to quantify pro-inflammatory cytokines were performed using commercially 
available paired antibodies and recombinant protein standards (R&D Systems). 96-well 
microtitre plates (Nunc) were coated with 100µL capture antibody diluted to 4µg/mL in 
PBS (Table 2.1), and incubated overnight at room temperature. The plate was washed 
3X with 250µL ELISA wash buffer (Table 2.1), and blocked by adding 250µL ELISA 
blocking solution (Table 2.1) and incubated at room temperature for 2h. Recombinant 
protein standard was diluted to 1000pg/mL in ELISA diluent buffer (Table 2.1), and a 
standard curve prepared by performing doubling dilutions down to approximately 
3.5pg/mL. The plate was washed 3X, and 100µL of sample supernatant, standards, and 
ELISA diluent buffer controls (blanks) were added to the plate in duplicate and incubated 
for 1h at room temperature. The plate was washed 3X, 100µL of biotinylated detection 
antibody (diluted to 25ng/mL in diluent buffer) added and the plate incubated for 1h at 
room temperature. The plate was washed 3X, 100µL strepavidin-HRP (diluted 1:5000 in 
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ELISA diluent buffer, Table 2.1) added and the plate incubated for 15min at room 
temperature with shaking. The plate was washed 3X, 100µL TMB solution (Table 2.1) 
added and the reaction allowed to develop in the dark for approximately 5min (or until 
background colour begins to appear in blank wells) before stopping the reaction with the 
addition of 50µL 2M H2SO4 (Table 2.1). Absorbance was measured at 450nm, on a 
microplate reader (Table 2.11). Absorbance readings of the experimental samples were 
compared to the standard curve, to enable quantification of each sample in pg/mL. The 
sensitivities of each assay were: CCL5 15pg/mL, IL-6, CXCL8 and CXCL5 7pg/mL, 
CXCL10 150pg/mL.  
2.2.2.4 Quantitative ELISA for IFN-λ1  
Measurement of IFN-λ1 in sample supernatants was performed using commercially 
available antibodies (Table 2.7), as described in 2.2.2.3, with the following exceptions. 
Capture antibody was diluted to 1µg/mL. Recombinant protein standard curve began at 
10,000pg/mL with 1/3 dilutions down to approximately 4.5pg/mL. Following incubation of 
samples and standards on the plate (2h with shaking), the plate was washed 3X, 100µL 
secondary anti-IFN-λ1 antibody added (at 1µg/mL in ELISA diluent buffer, Table 2.1), 
and incubated for 1h 45min at room temperature (with shaking). The plate was washed 
3X, 100µL of biotinylated detection antibody (diluted to 50ng/mL in ELISA diluent buffer) 
added and the plate incubated for 1h at room temperature. The plate was washed 3X, 
100µL strepavidin-HRP (diluted 1:5000 in ELISA diluent buffer, Table 2.1) added and 
the plate incubated for 10min at room temperature with shaking. The plate was washed 
3X, 100µL TMB solution (Table 2.1) added and the reaction allowed to develop in the 
dark for approximately 5min (or until background colour begins to appear in blank wells) 
before stopping the reaction with the addition of 50µL 2M H2SO4 (Table 2.1). The 
sensitivity of this assay was approximately 13pg/mL. 
2.2.2.5 Quantitative ELISA for IFN-β 
A commercially available human Interferon-β ELISA Kit (Table 2.2) was used according 
to manufacturers’ instructions. Briefly, 100mL of sample or standard was added to a 96-
well plate pre-coated with a primary polyclonal antibody to IFN-β. Standard was serially 
diluted 2-fold from 200IU/mL to 1.25IU/mL. 50µL of HRP-labelled anti-IFN-β monoclonal 
antibody was added to the plate, and incubated (with shaking) at room temperature for 
3h. The plate was washed 3X with IFN-β ELISA washing solution (Table 2.1). 100µL 
substrate solution (Table 2.1) was added to each well and the reaction developed at 
room temperature (with shaking), and stopped with 100µL stop solution (Table 2.1). 
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Absorbance was measured at 450nm using a microplate reader (Table 2.11). 
Absorbance readings of the experimental samples were compared to the standard 
curve, to enable quantification of each sample in IU/mL. The sensitivity of the assay was 
4.5 IU/mL.  
2.2.2.6 Sample preparation for Polyacrylamide gel electrophoresis 
(PAGE) 
Supernatants were removed and cells washed with D-PBS (Table 2.1). Protein sample 
buffer (Tris-glycine SDS sample buffer, Table 2.1) was added to the cells (100µL/well), 
and scraped with a 200µL pipette tip. Samples were collected, centrifuged at 12,000rpm 
for 2min (Table 2.11). In a fresh tube, samples were sonicated and 10% v/v β-
mercaptoethanol added, and samples heated for 5min at 95°C (Table 2.11).  
2.2.2.7 PAGE 
1L 1X running buffer (Table 2.1) was prepared and samples separated using a pre-cast 
4-12% bis-tris gel (NuPage, Invitrogen) or a tris-glycine gel (Novex, Invitrogen) in a 
novex mini gel tank (Table 2.11). The outer chamber consisted of 800mL running buffer 
and the inner chamber contained 200mL running buffer with 0.5mL NuPAGE anti-
oxidant (Table 2.1). Samples (20-30µL) were run alongside molecular weight markers 
(Invitrogen) for 1.5h at 90V.  
2.2.2.8 Protein transfer to nitrocellulose membrane 
Following PAGE, the gel was submerged for 15min in transfer buffer (Table 2.1) and 
then laid flat on Hybond-P nitrocellulose transfer membrane (GE Health care, 
Buckinghamshire, UK), pre-activated with neat methanol (Sigma-Aldrich) and 
equilibrated with transfer buffer. This gel-transfer membrane assembly was both under-
laid and overlaid with a pre-wetted blotting pad (Biorad, Hemel Hempstead, UK), and the 
blotting pad- filter paper -gel -blotting pad combination placed in either the Xcell II semi-
wet blot module (filled with transfer buffer) or the semi-dry trans-blot SD cell (Table 
2.11), and run at 20V for 2-3h. Following transfer of proteins onto the membrane, the 
membrane was washed with western blot washing solution (Table 2.1) for 15min and 
then incubated at room temperature with western blot blocking solution (Table 2.1) with 
shaking (Table 2.11), for 2h.  
2.2.2.9 Western blotting 
Blocking solution was removed and replaced with appropriate primary antibody (diluted 
in western blot blocking solution, Table 2.6), and incubated at 4°C with shaking, 
overnight. The membrane was washed with western blot washing solution 3X (5min 
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washes each) before adding a secondary antibody-HRP conjugate, (Table 2.6) diluted in 
western blot blocking solution and incubated at room temperature for 1h. The membrane 
was washed with western blot washing solution as above, and then detected using an 
ECL kit (Table 2.2), with X-ray film (GE Health care, Buckinghamshire, UK) and an X-ray 
film developer (Table 2.11). 
2.2.2.10 Stripping nitrocellulose membranes 
In certain scenarios, after detection the gel was thoroughly washed in western blot 
washing solution, prior to incubation with stripping buffer (Table 2.1) at 50°C for 30min, 
to remove primary and secondary antibodies. The stripped gel was then washed for 
15min, and blocked as in section 2.2.2.8 and re-probed with another primary antibody. 
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2.3 Molecular Biology Techniques 
2.3.1 RNA extraction and cDNA synthesis 
Cells were lysed using 350µL per well of RLT buffer (Table 2.2), and stored at -80°C 
until required. Total RNA was extracted using the RNeasy Mini kit (Qiagen, Table 2.2) 
according to manufacturers’ instructions. Briefly, the lysed sample is mixed with an 
equal volume of 70% ethanol, added to an RNeasy mini-spin column, and spun at 
10,000rpm for 30sec (Table 2.11). The column was washed in 350µL RW1 buffer, spun 
as above, and incubated with DNase I (RNase-free DNase, Qiagen; Table 2.1), for 
15min, followed by washing again in RW1 buffer. After spinning at 10,000rpm for 30sec, 
the columns are washed 2X further using RPE buffer. The columns are spun again as 
above to remove residual liquid, and RNA eluted from the spin column using 42µL 
nuclease-free water (Promega) (giving approximately 10µg RNA/sample extraction). 
42µL of RNA was used to prepare cDNA using an Omniscript Reverse Transcription Kit 
(Table 2.2). The components of the reaction were assembled as shown in Table 2.13, 
and the reaction was incubated in a 37°C water bath (Table 2.11) for 1.5h and stored at 
-80°C.        
 
          Table 2.13 Composition of cDNA reactions.  
Component Volume / reaction Final Concentration 
Ominiscript RT 3.0 µL 10 units/50 µL reaction 
10X Buffer RT  6.0 µL 1X 
dNTP mix (5mM each dNTP)  6.0 µL 0.5mM each dNTP 
Random primers 3.0 µL 10µM 
Template RNA 42.0 µL 2-5µg 
Total Volume 60.0 µL  
 
2.3.2 Realtime RT-PCR 
Realtime RT-PCR primer and probes were designed for all of the genes measured in 
this study (Table 2.9), with exception of CXCL8 (IL-8), IFN-β and IFN-λ1 (IL-29) that 
were already established within the lab. Primer and probe combinations were designed 
to hybridise to DNA over an exon-exon boundary to avoid non-specific amplification of 
the target gene. Genomic and mRNA sequences of the target gene were found using 
NCBI PubMed and compared to find the exon-exon boundaries within the DNA 
sequence. Primers and probe, over-lapping an exon-exon boundary, were selected 
using Primer Express v3.0 (Table 2.12). To optimise forward and reverse primer 
concentrations probe concentration was kept constant at 175nM per reaction and each 
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forward/reverse primer combination varied using 50nM, 300nM and 900nM 
concentrations. The primer pair combination which gave the lowest threshold value (CT) 
and the highest normalised reporter dye signal (∆Rn), with no primer-dimer formation 
were chosen for use in future taqman RT-PCR analysis. No template controls (NTC) 
were used to detect primer-dimers.    
mRNA for a number of genes were measured using TaqMan™ PCR (Applied 
Biosystems (ABI) 7500 machine; Table 2.11) and specific primer and probe sequences. 
On each 96-well optical PCR plate (ABI), each gene of interest and 18S rRNA was 
analysed to assess cDNA loading. Each reaction consisted of 12.5µL 2X QuantiTect 
probe PCR Master Mix (Table 2.1), sense and anti-sense primers (at optimised nM ratio, 
Table 2.8) and 175nM probe and 2µL cDNA. For 18S rRNA measurements, the cDNA 
was diluted 1/100 in nuclease-free water (Promega). Each well of the 96-well optical 
PCR plate was sealed with an optical lid (ABI) and the reactions analysed using an ABI 
7500 automated Taqman™ (ABI). The amplification cycle consisted of 50°C for 2 min, 
94°C for 10 min, and 45 cycles of 94°C for 15 s, 60°C for 15 s. Data was analysed using 
version 1.4 ABI Prism 7500 SDS Software (Table 2.12). Unknown samples were 
compared to a standard curve produced from running dsDNA standards in 10 fold 
dilutions from 107 copies per reaction, to 1 copy per reaction. Quantitative PCR data was 
normalised for 18S rRNA and presented as normalised copy number, or % of control 
treated cells, or as fold induction relative to medium control treated cells.  
2.3.3 Agarose Gel Electrophoresis 
A 1L solution of 1X TAE was prepared using TAE stock (50X, Table 2.1) and distilled 
water. A 1% agarose gel was prepared by addition of agarose (Table 2.1) to 1X TAE 
solution. The agarose was dissolved by boiling and cooled to approximately 40°C before 
pouring into a gel-casting tray, containing a well forming comb and leaving to set. The 
gel was placed into an electrophoresis tank (Table 2.11), the tank filled with 1X TAE so 
that the gel was submerged and the well forming comb removed. Samples were mixed 
with 10% (v/v) gel loading dye and 5µL of DNA ladder (Table 2.1) was loaded onto the 
gel to determine the size of the DNA fragments electrophoresed. Samples were run at a 
voltage of 100V and a current of 100mA for 1-2h. The gel was submerged in a solution 
of concentrated ethidium bromide in 500mL 1X TAE (Table 2.1) for approximately 1h 
before placing the gel on a ultra-violet trans-illuminator for visualisation (Table 2.11). 
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2.3.4 Gel extraction of electrophoresed PCR product 
RT-PCR products, or restriction digests were pooled (200-400µL) and mixed with 20-
40µL (10% v/v) gel loading buffer, and run on a 2% agarose gel as described in section 
2.3.3. Bands were visualised on a ultra-violet trans-illuminator (Table 2.11) and 
appropriate bands representing the target RT-PCR product, or desired restriction digest 
product were excised from the gel with a sterile scalpel, and extracted using a 
commercially available gel extraction kit (Qiagen, Table 2.2) according to manufacturers’ 
instructions. DNA was eluted in 30µL nuclease-free water and stored at -20°C. 
2.3.5 Ligation using pCR 2.1-TOPO and pGL3-basic vectors 
The pCR 2.1-TOPO vector (Invitrogen, Table 2.2) was used for cloning PCR products. 
Each ligation reaction consisted of 4µL gel extracted PCR product (15-100ng) or water 
(negative control ligation), 1µL salt solution and 1µL TOPO vector. The reaction was 
mixed by gentle pipetting and incubated at room temperature for 15min before placing 
reactions on ice. In other experiments, DNA fragments were ligated into a pGL3-basic 
vector (Promega, Table 2.10) using 1µL insert (25ng) or water (negative control ligation), 
1.3µL pGL3-linearised vector (150ng), 2µL 10X ligase buffer (Promega, Table 2.1), 2µL 
T4 DNA ligase (5U/µL; Promega, Table 2.1) and 13.7µL nuclease-free water in a total 
reaction volume of 20µL. The reaction was mixed by gentle pipetting and incubated at 
room temperature for 1h before transforming competent E.coli. 
2.3.6 Transformation of competent E.coli  
Approximately 5-6µL of a ligation reaction or 1µL of stock plasmid DNA was added to 
50µl of E.coli XL1 blue competent cells (section 2.1.8.1) and gently mixed with a pipette 
tip. The transformation reaction was incubated on ice for 30min, and transferred to a 
42°C water bath (Table 2.11) for 45sec, then placed on ice for 2min. LB broth (450µL, 
Table 2.3) was added to each transformation reaction and shaken for 1h at 37°C. 100µl 
of each transformation reaction was spread onto LB agar plates containing 100µg/mL 
ampicillin, and incubated at 37°C overnight.  
2.3.7 Colony Screening and mini-prep analysis of plasmid DNA 
Following E.coli transformation single colonies (10-20) were picked and used to 
inoculate 2mL LB broth with 100µg/mL ampicillin. Cultures were grown at 37°C 
overnight and plasmid DNA isolated using a mini-prep method. E.coli were pelleted, by 
spinning at 10,000 rpm for 10sec (Table 2.11), and the pellet re-suspended in 0.2mL 
solution 1 (Buffer P1, Table 2.2), mixed, and 0.2mL solution 2 (Buffer P2, Table 2.2) 
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added. After gentle mixing, 0.2mL of solution 3 (Buffer P3, Table 2.2) was added and 
the mixture was spun at 10,000rpm for 10min. The supernatant was then taken, and 
mixed with 1mL 100% ethanol (VWR, Lutterworth, UK). After incubating for 20min at 
room temperature, the plasmid DNA was precipitated by spinning at 10,000rpm for 
20min. The plasmid DNA pellet was then washed by spinning at 10,000rpm for 2min in 
70% ethanol and air-dried before re-suspension in 30µL nuclease free water (Promega). 
Mini-prep isolated plasmids were used in restriction digests to confirm the presence of a 
desired DNA insert or PCR product.  
2.3.8 Large scale maxi-prep isolation of plasmid DNA  
A single colony from section 2.3.6 were picked and grown at 37°C for 6h with shaking, 
and 2mL of this starter culture transferred into 100mL LB broth containing 100µg/mL 
ampicillin, shaken at 37°C overnight and plasmid DNA prepared using a Maxi-prep 
method (Qiagen, Table 2.2) according to the manufacturers’ instructions. The purified 
plasmid DNA was precipitated in 100% isopropanol (VWR, Lutterworth, UK), and 
spinning at 6,000rpm for 1h, the supernatant discarded, and the DNA pellet washed with 
2mL 70% ethanol and spun at 6,000rpm for 30min. Finally the pellet was air dried 
(10min), the isolated DNA re-suspended in 300µL sterile TE buffer (pH 8.0, Table 2.1), 
and stored at -80°c. Plasmids isolated by this method were used in transfection studies, 
or used as standards in Realtime TaqMan RT-PCR.  
2.3.9 Restriction digest of plasmid constructs 
Single restriction enzyme digests were performed on plasmids obtained in section 2.3.7 
to confirm successful ligation of PCR product into the pCR 2.1-TOPO vector (Table 2.2) 
using the restriction enzyme EcoR1. Double restriction enzyme digests were performed 
on the pGL3-basic vector (Table 2.10). Details of the restriction digest reactions are 
summarised in Tables 2.14 and 2.15. All reactions were carried out at 37°C in a water 
bath for 2-3h. 
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Table 2.14 Reaction components for single restriction digest of plasmid isolated by the 
mini-prep method, and double digest for plasmids isolated by maxi-prep method. 
1 restriction enzyme digest 2 restriction enzymes digest 
Component Concentration / 
Reaction 
Component Concentration / 
Reaction 
10X Reaction Buffer 1X 10X Reaction Buffer 1X 
Bovine serum albumin 
(BSA) (100µg/mL) 
10 µg/mL Bovine serum albumin 
(BSA, 100µg/mL) 
10 µg/mL 
EcoRI 10U Restriction enzyme(s) 10U each 
Plasmid DNA 2-5µg Plasmid DNA 20-50µg 
Nuclease-Free water 1X Nuclease-Free water - 
 
Table 2.15 Plasmids used in restriction digests, restriction enzyme, their reaction buffer 
used and restriction site. 
Name Restriction 
enzyme 
Reaction 
buffer 
Restriction 
site (5’-3’) 
pGL3-basic luciferase reporter plasmid BglΙΙ & HindΙΙΙ Buffer C A∨GATCT 
A∨AGCTT 
IFN-β promoter- & PRDI-IV mutant IFN-β 
promoter-activation reporter plasmids 
XhoΙΙ & HindΙΙΙ Buffer C A∨GATCT & 
A∨AGCTT 
IFN-β promoter- & PRDI-IV mutant IFN-β 
promoters in pGL3-basic luciferase 
reporter plasmid backbone 
NheΙ & HindΙΙΙ Buffer B G∨CTAGC & 
A∨AGCTT 
Realtime RT-PCR standard plasmids EcoR1 Buffer H G∨AATTC 
∨
 = position of restriction enzyme cleavage 
 
2.3.10 Quantification of plasmid DNA 
Mini-prep DNA was quantified using a GeneQuant DNA/RNA calculator (Table 2.11) 
Approximately 4µL DNA was loaded into a glass capillary and absorbance measured at 
A260nM. Maxi-prep DNA was diluted 1/100 with nuclease-free water, and absorbance 
measured at A260nM as above, but using a quartz cuvette and spectrophotometer (Table 
2.11) at A260nM. The quantity of DNA determined by assuming an absorbance at A260nM of 
1.0 is equal to 50µg/mL DNA.  
2.3.11 DNA sequencing 
Quantified plasmid DNA was diluted in distilled water to 100ng/µL, and a volume of 20µL 
was sequenced by the dideoxy-sequencing method at Lark Technologies (Takeley, 
Essex, UK). Sequencing of the ligated promoter inserts in pGL3 was performed using 
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20µM reverse primer for the luciferase gene. Sequences were verified by analysing the 
electrophoretogram using LaserGene software (Table 2.12), and by comparing to known 
sequences using CloneManager software (Table 2.12). 
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2.4 Specific Methods 
2.4.1 Transfection of HBECs  
All HBEC siRNA and plasmid transfections were performed in a designated “clean” (i.e. 
free of virus) category ΙΙ tissue culture hood (Table 2.11). All siRNA and plasmids used 
in this study are listed in Table 2.5 and Table 2.10 respectively.  
2.4.1.1 siRNA 
A siGLO RISC-free siRNA (DY-547 labelled) was used to optimise siRNA delivery into 
HBECs using the lipid-based transfection reagent Lipofectamine2000 (LP2000; Table 
2.1) according to manufacturers instructions. Confluent monolayer cells in 12-well plates 
(nunc) were transiently transfected with 100nM siGLO RISC-free siRNA using LP2000 
at 1.0, 2.5, 3.5 or 5.0µg/mL. Lipid-DNA complexes were removed from cells after 2h, 3h, 
4h and 5h, and the cells washed 2X with D-PBS (Table 2.1) and placed in BEBM (Table 
2.3) for 24h at 37°C (5% CO2) (Table 2.11). Cells were observed for transfection 
efficiency under a fluorescent microscope (Table 2.11). The optimised HBEC siRNA 
transfection procedure is described below. 
Confluent monolayer cells in 12-well plates (nunc) were transiently transfected with a 
specific gene targeting siRNA or control siRNA (siCONTROL non-targeting siRNA#2). 
siRNA stock (20µM) was diluted in Optimem-1 medium (Table 2.3) to give a 
concentration of 1µM, and a volume of 100µL per well to be transfected, and mixed by 
vortexing. Stock LP2000 (1mg/mL) was diluted in Optimem-1 medium to give a 
concentration of 25µg/mL and a volume of 100µL per well to be transfected. Diluted 
LP2000 was vortexed and incubated at room temperature for 5 min. Diluted LP2000 and 
diluted siRNA were combined, vortexed to mix and incubated at room temperature for 
20min to allow lipid-siRNA complexes to form. Spent medium was removed from the 
monolayer cells and replaced with 800µL/well BEBM. 200µL Lipid-siRNA complexes 
were added to each well, and gently rotated to mix. The final concentration of 
siRNA/well was 100nM. Transfections were incubated for 4h at 37°C (5% CO2), 
removed by washing 1X with D-PBS, and cells placed in BEBM and incubated for 24h at 
37°C (5% CO2). Cells were then infected with RV1B (MOI of 1, as in section 2.2.1.10) or 
placed in BEBM. After 1h RV1B or BEBM medium was removed, replaced with 1mL 
BEGM serum free medium and incubated for 24h at 37°C (5% CO2). Cells were 
harvested for RNA. Reagents and volumes required for 1 well of a 12-well plate to be 
transfected with siRNA and the order in which they are mixed, are shown in Table 2.16. 
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        Table 2.16 HBEC transfection with siRNA. 
Stage Volume / well 
Stage 1:  
 Stock siRNA 5.0 µL 
Optimem-1 medium  95 µL 
Stage 2:  
Stock LP2000 2.5 µL 
Optimem-1 medium  97.5 µL 
Stage 3:  
Combine diluted LP2000 / siRNA 
Total volume 200 µL 
2.4.1.2 Plasmid DNA 
Table 2.17 Transient HBEC plasmid transfections performed in this study. 
1 800ng wild-type or mutant PRD region (PRDI-IV) IFN-β promoter reporter + 200ng 
pCMVSPORT-βgal 
2 550ng ∆TRIF or pUNO1 or ∆RIG-I or pEFBOS + 250ng wild-type or mutant PRD region 
(PRDI-IV) IFN-β promoter reporter + 200ng pCMVSPORT-βgal 
3 550ng ∆TRIF or pUNO1 or ∆RIG-I or pEFBOS + 250ng of IFN-λ1 promoter or IFN-λ2/3 
promoter + 200ng pCMVSPORT-βgal 
4 550ng pUNO-TRAF3 or pUNO-TRAF6 or pUNO + 250ng of wild-type IFN-β promoter or NF-
κB or IRF3 or CXCL8 or IL-6 reporter or IFN-λ1 promoter or IFN-λ2/3 promoter + 200ng 
pCMVSPORT-βgal 
5 550ng ∆TRIF or pUNO1 or ∆RIG-I or pEFBOS + 250ng of NF-κB or IRF3 reporter + 200ng 
pCMVSPORT-βgal 
6 250ng ∆TRIF or pUNO1 
 
All stock plasmids were at 1µg/µL. Confluent monolayer cells in 12-well plates (nunc) 
were transiently transfected with plasmid DNA. A master mix of plasmid DNA diluted in 
Optimem-1 medium (Table 2.3), and a volume of 100µL per well to be transfected, was 
prepared and vortexed to mix. LP2000 (1mg/mL, Table 2.1) was diluted in Optimem-1 
medium to 20µg/mL, and a volume of 100µL per well to be transfected prepared, mixed 
by vortexing and incubated at room temperature for 5 min. Diluted LP2000 and diluted 
DNA were combined, vortexed to mix and incubated at room temperature for 20 min to 
allow lipid-DNA complexes to form. Spent medium was removed from cells and replaced 
with 800µL BEGM complete medium (Table 2.3). 200µL of complexes were added to 
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each well and rotated to mix. Transfections were incubated for 5h at 37°C (5% CO2).  
Cells were washed 2X with D-PBS, and cells placed in BEBM (Table 2.3) and incubated 
for 24h at 37°C (5% CO2). Cells were then either lysed for luciferase assay or infected 
with RV1B (MOI of 1, as in section 2.2.1.10) or placed in 1mL BEBM. After 1h RV1B or 
BEBM medium was removed, replaced with 1mL BEGM serum free medium and 
incubated for 24h at 37°C (5% CO2). Cells were then harvested for supernatants and 
RNA, or for luciferase assay. The reagents and volumes required for 1 well of a 12-well 
plate to be transfected (using a transfection with 250ng of plasmid as an example) and 
the order in which they are mixed, are shown in Table 2.18. 
 
                           Table 2.18 HBEC transfection with 250ng plasmid. 
Stage Volume / well 
Stage 1:  
Plasmid DNA  0.25 µL 
Optimem-1 medium  99.75 µL 
Stage 2:  
LP2000 2.0 µL 
Optimem-1 medium  98.0 µL 
Stage 3:  
Combine diluted LP2000 / Plasmid 
Total volume 200 µL 
 
2.4.2 Pre-treatment of HBEC with PI3K chemical inhibitors 
HBECs were grown as in section 2.2.1.1, plated into 12 well plates and placed in 1mL 
BEBM (Table 2.3) containing Wortmannin or LY-294002 (at doses of 10µM, 1µM, 
0.1µM), or BEBM medium alone, and incubated for 1.5h at 37°C. Supernatants were 
removed, and cells treated with Wortmannin or LY-294002 were infected with RV1B 
(MOI of 1, as in section 2.2.1.11), or placed in 1mL BEBM medium. After 1h RV1B or 
BEBM medium was removed, replaced with 1mL BEGM serum free medium and 
incubated for 24h at 37°C (5% CO2). Cells were harvested for supernatants and RNA. 
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2.4.3 Construction of IFN-β promoter-reporter constructs with 
mutant PRDs 
2.4.3.1 Mutant oligonucleotide primer design 
The human IFN-β promoter was mutated in site directed mutatgenesis studies to 
produce IFN-β promoters with mutated PRDs (PRDI, PRDII, PRDIII and PRDIV). The 
mutant forward and reverse oligonucleotides (Table 2.9) were designed based on 
previous studies that had mutated PRDI [318], PRDII [319] and PRDIV [189] and shown 
PRD region specific transcription factor binding and IFN-β promoter reporter activation 
[319] [189] to be abolished. Each primer was used in reactions using the QuickChange II 
XL Site-Directed Mutagenesis kit (Table 2.2) according to the manufacturers’ 
instructions.  
2.4.3.2 Site directed mutagenesis reactions 
Control and sample reactions were prepared, each containing plasmid DNA, reaction 
buffer, dNTP mix, QuickSolution and PfuUltra HF DNA polymerase. The control reaction 
received a non-mutated forward and reverse primer and the sample reaction the desired 
mutant forward and mutant reverse primer. Reactions were performed in a thermal 
cycler (Table 2.11), with 18 cycles of heating at 95°C (1min) to denature the plasmid 
DNA, annealing primers at 60°C (1min) and primer extending with PfuUltra HF DNA 
polymerase at 68°C (4min). Parental plasmid DNA (non-mutated) was then degraded 
using the restriction enzyme Dpn Ι and incubating at 37°C for 2h. Mutant vectors were 
transformed into XL10-GOLD ultra-competent cells (section 2.1.8.2) and grown in 0.5mL 
NZY+ broth (Table 2.3) according to manufacturers’ instructions. Transformation 
reactions were spread onto LB-ampicillin agar plates (Table 2.3) and incubated 
overnight at 37°C (Table 2.11).  
2.4.3.3 Colony screening of plasmids with mutated PRDs 
Individual colonies where picked and grown in 2mL NZY+ broth (Table 2.3) before 
preparing plasmid DNA using a Qiaprep spin mini-prep method (section 2.3.7). Plasmid 
identity was checked by dideoxy sequencing (section 2.3.11) before proceeding to large-
scale growth of mutant plasmids (100mL) and isolating plasmid DNA by maxi-prep 
(section 2.3.8).  
2.4.3.4 Re-cloning of mutants into pGL3-basic vector 
Plasmids with mutant PRDs and the parental IFN-β promoter were re-cloned into the 
pGL3-basic vector (Table 2.10). The mutated PRDI, PRDII, PRDIII and PRDIV IFN-β 
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promoter-activation reporter constructs and the wild-type IFN-β promoter-activation 
construct (100µg) were cut by restriction digest (section 2.3.9) from their back-bone 
vector, along with 200µg of the pGL3-basic vector. Restriction digest products were gel 
electrophoresed and gel extracted (section 2.3.4). The mutated and wild-type IFN-β 
promoter inserts were ligated into the pGL3-basic vector (section 2.3.5). Resulting 
colonies were screened by mini-prep of plasmid DNA (section 2.3.7), and then 
restriction digested to confirm inserts were present (section 2.3.9). Plasmids were then 
prepared by maxi-prep (section 2.3.8), quantified (section 2.3.10), sequence verified by 
dideoxy sequencing (section 2.3.11), aliquoted and stored at -80°C at 1µg/µL. 
2.4.5 Construction of plasmid standards for use in Realtime RT-
PCR 
TaqMan RT-PCR standards were made for IL-6, CXCL8 (IL-8), CCL5 (RANTES), 
CXCL10 (IP10), CXCL5 (ENA-78), IFNL2/3 (IL-28), RIG-I, MDA5, TLR3, TRIF and 
Cardif. Standards for IFN-β and IFN-λ (IL-29) were already established within the lab.  
2.4.5.1 Preparation of TaqMan RT-PCR cytokine gene products 
TaqMan RT-PCR product (section 2.3.2) for each cytokine was collected, agarose gel 
electrophoresed and gel extracted (section 2.3.4). Each TaqMan RT-PCR product was 
ligated into a pCR 2.1-TOPO vector (section 2.3.5), and recombinant vectors 
transformed into competent XL1 blue E.coli cells (section 2.1.8.2) and grown in 0.5mL 
LB broth (Table 2.3). Transformation reactions were spread onto LB-ampicillin agar 
plates (Table 2.3) and incubated overnight at 37°C (Table 2.11).  
2.4.5.2 Colony screening of plasmids containing PCR product inserts 
Individual colonies where picked and grown in 2mL LB broth (Table 2.3) before 
preparing plasmid DNA using a Qiaprep spin mini-prep method (section 2.3.7). 
Successful ligation of PCR product into the pCR 2.1-TOPO vector was confirmed by 
restriction enzyme digest (section 2.3.9) and TaqMan PCR (ABI 7500, Table 2.11) using 
primers and probes specific to each ligated PCR gene product (Table 2.8), before 
proceeding to large-scale growth of plasmids (100mL) and isolating plasmid DNA by 
maxi-prep (section 2.3.8). Plasmids were quantified (section 2.3.10) and diluted in 
distilled water to 5×109 plasmid copies/µL (using the formula below) and stored at -80°C.   
 
 Moles =   
plasmid DNA yield (g) 
plasmid molecular weight 
A. B. 
moles   x   6.02×1023  
plasmid volume (µL) 
 =  molecules (copies) / µL 
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2.4.5.3 TaqMan RT-PCR standard curve generation 
To create a TaqMan standard curve for each gene (by equating cycle threshold (ct) 
values to copy number), each plasmid was diluted to 108 copies/2µL in distilled water 
and further serial 10-fold dilutions performed to give plasmid copy numbers down to 10 
copies/2µL. Serially diluted plasmids (2µL) were combined in a TaqMan PCR reaction 
(ABI 7500, Table 2.11) with specific gene targeting forward and reverse primers/probe 
(Table 2.9), QuantiTect probe PCR Master Mix (Qiagen, Table 2.1) and distilled water. 
Ct values equating to each serially diluted gene copy number were recorded, transferred 
to Softmax Pro v3.1.2 software (Table 2.11) from where they could be used to convert 
future TaqMan RT-PCR results from Ct values into gene copies. 
2.5 Statistics 
Data are presented as means ±SEM (standard error of the mean). One to six 
experiments were performed for all figures. Data were analysed using one-way analysis 
of variance (ANOVA), at a 95% confidence interval with Bonferroni’s multiple 
comparison test, or the student’s unpaired or paired t-test was used for pairwise 
comparison of two groups of data. A p value of p<0.05 was considered statistically 
different.  
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Figure 3.1 Signalling pathways implicated in IFN-β and Pro-inflammatory cytokine 
production. Signalling molecules investigated in this chapter, for their role in RV1B-induced IFN 
and pro-inflammatory cytokine expression in HBEC are shaded.  
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3.1 Introduction 
Recent studies have shown asthmatics and normals to respond differently to RV 
infection, with asthmatics having increased frequency, severity and duration of lower 
respiratory tract symptoms, a greater decline in lung function [51], and deficient IFN-β 
[125] and IFN-λ [126] production. Studies have also shown RV infection of airway 
epithelial cell lines and / or HBEC, to increase pro-inflammatory cytokine expression 
including, CCL5 [79] [83], CXCL10 [91], IL-6 [77] [78] [80] [95], CXCL8 [79] [83] [77] [78] 
[80] [82] and CXCL5 [84], and increased pro-inflammatory cytokine expression has been 
observed in nasal aspirates, nasal washings and sputum of asthmatics infected with RV 
[85] [86] [87] [89] [88]. It is this combination of deficient IFN production and increased 
pro-inflammatory cytokine production which is believed to precipitate the exacerbation of 
asthmatic symptoms, with the chemo-attraction of inflammatory cells into the lung 
causing a local inflammatory response, impaired lung function, increased bronchial 
responsiveness and exacerbation of asthma symptoms. The mechanisms, by which viral 
infection leads to exacerbation of asthma symptoms is poorly studied, and a better 
understanding of the molecular mechanisms by which RV induces IFN-β, IFN-λ and pro-
inflammatory cytokines, may lead to the identification of potential therapeutic targets for 
viral exacerbations of asthma. 
Virus-induced triggering of host cell signalling pathways and therefore the induction of 
IFN-β, IFN-λ, and pro-inflammatory cytokines is thought to be mediated by the 
production of a dsRNA intermediate during viral replication. Many studies have 
suggested a role for viral replication in the up-regulation of several mediators, which is 
not observed with UV-inactivated virus [81] [83] [101]. The initial sensing of viral 
infection and activation of signalling pathways, which lead to the activation of 
transcription factors, and the induction of IFNs and pro-inflammatory cytokine 
expression, occurs through viral pattern recognition receptors (PRR). The dsRNA PRRs, 
Toll-like receptor-3 (TLR3), retinoic acid inducible gene (RIG)-I and melanoma 
differentiation associated gene (MDA)-5, have all been implicated in activation of the 
transcription factors NF-κB [215] [256] [258] [246], IRF3 [256] [258] [246] [216] [212] and 
ATF-2/c-Jun [218] [214] [254], which in turn are required for IFN and pro-inflammatory 
cytokine expression. Thus, TLR3, RIG-I and MDA5 have all been implicated in the viral 
and or polyIC-induction of IFN-β [246] [214] [259] [213] and pro-inflammatory cytokines 
[245] [259] [320] [321]. The dsRNA PRRs mediating viral induction of IFN-λ are less 
explored, and recently a role for RIG-I has been demonstrated [202]. The dsRNA PRR 
protein kinase R (PKR) has also been implicated in NF-κB activation [204] [205] but the 
role of PKR in IFN-β expression is generally disfavoured [207]. 
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TLR3 recognises endosomal dsRNA, and studies have implicated TLR3 in the in vitro 
antiviral response to RV [320], influenza A [212] and RSV [322]. A role for TLR3 in vivo 
is controversial, with TLR3 deficient mice showing both beneficial and detrimental 
effects on host cell viral infection [323] [324] [325]. RIG-I and MDA5 recognise 
cytoplasmic dsRNA. In vivo studies have shown RIG-I primarily to detect dsRNA 
transcribed in vitro [259], and synthetic polyIC to primarily be recognised by MDA5 [259]. 
The reason for this difference in RNA recognition has recently been determined to be 
due to the ability of RIG-I (and not MDA5) to detect 5’-triphosphate RNA [249] [250], 
which is generated by viral polymerases. In addition to the recognition of 5’-triphosphate 
RNA by RIG-I, In vitro studies have shown RIG-I to bind non-phosphorylated dsRNA 
(polyIC) [245] [246] [247]. This ability of RIG-I to bind both dsRNA and 5’-triphosphate 
RNA has recently been confirmed [326].  
RIG-I and MDA5 have also been shown to recognise distinct sets of RNA viruses, with 
RIG-I recognising NDV, SV, VSV, influenza virus and Japanese encephalitis virus (JEV) 
[259], and MDA5 recognising the picornavirus family members, EMCV, theiler’s and 
mengo viruses [259]. Whether all picornavirus family members are specifically 
recognised by MDA5 is unknown. The TLR3 pathway has been shown to signal 
independently to the RIG-I and MDA5 pathways, with IFN-β induction by the TLR3 
pathway unaffected by inhibition of RIG-I [254] or the RIG-I/MDA5 adaptor protein Cardif 
[254] [255] [228]. Furthermore, recognition of NDV, by RIG-I, and subsequent signalling 
to IRF3 activation is unaffected by the absence of the TLR3 adaptor protein TRIF [245]. 
Studies have also shown different cell types to preferentially rely upon RIG-I/MDA5 or 
TLR pathways to mediate an antiviral response. RIG-I/MDA5 and not TLR pathway 
activation is essential for sensing viral infection in MEFs and cDCs [258], and TLR 
pathways, but not RIG-I/MDA5, are essential for virus sensing in pDCs [258] [259]. With 
respect to RVs and their infection of HBEC, the PRRs required by RVs for the induction 
of IFN-β, IFN-λ and pro-inflammatory cytokines are not known. These important PRRs 
will be investigated in this chapter and in doing so we will begin to elucidate the 
mechanism(s) by which RV induces IFN-β, IFN-λ and pro-inflammatory cytokine 
production.  
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3.2 RV1B infection of Human Bronchial Epithelial Cells 
RV infection of airway epithelial cell lines has been demonstrated to induce pro-
inflammatory cytokine production [79] [91] [95] [82] [84], and RV infection of normal 
human bronchial epithelial cells (HBEC) to induce expression of IFN-β and IFN-λs [125] 
[126]. RV1B-induced pro-inflammatory cytokine (CCL5, CXCL10, IL-6, CXCL8, CXCL5), 
and interferon (IFN) (IFN-β, IFN-λ1, IFN-λ2/3) expression in HBEC was confirmed 
before commencing experiments to investigate a role for the pattern recognition 
receptors RIG-I, MDA5 and TLR3 in RV1B-induced pro-inflammatory cytokine and 
interferon expression.  
3.2.1 RV1B-induced pro-inflammatory cytokine and Interferon 
mRNA in HBEC 
HBEC were serum starved using bronchial epithelium basal medium (BEBM) for 24h 
and infected at time -1h with RV1B (MOI 1) for 1h, and then cultured for up to 72h. 
RV1B induced pro-inflammatory cytokine (CCL5, CXCL10, IL-6, CXCL8, CXCL5) and 
IFN (IFN-β, IFN-λ1, IFN-λ2/3) mRNA, was measured by TaqMan RT-PCR. Time-course 
analysis of RV1B-induced IFN-β, IFN-λ1 and IFN-λ2/3 showed their induction to occur 
early, with a significant increase in IFN-λ2/3 (p<0.05), and a non-significant increased in 
IFN-λ1, observed at 4h post-infection, and a significant increase in IFN-β (p<0.05) 
observed at 8h post-infection, versus uninfected cells (Fig. 3.2A-C). RV1B-induced IFN-
β, IFN-λ1 and IFN-λ2/3 mRNA remained significantly increased compared to uninfected 
cells, at later time points (8, 24h), rising steadily in a time-dependent manner up to 48h 
post-infection (IFN-β p<0.05, IFN-λ1 and IFN-λ2/3 p<0.001) (Fig. 3.2A-C). A slight 
decline in IFN-β, IFN-λ1 and IFN-λ2/3 mRNA was observed by 72h post-infection, but a 
significant difference remained between RV1B infected and uninfected cells (IFN-β 
p<0.05, IFN-λ1 and IFN-λ2/3 p<0.001) (Fig. 3.2A-C). RV1B-induction of the pro-
inflammatory cytokines CCL5, CXCL10 and CXCL8 (p<0.01) was observed by 8h post-
infection (Fig. 3.2D, E, G). The induction of CXCL10 and CXCL8 peaked at 24h post-
infection (CXCL10 p<0.001, CXCL8 p<0.05 versus uninfected cells), with CCL5 mRNA 
significantly induced (p<0.001 versus uninfected cells) by 24h post-infection and rising to 
a peak by 48h post-infection (p<0.01 versus uninfected cells) (Fig. 3.2D, E, G). A decline 
in RV1B-induced CXCL10 and CXCL8 mRNA was observed by 48h (CXCL10 p<0.01, 
CXCL8 p<0.05) and again further by 72h post-infection (CXCL10 p<0.05, CXCL8 
p<0.05), but both remained increased versus uninfected cells (Fig. 3.2E, G). CCL5 
mRNA induction declined by and was no longer significantly induced versus uninfected 
cells by 72h post-infection (Fig. 3.2D). An induction of IL-6 and CXCL5 by RV1B was not 
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observed compared to uninfected cells until 24h post-infection, at which point a peak in 
CXCL5, and a significant difference in IL-6 mRNA versus uninfected cells was observed 
(IL-6 p<0.05) (Fig. 3.2F, H). By 48h post-infection IL-6 and CXCL5 mRNA had declined 
and IL-6 mRNA was no longer significantly different from uninfected cells (Fig. 3.2F, H). 
IL-6 mRNA declined further by 72h post-infection and those of CXCL5 remain 
unchanged (Fig. 3.2F, H).  
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Figure 3.2 Time course of RV1B-induced Interferon and pro-inflammatory cytokine mRNA 
in HBEC. IFN-β (A), IFN-λ1 (B), IFN-λ2/3 (C), CCL5 (D), CXCL10 (E), IL-6 (F), CXCL8 (G) and 
CXCL5 (H) were measured by TaqMan RT-PCR in HBEC cultured with RV1B at an MOI of 1 
(closed squares) or with medium alone (open triangles). Total cell RNA was harvested for 
analysis at 0, 4, 8, 24, 48 and 72h post-infection. Data are the mean ± SEM of 3 separate 
experiments. 
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3.2.2 Analysis of RV1B-induced IFN-β and IFN-λs in different 
HBEC sources 
The HBEC used in this study were obtained from four different non-asthmatic subjects. 
In contrast to non-asthmatic (normal) bronchial epithelial cells, asthmatic bronchial 
epithelial cells have a reduced production of IFN-β and IFN-λs upon RV infection, and in 
severe examples IFNs are not induced [125] [126]. The ability of each HBEC source 
used in this study to induce IFN upon RV1B infection was confirmed by the levels of 
IFN-β and IFN-λ expression induced upon RV1B infection of each HBEC source. 
HBEC were serum starved using BEBM for 24h and infected at time -1h with RV1B 
(MOI 1) for 1h with agitation, and then cultured for 24h. RV1B-induced IFN-β, IFN-λ1 
and IFN-λ2/3 mRNA expression, in each HBEC source, were measured by TaqMan RT-
PCR. IFN-β mRNA was significantly induced upon RV1B infection in HBEC source 
4F0174 (p<0.01), 4F1604 (p<0.01) and 6F4181 (p<0.001) compared to uninfected cells 
(Fig.3.3). An induction in IFN-β mRNA, versus uninfected cells, was also observed in 
HBEC source 4F0872 (n=1). IFN-λ1 mRNA was significantly induced upon RV1B 
infection in all HBEC sources (all p<0.001 versus uninfected cells). IFN-λ2/3 mRNA was 
significantly induced by RV1B in HBEC source 4F1604 (p<0.001) and 6F4181 
(p<0.001). An induction of IFN-λ2/3 by RV1B, versus uninfected cells, was also 
observed in HBEC source AF0872 and 4F0174 (both n=2). Although IFN-β, IFN-λ and 
IFN-λ2/3 mRNA levels varied between HBEC sources, both in the absence and in the 
presence of RV1B infection, the data suggest that all HBEC sources used in this study 
were able to produce IFN-β, IFN-λ1 and IFN-λ2/3 upon RV1B infection. 
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Source:            4F0174             4F0872        4F1604             6F4181 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3 Comparison of RV1B-induced IFN-β, IFN-λ1 and IFN-λ2/3 mRNA in different 
HBEC sources. IFN-β, IFN-λ1 and IFN-λ2/3 mRNA was measured by TaqMan RT-PCR, from 
HBEC cultured with RV1B at an MOI of 1 (closed squares) or treated with infection medium alone 
(closed triangles). Total cell RNA was harvested for analysis at 24h post-infection. IFN-β data are 
the mean ± SEM of 5 (4F0174), 1 (4F0872), 5 (4F1604) and 6 (6F4181) separate experiments. 
IFN-λ1 data are the mean ± SEM of 5 (4F0174), 3 (4F0872), 5 (4F1604) and 5 (6F4181) 
separate experiments. IFN-λ2/3 data are the mean ± SEM of 2 (4F0174), 2 (4F0872), 5 (4F1604) 
and 6 (6F4181) separate experiments.  
 
 
 
RV
1B
 
Me
diu
m
 
100
101
102
103
104
105
106 **
IF
N
-
ββ ββ
(lo
g1
0 
co
pi
e
s 
/ 2
.
0x
10
5  
ce
lls
)
RV
1B
 
Me
diu
m
 
100
101
102
103
104
105
106
RV
1B
 
Me
diu
m
 
100
101
102
103
104
105
106 **
RV
1B
 
Me
diu
m
 
100
101
102
103
104
105
106 ***
RV
1B
 
Me
diu
m
 
100
101
102
103
104
105
106 ***
IF
N
-
λλ λλ 1
(lo
g1
0 
co
pi
e
s 
/ 2
.
0x
10
5  
ce
lls
)
RV
1B
 
Me
diu
m
 
100
101
102
103
104
105
106 ***
RV
1B
 
Me
diu
m
 
100
101
102
103
104
105
106 ***
RV
1B
 
Me
diu
m
 
100
101
102
103
104
105
106 ***
RV
1B
 
Me
diu
m
 10 -1
100
101
102
103
104
105
106
IF
N
-
λλ λλ 2
/3
(lo
g1
0 
co
pi
e
s 
/ 2
.
0x
10
5  
ce
lls
)
RV
1B
 
Me
diu
m
 
100
101
102
103
104
105
106
RV
1B
 
Me
diu
m
 
100
101
102
103
104
105
106 ***
RV
1B
 
Me
diu
m
 10 -1
100
101
102
103
104
105
106 ***
                                                                                                                             Chapter 3: Results 
 
109 
3.2.3  RV1B-induced pro-inflammatory cytokine production in 
HBEC is replication dependent 
HBEC were serum starved using BEBM for 24h and infected with RV1B (MOI 1) or 
treated with either UV-inactivated RV1B, filtered live virus inoculum (filtrate) or BEBM 
alone, for 1h with agitation, then cultured for 24h before harvesting supernatants for 
cytokine analysis by ELISA. Upon RV1B infection, levels of pro-inflammatory cytokines 
were increased, compared to medium treated control cells (CCL5, CXCL8, CXCL5 all 
p<0.001; CXCL10, IL-6 both p<0.01) measured by ELISA 24h post-infection and culture 
(Fig. 3.4). UV-inactivated RV1B significantly reduced RV-induced CCL5 (p<0.001), 
CXCL10 (p<0.01), IL-6 (p<0.01), CXCL8 (p<0.01) and CXCL5 (p<0.01) as did RV1B 
filtered through a 30kDa molecular weight cut off filter (CCL5 p<0.001, CXCL10 p<0.01, 
IL-6 p<0.05, CXCL8 p<0.001, CXCL5 p<0.01) compared to active RV1B.   
 
 
 
Figure 3.4 Requirement of RV1B replication for induction of pro-inflammatory cytokines 
and chemokines by RV1B in HBEC. RV1B-induced CCL5 (A), CXCL10 (B), IL-6 (C) CXCL8 (D) 
and CXCL5 (E) were measured by ELISA, from HBEC cultured with RV1B at an MOI of 1, UV-
RV1B, Filtrate or with medium alone for 1h with agitation. Cell supernatants were harvested for 
analysis at 24 post-infection. RV1B induced significantly greater pro-inflammatory cytokine copies 
compared to UV-RV1B, Filtrate and medium alone. Data are the mean ± SEM of 3 separate 
experiments performed in one HBEC donor.  
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3.3 Optimisation of siRNA transfection in HBEC 
As conditions for optimal siRNA delivery vary among mammalian cell types, the 
successful and reproducible delivery of an effective concentration of siRNA into HBEC 
was optimised. The degree of target gene inhibition with respect to timing of the 
experimental procedure also considered.    
3.3.1 Optimising of siRNA transfection 
HBEC were transfected with 100nM siGLO RISC-Free siRNA (DY-547 labelled) using 
the lipid based transfection reagent Lipofectamine2000 (LP2000). LP2000 concentration 
and length of time LP2000 remained in contact with cells (transfection time) was varied, 
and cells examined for siRNA transfection efficiency at 24h post-transfection. 
Fluorophore labelled siRNA was visualised using a fluorescent microscope to assess 
siRNA transfection efficiency and cell toxicity examined by eye using a light microscope. 
siRNA transfection using LP2000 at concentrations of 1.0, 2.5, 3.5 and 5.0µg/mL and 
incubation of LP2000:siRNA complexes with cells for 2, 3, 4 and 5h was preformed. The 
highest transfection efficiency (approximately 90% of cells) was obtained with LP2000 at 
2.5µg/mL with a 4h LP2000:siRNA complex incubation with cells (Fig. 3.5A, B). Toxicity 
was also minimal (Fig. 3.5C, D). This combination of LP2000 concentration and complex 
incubation time with cells was deemed optimal and all future siRNA transfection studies 
in HBEC employed this protocol.    
 
Figure 3.5 Optimisation of siRNA transfection into HBEC. HBEC were transiently transfected 
with 100nM siGLO RISC-Free siRNA (DY-547 labelled) using LP2000 at concentrations of 1.0, 
2.5, 3.5 and 5.0µg/mL and LP2000:siRNA complexes incubated with cells for 2, 3, 4 and 5h. 
siRNA transfection efficiency was visualised using fluorescent microscopy (A, B) and toxicity by 
light microscope (C, D). Images are shown for siRNA transfection using LP2000 at 2.5µg/mL with 
a 4h LP2000:siRNA complex incubation with cells. Transfection efficiency was approximately 
90% (A, B), and toxicity was minimal (C, D). Objective 10 x /0.30 Ph1, image size 432 x 342 (A, 
B) and 1200 x 1030 (C, D).  
A
B
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D
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3.3.2 Optimising siRNA delivery and RV infection 
HBEC were transfected with RIG-I, Cardif or non-targeting control siRNA at 100nM and 
then cultured for 24h or 48h and harvested for total RNA, or incubated with RV1B (MOI 
of 1) for 1h, and cultured for a further 24h and harvested for total RNA. Reduction in 
RIG-I and Cardif mRNA was analysed by TaqMan RT-PCR. RIG-I mRNA was reduced 
to 23% at 24h post-transfection and to 37% at 48h post-transfection, of values obtained 
by transfection with non-targeting control siRNA (Fig. 3.6A). Cardif mRNA was reduced 
to 9% at 24h post-transfection and to 6% at 48h post-transfection, of values obtained by 
transfection with non-targeting control siRNA (Fig. 3.6B). In cells which were transfected 
for 24h or 48h and then infected with RV1B, and cultured for a further 24h, RIG-I mRNA 
was reduced to 16% and to 35% respectively, of values obtained by transfection with 
non-targeting control siRNA (Fig. 3.6C). In cells which were transfected for 24h or 48h 
and then infected with RV1B, and cultured for a further 24h, Cardif mRNA was reduced 
to 14% and to 65% respectively, of values obtained by transfection with non-targeting 
control siRNA (Fig. 3.6D). Future siRNA experiments were therefore performed with cell 
harvesting for total RNA at 48h post-transfection (24h post-infection).           
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Figure 3.6 Reduction of RIG-I and Cardif mRNA by RIG-I and Cardif specific siRNA in the 
absence and presence of RV1B in HBEC. HBEC were transiently transfected with RIG-I, Cardif 
or non-targeting control siRNA (100nM). 24h or 48h post-transfection cells were harvested for 
total RNA or infected with RV1B (MOI of 1), cultured for a further 24h and harvested for total 
RNA. RIG-I and Cardif mRNA were measured by TaqMan RT-PCR. RIG-I siRNA reduced RIG-I 
mRNA to 23% at 24h and 37% at 48h post-transfection (A), and Cardif siRNA reduced Cardif 
mRNA to 9% at 24h and 6% at 48h post-transfection (B), compared to non-targeting control 
siRNA transfected cells. In cells transfected for 24h or 48h and then infected with RV1B, RIG-I 
siRNA reduced RIG-I mRNA to 16% and 35% respectively (C), and Cardif siRNA reduced Cardif 
mRNA to 14% and 65% respectively (D) compared to non-targeting control siRNA transfected 
cells. Data are the mean ± SEM of 1-2 separate experiments and expressed as % of control 
siRNA transfected cells =100%. 
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3.4 Effect of RIG-I, MDA5 and TLR3 inhibition on RV1B 
infected normal human bronchial epithelial cells 
Having demonstrated that replicating RV1B is required to induce pro-inflammatory 
cytokine production, and that IFN-β, IFN-λ-1 and IFN-λ2/3 mRNA are induced by RV1B, 
a functional role for the pattern recognition receptors RIG-I, MDA5 and TLR3 in 
response to RV1B infection, with respect to the pro-inflammatory cytokines (CCL5, 
CXCL10, IL-6, CXCL8, CXCL5) and IFNs was investigated using siRNA specifically 
targeting RIG-I, MDA5 and TLR3.  
3.4.1 Inhibition of RIG-I, MDA5 and TLR3 mRNA and protein by 
RIG-I, MDA5 and TLR3 specific siRNA 
HBEC were transfected with RIG-I, MDA5 or TLR3 specific siRNA, a non-targeting 
control siRNA or were untransfected, and then cultured for 24h before incubating with 
RV1B (MOI of 1) or treating with BEBM alone, and culturing for a further 24h. Cells were 
harvested for total RNA or protein, and reduction in RIG-I, MDA5 and TLR3 mRNA 
analysed by TaqMan RT-PCR or reduction in RIG-I, MDA5 and TLR3 protein by western 
blot analysis. Following RV1B infection, RIG-I, MDA5 and TLR3 siRNA reduced RIG-I, 
MDA5 and TLR3 mRNA levels respectively to 20%, 3% and 11% (all p<0.001), of 
expression levels obtained with non-targeting control siRNA (Fig. 3.7A, C, E). RIG-I and 
MDA5 protein was not detected in medium treated alone cells or in uninfected non-
targeting control siRNA transfected cells (data not shown). siRNA targeting RIG-I and 
MDA5 in RV1B infected cells, reduced RIG-I and MDA5 protein expression respectively, 
compared to RV1B infected non-targeting control siRNA transfected cells (Fig. 3.7B, D). 
TLR3 protein was detected in medium treated alone cells and in uninfected non-
targeting control siRNA and uninfected TLR3 specific siRNA transfected cells (Fig. 
3.7F). TLR3 targeting siRNA reduced TLR3 protein expression, compared to non-
targeting control siRNA in the absence of RV1B infection (Fig. 3.7F). The structural 
proteins β-actin or α-tubulin were used as controls to assess protein loading. 
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Figure 3.7 Reduction of RIG-I, MDA5 and TLR3 mRNA and protein by RIG-I, MDA5 and 
TLR3 specific siRNA in HBEC. HBEC were transiently transfected with RIG-I, MDA5, TLR3 or 
non-targeting control siRNA (100nM) or untransfected. 24h post-transfection, cells were infected 
with RV1B (MOI 1). At 24h post-infection, cells were harvested for total RNA or protein and RIG-I 
(A), MDA5 (C) and TLR3 (E) mRNA measured by TaqMan RT-PCR, or RIG-I (B), MDA5 (D) and 
TLR3 (F) protein measured by western blot. RIG-I, MDA5 and TLR3 mRNA expression was 
inhibited by RIG-I, MDA5 and TLR3 siRNA respectively (all p<0.001), versus non-targeting 
control siRNA. Data are the mean ± SEM of 6 (A), 5 (C), and 7 (E) separate experiments and 
expressed as % of control siRNA transfected cells =100%, (***p<0.001, **p<0.01, *p<0.05 versus 
non-targeting control siRNA). Western blots are representative of 2-3 experiments.  
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3.4.2  Inhibition of RIG-I during RV1B infection of HBEC inhibited 
IFN-β, but not IFN-λ1 or IFN-λ2/3 induction 
HBEC were transfected with RIG-I targeting siRNA, a non-targeting control siRNA or 
were untransfected, and then cultured for 24h before incubating with RV1B (MOI of 1) or 
treating with BEBM alone, and culturing for a further 24h. Cells were harvested for total 
RNA and IFN-β, IFN-λ1 and IFN-λ2/3 mRNA analysed by TaqMan RT-PCR. RIG-I 
siRNA significantly inhibited RV1B-induced IFN-β (p<0.001), but did not inhibit IFN-λ1 
(p>0.05), and enhanced RV1B-induced IFN-λ2/3 (p<0.05), compared to RV1B infected 
non-targeting control siRNA transfected cells (Fig. 3.8A-C). No significant difference 
between uninfected untransfected cells and uninfected non-targeting control siRNA 
transfected cells was observed (all p>0.05) indicating that control siRNA alone did not 
induce IFN-β, IFN-λ1 or IFN-λ2/3 mRNA.  
 
 
 
 
Figure 3.8 Effect of RIG-I siRNA on RV1B induced IFN-β, IFN-λ1 and IFN-λ2/3 mRNA 
expression in HBEC. HBEC were transiently transfected with RIG-I or non-targeting control 
siRNA, or untransfected. 24h post-transfection, cells were infected with RV1B (MOI 1), or treated 
with infection medium alone. 24h post-infection, cells were harvested for total RNA and IFN-β, 
IFN-λ1 and IFN-λ2/3 mRNA measured by TaqMan RT-PCR. RIG-I siRNA inhibited RV1B 
induced IFN-β (A) (p<0.001), did not inhibit IFN-λ1 (B) (p>0.05), and induced IFN-λ2/3 (C) 
(p<0.05) mRNA expression, compared to cells infected and transfected with control siRNA. Data 
are the mean ± SEM of 4−6 separate experiments and expressed as % of infected control 
=100%, (***p<0.001, **p<0.01, *p<0.05 versus non-targeting control siRNA), ### versus 
untransfected, uninfected control.   
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3.4.3 Inhibition of RIG-I during RV1B infection of HBEC inhibited 
pro-inflammatory cytokine induction 
In identical experiments to those produced in section 3.4.2, RIG-I siRNA significantly 
inhibited RV1B-induced CCL5 (p<0.05), CXCL10, IL-6 (both p<0.001), CXCL8 and 
CXCL5 (p<0.01), compared to RV1B infected non-targeting control siRNA transfected 
cells (Fig. 3.9A-E). No significant difference between uninfected untransfected cells and 
uninfected non-targeting control siRNA transfected cells was observed (all p>0.05) 
indicating that control siRNA alone did not induce pro-inflammatory cytokine mRNA.  
 
 
 
 
 
Figure 3.9 Effect of RIG-I siRNA on RV1B induced pro-inflammatory cytokine mRNA 
expression in HBEC. HBEC were transiently transfected with RIG-I or non-targeting control 
siRNA, or untransfected. 24h post-transfection, cells were infected with RV1B (MOI of 1), or 
treated with infection medium alone. 24h post-infection, cells were harvested for total RNA and 
pro-inflammatory cytokines measured by TaqMan RT-PCR. RIG-I siRNA inhibited RV1B induced 
CCL5 (A) (p<0.05), CXCL10 (B) (p<0.001), IL-6 (C) (p<0.001), CXCL8 (D) (p<0.001) and CXCL5 
(E) (p<0.01) mRNA expression, compared to cells infected and transfected with control Data are 
the mean ± SEM of 5−6 separate experiments and expressed as % of infected control =100%. 
siRNA (***p<0.001, **p<0.01, *p<0.05 versus non-targeting control siRNA), ### versus 
untransfected, uninfected control.   
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3.4.4  Inhibition of MDA5 during RV1B infection of HBEC 
inhibited IFN-β, IFN-λ1 and IFN-λ2/3 induction 
HBEC were transfected with MDA5 targeting siRNA, a non-targeting control siRNA or 
were untransfected, and then cultured for 24h before incubating with RV1B (MOI of 1) or 
treating with BEBM alone, and culturing for a further 24h. Cells were harvested for total 
RNA and IFN-β, IFN-λ1 and IFN-λ2/3 mRNA analysed by TaqMan RT-PCR. MDA5 
siRNA significantly inhibited RV1B-induced IFN-β, IFN-λ1 and IFN-λ2/3 (all p<0.001) 
compared to RV1B infected non-targeting control siRNA transfected cells (Fig. 3.10A-C). 
No significant difference between uninfected untransfected cells and un-infected non-
targeting control siRNA transfected cells was observed (all p>0.05) indicating that 
control siRNA alone did not induce IFN-β, IFN-λ1 or IFN-λ2/3 mRNA.  
 
 
 
 
 
Figure 3.10 Effect of MDA5 siRNA on RV1B induced IFN-β, IFN-λ1 and IFN-λ2/3 mRNA 
expression in HBEC. HBEC were transiently transfected with MDA5 or non-targeting control 
siRNA, or untransfected. 24h post-transfection, cells were infected with RV1B (MOI 1), or treated 
with infection medium alone. 24h post-infection, cells were harvested for total RNA and IFN-β, 
IFN-λ1 and IFN-λ2/3 mRNA measured by TaqMan RT-PCR. MDA5 siRNA inhibited RV1B 
induced IFN-β (A), IFN-λ1 (B) and IFN-λ2/3 (C) mRNA expression (all p>0.05), compared to cells 
infected and transfected with control siRNA. Data are the mean ± SEM of 4−5 separate 
experiments and expressed as % of infected control =100%, (***p<0.001, **p<0.01, *p<0.05 
versus non-targeting control siRNA), ### versus untransfected, uninfected control.   
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3.4.5  Inhibition of MDA5 during RV1B infection of HBEC 
inhibited pro-inflammatory cytokine induction 
In identical experiments to those produced in section 3.4.4, MDA5 siRNA significantly 
inhibited RV1B-induced CCL5, CXCL10, CXCL5, IL-6 and CXCL8 (all p<0.001) 
compared to RV1B infected non-targeting control siRNA transfected cells (Fig. 3.11A-E). 
No significant difference between uninfected untransfected cells and uninfected non-
targeting control siRNA transfected cells was observed (all p>0.05) indicating that 
control siRNA alone did not induce any of the pro-inflammatory cytokines measured. 
 
 
 
 
 
Figure 3.11 Effect of MDA5 siRNA on RV1B induced pro-inflammatory cytokine mRNA 
expression in HBEC. HBEC were transiently transfected with RIG-I or non-targeting control 
siRNA, or untransfected. 24h post-transfection, cells were infected with RV1B (MOI of 1), or 
treated with infection medium alone. 24h post-infection, cells were harvested for total RNA and 
pro-inflammatory cytokines measured by TaqMan RT-PCR. MDA5 siRNA inhibited RV1B 
induced CCL5 (A), CXCL10 (B), IL-6 (C), CXCL8 (D) and CXCL5 (E) (all p<0.001) mRNA 
expression, compared to cells infected and transfected with control siRNA. Data are the mean ± 
SEM of 3−5 separate experiments and expressed as % of infected control =100%, (***p<0.001, 
**p<0.01, *p<0.05 versus non-targeting control siRNA), ### versus untransfected, uninfected 
control.   
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3.4.6  Inhibition of TLR3 during RV1B infection of HBEC inhibited 
IFN-β, IFN-λ1 and IFN-λ2/3 induction 
HBEC were transfected with TLR3 targeting siRNA, a non-targeting control siRNA or 
were untransfected, and then cultured for 24h before incubating with RV1B (MOI of 1) or 
treating with BEBM alone, and culturing for a further 24h. Cells were harvested for total 
RNA and IFN-β, IFN-λ1 and IFN-λ2/3 mRNA analysed by TaqMan RT-PCR. TLR3 
siRNA significantly inhibited RV1B-induced IFN-β, IFN-λ1 (both p<0.001) and IFN-λ2/3 
(p<0.01) compared to RV1B infected non-targeting control siRNA transfected cells (Fig. 
3.12A-C). No significant difference between uninfected untransfected cells and 
uninfected non-targeting control siRNA transfected cells was observed (all p>0.05) 
indicating that control siRNA alone did not induce IFN-β, IFN-λ1 or IFN-λ2/3 mRNA.  
 
 
 
 
Figure 3.12 Effect of TLR3 siRNA on RV1B induced IFN-β, IFN-λ1 and IFN-λ2/3 mRNA 
expression in HBEC. HBEC were transiently transfected withTLR3 or non-targeting control 
siRNA, or untransfected. 24h post-transfection, cells were infected with RV1B (MOI 1), or treated 
with infection medium alone. 24h post-infection, cells were harvested for total RNA and IFN-β, 
IFN-λ1 and IFN-λ2/3 mRNA measured by TaqMan RT-PCR. TLR3 siRNA inhibited RV1B 
induced IFN-β (A) (p<0.001), IFN-λ1 (B) (p<0.001) and IFN-λ2/3 (C) (p<0.01) mRNA expression, 
compared to cells infected and transfected with control siRNA Data are the mean ± SEM of 6−7 
separate experiments and expressed as % of infected control =100%, (***p<0.001, **p<0.01, 
*p<0.05 versus non-targeting control siRNA), ### versus untransfected, uninfected control.     
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3.4.7  Inhibition of TLR3 during RV1B infection of HBEC inhibited 
pro-inflammatory cytokine induction 
In identical experiments to those produced in section 3.4.6, TLR3 siRNA significantly 
inhibited RV1B-induced CCL5, CXCL10, CXCL5, IL-6 and CXCL8 (all p<0.001) 
compared to RV1B infected non-targeting control siRNA transfected cells (Fig. 3.13A-E). 
No significant difference between uninfected untransfected cells and uninfected non-
targeting control siRNA transfected cells was observed (all p>0.05) indicating that 
control siRNA alone did not induce any of the pro-inflammatory cytokines measured.  
 
 
 
 
Figure 3.13 Effect of TLR3 siRNA on RV1B induced pro-inflammatory cytokine mRNA 
expression in HBEC. HBEC were transiently transfected with RIG-I or non-targeting control 
siRNA, or untransfected. 24h post-transfection, cells were infected with RV1B (MOI of 1), or 
treated with infection medium alone. 24h post-infection, cells were harvested for total RNA and 
pro-inflammatory cytokines measured by TaqMan RT-PCR. TLR3 siRNA inhibited RV1B induced 
CCL5 (A), CXCL10 (B), IL-6 (C), CXCL8 (D) and CXCL5 (E) (all p<0.001) mRNA expression 
compared to cells infected and transfected with control siRNA Data are the mean ± SEM of 5−7 
separate experiments and expressed as % of infected control =100%, (***p<0.001, **p<0.01, 
*p<0.05 versus non-targeting control siRNA), ### versus untransfected, uninfected control.   
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3.5 Effect of RIG-I, MDA5 and TLR3 siRNA on IFN and 
pro-inflammatory cytokine expression in HBEC 
Although siRNA have a high degree of specificity, non-specific off-target effects have 
been observed with particular siRNA sequence motifs and siRNA duplex lengths that 
induce interferon gene expression in a cell-type specific manner [327] [328]. Cationic 
lipids, e.g. LP2000, used to deliver siRNA into cells have also been demonstrated to 
induce changes in gene expression profiles. To ensure that the specific targeting siRNA 
used in this study did not significantly induce interferon (or the production of pro-
inflammatory cytokines) the effect of each specific targeting siRNA on interferon and 
pro-inflammatory cytokine gene expression, in the absence of RV infection, was 
assessed and compared to dsDNA transfected, and untransfected cells.  
3.5.1  RIG-I, MDA5 and TLR3 siRNA did not induce IFN gene 
expression in HBEC  
HBEC were transfected with RIG-I, MDA5 or TLR3 specific siRNA, or dsDNA, then 
cultured for 24h before replacing culture medium with fresh BEBM and culturing for a 
further 24h. Cells were harvested for total RNA and IFN-β, IFN-λ1 and IFN-λ2/3 mRNA 
analysed by TaqMan RT-PCR (Table 3.1). RIG-I siRNA transfection did not induce IFN-
β, IFN-λ1 or IFN-λ2/3 mRNA (all p>0.05) versus untransfected cells. MDA5 siRNA 
transfection did not induce IFN-β mRNA (p>0.05) and non-significantly induced IFN-λ1 
and IFN-λ2/3 mRNA (both p>0.05) versus untransfected cells. Transfection with TLR3 
siRNA did not induce IFN-β or IFN-λ2/3 mRNA (both p>0.05), and non-significantly 
induced IFN-λ1 (p>0.05), versus untransfected cells. IFN-β, IFN-λ1 and IFN-λ2/3 mRNA 
copies in dsDNA transfected cells were increased but not significantly different to their 
respective IFN-β, IFN-λ1 and IFN-λ2/3 mRNA copies (all p>0.05) in untransfected cells. 
Additionally, no-significant difference in IFN-β, IFN-λ1 or IFN-λ2/3 mRNA (all p>0.05) 
was observed between RIG-I, MDA5 or TLR3 siRNA transfected cells and dsDNA 
transfected cells.  
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 IFN-β IFN-λ1 IFN-λ2/3 
Un-transfected    
Mean copies ± SEM 2.3x104 ± 1.4x104 1.0x102 ± 5.8x101 1.3x103 ± 6.7x102 
dsDNA    
Mean copies ± SEM 3.1x104 ± 1.3x104 NS 2.2x103 ± 1.5x103 NS 1.9x103 ± 1.0x103 NS 
RIG-I siRNA    
Mean copies ± SEM 9.3x102 ± 4.8x102 NS/NS 1.3x101 ± 0.1x101 NS/NS 6.5x102 ± 4.5x102 NS/NS 
MDA5 siRNA    
Mean copies ± SEM 3.0x102 ± 2.6x102 NS/NS 6.3x102 ± 5.8x102 NS/NS 1.8x103 ± 1.3x103 NS/NS 
TLR3 siRNA    
Mean copies ± SEM 4.2x101 ± 0.5x101 NS/NS 1.1x102 ± 9.7x101 NS/NS 7.0x102 ± 6.5x102 NS/NS 
 
Figure 3.1 Effect of RIG-I, MDA5 and TLR3 siRNA or dsDNA transfection on IFN-β, IFN-λ1 
and IFN-λ2/3 mRNA expression in HBEC. HBEC were transiently transfected with RIG-I, 
MDA5, TLR3 siRNA or dsDNA. 24h post-transfection, medium was replaced and cells cultured in 
fresh infection medium for 24h. Total cell RNA was harvested for analysis at 48h post-
transfection and IFN-β, IFN-λ1 and IFN-λ2/3 measured by TaqMan RT-PCR. RIG-I, MDA5, TLR3 
siRNA or dsDNA transfection did not significantly induce IFN-β, IFN-λ1 or IFN-λ2/3 mRNA 
expression compared to un-transfected control cells (all p>0.05). Data are the mean mRNA copy 
number per 2x105 cells ± SEM of 5 separate experiments. Statistics are shown as dsDNA versus 
untransfected cells (NS), and each specific targeting siRNA versus dsDNA/untransfected cells 
respectively (NS/NS).  
3.5.2  RIG-I, MDA5 and TLR3 siRNA did not induce pro-
inflammatory cytokine gene expression in HBEC  
In identical experiments to those produced in section 3.5.1, RIG-I, MDA5 and TLR3 
siRNA transfection did not induce CCL5, CXCL10 or CXCL8 mRNA (all p>0.05), 
compared to untransfected cells (Table 3.2). RIG-I and TLR3 siRNA did not induce 
CXCL5 mRNA (both p>0.05), and MDA5 siRNA non-significantly induced CXCL5 mRNA 
(p>0.05), compared to untransfected cells. TLR3 siRNA did not induce IL-6 mRNA, and 
RIG-I and MDA5 non-significantly induced by RIG-I, MDA5 and TLR3 siRNA (all p>0.05) 
compared to untransfected cells. No-significant difference in CCL5, CXCL10, CXCL5, 
IL-6 or CXCL8 mRNA (all p>0.05) was observed between RIG-I, MDA5 or TLR3 siRNA 
transfected cells and dsDNA transfected cells. CCL5, CXCL10, CXCL5, IL-6 and CXCL8 
mRNA copies in dsDNA transfected cells were increased but not significantly different to 
their respective CCL5, CXCL10, CXCL5, IL-6 and CXCL8 mRNA copies (all p>0.05) in 
untransfected cells.  
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 CCL5 CXCL10 CXCL5 IL-6 CXCL8 
Un-transfected      
Mean copies 5.4x105 1.8x106 3.2x105 1.2x104 3.5x106 
± SEM ± 3.8x105 ± 9.0x105 ± 6.7x104 ± 4.4x103 ± 1.0x106 
dsDNA      
Mean copies 1.0x106 NS 2.5x106 NS 7.8x105 NS 1.7x104 NS 3.9x106 NS 
± SEM ± 4.0x105 ± 9.1x105 ± 2.1x105 ± 9.5x103 ± 1.0x106 
RIG-I siRNA      
Mean copies 1.4x105 NS/NS 4.8x105 NS/NS 2.9x105 NS/NS 2.3x104 NS/NS 3.3x106 NS/NS 
± SEM ± 9.1x104 ± 2.0x105 ± 1.3x105 ± 8.4x103 ± 6.9x105 
MDA5 siRNA      
Mean copies 1.8x105 NS/NS 6.1x105 NS/NS 3.7x105 NS/NS 1.9x104 NS/NS 3.2x106 NS/NS 
± SEM ± 9.7x104 ± 2.3x105 ± 1.0x105 ± 7.8x103 ± 1.0x106 
TLR3 siRNA      
Mean copies 9.3x104 NS/NS 5.5x105 NS/NS 2.6x105 NS/NS 1.2x104 NS/NS 1.7x106 NS/NS 
± SEM ± 5.9x104 ± 2.4x105 ± 1.2x105 ± 4.6x103 ± 4.8x105 
 
Figure 3.2 Effect of RIG-I, MDA5 and TLR3 siRNA or dsDNA transfection on CCL5, 
CXCL10, CXCL5, IL-6 and CXCL8 mRNA expression in HBEC. HBEC were transiently 
transfected with RIG-I, MDA5 or TLR3 siRNA or dsDNA. 24h post-transfection, medium was 
replaced and cells cultured for a further 24h. Total cell RNA was harvested for analysis at 48h 
post-transfection and pro-inflammatory cytokines measured by TaqMan RT-PCR. RIG-I, MDA5 or 
TLR3 siRNA or dsDNA transfection did not significantly induce CCL5, CXCL10, CXCL5, IL-6 or 
CXCL8 mRNA expression (all p>0.05) compared to un-transfected cells. Data are the mean 
mRNA copy number per 2x105 cells ± SEM of 5 separate experiments. Statistics are shown as 
dsDNA versus untransfected cells (NS), and each specific targeting siRNA versus 
dsDNA/untransfected cells respectively (NS/NS).  
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3.6 Effect of constitutively active RIG-I (∆RIG-I) and 
TRIF (∆TRIF) in HBEC 
The effect of constitutively active RIG-I (∆RIG-I) and TRIF (∆TRIF) on the activation of 
IRF3 and NF-κB, and IFN-β, IFN-λ1 and IFN-λ2/3 promoters was also investigated to 
support the involvement of RIG-I and TLR3 respectively, in RV1B-induced IFN-β and 
IFN-λ1 expression, and a role for TLR3 but not for RIG-I in RV1B-induced IFN-λ2/3 
expression.  
3.6.1  ∆RIG-I activated IRF3 and NF-κB dependent reporter 
constructs in HBEC   
HBEC were transfected with either constitutively active RIG-I (∆RIG-I) or pEFBOS 
control vector, a luciferase reporter construct containing either NF-κB or IRF3 binding 
sites, and a β-galactosidase expressing construct (pCMVSPORT-βgal) to control for 
transfection efficiency. Activation of NF-κB and IRF3 dependent reporter constructs was 
measured by Luciferase assay at 24h post-transfection. ∆RIG-I significantly induced the 
activation of NF-κB (p<0.001) and IRF3 (p<0.01) (Fig. 3.14A, B) compared to vector 
control (pEFBOS) transfected cells.   
 
 
 
 
Figure 3.14 Effect of ∆RIG-I on NF-κB and IRF3-dependent reporter constructs in HBEC. 
HBEC were transiently transfected with reporter constructs containing NF-κB- binding sites (A) or 
IRF3- binding sites (B) and β-galactosidase vector, together with ∆RIG-I or vector control 
(pEFBOS). Total cell lysates were collected 24h post-transfection and Luciferase measured. 
∆RIG-I induced activation of NF-κB- (A) (p<0.001) and IRF3- (B) (p<0.01) dependent reporter 
constructs, compared to vector control. Data are the mean ± SEM of 3−5 separate experiments. 
Data are presented as fold-induction of normalised luciferase levels relative to control vector 
(pEFBOS) transfected cells, (***p<0.001, **p<0.01, *p<0.05). 
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3.6.2  ∆RIG-I activated IFN-β and IFN-λ promoter reporter 
constructs in HBEC 
HBEC were transfected with either constitutively active RIG-I (∆RIG-I) or pEFBOS 
control vector, a wild-type IFN-β, IFN-λ1 or IFN-λ2/3 promoter reporter construct, and a 
β-galactosidase expressing construct (pCMVSPORT-βgal) to control for transfection 
efficiency. Activation of the IFN-β, IFN-λ1 and IFN-λ2/3 promoter reporter constructs 
was measured by Luciferase assay at 24h post-transfection. ∆RIG-I significantly induced 
the activation of wild-type IFN-β (p<0.001), IFN-λ1 and IFN-λ2/3 (both p<0.05) 
promoters, compared to control vector (pEFBOS) transfected cells (Fig. 3.15A-C).  
 
 
 
 
 
Figure 3.15 Effect of ∆RIG-I on wild-type IFN-β, IFN-λ1 and IFN-λ2/3 promoter reporter 
constructs in HBEC. HBEC were transiently transfected with reporter constructs containing wild-
type IFN-β promoter (A) wild-type IFN-λ1 promoter (B) or wild-type IFN-λ2/3 promoter (C) and β-
galactosidase vector, together with ∆RIG-I or vector control (pEFBOS). Total cell lysates were 
collected 24h post-transfection and Luciferase measured. ∆RIG-I induced activation of IFN-β (A) 
(p<0.001), IFN-λ1 (B) and IFN-λ2/3 (C) (both p<0.05) promoter reporter constructs, compared to 
vector control. Data are the mean ± SEM of 2−6 separate experiments. Data are presented as 
fold-induction of normalised luciferase levels relative to control vector (pEFBOS) transfected 
cells, (***p<0.001, **p<0.01, *p<0.05). 
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3.6.3  ∆TRIF activated IRF3 and NF-κB dependent reporter 
constructs in HBEC   
HBEC were transfected with either constitutively active TRIF (∆TRIF) or pUNO1 control 
vector, a luciferase reporter construct containing either NF-κB or IRF3 binding sites, and 
a β-galactosidase expressing construct (pCMVSPORT-βgal) to control for transfection 
efficiency. Activation of NF-κB and IRF3-dependent reporter constructs was measured 
by Luciferase assay at 24h post-transfection. ∆TRIF significantly induced the activation 
of NF-κB (p<0.01) and IRF3 (p<0.05), compared to vector control (pUNO1) transfected 
cells (Fig. 3.16A, B).   
 
 
 
 
Figure 3.16 Effect of ∆TRIF on NF-κB and IRF3-dependent reporter constructs in HBEC. 
HBEC were transiently transfected with reporter constructs containing NF-κB binding sites (A) or 
IRF3 binding sites (B) and β-galactosidase vector, together with ∆TRIF or vector control 
(pUNO1). Total cell lysates were collected 24h post-transfection and Luciferase measured. 
∆TRIF induced activation of NF-κB (A) (p<0.01) and IRF3 (B) (p<0.05) dependent reporter 
constructs, compared to vector control. Data are the mean ± SEM of 2−4 separate experiments. 
Data are presented as fold-induction of normalised luciferase levels relative to control vector 
(pUNO1) transfected cells, (***p<0.001, **p<0.01, *p<0.05). 
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3.6.4  ∆TRIF activated IFN-β and IFN-λ promoter reporter 
constructs in HBEC 
HBEC were transfected with either constitutively active TRIF (∆TRIF) or pUNO1 control 
vector, a wild-type IFN-β, IFN-λ1 or IFN-λ2/3 promoter reporter construct, and a β-
galactosidase expressing construct (pCMVSPORT-βgal) to control for transfection 
efficiency. Activation the IFN-β, IFN-λ1 and IFN-λ2/3 promoter reporter constructs was 
measured by Luciferase assay at 24h post-transfection. ∆TRIF significantly induced the 
activation of wild-type IFN-β, IFN-λ1, IFN-λ2/3 promoters (all p<0.001), compared to 
control vector (pUNO1) transfected cells (Fig. 3.17A-C). 
 
 
 
Figure 3.17 Effect of ∆TRIF on wild-type IFN-β, IFN-λ1 and IFN-λ2/3 promoter reporter 
constructs in HBEC. HBEC were transiently transfected with reporter constructs containing wild-
type IFN-β- promoter (A) wild-type IFN-λ1 promoter (B) or wild-type IFN-λ2/3 promoter (C) and β-
galactosidase vector, together with ∆TRIF or vector control (pUNO1). Total cell lysates were 
collected 24h post-transfection and Luciferase measured. ∆TRIF induced activation of IFN-β (A), 
IFN-λ1 (B) and IFN-λ2/3 (C) (all p<0.001) promoter reporter constructs, compared to vector 
control. Data are the mean ± SEM of 3−6 separate experiments. Data are presented as fold-
induction of normalised luciferase levels relative to control vector (pUNO1) transfected cells, 
(***p<0.001, **p<0.01, *p<0.05). 
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3.6.5  ∆TRIF induced IFN-β and IFN-λ1 secretion in HBEC 
HBEC were transfected with either constitutively active TRIF (∆TRIF) or pUNO1 control 
vector, or were untransfected, and then cultured for 24h. Cells were harvested for 
supernatants and IFN-β and IFN-λ1 secretion measured by ELISA. ∆TRIF significantly 
induced IFN-β and IFN-λ1 secretion (both p<0.001), compared to control vector 
(pUNO1) transfected cells (Fig. 3.18A, B).  
 
 
 
Figure 3.18 Effect of ∆TRIF on IFN-β and IFN-λ1 secretion in HBEC. HBEC were transiently 
transfected with ∆TRIF or vector control (pUNO1), or untransfected. Cell supernatants were 
collected 24h post-transfection and IFN-β and IFN-λ protein measured by ELISA. ∆TRIF induced 
IFN-β (A) and IFN-λ1 (B) (both p<0.001) secretion, compared to vector control (pUNO1) 
transfected cells. Data are the mean ± SEM of 3 separate experiments and shown as IU/mL or 
pg/mL, (***p<0.001, **p<0.01, *p<0.05). 
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3.7 Antiviral effect of RIG-I and MDA5 in RV infected 
HBEC 
To investigate whether RIG-I and/or MDA5 play a biological role in suppressing RV 
infection in HBEC, the effect of RIG-I and MDA5 inhibition on minor group virus RV1B 
and major group virus RV16 replication, by measuring RNA copy number and virus 
release from HBEC, was determined. 
3.7.1  Inhibition of RIG-I or MDA5 results in increased RV1B and 
RV16 replication in HBEC   
HBEC were transfected with RIG-I or MDA5 targeting siRNA or a non-targeting control 
siRNA and then cultured for 24h before incubating with RV1B (MOI of 1) or RV16 (MOI 
of 1) for 1h, and culturing for a further 24 or 48h. Cells were harvested for supernatants 
and total RNA at 24 and 48h post-infection. The reduction of RIG-I and MDA5 mRNA by 
specific siRNA was confirmed at each time-point using TaqMan RT-PCR (data not 
shown). Viral RNA copy number was measured using TaqMan RT-PCR, and 
supernatants assessed for infectious RV release, by titration on monolayer HeLa cell 
cultures. At 24h post-infection RV1B copy number was significantly increased by MDA5 
siRNA (p<0.05), and non-significantly increased by RIG-I siRNA (p>0.05), compared to 
non-targeting control siRNA transfected cells (Fig. 3.19A). At the same time-point RV16 
copy number was significantly increased by RIG-I siRNA (p<0.05), and non-significantly 
increased by MDA5 siRNA (p>0.05), compared to non-targeting control siRNA 
transfected cells (Fig. 3.19B). At 48h post-infection RV1B release was significantly 
increased by MDA5 siRNA (p<0.05), and non-significantly increased by RIG-I siRNA 
(p>0.05), compared to non-targeting control siRNA transfected cells (Fig. 3.19C). At the 
same time-point RV16 release was significantly increased by RIG-I siRNA (p<0.001), 
and non-significantly increased by MDA5 siRNA (p>0.05), compared to non-targeting 
control siRNA transfected cells (Fig. 3.19D).       
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Figure 3.19 Reduction of RV1B and RV16 copy number and RV1B and RV16 release by 
RIG-I and MDA5 specific siRNA in RV1B and RV16 infected HBEC. HBEC were transiently 
transfected with RIG-I, MDA5 or non-targeting control siRNA (100nM). 24h post-transfection, 
cells were infected with RV1B (MOI 1) or RV16 (MOI 1). At 24h post-infection, cells were 
harvested for total RNA and RV1B (A) and RV16 (B) viral RNA measured by TaqMan RT-PCR. 
At 48h post-infection cell supernatants were collected and RV1B (C) and RV16 (D) release 
measured by titration on monolayer HeLa cell cultures. RV1B copy number was significantly 
increased by MDA5 but not RIG-I siRNA (A) (p<0.05 and p>0.05 respectively), and RV16 copy 
number was significantly increased by RIG-I but not MDA5 siRNA (B) (p<0.05 and p>0.05 
respectively), versus non-targeting control siRNA. RV1B release was significantly increased by 
MDA5 but not RIG-I siRNA (C) (p<0.05 and p>0.05 respectively), and RV16 release was 
significantly increased by RIG-I but not MDA5 siRNA (D) (p<0.001 and p>0.05 respectively), 
versus non-targeting control siRNA. Data are the mean ± SEM of 4 separate experiments and 
expressed as % of control siRNA transfected cells =100%, (***p<0.001, **p<0.01, *p<0.05 versus 
non-targeting control siRNA).    
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3.8 Chapter 3: Discussion 
3.8.1 Primary Bronchial Epithelial Cells as an in vitro model 
system to study RV infection 
RV infects the epithelial cells of both the upper and lower respiratory tract. Normal 
primary human bronchial epithelial cells (HBEC) were selected for this study to better 
reflect the in vivo environment, and minimize the chances of obtaining non-physiological 
responses, which are known to occur in transformed (immortalised) cell lines. The 
HBEC used in this study were obtained from four different non-asthmatic, non-smoking 
(normal) subjects, in order to better reflect normal HBEC as they appear in vivo, rather 
than specific cells obtained from one individual. We also opted for undifferentiated, liquid 
culture systems rather than well differentiated air-liquid culture systems. The reasons for 
this were because of current expertise and experience within the lab, the lengthy time 
taken to grow air-liquid cultures, and the ability to manipulate liquid cultures (such as 
transfection) that is not yet available for air-liquid cultures. Recent work [127], has also 
shown that air-liquid cultures require higher levels of RV to achieve infection and 
mediator induction. For these reasons HBEC liquid cultures were chosen for this present 
study.   
The HBEC used in this study were determined to express the viral dsRNA pattern 
recognition receptors (PRRs) RIG-I, MDA5 and TLR3 at both the mRNA/protein level. 
Several studies have also identified TLR3 expression in normal primary human 
bronchial epithelial cells [239] [155] [329]. siRNA specifically targeting these PRRs was 
used to assess their individual requirement, by RV1B, for induction of IFNs and pro-
inflammatory cytokines in HBEC. The viral ssRNA pattern recognition receptors TLR7 
and TLR8 were not included in this study, as mRNA/protein for TLR7 and TLR8 was not 
detected in HBEC, in the presence or absence of RV1B infection (A. Skyes; data not 
shown). This finding is supported by studies, which were also unable to identify the 
expression of TLR7 or TLR8 in HBEC [242] or small airway epithelial cells [241].  
3.8.2  Suitability of siRNA to inhibit virus specific PRRs 
RNA interference (RNAi) is an evolutionary conserved post-transcriptional gene-
silencing mechanism in all multicellular organisms that is induced in a sequence specific 
manner by double-stranded RNA. In this manner RNAi has an important role in 
numerous biological processes in humans including developmental timing, growth 
control and differentiation. MicroRNAs (miRNAs) are a large family of human genome 
transcribed, non-coding RNAs of ∼21-23 nucleotides in length, that function as 
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endogenous triggers of the RNAi pathway. miRNAs are initially transcribed in a large 
precursor stem-loop form (pri-miRNA), which is cleaved in the nucleus by the RNAse III 
endonuclease Drosha and its co-factor DGCR8, into a smaller stem-loop structure (pre-
miRNA) [330] [331]. The pre-miRNA is actively transported into the cytoplasm by the 
nuclear export factor exportin 5 [332]. Here the terminal loop of pre-miRNA is removed 
by the RNAse III endonuclease Dicer and its co-factor TRBP, leaving a dsRNA structure 
containing a 2-nt 3’ overhangs and termed the mature miRNA [333] [331]. One strand of 
the miRNA is incorporated into a multi-protein RNA-induced silencing complex (RISC) 
[334], containing the protein argonaute2 which is believed to interact with Dicer and 
facilitate the incorporation of miRNA into the RISC [335]. The single strand of the miRNA 
acts to guide RISC to homologous mRNA species [336], where RISC mediates mRNA 
cleavage and consequently gene silencing. In addition to this RNAi pathway, initated by 
genes encoding miRNA, and functioning to control biological processes, RNAi is also a 
natural anti-viral mechanism in plants and invertebrates [337]. In this case, Dicer directly 
processes the long dsRNA (>30bp) produced by viruses into short interfering RNA 
(siRNA) duplexes of ∼21-23 nucleotides in length (containing 2-nt 3’ overhangs). These 
siRNA are incorporated into the RISC complex, where the anti-sense RNA strand guides 
RISC-mediated cleavage of homologous viral genomic RNA. Although synthetic siRNA 
transfected into mammalian cells can harness the RNAi mechanism and inhibit the 
replication of a wide range of viruses [338], it is currently unclear whether RNAi acts as 
a natural mechanism involved in anti-viral defence in mammalian cells [338] [337].  
Synthetic siRNAs, transfected into cells, have been used to trigger the RNAi pathway 
and inhibit the expression of specific genes of interest in this study. Although the use of 
siRNA to inhibit gene expression is simple, potent, rapid and specific, the success of 
siRNA mediated target gene inhibition is transfection dependent. Transfection of siRNA 
into HBEC was optimised in this study to be efficient and reproducible. A disadvantage 
of using siRNA is that they can induce interferon [339], and both PKR [339] and TLR3 
[340] have been implicated as links between siRNA and interferon induction in MEFs 
and HEK293 cells respectively. The known ability of RIG-I to bind to dsRNA [245] [246] 
[247] also infers of the potential of RIG-I to recognise siRNA and initate signalling to 
interferon production. In this respect, a recent study has shown RIG-I to interact with, 
and to be actived by blunt-ended siRNA, and additionally for blunt-ended siRNA to 
induce type I IFN-α production in a glioblastoma cell line [341]. However, the activation 
of RIG-I by siRNA in this study, and its subsequent signalling to IRF-3 transcription 
factor activation, could be overcome by design of siRNA with 2-nt 3’ overhangs [341]. All 
of the siRNA used in this study contained 2-nt 3’ overhangs. Cell type, siRNA duplex 
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length, siRNA concentration and sequence have all been shown to influence the 
induction of interferon [327] [328] [342]. Each siRNA used in this study was therefore 
confirmed not to significantly induce IFN expression in HBEC, in the absence of RV1B 
infection. The results in this chapter demonstrate that the transfection of non-targeting 
control siRNA alone did not significantly induce IFN or pro-inflammatory cytokine 
expression, compared to expression levels detected in untransfected cells. siRNA 
specifically targeting RIG-I, MDA5 and TLR3 siRNAs alone, also did not significantly 
induce IFN expression or pro-inflammatory cytokine expression, compared to 
expression levels detected in untransfected cells, or cells transfected with dsDNA used 
as a transfection control. These data verifying that specific PRR targeting siRNA do not 
induce IFN or pro-inflammatory cytokines, coupled with the data generated from using 
these siRNA being robust enough to establish a role for the PRRs in RV1B-induced IFN 
and pro-inflammatory cytokine expression, indicates that siRNA is a suitable technique 
to inhibit the genes of interest in this study. 
In addition to potentially triggering interferon gene expression, siRNA-mediated off-
target effects can occur, through partial complementarity of the siRNA with un-intended 
mRNA targets [343] [344]. Off-target effects have been linked to siRNA concentration 
[343] and matches between nucleotides in the seed regions (positions 2-7) of the siRNA 
anti-sense strand and the 3’ UTR of off-targeted genes [345] [346]. Approaches to help 
minimise non-specific, off-target gene modulation have included applying more rigorous 
bioinformatics to siRNA design, chemically modifying siRNA [347] and reducing siRNA 
concentration [343]. The latter has been achieved without compromising siRNA target 
gene knockdown, by the pooling of a low concentration of four individual siRNAs 
targeting the same gene [348]. Further, we have found that siRNA pools have 
comparable gene knockdown to each individual member of the pool. The non-specific 
off-target effects of the siRNA used in this study were not assessed, as these are only 
apparent when global gene expression studies are performed and this study did not 
warrant the time and expense of these studies. The study of siRNA off-target effects is 
of greatest importance when considering the use of siRNA as a potential therapeutic. At 
the time of this study, we purchased the latest generation of siRNA with respect to 
sequence, structure and chemical modifications to reduce off-target effects. All siRNA 
duplexes used in this study were therefore chemically modified to prevent siRNA sense 
strand interactions with the RISC, and help to minimise off-target effects. Our 
consideration of potential off-target effects, and our use of siRNA designed to minimise 
them, further supports the use of siRNA as a suitable technique to inhibit the genes of 
interest in this study.  
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Further to our use of siRNA designed to minimise potential off-target effects, we have 
made the assumption that all of the siRNA used in this study are target specific, and 
thus do not non-specifically inhibit the expression of one or more genes which could 
influence or alternatively be responsible for our experimental findings. Additionally we 
have made the assumption that the siRNA used in this study specifically target genes 
within signalling pathways that are directly activated following RV1B infection (i.e. TLR3, 
RIG-I, MDA5), and not alternative signalling pathways that contain one or more common 
signalling intermediates, but are instead activated directly by other stimuli e.g. TNFα and 
IL-1β. Experiments to confirm that alternative signalling pathways were not affected by 
the siRNA used in this study would include the use of stimuli such as TNFα or IL-1β, and 
verification that activation of these signalling pathways are not inhibited in HBECs 
transfected with specific gene targeting siRNA versus non-targeting control siRNA.    
3.8.3 TLR3 is required for RV1B-induced IFN-β, IFN-λ and pro-
inflammatory cytokine expression 
TLR3 siRNA significantly inhibited RV1B-induced IFN-β, IFN-λ1 and IFN-λ2/3 mRNA, 
suggesting TLR3 to be required for their induction by RV1B in HBEC. Expression of a 
constitutively active form of the TLR3 adaptor protein TRIF (∆TRIF), in HBEC, induced 
activation of the IFN-β, IFN-λ1 and IFN-λ2/3 promoters, and IFN-β and IFN-λ1 protein 
secretion, indirectly supporting a role for TLR3 in endogenous IFN-β and IFN-λ 
expression. Further supporting our findings, studies have shown a role for TLR3 in 
polyIC-induced IFN-β [213] [214] [215] [218], using TLR3 blocking antibodies [213], 
siRNA [214], and gene knockout mice [215] [218], and TRIF over-expression to induce 
IFN-β [219] [214] [216] [221], IFN-λ1 and IFN-λ2/3 [203] promoter activation. This is the 
first study to investigate a role for TLR3 in IFN-λ1 and IFN-λ2/3 expression, using 
inhibitory rather than stimulatory techniques.  
TLR3 siRNA significantly inhibited RV1B-induced CCL5, CXCL10, IL-6, CXCL8 and 
CXCL5 mRNA, suggesting TLR3 to be required for their induction by RV1B in HBEC. In 
support of our finding of a role for TLR3 in RV1B-induced pro-inflammatory cytokine 
expression, studies have shown a role for TLR3 in polyIC-induced CXCL5 expression 
[329], Influenza A virus-induced CXCL8, CCL5 and IL-6 expression [321] and RSV-
induced CXCL10 and CCL5 expression [322], using dominant negative [321] and siRNA 
[322] [329] techniques.  
Expression of ∆TRIF, in HBEC, activated the transcription factors NF-κB and IRF3. A 
role for TRIF over-expression in NF-κB [219] [214] [216] [221] [222] and IRF3 [216] [222] 
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[223] dependent reporter activation has previously been reported, supporting our finding. 
RV transcriptional activation of CXCL8 [82], IL-6 [95] and CXCL10 [91] has been shown 
to require NF-κB, and this study is the first to report a role for NF-κB in RV-induced 
CCL5 and CXCL5 expression (Results Chapter 6). RV transcriptional activation of 
CXCL10 has also been reported to require an ISRE (IRF) binding site in the CXCL10 
promoter, and NF-κB and IRF3 have been shown to be required for CCL5 expression 
[155]. Activation of NF-κB and IRF3 by ∆TRIF, in HBEC, therefore supports our finding 
of a requirement for TLR3 in RV1B-induced expression of these pro-inflammatory 
cytokines, and that this up-regulation is likely to be via increased gene transcription. 
3.8.4 MDA5 is required for RV1B-induced IFN-β, IFN-λ and pro-
inflammatory cytokine expression 
MDA5 siRNA significantly inhibited RV1B-induced CCL5, CXCL10, IL-6, CXCL8, 
CXCL5, IFN-β, IFN-λ1 and IFN-λ2/3 mRNA, suggesting MDA5 to be required for the 
expression of these pro-inflammatory cytokines and IFNs in HBEC upon RV1B infection. 
In support of our findings, in vivo studies have demonstrated a role for MDA5 in 
picornavirus (EMCV) induced IFN-β, CCL5, CXCL10 and IL-6 [259], and polyIC-induced 
IL-6 [349] using MDA5 deficient cells. This is the first report investigating a role for 
MDA5 in the expression of IFN-λ1, IFN-λ2/3, CXCL8 and CXCL5.  
MDA5 siRNA significantly inhibited RV1B-induced IFN-β mRNA by 96%, despite our 
identified role for TLR3 and RIG-I (discussed below) in RV1B-induced IFN-β expression. 
This may partially be explained by MDA5 siRNA resulting in the inhibition of IFN 
stimulated up-regulation of RIG-I protein, and thus reduced induction of IFN-β mRNA via 
the RIG-I signalling pathway. As we did not identify TLR3 to be an IFN stimulated gene it 
is expected that the TLR3 signalling pathway to IFN-β is intact in the presence of MDA5 
siRNA. However, we cannot rule out the possibility that inhibition of MDA5 is affecting 
the expression level of TLR3 by an as yet unidentified mechanism. Secondly, the 
relative importance of TLR3 and MDA5 signalling to IFN-β induction post infection may 
be time dependent. In this respect, at this time-point of analysis (24h post infection) the 
MDA5 signalling pathway may predominate over the TLR3 pathway in the induction of 
IFN-β mRNA. This possibility is supported by the cytoplasmic localisation of MDA5 and 
its recognition of RV1B dsRNA replication intermediates at 24h post infection. In 
contrast, the endosomal localisation of TLR3 infers of its role in initial RV1B recognition 
upon RV1B cell entry, and thus of its potentially predominant role in IFN-β induction at 
early time-points post infection. A third possible explanation for our finding is that 
complete phosphorylation of IRF3 requires both the TLR3 and MDA5 signalling 
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pathways, and that MDA5 siRNA results in incomplete phosphorylation of IRF3 and thus 
inhibition of IFN-β transcription.            
3.8.5 RIG-I is required for RV1B-induced IFN-β and Pro-
inflammatory cytokine expression, but not IFN-λ 
expression 
Targeting RIG-I with siRNA significantly inhibited RV1B-induced IFN-β mRNA, 
implicating RIG-I in mediating the expression of IFN-β in HBEC upon RV1B infection. 
Expression of constitutively active RIG-I (∆RIG-I) in HBEC induced activation of the IFN-
β promoter, supporting a role for RIG-I in RV1B-induced IFN-β endogenous expression. 
This finding is consistent with that of another study showing induction of IFN-β promoter 
activation, by constitutively active RIG-I [245].  
A role for RIG-I has previously been shown in vitro in NDV-induced IFN-β expression 
[245] [246], and in vivo using RIG-I deficient cells, to be essential for IFN-β expression in 
the response to NDV, SV, VSV and influenza virus [259]. In contrast to our findings, 
RIG-I has been reported to be dispensable for IFN-β production in response to 
picornavirus infection in vivo [259]. This is supported by studies showing RIG-I to 
recognise 5’-triphosphate containing RNA [249] [250], which picornaviruses do not 
produce [350]. However, in addition to the recognition of 5’-triphosphate RNA by RIG-I, 
in vitro studies have shown RIG-I to bind non-phosphorylated dsRNA (polyIC) [245] 
[246] [247], and a recent study has demonstrated RIG-I binding to both dsRNA and 5’-
triphosphate RNA [326]. Furthermore, RIG-I has been shown to respond to polyIC by 
enhancing IFN-β promoter activation [245] [246]. It is therefore possible that in this 
present study, RIG-I is binding and responding to the un-phosphorylated dsRNA 
replication intermediates produced by RV1B replication. This would provide an 
explanation for our observed inhibition of RV1B-induced IFN-β expression upon RIG-I 
specific siRNA transfection. In further support of the possibility of a role for RIG-I in 
response to a picornavirus infection, RIG-I over-expression has been demonstrated to 
offer a protective effect to mouse L292 cells challenged with EMCV [245].  
Of noteworthy observation is that although in vivo studies have determined RIG-I and 
not MDA5 to be essential for type I IFN induction in response to NDV, SV, VSV and 
influenza virus [259], both RIG-I and MDA5 siRNA has been shown to inhibit NDV-
induced IFN-β expression in vitro [246]. This would suggest that despite gene knockout 
studies showing RIG-I and MDA5 not be essential in the anti-viral response to certain 
viruses, that RIG-I and MDA5 can still play a role in and thus contribute to the anti-viral 
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response to these viruses. This is further supported by the recent observation that the V 
proteins of NDV and SV act to inhibit MDA5 function and not RIG-I function [351], 
despite the essential role of RIG-I and not MDA5 in the anti-viral response to NDV and 
SV in vivo [259].  
RV1B-induced IFN-λ1 expression was not inhibited by RIG-I siRNA, suggesting that 
RIG-I is not required for RV1B-induced IFN-λ1 expression. Additionally, RV1B-induced 
IFN-λ2/3 expression was significantly increased by RIG-I siRNA, suggesting that RIG-I 
is not required for RV1B-induced IFN-λ2/3 expression. As the inhibition of MDA5 or 
TLR3 reduced IFN-λ1 and IFN-λ2/3 expression, but not RIG-I, these findings indicate 
that RIG-I cannot replace the function of MDA5 or TLR3 and maintain IFN-λ expression, 
and thus that RIG-I is not functionally redundant for IFN-λ expression with MDA5 or 
TLR3. Contrary to our finding of no role for RIG-I in RV1B-induced IFN-λ expression, 
NDV-induced IFN-λ2/3 expression has been reported to be absent in RIG-I deficient 
MEFs [202]. However, this later finding is in murine cells and RIG-I (and not MDA5) has 
previously been demonstrated in vivo to be essential in the anti-viral response to NDV 
infection [259]. Thus, our finding of no role for RIG-I in IFN-λ2/3 expression could be 
explained by our different cell type and virus. Also inconsistent with our RIG-I siRNA 
findings, we show expression of ∆RIG-I in HBEC to significantly induce IFN-λ1 and IFN-
λ2/3 promoter reporter activation, suggesting that constitutive activation of the RIG-I 
pathway can result in IFN-λ1 and IFN-λ2/3 transcription. This finding is supported by 
another study, reporting constitutively active RIG-I to induce endogenous IFN-λ1 and 
IFN-λ2 expression in HEK293 cells [202]. However, constitutive activation studies do not 
reflect what would be a natural level of pathway activation and can only demonstrate 
whether a factor can have a role, and not whether it has an essential/physiological role. 
The latter is better determined with loss of function studies, such as siRNA, and so our 
determined non-requirement for RIG-I in RV1B-induced IFN-λ1 and IFN-λ2/3 expression 
using siRNA we feel is more accurate than the over-expression studies.  
Why RIG-I siRNA enhanced RV1B-induced IFN-λ2/3 expression is unclear, however, a 
similar result has been reported in two other studies, where RIG-I siRNA, resulted in 
enhanced RSV-induced [352] and polyIC-induced [353] pro-inflammatory cytokine 
expression compared to control siRNA. As RIG-I siRNA did not induce IFN-λ2/3 
expression in the absence of RV1B infection, the RIG-I siRNA duplex itself can be ruled 
out as being responsible for enhancing RV1B-induced IFN-λ2/3 expression. Dual 
knockdown experiments with either RIG-I/MDA5, or RIG-I/TLR3 siRNA, would determine 
whether the enhanced RV1B-induced IFN-λ2/3 expression can be reversed by MDA5 or 
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TLR3 siRNA. If this occurred, it would suggest that the enhanced IFN-λ2/3 expression 
observed in RIG-I siRNA knockdown cells is mediated by MDA5 and/or TLR3 pathways.  
Targeting RIG-I with siRNA significantly inhibited RV1B-induced CCL5, CXCL10, IL-6, 
CXCL8 and CXCL5 mRNA, implicating RIG-I in mediating the expression of these pro-
inflammatory cytokines in HBEC upon RV1B infection. In support of these findings, a 
role for RIG-I in the expression of NDV, SV and VSV-induced CXCL10, CCL5 and IL-6 
expression [245] [258] has previously been demonstrated using siRNA [245] or RIG-I 
deficient cells [258]. A potential role for RIG-I in CXCL8 expression has been shown 
using over-expression studies [354] [355]. This is the first report investigating a role for 
RIG-I in CXCL5 expression. Consistent with the findings of other studies [245] [246], 
expression of ∆RIG-I, in HBEC, activated the transcription factors NF-κB and IRF3. This 
finding supports a role for RIG-I in CXCL8, IL-6, CCL5, CXCL10 and CXCL5 which all 
contain an NF-κB-binding site in their promoters [95] [82] [172] [155] [91] [173] [174], 
and CCL5 and CXCL10 which contain IRF binding sites in their promoters [154] [91].   
3.8.6 RIG-I and MDA5 both exhibit anti-RV activity in HBEC 
HBEC transfected with RIG-I specific siRNA and infected with RV1B or RV16 resulted in 
increased RV1B and significantly increased RV16 viral copy number, and increased 
RV1B release and significantly increased RV16 release from HBEC. These findings 
support a role for RIG-I in the anti-viral response to RV in HBEC. A role for MDA5 in the 
antiviral response to RV1B and RV16 in HBEC is also supported by the observation that 
MDA5 specific siRNA results in significantly increased RV1B viral copy number and 
release, and increased RV16 viral copy number and release. While the pronounced 
inhibition of RIG-I on RV16 and MDA5 on RV1B infection may reflect slightly better 
knockdown for each siRNA in the experiment, it is possible that RIG-I and MDA5 might 
have sequence specificities for RV16 and RV1B respectively. Further work is required to 
investigate this.  
3.8.7 Summary 
This is the first report to investigate a role for RIG-I, MDA5 and TLR3 in RV infected 
primary HBEC, with respect to the induction of pro-inflammatory cytokines, IFN-β, IFN-
λ1 and IFN-λ2/3. These results support a hypothesis that RV1B-induced IFN-β, and pro-
inflammatory cytokine expression in HBEC is at least in part dependent upon RIG-I, 
MDA5 and TLR3, and that IFN-λ1 and IFN-λ2/3 expression is at least in part dependent 
on MDA5 and TLR3. This is also the first report showing a role for RIG-I in IFN-β, IFN-λ 
and pro-inflammatory cytokine expression in response to a picornavirus infection. With 
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the exception of RIG-I siRNA and IFN-λ expression, siRNA targeting each of the 
different PRRs inhibited RV1B-induced IFN or pro-inflammatory cytokine expression in 
HBEC. This finding suggests that RIG-I, MDA5 and TLR3 signalling pathways act in 
parallel upon RV1B infection of HBEC. This exciting finding of a role for both TLR3 and 
RNA helicases in RV-induced responses is expanded upon in the next chapter.  
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Chapter 4: Results. RIG-I and MDA5 are both 
virus and interferon inducible genes in 
normal human bronchial epithelial cells 
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4.1 Introduction 
The sub-cellular localisation of pattern recognition receptors may represent an important 
factor in understanding their relative roles in the host cell response to viral infection. 
Viruses can enter the host cell through direct membrane fusion, or by receptor-mediated 
endocytosis followed by endosomal fusion. As the viral nucleic acid recognising pattern 
recognition receptors (TLR3, TLR7/8, TLR9) are localised to endosomal compartments, 
they may act to sense viruses when initial virus entry into the cell occurs through the 
endosome. In contrast, viruses that enter the cell by membrane fusion, will initially 
encounter the cytoplasmic pattern recognition receptors RIG-I and MDA5. Hence both 
endosomal and intracellular forms of viral recognition are likely important depending on 
the mode of entry and sites of viral replication within the cell. 
Picornavirus entry into cells is well studied, and RV has often been used as a model 
virus for the study of picornavirus entry and replication. After receptor binding, RV is 
internalised into endosomal compartments, and decreased pH of the endosome is 
required for virus uncoating, supported by the fact that RV entry can be blocked, by 
endosomal acidification inhibitors [74] [76] [75]. It can therefore be argued that the 
endosomal viral RNA pattern recognition receptors TLR3, TLR7/8 are likely important in 
the initial sensing of RV infection. As HBECs have little or no mRNA and protein 
expression of the ssRNA pattern recognition receptors TLR7 and TLR8 [242] (A. Sykes 
data not shown), TLR3 would appear to be the initial sensor of RV infection in HBEC. 
This is complicated by the fact that RV is a ssRNA virus, however it has long been 
appreciated that the ssRNA picornavirus genome has many dsRNA structures, including 
a 5’ clover leaf structure that is important for translation initiation [69]. This data 
suggests that TLR3 may recognise the RV genome within the endosome of infected 
HBECs. 
The replication of RV occurs in the host cell cytoplasm, where negative strand viral 
mRNA is translated and also serves as the template for progeny genomic positive strand 
ssRNA. These replicative events may be numerous and take place throughout the host 
cell cytoplasm. Thus, the cytoplasmic pattern recognition receptors RIG-I and MDA5 
may function as a secondary intracellular viral recognition system. Our identified 
requirement for TLR3, RIG-I and MDA5 in RV1B-induced IFN-β and pro-inflammatory 
cytokine expression may therefore reflect the requirement for, and dual importance of 
both TLR3 and RIG-I/MDA5 pattern recognition systems.  
In this Chapter, we attempted to gain a better understanding of how the TLR3, RIG-I and 
MDA5 signalling pathways co-operate to mediate the anti-viral response to RV1B 
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infection of HBEC. While RIG-I and MDA5 are important for IFN and pro-inflammatory 
cytokine gene expression, we report in this Chapter that they are virus and IFN inducible 
genes (ISGs). Following RV1B infection, RIG-I and MDA5 mRNA and protein were 
increased in a time dependent manner, however the abundance of TLR3 mRNA did not 
change. Furthermore, TLR3 specific siRNA inhibited RV1B-induced RIG-I and MDA5 
mRNA expression, suggesting that initial viral infection, and likely later virus induced 
IFN, both up-regulate the abundance of these two important cytoplasmic PRRs.  
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4.2 RIG-I and MDA5 are RV and IFN inducible genes in 
HBEC 
The effect of RV1B on the expression of the pattern recognition receptors RIG-I, MDA5 
and TLR3 and the RIG-I and MDA5 adaptor protein Cardif, in HBEC, was investigated. 
Studies have previously identified RIG-I, MDA5 [251] [245] [252] and TLR3 [356] [357] 
[358] to be virus and IFN inducible, using cells other than HBEC and viruses other than 
RV.  
4.2.1 RIG-I and MDA5 mRNA and protein were induced, but not 
TLR3 mRNA, upon RV1B infection of HBEC  
HBEC were serum starved using BEBM for 24h and infected at time -1h with RV1B 
(MOI 1), or incubated with BEBM alone for 1h with agitation, and then cultured for up to 
48h. Cells were harvested for total RNA or protein, and RIG-I, and MDA5 mRNA levels 
analysed by TaqMan RT-PCR or RIG-I, and MDA5 protein by western blot analysis. 
Time-course analysis of RV1B-induced RIG-I and MDA5 mRNA, showed both to be 
induced early at 4h post-infection, and for induction to continue in a time-dependent 
manner with RIG-I induction peaking at 12h (Fig. 4.1A), and MDA5 at 18h (Fig. 4.1C), 
post-infection. MDA5 induction remained consistent between 18h and 48h post-infection 
(Fig. 4.1C). Between 12 and 24h post-infection, RIG-I mRNA declined and then 
increased again to a significant induction by 48h post-infection (compared to medium 
treated control cells p<0.05), and to a level equivalent to that observed at 12h. RV1B 
time-course analysis did not show an increased TLR3 mRNA, relative to medium treated 
control cells, at any of the time-points analysed (data not shown). RIG-I protein was 
detected in medium treated control cells at each of the time-points analysed (Fig. 4.1B). 
MDA5 protein was not detected in medium treated control cells at 0h, and detected in 
medium treated control cells at each further time-point analysed (Fig. 4.1C) RIG-I and 
MDA5 expression was increased, compared to medium treated control cells, by 4h post-
infection (Fig. 4.1B, D). 
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Figure 4.1 Time course of RV1B-induced RIG-I and MDA5 mRNA and protein in HBEC. 
HBEC were cultured with RV1B at an MOI of 1 (closed squares) or with BEBM medium alone 
(open squares). Total cell RNA or protein was harvested for analysis at 0, 4, 8, 12, 18, 24 and 
48h post-infection, and RIG-I (A) and MDA5 (C) mRNA measured by TaqMan RT-PCR, and RIG-
I (B) and MDA5 (D) protein by western blot. Data are the mean ± SEM of 3 separate experiments 
(A and C) and western blots representative of 2-3 experiments (B and D). 
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4.2.2 RV1B induction of IFN-β, IFN-λ1 and IFN-λ2/3 mRNA occurs 
simultaneously with RIG-I and MDA5 mRNA induction in 
HBEC 
HBEC were serum starved using BEBM for 24h and infected at time -1h with RV1B 
(MOI 1), or incubated with BEBM alone for 1h with agitation, and then cultured for up to 
48h. Cells were harvested for total RNA and IFN-β, IFN-λ1 and IFN-λ2/3 mRNA 
measured by TaqMan RT-PCR. Time-course analysis of RV1B-induced IFN-β, IFN-λ1 
and IFN-λ2/3 showed their induction to occur early, with a significant increase in IFN-λ1 
(p<0.01), and a non-significant increase in IFN-β and IFN-λ2/3, observed at 4h post-
infection (Fig. 4.2A, B, C) A significant increase in IFN-β (p<0.05) was observed at 8h 
post-infection (Fig. 4.2A), and IFN-λ2/3 expression increased further at 8h, and was 
significantly increased at 12h post-infection (p<0.05; Fig. 4.2C), versus uninfected cells. 
At 8h RV1B-induced IFN-λ1 (Fig. 4.2B), and at 12h RV1B-induced IFN-β mRNA (Fig. 
4.2A) had increased further, and remained significantly increased compared to 
uninfected cells. IFN-β induction remained consistent between 12h and 48h post-
infection, and a significant difference remained between RV1B infected and uninfected 
cells between 12 and 24h post-infection (p<0.05; Fig. 4.2A). Expression of IFN-λ1 and 
IFN-λ2/3 mRNA remained consistent and significantly increased compared to uninfected 
cells between 12 and 18h post-infection (IFN-λ1 p<0.01 and IFN-λ2/3 p<0.05; Fig. 4.2B, 
C). IFN-λ1 and IFN-λ2/3 mRNA increased further between 18h and 48h post-infection, 
to their peak at 48h post-infection (IFN-λ1 p<0.01 and IFN-λ2/3 p<0.01; Fig. 4.2B, C). 
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Figure 4.2 Time course of RV1B-induced IFN-β, IFN-λ1 and IFN-λ2/3 mRNA in HBEC. IFN-β 
(A), IFN-λ1 (B) and IFN-λ2/3 (C) were measured by TaqMan RT-PCR in HBEC cultured with 
RV1B at an MOI of 1 (closed squares) or with medium alone (open squares). Total cell RNA was 
harvested for analysis at 0, 4, 8, 12, 18, 24 and 48h post-infection. Data are the mean ± SEM of 3 
separate experiments. 
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4.2.3 IFN-β and IFN-λ treatment induced RIG-I and MDA5 protein 
in HBEC 
HBEC were serum starved using BEBM for 24h and treated at time -1h with fresh 
BEBM, recombinant IFN-β or recombinant IFN-λ for 1h with agitation, and then cultured 
for up to 48h. Cells were harvested for protein and RIG-I and MDA5 protein measured 
by western blot. Time-course analysis of IFN-β and IFN-λ treatment showed RIG-I 
protein to be detected at 4h post IFN-β or IFN-λ treatment and to be increased at 8h 
post IFN treatment (Fig. 4.3A, C). RIG-I protein expression remained constant between 
8 and 12h, and slowly declined thereafter, in a time dependent manner (Fig. 4.3A, C). 
MDA5 protein was not detected at 0h post IFN-β and IFN-λ treatment, and was detected 
at 4h post IFN-β and IFN-λ treatment (Fig. 4.3B, D). MDA5 protein levels remained 
constant at later time-points (8, 12, 18, 24h) post IFN-β treatment (Fig. 4.3B). MDA5 
protein had increased at 8h post IFN-λ treatment, and further increased at 12h, and its 
expression remained constant at later time-points (18, 24h) post IFN-λ treatment (Fig. 
4.3D). The structural proteins β-actin and α-tubulin were used to control for protein 
loading in each blot. 
Medium 
 
 
 
 
 
IFN-β treatment (10 IU/mL) 
 
 
IFN-λ treatment (10 ng/mL) 
 
 
 
 
 
Figure 4.3 Time course of IFN-β and IFN-λ induced RIG-I and MDA5 protein in HBEC. HBEC 
were treated with medium, IFN-β or IFN-λ. Cells were harvested for analysis at 0, 4, 8, 12, 18 
and 24h post-treatment and RIG-I (A and C) and MDA5 (B and D) protein measured by western 
blot ( representative of 2-3 experiments). 
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4.3 TLR3 and TRIF are required for RV1B-induced RIG-I 
and MDA5 expression in HBEC 
4.3.1 TLR3 inhibition during RV1B infection of HBEC reduced 
RIG-I and MDA5 mRNA expression 
HBEC were transfected with TLR3 specific siRNA, a non-targeting control siRNA, or 
were untransfected, and then cultured for 24h before incubating with RV1B (MOI of 1) or 
treating with BEBM alone, and culturing for a further 24h. Cells were harvested for total 
RNA and TLR3, RIG-I and MDA5 mRNA analysed by TaqMan RT-PCR. Following 
RV1B infection, TLR3 specific siRNA reduced TLR3 mRNA to 7% (p<0.001) of 
expression levels obtained with non-targeting control siRNA (Fig. 4.4A). TLR3 siRNA 
significantly inhibited RV1B-induced RIG-I and MDA5 (both p<0.001), compared to 
RV1B infected non-targeting control siRNA transfected cells (Fig. 4.4B, C). No 
significant difference between uninfected untransfected cells and uninfected non-
targeting control siRNA transfected cells was observed (both p>0.05) indicating that 
control siRNA alone did not induce RIG-I or MDA5 mRNA. 
 
 
 
Figure 4.4 Effect of TLR3 siRNA on RV1B induced RIG-I and MDA5 mRNA expression in 
HBEC. HBEC were transiently transfected with TLR3 or non-targeting control siRNA, or 
untransfected. 24h post-transfection, cells were infected with RV1B (MOI 1), or treated with 
infection medium alone. 24h post-infection, cells were harvested for total RNA and TLR3, RIG-I 
and MDA5 mRNA measured by TaqMan RT-PCR. TLR3 siRNA inhibited TLR3 mRNA (A) 
(p<0.001) versus non-targeting control siRNA, and inhibited RV1B induced RIG-I (B) and MDA5 
(C) (both p<0.001) mRNA expression, compared to cells infected and transfected with control 
siRNA. Data are the mean ± SEM of 4 separate experiments and expressed as % of infected 
control =100%, (***p<0.001, **p<0.01, *p<0.05 versus non-targeting control siRNA), ### versus 
untransfected, uninfected control.   
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4.3.2 Inhibition of RIG-I or MDA5 during RV1B infection of HBEC 
did not inhibit TLR3 mRNA expression 
HBEC were transfected with RIG-I or MDA5 specific siRNA, a non-targeting control 
siRNA or were untransfected, and then cultured for 24h before incubating with RV1B 
(MOI of 1) or treating with BEBM alone, and culturing for a further 24h. Cells were 
harvested for total RNA and RIG-I, MDA5 and TLR3 mRNA analysed by TaqMan RT-
PCR. Following RV1B infection, RIG-I and MDA5 specific siRNA reduced RIG-I and 
MDA5 mRNA levels respectively to 24% and 5% (both p<0.01), of expression levels 
obtained with non-targeting control siRNA (Fig. 4.5A, B). RIG-I siRNA did not inhibit 
TLR3 mRNA (p>0.05), and MDA5 siRNA non-significantly reduced TLR3 mRNA 
(p>0.05), compared to non-targeting control siRNA transfected cells in the presence of 
RV1B infection (Fig. 4.5C). TLR3 expression in non-targeting control siRNA transfected 
cells, infected versus uninfected, was not significantly different (p>0.05), confirming 
TLR3 mRNA not to be induced during RV1B infection (Fig. 4.5C).  
 
 
 
 
Figure 4.5 Effect of RIG-I and MDA5 siRNA on TLR3 mRNA expression in RV1B infected 
HBEC. HBEC were transiently transfected with RIG-I, MDA5, non-targeting control siRNA, or 
untransfected. 24h post-transfection, cells were infected with RV1B (MOI 1), or treated with 
infection medium alone. 24h post-infection, cells were harvested for total RNA and RIG-I, MDA5 
and TLR3 mRNA measured by TaqMan RT-PCR. RIG-I and MDA5 mRNA expression was 
inhibited by RIG-I (A) and MDA5 siRNA (B) respectively (both p<0.01), versus non-targeting 
control siRNA. RIG-I or MDA5 siRNA did not inhibit TLR3 (C) (both p>0.05) mRNA expression, 
compared to cells infected and transfected with control siRNA. Data are the mean ± SEM of 4 
(using RIG-I siRNA) and 3 (using MDA5 siRNA) separate experiments and expressed as % of 
infected control =100%, (***p<0.001, **p<0.01, *p<0.05 versus non-targeting control siRNA). 
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4.3.3 RIG-I siRNA did not inhibit MDA5 expression, and MDA5 
siRNA did not inhibit RIG-I expression, in the absence of 
RV1B infection 
HBEC were transfected with RIG-I or MDA5 specific siRNA, a non-targeting control 
siRNA or were untransfected, and then cultured for 24h before replacing culture medium 
with fresh BEBM, and culturing for a further 24h. Cells were harvested for total RNA and 
RIG-I and MDA5 mRNA analysed by TaqMan RT-PCR. RIG-I siRNA did not inhibit 
MDA5 mRNA (p>0.05), and MDA5 siRNA did not inhibit RIG-I mRNA (p>0.05), 
compared to non-targeting control siRNA transfected cells (Fig. 4.6 A, B). 
 
 
 
Figure 4.6 Effect of RIG-I siRNA on MDA5 mRNA expression, and MDA5 siRNA on RIG-I 
mRNA expression in uninfected HBEC. HBEC were transiently transfected with RIG-I, MDA5 
or non-targeting control siRNA, or untransfected. 24h post-transfection cells were treated with 
fresh infection medium alone. 48h post-transfection, cells were harvested for total RNA and RIG-
I, MDA5 mRNA measured by TaqMan RT-PCR. RIG-I siRNA did not inhibit MDA5 mRNA 
expression (A), and MDA5 siRNA did not inhibit RIG-I mRNA expression (B) (both p<0.05), 
compared to cells transfected with non-targeting control siRNA. Data are the mean ± SEM of 3 
separate experiments and expressed as % of infected control =100%, (***p<0.001, **p<0.01, 
*p<0.05). 
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4.3.4 TRIF inhibition during RV1B infection of HBEC reduced 
RIG-I and MDA5 mRNA expression 
HBEC were transfected with TRIF specific siRNA, a non-targeting control siRNA or were 
untransfected, and then cultured for 24h before incubating with RV1B (MOI of 1) or 
treating with BEBM alone, and culturing for a further 24h. Cells were harvested for total 
RNA and TRIF, RIG-I and MDA5 mRNA analysed by TaqMan RT-PCR. Following RV1B 
infection, TRIF specific siRNA reduced TRIF mRNA to 17% (p<0.001) of expression 
levels obtained with non-targeting control siRNA (Fig. 4.7A) TRIF siRNA also inhibited 
TRIF protein, compared to control siRNA (data not shown). TRIF siRNA significantly 
inhibited RV1B-induced RIG-I and MDA5 mRNA (both p<0.001), compared to cells 
infected and transfected with non-targeting control siRNA (Fig. 4.7B, C). No significant 
difference between uninfected untransfected cells and uninfected non-targeting control 
siRNA transfected cells was observed (both p>0.05) indicating that control siRNA alone 
did not induce RIG-I or MDA5 mRNA. 
 
 
 
 
Figure 4.7 Effect of TRIF siRNA on RIG-I and MDA5 mRNA expression in RV1B infected 
HBEC. HBEC were transiently transfected with TRIF or non-targeting control siRNA, or 
untransfected. 24h post-transfection, cells were infected with RV1B (MOI 1), or treated with 
infection medium alone. 24h post-infection, cells were harvested for total RNA and TRIF, RIG-I, 
MDA5 mRNA measured by TaqMan RT-PCR. TRIF mRNA was inhibited by TRIF siRNA (A) 
(p<0.001), versus non-targeting control siRNA. TRIF siRNA inhibited RV1B-induced RIG-I (B), 
and MDA5 (C) mRNA expression (both p<0.001), compared to cells infected and transfected with 
control siRNA. Data are the mean ± SEM of 4 separate experiments and expressed as % of 
infected control =100%, (***p<0.001, **p<0.01, *p<0.05 versus non-targeting control siRNA), ### 
versus untransfected, uninfected control.   
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4.3.5 Constitutive activation of the TLR3 pathway, by ∆TRIF, 
induced RIG-I and MDA5 mRNA expression in HBEC 
HBEC were initially transfected with 0.25µg, 0.50µg or 1.0µg of constitutively active 
TRIF (∆TRIF) or pUNO1 control vector, or untransfected, and then cultured for 24h 
before harvesting cells for total RNA and measuring RIG-I and MDA5 mRNA by TaqMan 
RT-PCR. Experiments were then performed with 0.25µg ∆TRIF or pUNO1 control 
vector. Transfection of cells with ∆TRIF significantly induced RIG-I and MDA5 mRNA 
expression (both p<0.001), compared to control vector (Fig 4.8A, B). Transfection with 
pUNO1 control vector, significantly induced RIG-I (p<0.05) and MDA5 mRNA (p<0.01), 
relative to untransfected cells, demonstrating that plasmid transfection itself induced 
both RIG-I and MDA5 gene expression in HBEC. 
 
 
 
Figure 4.8 Effect of ∆TRIF on RIG-I and MDA5 mRNA expression in HBEC. HBEC were 
transiently transfected with ∆TRIF or vector control (pUNO1). 24h post-transfection, cells were 
harvested total RNA and RIG-I and MDA5 mRNA measured by TaqMan RT-PCR. ∆TRIF induced 
RIG-I (A) and MDA5 (B) expression (p<0.001), compared to vector control. Data are the mean ± 
SEM of 3 separate experiments and shown as Log mRNA copies/2x105 cells (***p<0.001, 
**p<0.01, *p<0.05). 
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4.4 Chapter 4: Discussion 
There are currently two major locations for the recognition of virus infection by PRRs, 
the endosome and the intracellular/cytoplasmic compartment. As previous results 
suggested that the endosomal receptor TLR3 and the intracellular RNA helicases RIG-I 
and MDA5 were required for the induction of either IFNs or pro-inflammatory cytokines 
by RV, we attempted to further explore the relationship between these PRRs and RV 
infection in HBECs in vitro.  
4.4.1 RIG-I and MDA5 are increased upon RV infection or IFN 
treatment and are ISGs 
We detected a low level of RIG-I and MDA5 protein in uninfected HBEC, and these 
levels were increased upon IFN treatment. Type I and Type III IFNs are important 
molecules in viral defence, are produced by infected cells and function by binding to 
appropriate receptors on uninfected cells and preparing these cells for viral infection. 
The anti-viral activity of IFNs occurs by increasing the abundance of a large range of 
ISGs, including those that degrade viral RNA, such as RNAse L and OAS proteins and 
others interfere with viral protein synthesis, such as Viperin and Mx GTPase proteins 
[117] [118] [120] [121]. IFN may also activate certain immune cells, including NK cells 
and DCs, or contribute to their differentiation [359] [360], hence IFN production and the 
activity of IFN on uninfected cells is highly associated with defence against viruses. The 
induction of RIG-I and MDA5 by type I IFN and virus infection, has been shown in 
previous studies [251] [245] [252], however the observation that RIG-I and MDA5 protein 
was also induced by IFN-λ treatment, has not previously been reported. Our results 
suggest that RIG-I and MDA5 transcription is induced by both the binding of type I IFN 
protein to IFNAR1, the subsequent activation of the JAK-STAT signalling pathway and 
activation of the complex ISGF3; and also IFN-λ signalling through the IFN-λR1/IL-28Rα 
receptor. Like type I IFNs, IFN-λs have been shown to induce ISGs via JAK/STAT 
signalling [124] [123], supporting our finding that RIG-I and MDA5 protein expression is 
a product of both IFN-β and IFN-λ production. 
4.4.2 TRIF and TLR3 are required for RV induced RIG-I and 
MDA5 
We observed a low level of RIG-I and MDA5 protein in uninfected cells, and this was 
increased quite quickly after RV infection. Interestingly, inhibition of TLR3 or TRIF by 
siRNA abolished this induction. Although at a low level, and difficult to detect by western 
blotting, the presence of RIG-I and MDA5 may be required to enable the rapid detection 
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of a replicating virus within the intracellular compartment, and thus rapidly induce the 
initiation of signalling pathways leading to interferon and pro-inflammatory cytokine 
production. Why RIG-I and MDA5 were induced quickly within the infection cycle (by 4h 
for mRNA and protein) is a very interesting observation. This may reflect that RIG-I and 
MDA5 are increased during viral infection, to combat the increase in RV replicative 
intermediates present in the cytoplasm. 
Previous studies have described the TLR3 pathway and the RIG-I, MDA5 pathways to 
be separate, distinct, viral recognition pathways [245] [254] [255] [228] [258] [259]. Our 
data suggests that while still separate pathways, with distinct adaptor proteins, TLR3 
and the RIG-I/MDA5 pathways may operate in concert, and are both required for 
effective anti-viral host defence. This is particulary attractive for RV infection, which 
utilises both endosomal and intracellular sites for entry and replication. We observed a 
rapid increase in RIG-I and MDA5 mRNA by 4h post-infection, and this occurred 
simultaneously with the induction of IFN-β, IFN-λ1 and IFN-λ2/3 mRNA. It is unlikely, but 
not impossible that the increase in RIG-I and MDA5 is dependent upon RV induced IFN-
β or IFN-λ production. As the translation of IFN-β/IFN-λ mRNA into protein, and their 
signalling through their respective receptors would take time, the early co-induction of 
RIG-I and MDA5 with IFN mRNA suggests that the initial up-regulation of RIG-I and 
MDA5 mRNA may not be due to the presence of IFN protein. We argue that this early 
induction is via TLR3 and TRIF, in an interferon independent manner. However, we did 
not investigate time-points before 4h post-infection, and can therefore not rule out the 
interferon dependency of this observation. It should also be noted, that the classic 
interferon literature supports the idea that low level of type I interferon exist in order to 
prime the interferon system [361] [362] [363], and this is important to the biology of 
interferon and anti-viral defence. 
Knockdown of TLR3 and TRIF reduced RV induced RIG-I and MDA5 at 24h post 
infection, and transfection with constitutively active TRIF also induced RIG-I and MDA5. 
In these experiments, at this time point (24h) we can not rule out a role for IFN in RV or 
TRIF induced RIG-I and MDA5 mRNA at this time. In these experiments the presence 
of IFN protein was not investigated at time-points earlier than 24h post-infection, or 
during transfection. The determination of IFN protein presence, or IFN activity such as 
by measuring STAT1 phosphorylation could help clarify this issue. Therefore, we cannot 
rule out the possibility that IFN protein is present at early time-points post RV1B 
infection, and is responsible for early up-regulation of RV induced RIG-I and MDA5 
mRNA. These experiments are required before the above results can be truly 
interpreted. Experiments were designed using the protein transport inhibitors monensin 
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and brefeldin A, in order to block both TRIF-induced IFN-β and IFN-λ. Unfortunately, the 
effects of these results on RIG-I and MDA5 mRNA were unclear (data not shown). One 
explanation could be that TRIF-induced RIG-I and MDA5 is both IFN and non-IFN 
dependant, and by 24h post transfection, TLR3/TRIF and IFN mediated pathways both 
contribute to the increased RIG-I and MDA5 mRNA and protein observed. 
Since the writing of this thesis, several observations have been made that indirectly 
support the role of TLR3 and TRIF in virus-induced RIG-I and MDA5 production. Using 
whole lung mRNA analysis, a recent study using IFNAR1 knockout mice, which are 
deficient in both lung IFN-β signalling and IFN-λ production, exhibited equal levels of 
RV1B induced RIG-I and MDA5 mRNA at 4h post-infection as wild-types (N. Bartlett & 
M. Edwards, unpublished observations). The induction of RIG-I and MDA5 mRNA did 
not continue at time-points later than 8h post-infection in IFNAR1 knockout mice, but 
continued to increase in wild-type mice. This finding indicates that initial early RIG-I and 
MDA5 mRNA up-regulation by RV1B is IFN-independent, and that RIG-I and MDA5 
expression at later times is IFN-dependent. Additionally, a recent study has shown SV to 
induce MDA5 mRNA at 6h post-infection in IFNAR1 and STAT1 knockout cDC [364]. 
Furthermore, the TLR3 ligand polyIC induces RIG-I and MDA5 mRNA production at 4h 
post treatment, and increased protein can be visualised by 8h post treatment (A. Sykes 
& M. Edwards unpublished observations). Further experiments are required to 
completely understand the interplay between TLR3 signalling, and RIG-I and MDA5 in 
RV infection in HBECs. 
4.4.3 Summary  
Type I and type III interferons exert their anti-viral effects by the induction and activation 
of a range of ISGs. RIG-I and MDA5 are viral and interferon inducible genes in HBECs. 
Interestingly, RIG-I and MDA5 mRNA were induced by RV1B by 4h, and in a manner 
dependent upon the endosomal receptor TLR3 and its adaptor TRIF. While this 
induction by RV is possibly interferon dependent and independent, our results support 
the hypothesis that both TLR3, and the intracellular RNA helicases RIG-I and MDA5 
work together for maximal interferon and pro-inflammatory cytokine production. 
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Chapter 5: Results. The role of signalling 
adaptors and kinases in RV1B induced IFN-β, 
IFN-λ and pro-inflammatory cytokine 
production in normal human bronchial 
epithelial cells 
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Figure 5.1 Signalling pathways implicated in IFN-β and Pro-inflammatory cytokine 
production. Signalling molecules investigated in this chapter, for their role in RV1B-induced IFN 
and pro-inflammatory cytokine expression in HBEC are included in the shaded area. 
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5.1 Introduction 
Numerous studies have implicated several signalling molecules downstream of TLR3 
and RIG-I/MDA5, to be involved in the activation of the transcription factors NF-κB, 
IRF3/7 and ATF-2/c-Jun, which are in turn shown to be required for either IFN-β, IFN-λ 
or pro-inflammatory cytokine/chemokine gene expression. These studies have primarily 
focused on viruses other than RV and have been performed typically in cell lines or 
primary cells, which are not associated with the respiratory tract. In order to assess the 
contribution of the molecules in RV-induced IFN and pro-inflammatory 
cytokine/chemokine expression in HBEC, siRNA studies were designed to inhibit a 
number of important signalling molecules, and therefore ascertain their importance in 
RV-induced IFN and pro-inflammatory cytokine/chemokine expression.  
TLR3 has been shown to activate downstream effectors through the adaptor protein 
TRIF [214] [219] [212] [218] [220]. TRIF in turn has been shown to interact with several 
signalling molecules including; TRAF3 [307] [308], TRAF6 [221] [303], RIP1 [301] [365], 
NAP1 [311], the kinases TBK-1 [221] [216] [223] and IKKε [216] [223] and the 
transcription factors IRF3 [219] [223] and IRF7 [223].  
The RIG-I/MDA5 pathways activate downstream effectors through the adaptor protein 
Cardif [256] [255] [228] [254]. Like TRIF, Cardif has been shown to interact with TRAF3 
[309] [293], TRAF6 [256] [254] [293], RIP1 [255] [293], NAP1 [312], TBK-1 [256] and 
IKKε [228] [293], IRF3 [256] and IRF7 [256] and in addition, TANK [306], TAK1 [256] 
and IKK-β [228] [293].  
The IKKε/TBK-1 Kinase complex scaffold proteins TANK and NAP1, and the adaptor 
proteins TRAF3 and TRAF6 are believed to function to link TRIF and Cardif with 
kinases, as evidenced by an identified TANK-TBK-1/IKKε interaction [270] [271], NAP1- 
TBK-1/IKKε interaction [310], TRAF3-TBK-1/IKKε interaction [308], and the fact that 
TAB2 has been shown to recruit the MAPKKK TAK1 to TRAF6 [297]. In addition TAK1 
in turn activates IKK-β and JNK1/2 MAPK [296] [300]. TBK-1/IKKε activate IRF3/IRF7 
[153], IKK-β activates NF-κB [167], and MAPKs activate ATF-2/c-Jun [279] [281].  
TBK-1/IKKε have additionally been shown to activate NF-κB [313] [270], although it has 
been suggested that TBK-1/IKKε are not required for NF-κB activation by the TLR3 
[273] and RIG-I/MDA5 [272] pathways. Activated (phosphorylated) TLR3 additionally 
interacts with PI3Kα [286], which in turn is implicated in IRF3 [286] and NF-κB activation 
[291] [212] [290]. Thus a comprehensive understanding of how viral infection is 
recognised and activates specific signal transduction is now available. 
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With respect to RV infection of HBEC, the signalling molecules downstream of TLR3 
and RIG-I/MDA5 and required by RV to induce IFN-β, IFN-λ and pro-inflammatory 
cytokine expression are unknown. This aspect of RV mediated signalling was 
investigated in this chapter, in order to better understand the signalling pathways by 
which RV induces IFN-β, IFN-λ and pro-inflammatory cytokines. This study aimed to 
identify any differences in the signalling molecules that are required for IFN expression, 
from those that are required for pro-inflammatory cytokine expression. In doing so, a 
better understanding of the signalling molecules required for IFN expression, and 
therefore which may be deficient in asthmatic BEC will be obtained. The modulation of 
which may enhance IFN production and not cause elevated pro-inflammatory cytokine 
expression. Additionally, any signalling molecules identified to be specific to RV-induced 
pro-inflammatory cytokine induction but not IFN induction will represent potential 
therapeutic target molecules for virus-induced asthma exacerbations. The modulation of 
which, may allow the inhibition of pro-inflammatory cytokine production but not affect 
IFN expression.  
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5.2 Effect of Cardif and TRIF inhibition on RV1B 
infected HBEC  
Having demonstrated that the pattern recognition receptors RIG-I, MDA5 and TLR3 
have a role in RV1B induced IFN-β and pro-inflammatory cytokine production, and that 
MDA5 and TLR3 have a role in RV1B-induced IFN-λ1 and IFN-λ2/3 production, the 
requirement for the RIG-I/MDA5 adaptor protein Cardif and the TLR3 adaptor protein 
TRIF for RV1B-induced IFN and pro-inflammatory cytokine expression was determined 
using siRNA specifically targeting Cardif and TRIF.  
5.2.1 Inhibition of Cardif and TRIF mRNA and protein by Cardif 
and TRIF specific siRNA 
HBEC were transfected with Cardif, TRIF or a non-targeting control siRNA or were 
untransfected, and then cultured for 24h, before incubating with RV1B (MOI of 1), or 
treating with BEBM alone, and culturing for a further 24h. Cells were harvested for total 
RNA or protein, and reduction in Cardif and TRIF mRNA analysed by TaqMan RT-PCR 
or Cardif and TRIF protein by western blot analysis. Following RV1B infection, Cardif 
and TRIF siRNA reduced Cardif and TRIF mRNA levels respectively, to 15% and 14% 
(both p<0.001), of expression levels obtained with non-targeting control siRNA (Fig. 
5.2A, C). Cardif and TRIF proteins were detected in medium treated alone cells (Fig. 
5.2B, D). In uninfected non-targeting control siRNA transfected cells Cardif and TRIF 
proteins were detected, and their expression not enhanced compared to medium treated 
alone cells (Fig. 5.2B, D). Cardif and TRIF targeting siRNA reduced Cardif and TRIF 
protein expression respectively, compared to non-targeting control siRNA in the 
absence of RV1B infection (Fig. 5.2B, D). RV1B infection did not induce Cardif and TRIF 
protein expression compared to medium treated alone cells (Fig. 5.2B, D). siRNA 
targeting either Cardif or TRIF in the presence of RV1B infection reduced Cardif and 
TRIF protein respectively, compared to RV1B infected non-targeting control siRNA 
transfected cells (Fig. 5.2B, D). The structural proteins β-actin and α-tubulin were used 
as controls to assess protein loading. 
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Figure 5.2 Reduction of TRIF and Cardif mRNA and protein by TRIF and Cardif specific 
siRNA in HBEC. HBEC were transiently transfected with TRIF, Cardif, or non-targeting control 
siRNA (100nM) or untransfected. 24h post-transfection, cells were infected with RV1B (MOI 1) or 
treated with infection medium alone. At 24h post-infection, cells were harvested for total RNA or 
protein and TRIF (A) and Cardif (C) mRNA measured by TaqMan RT-PCR, or TRIF (B) and 
Cardif (D) protein measured by western blot. TRIF and Cardif mRNA expression was inhibited by 
TRIF and Cardif siRNA respectively (both p<0.001), versus non-targeting control siRNA. Data are 
the mean ± SEM of 6 separate experiments and expressed as % of control siRNA transfected 
cells =100%, (***p<0.001, **p<0.01, *p<0.05 versus non-targeting control siRNA). Western blots 
are representative of 2-3 experiments. 
5.2.2 TRIF siRNA inhibited RV1B-induced IFN-β, IFN-λ1 and IFN-
λ2/3 and Cardif siRNA inhibited RV1B-induced IFN-β and 
IFN-λ1 but not IFN-λ2/3   
HBEC were transfected with Cardif or TRIF specific siRNA, a non-targeting control 
siRNA or were untransfected, and cultured for 24h before incubating with RV1B (MOI of 
1), or treating with BEBM alone, and culturing for a further 24h. Cells were harvested for 
total RNA and IFN-β, IFN-λ1 and IFN-λ2/3 mRNA analysed by TaqMan RT-PCR. TRIF 
siRNA significantly inhibited RV1B-induced IFN-β, IFN-λ1 (both p<0.001) and IFN-λ2/3 
(p<0.01) compared to non-targeting control siRNA transfected cells (Fig. 5.3A-C). Cardif 
siRNA significantly inhibited RV1B-induced IFN-β and IFN-λ1 (both p<0.001), but not 
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RV1B-induced IFN-λ2/3 (p>0.05), compared to non-targeting control siRNA transfected 
cells (Fig. 5.3A-C). No significant difference between uninfected untransfected cells and 
uninfected non-targeting control siRNA transfected cells was observed (all p>0.05) 
indicating that control siRNA alone did not induce IFN-β, IFN-λ1 or IFN-λ2/3 mRNA.  
 
 
 
Figure 5.3 Effect of TRIF and Cardif siRNA on RV1B induced IFN-β, IFN-λ1 and IFN-λ2/3 
mRNA expression in HBEC. HBEC were transiently transfected with TRIF, Cardif or non-
targeting control siRNA, or untransfected. 24h post-transfection, cells were infected with RV1B 
(MOI 1), or treated with infection medium alone. At 24h post-infection, total cell RNA was 
harvested and IFN-β, IFN-λ1 and IFN-λ2/3 mRNA measured by TaqMan RT-PCR. TRIF siRNA 
inhibited RV1B induced IFN-β (A), IFN-λ1 (B) (both p<0.001) and IFN-λ2/3 (C) (p<0.05) mRNA 
expression, and Cardif siRNA inhibited RV1B induced IFN-β (A) and IFN-λ1 (B) (both p<0.001), 
but not IFN-λ2/3 (C) (p>0.05) mRNA expression compared to cells transfected with control 
siRNA. Data are the mean ± SEM of 4−6 separate experiments and expressed as % of infected 
control =100%, (***p<0.001, **p<0.01, *p<0.05 versus non-targeting control siRNA), ### versus 
untransfected, uninfected control.   
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5.2.3 Inhibition of TRIF or Cardif during RV1B infection of HBEC 
inhibited pro-inflammatory cytokine gene expression 
In identical experiments to those produced in section 5.2.2, TRIF and Cardif siRNA 
significantly inhibited RV1B-induced CCL5, CXCL10, CXCL5 and IL-6 (all p<0.001), 
compared to non-targeting control siRNA transfected cells (Fig. 5.4A, B, C, E). RV1B-
induced CXCL8 was also inhibited by TRIF siRNA (p<0.001) and Cardif siRNA (p<0.01) 
compared to non-targeting control siRNA transfected cells (Fig. 5.4D). No significant 
difference between uninfected untransfected cells and uninfected non-targeting control 
siRNA transfected cells was observed (all p>0.05) indicating that control siRNA alone 
did not induce any of the pro-inflammatory cytokines measured.  
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Figure 5.4 Effect of TRIF and Cardif siRNA on RV1B induced pro-inflammatory cytokine 
mRNA expression in HBEC. HBEC were transiently transfected with TRIF, Cardif or non-
targeting control siRNA, or untransfected. 24h post-transfection, cells were infected with RV1B 
(MOI of 1), or treated with infection medium alone. 24h post-infection, cells were harvested for 
total RNA and pro-inflammatory cytokines measured by TaqMan RT-PCR. TRIF and Cardif 
siRNA inhibited RV1B induced CCL5 (A), CXCL10 (B), IL-6 (C), CXCL8 (D) and CXCL5 (E) 
mRNA expression compared to cells infected and transfected with control siRNA. Data are the 
mean ± SEM of 4−5 (using TRIF siRNA) and 3−4 (using Cardif siRNA) separate experiments and 
expressed as % of infected control =100%, (***p<0.001, **p<0.01, *p<0.05 versus non-targeting 
control siRNA), ### versus untransfected, uninfected control.   
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5.3 Effect of TRAF3 and TRAF6 inhibition on RV1B 
infected HBEC  
The ubiquitin ligases TRAF3 and TRAF6 which interact with the adaptor proteins Cardif 
and TRIF, and which mediate down-stream signalling from these adaptor proteins were 
investigated for their role in RV1B induced interferon (IFN-β, IFN-λ-1, IFN-λ2/3) and pro-
inflammatory cytokine (CCL5, CXCL10, IL-6, CXCL8, CXCL5) expression, using siRNA 
specifically targeting TRAF3 and TRAF6.  
5.3.1 Inhibition of TRAF3 and TRAF6 mRNA and protein by 
TRAF3 and TRAF6 specific siRNA 
HBEC were transfected with TRAF3 or TRAF6 specific siRNA, a non-targeting control 
siRNA or were untransfected, and cultured for 24h before incubating with RV1B (MOI of 
1), or treating with BEBM alone, and culturing for a further 24h. Cells were harvested for 
total RNA or protein, and reduction in TRAF3 and TRAF6 mRNA analysed by TaqMan 
RT-PCR, or TRAF3 and TRAF6 protein by western blot analysis. Following RV1B 
infection, TRAF3 and TRAF6 siRNA reduced TRAF3 and TRAF6 mRNA levels 
respectively to 12% and 18% (both p<0.001), of expression levels obtained with non-
targeting control siRNA transfected cells (Fig. 5.5A, C). TRAF3 and TRAF6 proteins 
were detected in medium treated alone cells (Fig. 5.5B, D). In uninfected non-targeting 
control siRNA transfected cells TRAF3 and TRAF6 proteins were detected, but their 
expression not enhanced compared to medium treated alone cells (Fig. 5.5B, D). RV1B 
infection did not induce TRAF3 or TRAF6 protein expression compared to medium 
treated alone cells (Fig. 5.5B, D). siRNA targeting TRAF3 and TRAF6, in the presence 
of RV1B infection, reduced TRAF3 and TRAF6 protein respectively, compared to RV1B 
infected non-targeting control siRNA transfected cells (Fig. 5.5B, D). The structural 
protein β-actin was used as a control for protein loading.  
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Figure 5.5 Reduction of TRAF3 and TRAF6 mRNA and protein by TRAF3 and TRAF6 
specific siRNA in HBEC. HBEC were transiently transfected with TRAF3, TRAF6, or non-
targeting control siRNA (100nM) or un-transfected. 24h post-transfection, cells were infected with 
RV1B (MOI 1) or treated with infection medium alone. 24h post-infection, cells were harvested for 
total RNA or protein and TRAF3 (A) and TRAF6 (C) mRNA measured by TaqMan RT-PCR, or 
TRAF3 (B) and TRAF6 (D) protein measured by western blot. TRAF3 and TRAF6 mRNA 
expression was inhibited by TRAF3 and TRAF6 siRNA respectively (both p<0.001), versus non-
targeting control siRNA. Data are the mean ± SEM of 6 (A) and 5 (C) separate experiments and 
expressed as % of control siRNA transfected cells =100%, (***p<0.001, **p<0.01, *p<0.05 versus 
non-targeting control siRNA). Western blots are representative of 2-3 experiments. 
5.3.3 TRAF3 & TRAF6 siRNA did not inhibit RV1B-induced IFN-β 
or IFN-λ1; TRAF6 siRNA did not inhibit RV1B-induced IFN-
λ2/3 & TRAF3 siRNA enhanced RV1B-induced IFN-λ2/3   
HBEC were transfected with TRAF3, TRAF6 or non-targeting control siRNA or were 
untransfected, and then cultured for 24h before incubating with RV1B (MOI of 1), or 
treating with BEBM alone, and culturing for a further 24h. Cells were harvested for total 
RNA and IFN-β, IFN-λ1 and IFN-λ2/3 mRNA analysed by TaqMan RT-PCR. TRAF3 and 
TRAF6 siRNA did not inhibit RV1B-induced IFN-β or IFN-λ1 mRNA, and TRAF6 siRNA 
did not inhibit RV1B-induced IFN-λ2/3 mRNA (all p>0.05), compared to RV1B infected 
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non-targeting control siRNA transfected cells (Fig. 5.6A-C). TRAF3 siRNA enhanced 
RV1B-induced IFN-λ2/3 mRNA (p<0.01), compared to RV1B infected non-targeting 
control siRNA transfected cells (Fig. 5.6C). No significant difference between uninfected 
untransfected cells and uninfected non-targeting control siRNA transfected cells was 
observed (all p>0.05) indicating that control siRNA alone did not induce IFN-β, IFN-λ1 or 
IFN-λ2/3 mRNA.  
  
Figure 5.6 Effect TRAF3 or TRAF6 siRNA on RV1B induced IFN-β, IFN-λ1 and IFN-λ2/3 
mRNA expression in HBEC. HBEC were transiently transfected with TRAF3, TRAF6, non-
targeting control siRNA, or untransfected. 24h post-transfection, cells were infected with RV1B 
(MOI of 1) or treated with infection medium alone. 24h post-infection, cells were harvested for 
total RNA and IFN-β, IFN-λ1 and IFN-λ2/3 measured by TaqMan RT-PCR.TRAF6 siRNA did not 
inhibit RV1B induced IFN-β (A), IFN-λ1 (B) or IFN-λ2/3 (C) (all p>0.05) mRNA expression, and 
TRAF3 siRNA did not inhibit RV1B induced IFN-β (A) or IFN-λ1 (B) (both p<0.05) and enhanced 
IFN-λ2/3 (C) (p<0.01) mRNA expression, compared to cells infected and transfected with non-
targeting control siRNA. Data are the mean ± SEM of 4−6 (using TRAF3 siRNA) and 4−5 (using 
TRAF6 siRNA) separate experiments and expressed as % of infected control =100%, 
(***p<0.001, **p<0.01, *p<0.05 versus non-targeting control siRNA), ### versus untransfected, 
uninfected control.   
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5.3.4 TRAF3 & TRAF6 siRNA inhibited RV1B-induced CXCL5, IL-
6 & CXCL8 & did not affect RV1B-induced CXCL10; TRAF3 
siRNA enhanced RV1B-induced CCL5 & TRAF6 siRNA did 
not affect RV1B-induced CCL5 
In identical experiments to those produced in section 5.3.3, TRAF3 and TRAF6 siRNA 
inhibited RV1B-induced IL-6, CXCL8 (both p<0.001) and CXCL5 (p<0.05 and p<0.01 
respectively) expression, compared to RV1B infected non-targeting control siRNA 
transfected cells (Fig. 5.7C, D, E). RV1B-induced CCL5 expression was enhanced by 
TRAF3 siRNA (p<0.01), and was not affected by TRAF6 siRNA (p>0.05), compared to 
RV1B infected non-targeting control siRNA transfected cells (Fig. 5.7A). TRAF3 and 
TRAF6 siRNA enhanced RV1B-induced CXCL10 expression (both p<0.05), compared 
to RV1B infected non-targeting control siRNA transfected cells (Fig. 5.7B). No significant 
difference between uninfected untransfected cells and uninfected non-targeting control 
siRNA transfected cells was observed (all p>0.05) indicating that control siRNA alone 
did not induce any of the pro-inflammatory cytokines measured. 
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Figure 5.7 Effect TRAF3 or TRAF6 siRNA on RV1B induced CCL5, CXCL10, IL-6, CXCL8 
and CXCL5 mRNA expression in HBEC. HBEC were transiently transfected with TRAF3, 
TRAF6, non-targeting control siRNA, or untransfected. 24h post-transfection, cells were infected 
with RV1B (MOI of 1) or treated with infection medium alone.  24h post-infection, cells were 
harvested for total RNA and CCL5, CXCL10, IL-6, CXCL8 and CXCL5 measured by TaqMan RT-
PCR. TRAF3 siRNA enhanced RV1B-induced CCL5 (A) (p<0.01) and CXCL10 (B) (p<0.05) and 
inhibited RV1B-induced IL-6 (C), CXCL8 (D) (both p<0.001) and CXCL5 (E) (p<0.05) mRNA 
expression, and TRAF6 siRNA did not affect RV1B-induced CCL5 (A) or CXCL10 (B) (both 
p>0.05), and inhibited RV1B-induced IL-6 (C), CXCL8 (D) (both p<0.001) and CXCL5 (E) 
(p<0.01) mRNA expression, compared to cells infected and transfected with non-targeting control 
siRNA. Data are the mean ± SEM of 4−6 (using TRAF3 siRNA) and 4−5 (using TRAF6 siRNA) 
separate experiments and expressed as % of infected control =100%, (***p<0.001, **p<0.01, 
*p<0.05 versus non-targeting control siRNA), ### versus untransfected, uninfected control.   
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5.4 Effect of adaptor protein targeting siRNA on IFN 
and pro-inflammatory cytokine expression in HBEC 
To ensure that all of the adaptor protein (Cardif, TRIF, TRAF3, TRAF6) targeting siRNA 
used in this study did not significantly induce interferon or the production of pro-
inflammatory cytokine mRNA, the effect of each adaptor protein targeting siRNA on 
interferon and pro-inflammatory cytokine gene expression, in the absence of RV 
infection, was assessed in parallel experiments and compared to untransfected cells. 
Non-specific, oligonucleotide dsDNA was used as a transfection control.  
5.4.1 Cardif, TRIF, TRAF3 and TRAF6 siRNA did not induce IFNs 
in HBEC  
HBEC were transfected with Cardif, TRIF, TRAF3, TRAF6 specific siRNA or oligo 
dsDNA, then cultured for 24h before replacing culture medium with fresh BEBM and 
culturing for a further 24h. Cells were harvested for total RNA and IFN-β, IFN-λ1 and 
IFN-λ2/3 mRNA analysed by TaqMan RT-PCR (Table 5.1). TRIF siRNA transfection did 
not induce IFN-β, IFN-λ1 or IFN-λ2/3 mRNA compared to untransfected control cells (all 
p>0.05). Cardif and TRAF6 siRNA transfection did not induce IFN-β or IFN-λ2/3 mRNA 
(both p>0.05), and induced IFN-λ1 mRNA compared to untransfected control cells, but 
this difference was not significant (both p>0.05). Transfection with TRAF3 siRNA did not 
induce IFN-λ1 or IFN-λ2/3 mRNA (both p>0.05), and induced IFN-β mRNA compared to 
untransfected control cells, but this difference was not significant (both p>0.05). IFN-β, 
IFN-λ1 and IFN-λ2/3 mRNA copies in dsDNA transfected cells, were non-significantly 
increased compared to their respective IFN-β, IFN-λ1 and IFN-λ2/3 mRNA copies in 
untransfected control cells (all p>0.05). No-significant difference in IFN-β, IFN-λ1 or IFN-
λ2/3 mRNA (all p>0.05) was observed between Cardif, TRIF, TRAF3 or TRAF6 siRNA 
transfected cells and dsDNA transfected cells.  
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 IFN-β IFN-λ1 IFN-λ2/3 
Un-transfected    
Mean copies ± SEM  2.3x104 ± 1.4x104 1.0x102 ± 5.8x101 1.3x103 ± 6.7x102 
dsDNA    
Mean copies ± SEM 3.1x104 ± 1.3x104 NS 2.2x103 ± 1.5x103 NS 1.9x103 ± 1.0x103 NS 
TRIF siRNA    
Mean copies ± SEM 4.2x101 ± 0.5x101 NS/NS 1.5x101 ± 0.1x101 NS/NS 3.2x102 ± 2.1x102 NS/NS 
Cardif siRNA    
Mean copies ± SEM 1.1x103 ± 7.0x102 NS/NS 4.0x102 ± 3.5x102 NS/NS 1.1x103 ± 9.3x102 NS/NS 
TRAF6 siRNA    
Mean copies ± SEM 3.4x103 ± 2.1x103 NS/NS 3.2x102 ± 2.6x102 NS/NS 1.2x103 ± 8.1x102 NS/NS 
TRAF3 siRNA    
Mean copies ± SEM 2.6x104 ± 1.6x104 NS/NS 7.6x101 ± 4.7x101 NS/NS 1.3x102 ± 1.0x102 NS/NS 
 
Figure 5.1 Effect of Cardif, TRIF, TRAF3 and TRAF6 siRNA or dsDNA transfection on IFN-β, 
IFN-λ1 and IFN-λ2/3 mRNA expression in HBEC. HBEC were transiently transfected with 
either Cardif, TRIF, TRAF3, TRAF6 siRNA or dsDNA. 24h post-transfection, medium was 
replaced and cells cultured in fresh infection medium for 24h. Total cell RNA was harvested for 
analysis at 48h post-transfection and IFN-β, IFN-λ1 and IFN-λ2/3 measured by TaqMan RT-
PCR. Cardif, TRIF, TRAF3, TRAF6 siRNA or dsDNA transfection did not significantly induce IFN-
β, IFN-λ1 or IFN-λ2/3 mRNA expression compared to un-transfected control cells (all p>0.05). 
Data are the mean mRNA copy number per 2x105 cells ± SEM of 6 separate experiments. 
Statistics are shown as dsDNA versus untransfected cells (NS), and each specific targeting siRNA 
versus dsDNA/untransfected cells respectively (NS/NS).  
5.4.2 Cardif, TRIF, TRAF3 and TRAF6 siRNA did not induce pro-
inflammatory cytokines in HBEC 
HBEC were transfected with Cardif, TRIF, TRAF3 or TRAF6 specific siRNA, or dsDNA, 
then cultured for 24h before replacing culture medium with fresh BEBM and culturing for 
a further 24h. Cells were harvested for total RNA and CCL5, CXCL10, CXCL5, IL-6 and 
CXCL8 mRNA analysed by TaqMan RT-PCR (Table 5.2). Cardif and TRIF siRNA 
transfection did not induce CCL5, CXCL10 or CXCL5 mRNA (all p>0.05), and non-
significantly induced IL-6 and CXCL8 mRNA (both p>0.05) compared to untransfected 
control cells. TRAF6 siRNA transfection did not induce CXCL10, IL-6 or CXCL8 mRNA 
(all p>0.05), and non-significantly induced CCL5 and CXCL5 (both p>0.05) compared to 
untransfected control cells. Transfection with TRAF3 siRNA did not induce CXCL10, 
CXCL5 or CXCL8 mRNA (all p>0.05), and non-significantly induced CCL5 and IL-6 
mRNA (both p>0.05) compared to un-transfected control cells. CCL5, CXCL10, CXCL5, 
IL-6 and CXCL8 mRNA copies in dsDNA transfected cells, were non-significantly 
increased compared to their respective mRNA copies in untransfected control cells (all 
p>0.05). No-significant difference in CCL5, CXCL10, CXCL5, IL-6 or CXCL8 mRNA (all 
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p>0.05) was observed between Cardif, TRIF, TRAF3 or TRAF6 siRNA transfected cells 
and dsDNA transfected cells.    
 
 CCL5 CXCL10 CXCL5 IL-6 CXCL8 
Un-transfected      
Mean copies 5.4x105 1.8x106 3.2x105 1.2x104 3.5x106 
± SEM ± 3.8x105 ± 9.0x105 ± 6.7x104 ± 4.4x103 ± 1.0x106 
dsDNA      
Mean copies 1.0x106 NS 2.5x106 NS 7.8x105 NS 1.7x104 NS 3.9x106 NS 
± SEM ± 4.0x105 ± 9.1x105 ± 2.1x105 ± 9.5x103 ± 1.0x106 
TRIF siRNA      
Mean copies 2.1x105 NS/NS 9.3x105 NS/NS 2.5x105 NS/NS 2.1x104 NS/NS 4.4x106 NS/NS 
± SEM ± 1.3x105 ± 2.8x105 ± 1.0x105 ± 1.0x104 ± 1.9x106 
Cardif siRNA      
Mean copies 3.4x105 NS/NS 1.9x105 NS/NS 1.2x105 NS/NS 2.4x104 NS/NS 3.9x106 NS/NS 
± SEM ± 2.9x105 ± 7.1x104 ± 7.0x104 ± 9.5x103 ± 1.4x106 
TRAF6 siRNA      
Mean copies 6.5x105 NS/NS 1.2x106 NS/NS 3.3x105 NS/NS 5.2x103 NS/NS 1.5x106 NS/NS 
± SEM ± 3.8x105 ± 2.7x105 ± 6.9x104 ± 1.9x103 ± 4.8x105 
TRAF3 siRNA      
Mean copies 6.2x105 NS/NS 1.6x106 NS/NS 2.7x105 NS/NS 1.8x104 NS/NS 2.1x106 NS/NS 
± SEM ± 2.2x105 ± 3.7x105 ± 6.7x104 ± 9.8x103 ± 7.3x105 
 
Figure 5.2 Effect of Cardif, TRIF, TRAF6 and TRAF3 siRNA or dsDNA transfection on 
CCL5, CXCL10, CXCL5, IL-6 and CXCL8 mRNA expression in HBEC. HBEC were transiently 
transfected with either Cardif, TRIF, TRAF6 or TRAF3 siRNA or dsDNA. 24h post-transfection, 
medium was replaced and cells cultured for a further 24h. Total cell RNA was harvested for 
analysis at 48h post-transfection and pro-inflammatory cytokines measured by TaqMan RT-PCR. 
Cardif, TRIF, TRAF6, TRAF3 siRNA or dsDNA transfection did not significantly induce CCL5, 
CXCL10, CXCL5, IL-6 or CXCL8 mRNA expression compared to un-transfected cells (all 
p>0.05). Data are the mean mRNA copy number per 2x105 cells ± SEM of 6 separate 
experiments. Statistics are shown as dsDNA versus untransfected cells (NS), and each specific 
targeting siRNA versus dsDNA/untransfected cells respectively (NS/NS).  
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5.5 Effect of IKK-β, IKKε and TBK-1 inhibition on RV1B 
infected HBEC  
The signalling kinases IKK-β, IKKε and TBK-1, are responsible for the phosphorylation 
and subsequent activation of transcription factors required for IFN and pro-inflammatory 
cytokine gene transcription. Each kinase was investigated for their role in RV1B induced 
interferon (IFN-β, IFN-λ1, IFN-λ2/3) and pro-inflammatory cytokine (CCL5, CXCL10, IL-
6, CXCL8, CXCL5) expression, using siRNA specifically targeting IKK-β, IKKε and TBK-
1.  
5.5.1 Inhibition of IKK-β, IKKε and TBK-1 mRNA and protein by 
IKK-β, IKKε and TBK-1 siRNA 
HBEC were transfected with IKK-β, IKKε or TBK-1 specific siRNA, a non-targeting 
control siRNA or were untransfected, and cultured for 24h before incubating with RV1B 
(MOI of 1), or treating with BEBM alone, and culturing for a further 24h. Cells were 
harvested for total RNA or protein, and reduction in IKK-β, IKKε and TBK-1 mRNA 
analysed by TaqMan RT-PCR, or IKK-β, IKKε and TBK-1 protein by western blot 
analysis. Following RV1B infection, IKK-β, IKKε and TBK-1 siRNA reduced IKK-β, IKKε 
and TBK-1 mRNA levels respectively to 12%, 21% and 13% (all p<0.001), of expression 
levels obtained with non-targeting control siRNA (Fig. 5.8A, C, E). IKK-β, IKKε and TBK-
1 proteins were detected in medium treated alone cells (Fig. 5.8B, D, F). In uninfected 
non-targeting control siRNA transfected cells IKK-β, IKKε and TBK-1 proteins were 
detected, and their expression not enhanced compared to medium treated alone cells 
(Fig. 5.8B, D, F). IKK-β, IKKε and TBK-1 targeting siRNA reduced IKK-β, IKKε and TBK-
1 protein respectively, compared to non-targeting control siRNA in the absence of RV1B 
infection (Fig. 5.8B, D, F). RV1B infection did not induce IKK-β or IKKε protein 
expression (Fig. 5.8B, D) and slightly induced TBK-1 protein expression (Fig. 5.8F), 
compared to medium treated alone cells. siRNA targeting either IKK-β, IKKε or TBK-1 
during RV1B infection reduced IKK-β, IKKε and TBK-1 protein respectively, compared to 
RV1B infected non-targeting control siRNA transfected cells (Fig. 5.8A, C, E). The 
structural proteins β-actin or α-tubulin were used as a control to assess protein loading. 
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Figure 5.8 Reduction of IKK-β, IKKε and TBK1 mRNA and protein by IKK-β, IKKε and TBK-1 
specific siRNA in HBEC. HBEC were transiently transfected with IKK-β, IKKε, TBK-1 or non-
targeting control siRNA (100nM) or untransfected. 24h post-transfection, cells were infected with 
RV1B (MOI 1) or treated with infection medium alone. 24h post-infection, cells were harvested for 
total RNA or protein and IKK-β (A), IKKε (C) and TBK-1 (E) mRNA measured by TaqMan RT-
PCR, or IKK-β (B), IKKε (D) and TBK-1 (F) protein measured by western blot. IKK-β, IKKε and 
TBK-1 mRNA was inhibited by IKK-β, IKKε and TBK-1 siRNA respectively (all p<0.001), versus 
non-targeting control siRNA. Data are the mean ± SEM of 5 (A), 6 (C), and 8 (E) separate 
experiments and expressed as % of control siRNA transfected cells =100%, (***p<0.001, 
**p<0.01, *p<0.05 versus non-targeting control siRNA). Western blots are representative of 2-3 
experiments. 
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5.5.2 IKK-β and TBK-1 siRNA inhibited RV1B-induced IFN-β, IFN-
λ1 and IFN-λ2/3; IKKε siRNA inhibited RV1B-induced IFN-β 
and IFN-λ2/3 but did not affect IFN-λ1   
HBEC were transfected with IKK-β, IKKε or TBK-1 specific siRNA, a non-targeting 
control siRNA or were untransfected, and cultured for 24h before incubating with RV1B 
(MOI of 1), or treating with BEBM alone, and culturing for a further 24h. Cells were 
harvested for total RNA and IFN-β, IFN-λ1 and IFN-λ2/3 mRNA analysed by TaqMan 
RT-PCR. IKK-β specific siRNA inhibited RV1B-induced IFN-β (p<0.001), IFN-λ1 and 
IFN-λ2/3 (both p<0.01) compared to RV1B infected non-targeting control siRNA 
transfected cells (Fig.5.9A-C). IKKε specific siRNA inhibited RV1B-induced IFN-β and 
IFN-λ1 (both p<0.05), but did not significantly inhibit IFN-λ2/3 mRNA (p>0.05), 
compared to RV1B infected non-targeting control siRNA transfected cells (Fig.5.9A-C). 
TBK-1 specific siRNA inhibited RV1B-induced IFN-β, IFN-λ1 and IFN-λ2/3 (all p<0.001) 
compared to RV1B infected non-targeting control siRNA transfected cells (Fig. 5.9A-C). 
No significant difference between uninfected untransfected cells and uninfected non-
targeting control siRNA transfected cells was observed (all p>0.05) indicating that 
control siRNA alone did not induce IFN-β, IFN-λ1 or IFN-λ2/3 mRNA.  
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Figure 5.9 Effect of IKK-β, IKKε and TBK-1 siRNA on RV1B induced IFN-β, IFN-λ1 and IFN-
λ2/3 mRNA expression in HBEC. HBEC were transiently transfected with IKK-β, IKKε, TBK-1, 
non-targeting control siRNA, or untransfected. 24h post-transfection, cells were infected with 
RV1B (MOI of 1) or treated with infection medium alone. 24h post-infection, cells were harvested 
for total RNA and IFN-β, IFN-λ1 and IFN-λ2/3 measured by TaqMan RT-PCR. IKK-β siRNA 
inhibited RV1B induced IFN-β (A) (p<0.001), IFN-λ1 (B) and IFN-λ2/3 (C) (both p<0.001) mRNA 
expression, IKKε siRNA inhibited RV1B induced IFN-β (A) and IFN-λ1 (B) (both p<0.05), but not 
IFN-λ2/3 (C) (p>0.05) mRNA expression, and TBK-1 siRNA inhibited RV1B induced IFN-β (A), 
IFN-λ1 (B) and IFN-λ2/3 (C) (all p<0.001) mRNA expression, compared to cells infected and 
transfected with non-targeting control siRNA. Data are the mean ± SEM of 4−5 (using IKK-β 
siRNA), 6 (using IKKε siRNA) and 7−8 (using TBK-1 siRNA) separate experiments and 
expressed as % of infected control =100%, (***p<0.001, **p<0.01, *p<0.05 versus non-targeting 
control siRNA), ### versus untransfected, uninfected control.   
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5.5.3  IKK-β, IKKε and TBK-1 siRNA inhibited RV1B-induced pro-
inflammatory cytokine gene expression 
In identical experiments to those produced in section 5.5.2, IKK-β siRNA inhibited 
RV1B-induced CCL5 and CXCL10, IL-6, CXCL8 and CXCL5 (all p<0.001) compared to 
RV1B infected non-targeting control siRNA transfected cells (Fig. 5.10A-E). IKKε siRNA 
inhibited RV1B-induced CCL5 and CXCL10, IL-6, CXCL8 (all p<0.001) and CXCL5 
(p<0.01), compared to RV1B infected non-targeting control siRNA transfected cells (Fig. 
5.10A-E). Transfection with TBK-1 siRNA also inhibited RV1B-induced CCL5 (p<0.01) 
and CXCL10, IL-6, CXCL8 and CXCL5 (all p<0.001) compared to RV1B infected non-
targeting control siRNA transfected cells (Fig. 5.10A-E). No significant difference 
between uninfected untransfected cells and uninfected non-targeting control siRNA 
transfected cells was observed (all p>0.05) indicating that control siRNA alone did not 
induce any of the pro-inflammatory cytokines measured.  
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Figure 5.10 Effect IKK-β, IKKε and TBK-1 siRNA on RV1B induced CCL5, CXCL10, IL-6, 
CXCL8 and CXCL5 mRNA expression in HBEC. HBEC were transiently transfected with IKK-β, 
IKKε, TBK-1, non-targeting control siRNA, or untransfected. 24h post-transfection, cells were 
infected with RV1B (MOI of 1) or treated with infection medium alone.  24h post-infection, cells 
were harvested for total RNA CCL5, CXCL10, IL-6, CXCL8 and CXCL5 measured by TaqMan 
RT-PCR. IKK-β siRNA inhibited RV1B-induced CCL5, CXCL10, IL-6, CXCL8 and CXCL5 (all 
p<0.001) mRNA expression, IKKε siRNA inhibited RV1B-induced CCL5, CXCL10, IL-6, CXCL8 
(all p<0.01) and CXCL5 (all p<0.01) mRNA expression, and TBK-1 siRNA inhibited RV1B-
induced CCL5 (p<0.01), CXCL10, IL-6, CXCL8 and CXCL5 (all p<0.001) mRNA expression, 
compared to cells infected and transfected with non-targeting control siRNA. Data are the mean ± 
SEM of 3−4 (using IKK-β siRNA), 4−5 (using IKKε siRNA) and 7−8 (using TBK-1 siRNA) separate 
experiments and expressed as % of infected control =100%, (***p<0.001, **p<0.01, *p<0.05 
versus non-targeting control siRNA), ### versus untransfected, uninfected control.   
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5.6 Effect of JNK2 and PI3Kα inhibition on RV1B 
infected HBEC  
The MAPK JNK2 resides up-stream of, and is responsible for the phosphorylation and 
subsequent activation of the transcription factors ATF-2 [279] [280] and c-Jun [281] 
[282]. PI3Kα interacts with TLR3 and is required for complete IRF3 phosphorylation 
[286]. Both kinases were investigated for their roles in RV1B-induced interferon (IFN-β, 
IFN-λ-1, IFN-λ2/3) and pro-inflammatory cytokine (CCL5, CXCL10, IL-6, CXCL8, 
CXCL5) production using siRNA differentially targeting JNK2 or PI3Kα.  
5.6.1 Inhibition of JNK2 and PI3Kα mRNA and protein by JNK2 
and PI3K specific siRNA 
HBEC were transfected with JNK2 or PI3Kα specific siRNA, a non-targeting control 
siRNA or were untransfected, and cultured for 24h before incubating with RV1B (MOI of 
1), or treating with BEBM alone, and culturing for a further 24h. Cells were harvested for 
total RNA or protein, and reduction in JNK2 and PI3Kα mRNA analysed by TaqMan RT-
PCR, or JNK2 and PI3Kα protein by western blot analysis. Following RV1B infection, 
JNK2 and PI3Kα siRNA reduced JNK2 and PI3Kα mRNA levels respectively to 14% and 
18% (both p<0.001), of expression levels obtained with non-targeting control siRNA (Fig. 
5.11A, C). JNK2 and PI3Kα proteins were detected in medium treated alone cells (Fig. 
5.11B, D). In uninfected non-targeting control siRNA transfected cells JNK2 and PI3Kα 
proteins were detected and their expression reduced by their respective targeting siRNA 
in the absence of RV1B infection (Fig. 5.11B, D). RV1B infection slightly induced JNK2 
and PI3Kα protein levels, compared to medium treated alone cells (Fig. 5.11B, D). 
siRNA targeting either JNK2 or PI3Kα during RV1B infection reduced JNK2 and PI3Kα 
protein levels respectively, compared to RV1B infected non-targeting control siRNA 
transfected cells (Fig. 5.11B, D). The structural proteins β-actin or α-tubulin were used 
as controls to assess protein loading. 
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Figure 5.11 Reduction of JNK2 and PI3Kα mRNA and protein by JNK2 and PI3Kα specific 
siRNA in HBEC. HBEC were transiently transfected with JNK2, PI3Kα or non-targeting control 
siRNA (100nM) or untransfected. 24h post-transfection, cells were infected with RV1B (MOI 1) or 
treated with infection medium alone. 24h post-infection, cells were harvested for total RNA or 
protein and JNK2 (A), and PI3Kα (C) mRNA measured by TaqMan RT-PCR, or JNK2 (B) and 
PI3Kα (D) protein measured by western blot. JNK2 and PI3Kα mRNA was inhibited by JNK2 and 
PI3Kα siRNA respectively (both p<0.001), versus non-targeting control siRNA. Data are the 
mean ± SEM of 8 (A), and 8 (C) separate experiments and expressed as % of control siRNA 
transfected cells =100%, (***p<0.001, **p<0.01, *p<0.05 versus non-targeting control siRNA). 
Western blots are representative of 2-3 experiments. 
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5.6.2 Inhibition of JNK2 during RV1B infection did not affect 
RV1B-induced IFN-β, IFN-λ1 or IFN-λ2/3 gene expression   
HBEC were transfected with JNK2 specific siRNA, a non-targeting control siRNA or 
were untransfected, and cultured for 24h before incubating with RV1B (MOI of 1), or 
treating with BEBM alone, and culturing for a further 24h. Cells were harvested for total 
RNA and IFN-β, IFN-λ1 and IFN-λ2/3 mRNA analysed by TaqMan RT-PCR. JNK2 
siRNA did not inhibit RV1B-induced IFN-β, IFN-λ1 or IFN-λ2/3 (all p>0.05) compared to 
RV1B infected non-targeting control siRNA transfected cells (Fig.5.12A-C). No 
significant difference between uninfected untransfected cells and uninfected non-
targeting control siRNA transfected cells was observed (all p>0.05) indicating that 
control siRNA alone did not induce IFN-β, IFN-λ1 or IFN-λ2/3 mRNA.  
 
 
 
Figure 5.12 Effect of JNK2 siRNA on RV1B induced IFN-β, IFN-λ1 and IFN-λ2/3 mRNA 
expression in HBEC. HBEC were transiently transfected with JNK2, non-targeting control 
siRNA, or untransfected. 24h post-transfection, cells were infected with RV1B (MOI of 1) or 
treated with infection medium alone. 24h post-infection, cells were harvested for total RNA and 
IFN-β, IFN-λ1 and IFN-λ2/3 measured by TaqMan RT-PCR. JNK2 siRNA did not inhibit RV1B 
induced IFN-β (A), IFN-λ1 (B) or IFN-λ2/3 (C) (all p>0.05) mRNA expression, compared to cells 
infected and transfected with non-targeting control siRNA. Data are the mean ± SEM of 6 
separate experiments and expressed as % of infected control =100%, (***p<0.001, **p<0.01, 
*p<0.05 versus non-targeting control siRNA), ### versus untransfected, uninfected control.   
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5.6.3 Inhibition of JNK2 during RV1B infection did not affect 
RV1B-induced CCL5 or CXCL10, but inhibited IL-6, CXCL8 
and CXCL5 expression 
In identical experiments to those produced in section 5.6.2, JNK2 siRNA did not inhibit 
RV1B-induced CCL5, or CXCL10 (both p>0.05), and inhibited RV1B-induced IL-6, 
CXCL8 and CXCL5 (all p<0.001) compared to RV1B infected non-targeting control 
siRNA transfected cells (Fig. 5.13A-E). No significant difference between uninfected 
untransfected cells and uninfected non-targeting control siRNA transfected cells was 
observed (all p>0.05) indicating that control siRNA alone did not induce any of the pro-
inflammatory cytokines measured.  
 
 
Figure 5.13 Effect JNK2 siRNA on RV1B induced CCL5, CXCL10, IL-6, CXCL8 and CXCL5 
mRNA expression in HBEC. HBEC were transiently transfected with JNK2, non-targeting 
control siRNA, or untransfected. 24h post-transfection, cells were infected with RV1B (MOI of 1) 
or treated with infection medium alone.  24h post-infection, cells were harvested for total RNA 
and CCL5, CXCL10, IL-6, CXCL8 and CXCL5 measured by TaqMan RT-PCR. JNK2 siRNA did 
not inhibit RV1B-induced CCL5 (A) or CXCL10 (B) (both p>0.05), and inhibited RV1B-induced IL-
6 (C), CXCL8 (D) and CXCL5 (E) (all p<0.001) mRNA expression, compared to cells infected and 
transfected with non-targeting control siRNA. Data are the mean ± SEM of 5−8 separate 
experiments and expressed as % of infected control =100%, (***p<0.001, **p<0.01, *p<0.05 
versus non-targeting control siRNA), ### versus untransfected, uninfected control.   
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5.6.4 Inhibition of PI3Kα during RV1B infection did not affect 
RV1B-induced IFN-β, IFN-λ1 & IFN-λ2/3 gene expression   
HBEC were transfected with PI3Kα specific siRNA, a non-targeting control siRNA or 
were untransfected, and cultured for 24h before incubating with RV1B (MOI of 1), or 
treating with BEBM alone, and culturing for a further 24h. Cells were harvested for total 
RNA and IFN-β, IFN-λ1 and IFN-λ2/3 mRNA analysed by TaqMan RT-PCR. PI3Kα 
siRNA did not inhibit RV1B-induced IFN-β, IFN-λ1 or IFN-λ2/3 (all p>0.05) compared to 
RV1B infected non-targeting control siRNA transfected cells (Fig. 5.14A-C). No 
significant difference between uninfected untransfected cells and uninfected non-
targeting control siRNA transfected cells was observed (all p>0.05) indicating that 
control siRNA alone did not induce IFN-β, IFN-λ1 or IFN-λ2/3 mRNA.  
 
 
 
 
Figure 5.14 Effect of PI3Kα siRNA on RV1B induced IFN-β, IFN-λ1 and IFN-λ2/3 mRNA 
expression in HBEC. HBEC were transiently transfected with PI3Kα, non-targeting control 
siRNA, or untransfected. 24h post-transfection, cells were infected with RV1B (MOI of 1) or 
treated with infection medium alone. 24h post-infection, cells were harvested for total RNA and 
IFN-β, IFN-λ1 and IFN-λ2/3 measured by TaqMan RT-PCR. PI3Kα siRNA did not inhibit RV1B 
induced IFN-β (A), IFN-λ1 (B) or IFN-λ2/3 (C) (all p>0.05) mRNA expression, compared to cells 
infected and transfected with non-targeting control siRNA. Data are the mean ± SEM of 8 
separate experiments and expressed as % of infected control =100%, (***p<0.001, **p<0.01, 
*p<0.05 versus non-targeting control siRNA), ### versus untransfected, uninfected control.   
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5.6.5 Inhibition of PI3Kα during RV1B infection did not affect 
RV1B-induced CCL5, but inhibited CXCL10, IL-6, CXCL8 
and CXCL5 expression 
In identical experiments to those produced in section 5.6.4, PI3Kα specific siRNA did not 
inhibit RV1B-induced CCL5 (p>0.05), and inhibited RV1B-induced CXCL10 (p<0.01), IL-
6, CXCL8 and CXCL5 mRNA (all p<0.001), compared to RV1B infected non-targeting 
control siRNA transfected cells (Fig. 5.15A-E). No significant difference between 
uninfected untransfected cells and uninfected non-targeting control siRNA transfected 
cells was observed (all p>0.05) indicating that control siRNA alone did not induce any of 
the pro-inflammatory cytokines measured.  
 
Figure 5.15 Effect PI3Kα siRNA on RV1B induced CCL5, CXCL10, IL-6, CXCL8 and CXCL5 
mRNA expression in HBEC. HBEC were transiently transfected with PI3Kα, non-targeting 
control siRNA, or untransfected. 24h post-transfection, cells were infected with RV1B (MOI of 1) 
or treated with infection medium alone. 24h post-infection, cells were harvested for total RNA and 
CCL5, CXCL10, IL-6, CXCL8 and CXCL5 measured by TaqMan RT-PCR. PI3Kα siRNA did not 
inhibit RV1B-induced CCL5 (A) (p>0.05), and inhibited RV1B-induced CXCL10 (B) (p<0.01), IL-6 
(C), CXCL8 (D) and CXCL5 (E) (all p<0.001) mRNA expression, compared to cells infected and 
transfected with non-targeting control siRNA. Data are the mean ± SEM of 5−8 separate 
experiments and expressed as % of infected control =100%, (***p<0.001, **p<0.01, *p<0.05 
versus non-targeting control siRNA), ### versus untransfected, uninfected control.   
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5.7 Effect of kinase targeting siRNA on IFN and pro-
inflammatory cytokine expression in HBEC 
To ensure that all of the kinase targeting siRNA used in this study did not significantly 
induce interferon or the production of pro-inflammatory cytokine mRNA, the effect of 
each kinase targeting siRNA on interferon and pro-inflammatory cytokine gene 
expression, in the absence of RV infection, was assessed in parallel experiments and 
compared to un-transfected cells. Non-specific, oligonucleotide dsDNA was used as a 
transfection control. 
5.7.1 IKK-β, IKKε, TBK-1, JNK2 and PI3Kα siRNA did not induce 
IFNs in HBEC  
HBEC were transfected with IKK-β, IKKε, TBK-1, JNK2 or PI3Kα specific siRNA or oligo 
dsDNA, then cultured for 24h before replacing culture medium with fresh BEBM and 
culturing for a further 24h. Cells were harvested for total RNA and IFN-β, IFN-λ1 and 
IFN-λ2/3 mRNA analysed by TaqMan RT-PCR (Table 5.3). IFN-β mRNA was not 
induced (p>0.05), and IFN-λ1 mRNA was non-significantly induced by IKK-β, IKKε, TBK-
1, JNK2 and PI3Kα siRNA transfection (all p>0.05), compared to un-transfected control 
cells. Transfection with IKK-β, TBK-1, JNK2 and PI3Kα siRNA did not induce IFN-λ2/3 
mRNA (all p>0.05), and IKKε siRNA transfection non-significantly induced IFN-λ2/3 
mRNA (p>0.05) compared to untransfected control cells. IFN-λ1 and IFN-λ2/3 mRNA 
copies, in dsDNA transfected cells, were non-significantly increased (both p>0.05) 
compared to their respective IFN-λ1 and IFN-λ2/3 mRNA copies in untransfected control 
cells, and no significant difference between IFN-β mRNA copies in dsDNA transfected 
and untransfected cells was observed (p>0.05). No-significant difference in IFN-β, IFN-
λ1 or IFN-λ2/3 mRNA (all p>0.05) was observed between IKK-β, IKKε, TBK-1, JNK2 or 
PI3Kα siRNA transfected cells and dsDNA transfected cells. 
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 IFN-β IFN-λ1 IFN-λ2/3 
Un-transfected    
Mean copies ± SEM 3.4x104 ± 1.5x104 6.2x101 ± 4.6x101 1.1x103 ± 5.7x102 
dsDNA    
Mean copies ± SEM 3.1x104 ± 1.3x104 NS 2.2x103 ± 1.5x103 NS 1.9x103 ± 1.0x103 NS 
IKK-β siRNA    
Mean copies ± SEM 3.4x104 ± 1.4x104 NS/NS 5.3x102 ± 3.1x102 NS/NS 7.8x102 ± 3.3x102 NS/NS 
IKKε siRNA    
Mean copies ± SEM 2.5x104 ± 1.5x104 NS/NS 6.4x102 ± 4.3x102 NS/NS 2.0x103 ± 8.4x102 NS/NS 
TBK-1 siRNA    
Mean copies ± SEM 1.9x104 ± 1.0x104 NS/NS 4.8x102 ± 3.1x102 NS/NS 9.3x102 ± 2.7x102 NS/NS 
PI3Kα siRNA    
Mean copies ± SEM 2.8x104 ± 8.2x103 NS/NS 3.4x102 ± 2.4x102 NS/NS 2.5x102 ± 1.1x102 NS/NS 
JNK2 siRNA    
Mean copies ± SEM 2.6x104 ± 9.9x103 NS/NS 1.2x102 ± 6.1x101 NS/NS 1.1x103 ± 4.3x102 NS/NS 
 
Figure 5.3 Effect of IKK-β, IKKε, TBK-1, JNK2 and PI3Kα siRNA or dsDNA transfection on 
IFN-β, IFN-λ1 and IFN-λ2/3 mRNA expression in HBEC. HBEC were transiently transfected 
with either IKK-β, IKKε, TBK-1, JNK2, PI3Kα siRNA or dsDNA. 24h post-transfection, medium 
was replaced and cells cultured in fresh infection medium for 24h. Total cell RNA was harvested 
for analysis at 48h post-transfection and IFN-β, IFN-λ1 and IFN-λ2/3 measured by TaqMan RT-
PCR. IKK-β, IKKε, TBK-1, JNK2, PI3Kα siRNA or dsDNA transfection did not significantly induce 
IFN-β, IFN-λ1 or IFN-λ2/3 mRNA expression compared to un-transfected control cells (all 
p>0.05). Data are the mean mRNA copy number per 2x105 cells ± SEM of 6 separate 
experiments. Statistics are shown as dsDNA versus untransfected cells (NS), and each specific 
targeting siRNA versus dsDNA/untransfected cells respectively (NS/NS).  
5.7.2  IKK-β, IKKε, TBK-1, JNK2 and PI3Kα siRNA did not induce 
pro-inflammatory cytokines in HBEC  
HBEC were transfected with IKK-β, IKKε, TBK-1, JNK2 or PI3Kα specific siRNA or oligo 
dsDNA, then cultured for 24h before replacing culture medium with fresh BEBM and 
culturing for a further 24h. Cells were harvested for total RNA and CCL5, CXCL10, 
CXCL5, IL-6 and CXCL8 mRNA analysed by TaqMan RT-PCR (Table 5.4). CCL5 
mRNA was not induced by IKK-β, IKKε, TBK-1, JNK2 or PI3Kα siRNA transfection (all 
p>0.05), compared to untransfected control cells. IKK-β, TBK-1 or PI3Kα siRNA 
transfection did not induce CXCL10 or CXCL5 mRNA (both p>0.05), and IKKε or JNK2 
siRNA transfection non-significantly induced CXCL10 and CXCL5 mRNA (both p>0.05), 
compared to untransfected control cells. TRAF6 siRNA transfection did not induce 
CXCL10, IL-6 or CXCL8 mRNA (all p>0.05), and non-significantly induced CCL5 and 
CXCL5 (both p>0.05) compared to untransfected control cells. Transfection with IKKε, 
TBK-1 or PI3Kα siRNA did not induce IL-6 mRNA (all p>0.05), and IKK-β or JNK2 
siRNA transfection non-significantly induced IL-6 mRNA (both p>0.05) compared to 
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untransfected control cells. IKK-β, IKKε, TBK-1 or JNK2 siRNA transfection non-
significantly induced CXCL8 mRNA (all p>0.05), and PI3Kα siRNA transfection did not 
induce CXCL8 mRNA (p>0.05), compared to untransfected control cells. CCL5, 
CXCL10, CXCL5, IL-6 and CXCL8 mRNA copies in dsDNA transfected cells were non-
significantly increased compared to their respective copies in untransfected control cells 
(all p>0.05). No-significant difference in CCL5, CXCL8, CXCL5 or IL-6 mRNA (all 
p>0.05) was observed between IKKε, TBK-1, JNK2 or PI3Kα siRNA transfected cells 
and dsDNA transfected cells, and CXCL10 mRNA (p<0.05) was reduced in IKK-β siRNA 
transfected cells compared to dsDNA transfected cells.   
 
 CCL5 CXCL10 CXCL5 IL-6 CXCL8 
Un-transfected      
Mean copies 7.3x105 8.7x105 5.6x105 7.5x103 3.6x106 
± SEM ± 3.8x105 ± 2.4x105 ± 2.9x105 ± 2.8x103 ± 1.1x106 
dsDNA      
Mean copies 1.0x106 NS 2.5x106 NS 7.8x105 NS 1.7x104 NS 3.9x106 NS 
± SEM ± 4.0x105 ± 9.1x105 ± 2.1x105 ± 9.5x103 ± 1.0x106 
IKK-β siRNA      
Mean copies 2.2x105 NS/NS 5.7x105 */NS 4.6x105 NS/NS 8.9x103 NS/NS 5.2x106 NS/NS 
± SEM ± 8.6x104 ± 1.3x105 ± 2.7x105 ± 2.8x103 ± 3.0x106 
IKKε siRNA      
Mean copies 2.2x105 NS/NS 9.6x105 NS/NS 6.9x105 NS/NS 6.1x103 NS/NS 6.5x106 NS/NS 
± SEM ± 5.5x104 ± 3.4x105 ± 4.0x105 ± 2.6x103 ± 3.0x106 
TBK-1 siRNA      
Mean copies 1.5x105 NS/NS 7.3x105 NS/NS 3.7x105 NS/NS 6.6x103 NS/NS 4.3x106 NS/NS 
± SEM ± 3.5x104 ± 2.4x105 ± 2.0x105 ± 2.9x103 ± 3.1x106 
PI3Kα siRNA      
Mean copies 4.2x105 NS/NS 6.7x105 NS/NS 3.7x105 NS/NS 7.6x103 NS/NS 3.5x106 NS/NS 
± SEM ± 1.6x105 ± 2.1x105 ± 1.7x105 ± 4.2x103 ± 2.0x106 
JNK2 siRNA      
Mean copies 4.9x105 NS/NS 1.2x106 NS/NS 6.4x105 NS/NS 1.1x104 NS/NS 6.2x106 NS/NS 
± SEM ± 1.6x105 ± 4.4x105 ± 3.8x105 ± 4.8x103 ± 3.3x106 
 
Figure 5.4 Effect of IKK-β, IKKε, TBK-1, JNK2 and PI3Kα siRNA or dsDNA transfection on 
CCL5, CXCL10, CXCL5, IL-6 and CXCL8 mRNA expression in HBEC. HBEC were transiently 
transfected with either IKK-β, IKKε, TBK-1, JNK2 or PI3Kα siRNA or dsDNA. 24h post-
transfection, medium was replaced and cells cultured in fresh infection medium for 24h. Total cell 
RNA was harvested for analysis at 48h post-transfection and IFN-β, IFN-λ1 and IFN-λ2/3 
measured by TaqMan RT-PCR. IKK-β, IKKε, TBK-1, JNK2, PI3Kα siRNA or dsDNA transfection 
did not significantly induce CCL5, CXCL10, CXCL5, IL-6 or CXCL8 mRNA expression compared 
to un-transfected cells (all p>0.05). Data are the mean mRNA copy number per 2x105 cells ± 
SEM of 6 separate experiments. Statistics are shown as dsDNA versus untransfected cells (NS), 
and each specific targeting siRNA versus dsDNA/untransfected cells respectively (e.g. NS/NS).  
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5.8 Effect of PI3K inhibitors LY294002 and Wortmannin 
on RV1B infected HBEC 
HBEC were incubated with BEBM containing the pan PI3K isoform inhibitor LY294002 
or Wortmannin (at doses of 10µM, 1µM and 0.1µM), or BEBM alone for 2h, before 
incubating with RV1B (MOI of 1), or treating with BEBM alone, and culturing for a further 
24h. Cells were harvested for total RNA and IFN-β, IFN-λ1, IFN-λ2/3, CCL5, CXCL10, 
CXCL5, IL-6 and CXCL8 mRNA analysed by TaqMan RT-PCR. Used at 1µM, 
Wortmannin inhibited RV1B-induced IFN-λ1 (p<0.05) and IFN-λ2/3 (p<0.01), and at 
10µM inhibited RV1B-induced IFN-β (p<0.01), IFN-λ1 (p<0.01) and IFN-λ2/3 (p<0.001) 
compared to RV1B infected control cells (Fig. 5.16A). LY294002 inhibited RV1B-induced 
IFN-λ1 (p<0.05) when used at 1µM, and IFN-β (p<0.05) and IFN-λ1 (p<0.01) when used 
at 10µM, compared to RV1B infected control cells (Fig. 5.17A). Used at 10µM and 1µM 
LY294002 reduced, but did not significantly inhibit RV1B-induced IFN-λ2/3 (p>0.05), 
compared to RV1B infected control cells (Fig. 6.17A). At 0.1µM Wortmannin inhibited 
RV1B-induced CXCL8 (p<0.001), CCL5 (p<0.05) and CXCL10 (p<0.01), but not IL-6 or 
CXCL5 compared to RV1B infected control cells (Fig. 5.16B, C). At higher doses of 1µM 
and 10µM Wortmannin inhibited RV1B-induced CXCL8 (both p<0.001), IL-6 (p<0.001 
and p<0.01 respectively), CXCL5 (p<0.05 and p<0.01 respectively), CCL5 (both p<0.01) 
and CXCL10 (both p<0.001) compared to RV1B infected control cells (Fig. 5.16B, C). 
LY294002 inhibited RV1B-induced IL-6 when used at 1µM, and at 10µM inhibited RV1B-
induced CXCL8 (p<0.05), IL-6 (p<0.01), CXCL5 (p<0.05) and CCL5 (p<0.01) compared 
to RV1B infected control cells (Fig. 5.17B, C). Used at 10µM LY294002 reduced, but did 
not significantly inhibit RV1B-induced CXCL10 (p>0.05), compared to RV1B infected 
control cells (Fig. 5.17C). 
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Figure 5.16 Effect of PI3K inhibitor Wortmannin on RV1B induced IFN and Pro-
inflammatory cytokine/chemokine mRNA expression in HBEC. HBEC were incubated with 
infection medium containing Wortmannin at doses of 10µM, 1µM or 0.1µM, or treated with 
infection medium alone for 2h. Cells were infected with RV1B (MOI of 1) or treated with infection 
medium alone. 24h post-infection, cells were harvested for total RNA and IFN-β, IFN-λ1, IFN-
λ2/3, CXCL8, IL-6, CXCL5, CCL5 and CXCL10 measured by TaqMan RT-PCR. Wortmannin 
significantly inhibited RV1B-induced CXCL8, CCL5 and CXCL10 mRNA at all doses, IL-6, 
CXCL5, IFN-λ1 and IFN-λ2/3 mRNA at 1µM and 10µM, and IFN-β mRNA expression at 10µM, 
compared to control cells infected with RV1B alone. Data are the mean ± SEM of 4 separate 
experiments and expressed as % of infected control =100%, (***p<0.001, **p<0.01, *p<0.05).   
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Figure 5.17 Effect of PI3K inhibitor LY294002 on RV1B induced IFN and pro-inflammatory 
cytokine/chemokine mRNA expression in HBEC. HBEC were incubated with infection medium 
containing LY294002 at doses of 10µM, 1µM or 0.1µM, or treated with infection medium alone for 
2h. Cells were infected with RV1B (MOI of 1) or treated with infection medium alone. 24h post-
infection, cells were harvested for total RNA and IFN-β, IFN-λ1, IFN-λ2/3, CXCL8, IL-6, CXCL5, 
CCL5 and CXCL10 measured by TaqMan RT-PCR. LY294002 significantly inhibited RV1B-
induced IFN-λ1 and IL-6 mRNA at 1µM and IFN-β, IFN-λ1, CXCL8, IL-6, CXCL5 and CCL5 
mRNA at 10µM compared to control cells infected with RV1B alone. LY294002 did not 
significantly inhibit RV1B-induced CXCL10 mRNA. Data are the mean ± SEM of 4 separate 
experiments and expressed as % of infected control =100%, (***p<0.001, **p<0.01, *p<0.05).  
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5.9 Effect of TRAF3 and TRAF6 over-expression in 
HBEC 
The effect of TRAF3 and TRAF6 over-expression on the activation of IRF3 and NF-κB 
transcription factors and on the activation of IL-6, CXCL8, IFN-β, IFN-λ1 and IFN-λ2/3-
promoters was investigated in HBEC.  
5.9.1 TRAF6 but not TRAF3 over-expression, activated an NF-
κB-dependent reporter construct and CXCL8 / IL-6 
promoter reporter constructs in HBEC   
HBEC were transfected with either pUNO-TRAF3, pUNO-TRAF6 or pUNO control 
vector, a luciferase reporter construct containing either NF-κB-binding sites, the CXCL8 
promoter (-543bp) or the IL-6 promoter (-651bp) and a β-galactosidase expressing 
construct (pCMVSPORT-βgal) to control for transfection efficiency. Activation of NF-κB-
responsive, CXCL8 promoter and IL-6 promoter reporter constructs were measured by 
Luciferase assay at 24h post-transfection. pUNO-TRAF3 did not induce activation of NF-
κB-responsive, CXCL8 promoter or IL-6 promoter reporter constructs (all p>0.05) 
compared to control vector (pUNO) transfected cells (Fig. 5.18A-C). pUNO-TRAF6 
significantly induced activation of NF-κB-responsive, CXCL8 promoter and IL-6 
promoter reporter constructs (all p<0.001) compared to control vector (pUNO) 
transfected cells (Fig. 5.18A-C). 
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Figure 5.18 Effect of TRAF3 and TRAF6 over-expression on NF-κB-dependent and CXCL8 
and IL-6 promoter reporter constructs in HBEC. HBEC were transiently transfected with 
reporter constructs containing either NF-κB-binding sites (A) the CXCL8 promoter (-543bp) (B) or 
the IL-6 promoter (-651bp) (C) and β-galactosidase vector, together with pUNO-TRAF3, or 
pUNO-TRAF6 or empty vector pUNO (control). Total cell lysates were collected 24h post-
transfection and Luciferase measured. TRAF3 over-expression did not activate NF-κB-dependent 
or CXCL8 and IL-6 promoter reporter constructs (all p>0.05), and TRAF6 over-expression 
induced NF-κB-dependent or CXCL8 and IL-6 promoter reporter constructs (all p<0.001), 
compared to vector control. Data are the mean ± SEM of 3 separate experiments. Data are 
presented as fold-induction of normalised luciferase levels relative to control vector (pUNO) 
tranfected cells. 
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5.9.2 TRAF3 or TRAF6 over-expression did not activate IFN-β / 
IFN-λ promoter reporter constructs, or an IRF3-dependent 
reporter construct in HBEC 
HBEC were transfected with either pUNO-TRAF3, pUNO-TRAF6 or pUNO control 
vector, a luciferase reporter construct containing either IRF3- binding sites, the wild-type 
IFN-β, IFN-λ1 or IFN-λ2/3 promoter reporter construct, and a β-galactosidase 
expressing construct (pCMVSPORT-βgal) to control for transfection efficiency. 
Activation of the IFN-β, IFN-λ1 and IFN-λ2/3 promoter reporter constructs was 
measured by Luciferase assay at 24h post-transfection. pUNO-TRAF3 and pUNO-
TRAF6 expression constructs did not induce activation of IRF3-dependent, IFN-β, IFN-
λ1 or IFN-λ2/3 promoter reporter constructs (all p>0.05) compared to control vector 
(pUNO) transfected cells (Fig. 5.19A-C).   
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Figure 5.19 Effect of TRAF3 and TRAF6 over-expression on IRF3-dependent and IFN-β, 
IFN-λ1 and IFN-λ2/3 promoter reporter constructs in HBEC. HBEC were transiently 
transfected with reporter constructs containing either; IRF3- binding sites (A) wild-type IFN-β 
promoter (B) wild-type IFN-λ promoter (C), wild-type IFN-λ2/3 promoter (D) and β-galactosidase 
vector, together with pUNO-TRAF3, or pUNO-TRAF6 or empty vector pUNO (control). Total cell 
lysates were collected 24h post-transfection and Luciferase measured. TRAF3 and TRAF6 over-
expression did not activate IRF3-dependent or IFN-β, IFN-λ1 and IFN-λ2/3 promoter reporter 
constructs (all p>0.05), compared to vector control. Data are the mean ± SEM of 3-4 separate 
experiments. Data are presented as fold-induction of normalised luciferase levels relative to 
control vector (pUNO) tranfected cells. 
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5.10 Chapter 5: Discussion 
5.10.1 Cardif and TRIF 
The RIG-I and MDA5 adaptor protein Cardif, and the TLR3 adaptor protein TRIF, are 
responsible for relaying the signal from RIG-I/MDA5 and TLR3 respectively, 
downstream, to further adaptor proteins and signalling protein kinases. The inhibition of 
Cardif or TRIF expression, by siRNA, inhibited RV1B-induced CCL5, CXCL10, IL-6, 
CXCL8, CXCL5, IFN-β and IFN-λ1 mRNA expression, suggesting that these adaptor 
proteins are required for RV1B-induced IFNs and pro-inflammatory cytokines in HBEC. 
Targeting of TRIF, but not Cardif with siRNA, inhibited RV1B-induced IFN-λ2/3, 
suggesting each adaptor to be differentially required for the expression of IFN-λ2/3. 
These Cardif siRNA results should be interpreted with caution due to the variability in 
the data measuring IFN-λ2/3 gene expression, following treatment with Cardif siRNA. 
Cardif has been implicated in endogenous IFN-λ1 and IFN-λ2/3 expression [202] and 
IFN-λ1 and IFN-λ2/3 promoter activation [203] in Cardif over-expression studies, 
suggesting a role for Cardif in IFN-λ induction. 
Our observation that TRIF and Cardif are required for RV1B-induced IFN and pro-
inflammatory cytokine expression supports our previous finding of a role for TLR3 and 
RIG-I or MDA5, in RV1B-induction of these IFNs and pro-inflammatory cytokines 
(Results Chapter 1). Studies have shown the over-expression of Cardif to induce IFN-β 
[255] [254] [228], CXCL10 [255], IL-6 [228], CXCL8 [255] and CCL5 [254] [228] 
expression. Studies have also shown virus-induced CCL5 [254] [260], CXCL10 and IL-6 
expression [260] to be inhibited by Cardif siRNA. Collectively, these studies further 
confirm a role for Cardif in the production of these IFNs and pro-inflammatory cytokines. 
TRIF has previous been shown to be required for TLR3-mediated IFN-β [218] [220], 
CCL5 [218], CXCL10 [218] and IL-6 [349] expression, and TRIF over-expression shown 
to activate IFN-λ1/IFN-λ2/3 promoters [203]. These studies support our TRIF targeting 
siRNA findings. This is the first report investigating a role for Cardif and TRIF in RV1B-
induced IFN and pro-inflammatory cytokine expression in HBEC, and the first report to 
investigate a role for Cardif in CXCL5, and a role for TRIF in CXCL8 and CXCL5 
expression.  
5.10.2 TRAF6 
TRAF6 interacts with TRIF and Cardif, and relays the signal from TRIF and Cardif 
downstream, to the signalling protein kinases TAK1, IKK-β and JNK2, leading to NF-κB 
and ATF-2/c-Jun activation. Targeting of TRAF6 with siRNA inhibited RV1B-induced IL-
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6, CXCL8, and CXCL5 mRNA expression, suggesting TRAF6 to be required for their 
induction by RV1B. This finding is indirectly supported by the presence of NF-κB and 
AP-1 binding sites in the promoters of IL-6 [366] [367] and CXCL8 [368] [369] and an 
NF-κB binding site in the CXCL5 promoter [173] [174]. Over-expression of TRAF6, in 
HBEC, significantly activated NF-κB-dependent, and IL-6 and CXCL8 promoter reporter 
constructs, supporting a role for TRAF6 in IL-6 and CXCL8 induction, and indirectly in 
CXCL5 induction. Consistent with our finding, studies have shown over-expression of 
TRAF6 to induce NF-κB activation [370] [371]. Studies have also shown inhibition of the 
TRAF6 downstream MAPKKK TAK1 [304], and in turn the downstream kinase IKK-β 
[37] and the MAPK JNK2 [304] to be required for CXCL8 induction. Results of this study, 
using IKK-β and JNK2 siRNA (discussed below), show inhibition of RV1B-induced IL-6, 
CXCL8, and CXCL5, also indirectly support a role for the up-stream activator TRAF6 in 
their induction. TRAF6 siRNA did not significantly inhibit RV1B-induced expression of 
CCL5, CXCL10, IFN-β, IFN-λ1 or IFN-λ2/3. In contrast, polyIC-stimulated TRAF6 
deficient MEFs show reduced CCL5 production [302]. Differences in these findings may 
be due to cell type and/or stimuli specific differences.  
Studies have determined IRF3 activation not to require TRAF6 [222] [223] [256] [221]. 
As viruses may also induce CCL5 and CXCL10 in an IRF dependent manner [155] [91], 
continued IRF3 activation in the presence of TRAF6 siRNA, would suggest an 
explanation as to why the expression of CCL5, CXCL10, IFN-β, IFN-λ1 or IFN-λ2/3 are 
not inhibited. Due to TRAF6 siRNA mediated, inhibition of NF-κB activation, and the 
known presence of NF-κB binding sites in the promoters of CCL5, CXCL10, IFN-β, IFN-
λ1 and IFN-λ2/3 genes, inhibition of their expression through this mechanism might 
have been expected. Although, NF-κB activation can occur independently of TRAF6 (via 
RIP1 signalling), this does not appear to be occurring in the present study, as TRAF6 
inhibition alone is sufficient to inhibit RV1B-induced IL-6, CXCL8, and CXCL5 
expression. A non-essential requirement for NF-κB in RV1B-induced transcription of 
CCL5, CXCL10, IFN-β, IFN-λ1 and IFN-λ2/3 genes would provide an explanation for our 
findings. Over-expression of TRAF6, in HBEC, did not induce IRF3-dependent or IFN-β 
and IFN-λ promoter activation, supporting our identification of no role for TRAF6 in the 
expression of CCL5, CXCL10, IFN-β, IFN-λ1 and IFN-λ2/3 genes. Alternatively, TRAF6 
may activate certain Rel species, such as p65, and this is not required for CCL5, 
CXCL10, IFN-β, IFN-λ1 and IFN-λ2/3 genes.  
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These findings suggest TRAF6 to be a potential therapeutic target for virus-induced 
asthma exacerbations, the inhibition of which will decrease pro-inflammatory cytokine 
and chemokine production but will not inhibit IFN production in asthmatic BEC. 
5.10.3 TRAF3 
TRAF3 interacts with TRIF, Cardif and TANK and is proposed to link both TRIF and 
Cardif with the downstream kinase complex TANK/TBK-1/IKKε, required for IRF3/IRF7 
activation. Targeting of TRAF3 with siRNA significantly enhanced RV1B-induced IFN-
λ2/3, CCL5 and CXCL10 mRNA, and non-significantly increased RV1B-induced IFN-β 
and IFN-λ1 mRNA expression, suggesting that TRAF3 is not required for their induction. 
No role for TRAF3 in RV1B-induction of these genes is supported by the observation 
that TRAF3 over-expression did not induce IRF3-dependent, or IFN-β or IFN-λ promoter 
reporter construct activation in HBEC. It is possible that TRAF3 may be a negative 
regulator of IFNs in HBECs, however we did not observe inhibition of IRF3-dependent 
reporter construct activation upon TRAF3 over-expression, suggesting that TRAF3 is not 
acting to negatively regulate IRF3-dependent gene transcription in uninfected HBEC. 
TRAF3 siRNA enhanced production of IFN-λ2/3, CCL5 and CXCL10, and possibly IFN-β 
and IFN-λ1, is therefore not explained by removal of their negative regulation by 
inhibition of TRAF3 expression.  
In contrast to our finding, studies have identified TRAF3 to be required for polyIC-
induced IFN-β production in macrophages [308] and in VSV [308] [309] and SV-induced 
[309] IFN-β production in MEFs. The reasons for our findings are unclear, but suggest 
that cell type and stimuli specific roles for TRAF3 exist, and at least in HBEC, an 
alternative signalling molecule other than TRAF3 is capable of linking TRIF and Cardif to 
TANK/TBK-1/IKKε, leading to transcription of IRF3-dependent genes. In support of this 
possibility, a scaffold protein alternative to TANK named NAP1, that can bind to TBK-
1/IKKε [310], and can also interact with TRIF [311] and Cardif [312] has been identified. 
Studies have shown NAP1 to be required for IRF3 activation and IFN-β production in 
both the TLR3 [311] and RIG-I [312] dependent pathways. As no interaction between 
NAP1 and TRAF3 has yet been reported, it is possible that in HBEC a TRIF-NAP1/TBK-
1/IKKε-IRF3/IRF7 and/or Cardif-NAP1/TBK1/IKKε-IRF3/IRF7 signalling pathway is 
occurring and mediating RV1B-induced IFN-β, IFN-λ1, IFN-λ2/3, CCL5 and CXCL10 
expression.  
Studies have shown NF-κB activation not to require TRAF3 [308] [309], these support 
our finding that TRAF3 over-expression does not activate NF-κB-dependent, and IL-6 
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and CXCL8 promoter reporter constructs in HBEC. However, in contrast to this finding, 
TRAF3 siRNA significantly inhibited RV1B-induced IL-6, CXCL8 and CXCL5 in HBEC. 
The reason for this finding is unclear, but may suggest that knocking out TRAF3 
inadvertently affects other proteins in a complex that TRAF3 may form a part of, and 
which are required for NF-κB activation by RV1B in HBEC. Further research is required 
to fully understand the role of TRAF3 in RV-induced responses in HBEC. 
5.10.4 IKK-β 
Downstream of TRAF6, IKK-β forms part of the IKK-α/β Kinase complex phosphorylating 
NF-κB inhibitory proteins (IκBs), and hence the release of Rel proteins into the nucleus. 
IKK-β siRNA significantly inhibited RV1B-induced CCL5, CXCL10, IL-6, CXCL8, CXCL5, 
IFN-β, IFN-λ1 and IFN-λ2/3 mRNA, suggesting IKK-β to be required for the induction of 
these pro-inflammatory cytokines, and IFNs, in HBEC, upon RV1B infection. In support 
of our finding, a role for IKK-β has been identified in polyIC and VSV-induced IFN-β 
expression [167]. The present study is the first report investigating a role for IKK-β in 
IFN-λ expression.  Studies have shown activation of NF-κB by TRIF [223] or Cardif [256] 
[255] to require IKK-β, suggesting IKK-β to be required for the induction of the same 
genes for which TRIF and / or Cardif are required. This is also true of our findings in this 
study. NF-κB binding sites are found in the promoters of IFN-β [185] [187], IFN-λ1, IFN-
λ2/3 [202] [203], CXCL8 [82], IL-6 [95], CCL5 [172] [155], CXCL10 [91] and CXCL5 
[173] [174], indirectly support our finding of a role for IKK-β in RV1B-induction of the 
IFNs and pro-inflammatory cytokines measured. Also, CXCL8 induction by RV has been 
shown to require IKK-β [37] in BEAS-2B cells. Our identified role for IKK-β in RV1B-
induced IFN expression is not supported by our identified non-requirement for TRAF6 in 
RV1B-induced IFN expression, as TRAF6 is known to function above IKK-β in the 
activation of NF-κB. This may suggest that the role of IKK-β in RV1B-induced IFN 
expression is not mediated through its activation of NF-κB, but instead through a 
possible role for IKK-β in the activation of IRF3/7. This possibility is supported by one 
study showing dominant negative IKK-β (but not TRAF6) to inhibit virus-induced ISRE 
activation [223]. Further work is required to identify how IKK-β itself is activated by RV in 
HBEC, and which are the important adaptors mediating these signalling events.  
5.10.5 TBK-1 and IKKε 
Downstream of TRAF3, the kinases TBK-1 and IKKε are responsible for activation of the 
transcription factors IRF3 and IRF7. Targeting TBK-1 or IKKε with siRNA, inhibited 
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RV1B-induced IFN-β, IFN-λ2/3, CCL5, CXCL10, IL-6, CXCL8, and CXCL5 expression, 
suggesting both kinases to be required for their induction by RV1B in HBEC. TBK-1, but 
not IKKε targeting siRNA inhibited RV1B-induced IFN-λ1 expression, suggesting TBK-1 
and not IKKε to be required for IFN-λ1 induction. These IKKε siRNA results should be 
interpreted with caution due to the variability in the data measuring IFN-λ1 gene 
expression, following treatment with IKKε siRNA. 
One noteworthy observation is that where inhibition of RV1B-induced IFN gene 
expression by IKKε or TBK-1 siRNA occurred, the level of IFN inhibition did not match 
the extent to which IKKε and TBK1 mRNA was inhibited by their respective targeting 
siRNA. This may be due to an unequal level of mRNA versus target protein inhibition by 
the siRNA, or functional redundancy between TBK-1 and IKKε for RV1B-induced IFN 
expression. Functional redundancy between IKKε and TBK-1 has previously been 
demonstrated [273] and also suggests an alternative explanation as to why IKKε siRNA 
did not inhibit RV1B-induced IFN-λ1 expression, other than its possible non-requirement 
in IFN-λ1 induction. Consistent with our finding of a role for TBK-1 and IKKε in IFN-λ2/3 
expression, and TBK-1, and possibly IKKε in IFN-λ1 expression, TBK-1 and IKKε over-
expression have been shown to induce activation of IFN-λ promoters [203]. TBK-1 
deficient MEFs have reduced but not absent virus-induced IFN-λ2/3, with residual 
induction suggested to be due to IKKε [202], supporting the possibility that TBK-1 and 
IKKε have redundant roles in RV1B-induced IFN expression in HBEC. Our observed 
inhibition of RV1B-induced CCL5 and CXCL10, by IKKε and TBK-1 siRNA, is indirectly 
supported by studies showing the transcription of CCL5 [155] and CXCL10 [91] to be 
partially dependent on IRF3 binding to their promoter regions. Studies have also shown 
inhibition of virus-induced CCL5 and CXCL10 production in TBK-1 deficient cells [273] 
[272], and CCL5 by IKKε or TBK-1 siRNA [216].  
The transcription of CXCL8 [82], IL-6 [95] and CXCL5 [173] [174] requires NF-κB. 
Therefore IKKε and TBK-1 are implicated in the activation of NF-κB in HBEC upon 
RV1B infection, with IKKε or TBK-1 siRNA inhibition reducing NF-κB activation and pro-
inflammatory cytokine production. Contrary to our finding, studies have suggested IKKε 
and TBK-1 not to be required for Cardif [255] or TRIF [223] [273] mediated NF-κB 
activation. However these studies were not performed in HBEC and used over-
expression of Cardif or TRIF, or polyIC stimulation, to induce NF-κB activation. 
Therefore a cell type and/or stimulus specific requirement for TBK-1 and IKKε in the 
expression of NF-κB regulated genes may exist. In support of a possible role for TBK-1 
                                                                                                                             Chapter 5: Results 
 
200 
and IKKε in IL-6, CXCL8, and CXCL5 expression, the over-expression of TBK-1 or IKKε 
has been reported to induce NF-κB activation [313] [270]. TBK-1 and IKKε have also 
been demonstrated to phosphorylate IκBα [313] [314] and TBK-1 to phosphorylate IKK-
β [314], therefore a possible role for TBK-1 and IKKε in RV-induced NF-κB activation in 
HBEC is likely.  
5.10.6 JNK2 
Downstream of TRAF6, the MAPK JNK2 is an up-stream activating kinase of the 
transcription factors ATF-2 and c-Jun. Targeting JNK2 with siRNA significantly inhibited 
RV1B-induced IL-6, CXCL8, and CXCL5, but not CCL5, CXCL10, IFN-β, IFN-λ1 or IFN-
λ2/3 mRNA expression. JNK2 is therefore suggested to be required for the induction of 
IL-6, CXCL8, and CXCL5 by RV1B in HBEC, and is supported by studies reporting 
JNK2 deficient MEFs to have defective IL-6 mRNA induction in response to polyIC [167], 
and chemical inhibition of JNK in airway smooth muscle cells to inhibit CXCL8 induction 
[372]. In contrast Edwards et al [37] did not find a role for JNK2 in RV16 induced 
CXCL8-promoter reporter activation in BEAS-2B cells, using both dominant negative 
and chemical inhibitor approaches. A cell type specific role for JNK2 in CXCL8 induction 
may therefore exist. This is the first study to investigate a role for JNK2 in CXCL5 
expression. In further support of our findings, an indirect role for JNK2 in the regulation 
of CXCL8 and IL-6 expression is suggested by studies showing AP-1 binding sites to 
exist in the promoters of IL-6 and CXCL8 [367] [368], and the JNK2 activating 
transcription factor c-Jun identified as the principal component of the AP-1 transcription 
factor [175] [373] [374]. CXCL5 induction has also been shown to co-incide with 
increased AP-1 activity in a melanoma cell line [375], suggesting a possible role for 
JNK2 in regulating its expression. 
RV1B-induced IL-6, CXCL8, and CXCL5 mRNA was not completely abrogated by JNK2 
siRNA; this may be due to residual JNK2 protein remaining. In addition to JNK2, the 
MAPKs JNK1 and p38 also activate c-Jun and ATF-2 respectively [282] [376] [377], and 
so functional redundancy between JNK2 and JNK1 for c-Jun activation, and between 
JNK2 and p38 MAPK for ATF-2 activation may exist. This may alternatively account for 
the incomplete inhibition of RV1B-induced IL-6, CXCL8, and CXCL5 by JNK2 siRNA. In 
support of the later possibility, RV-induced IL-6, CXCL8 and CXCL5 production is 
inhibited upon chemical inhibition of the ATF-2 activating MAPK p38 [80].  
Our JNK2 specific siRNA results suggest that JNK2 is not required for RV1B-induced 
CCL5 and CXCL10 mRNA expression in HBEC. In contrast to these findings, chemical 
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inhibition has shown a requirement for JNK in CCL5 protein secretion in a bronchial 
epithelial cell line in response to influenza A virus [378], and in CXCL10 mRNA in a 
human astrocyte cell line stimulated with polyIC [379]. A cell type and / or stimulus 
specific role for JNK2 in CCL5 and CXCL10 expression may therefore exist.  
In contrast to our finding of no role for JNK2 in RV1B-induced IFN-β, IFN-λ1 or IFN-λ2/3 
mRNA expression, a role for JNK2 in polyIC and VSV-induced IFN-β expression has 
been shown using JNK2 deficient MEFs [167]. However, residual IFN-β expression 
remained in these studies, and JNK1 deficiency also reduced IFN-β induction, 
suggesting functional redundancy between JNK1 and JNK2. The latter fact may explain 
the inability of JNK2 siRNA to inhibit RV1B-induced IFN-β expression in our study. This 
is the first report investigating a role for JNK2 in IFN-λ expression, and suggests that 
JNK2 is not essential for RV1B-induced IFN-λ expression in HBEC.  
These findings suggest JNK2 to be a potential therapeutic target for virus-induced 
asthma exacerbations with JNK2 inhibition decreasing pro-inflammatory cytokine and 
chemokine production without inhibiting IFN production in asthmatic BEC. 
5.10.7 PI3Kα 
PI3Kα has been recently shown to interact with phosphorylated TLR3 and is required for 
IRF3 transcriptional activation following polyIC-induced TLR3 pathway activation [286]. 
The literature surrounding a role for PI3K in TLR3-mediated NF-κB activation is unclear. 
Using different cell types and/or TLR3 ligands, studies have shown PI3K inhibition to not 
inhibit NF-κB activation [288], to inhibit NF-κB activation [212] [290] [291] or to increase 
NF-κB activation [289]. With respect to RNA helicase mediated NF-κB activation, PI3K 
has been implicated in RIG-I mediated NF-κB activation [292]. 
Targeting PI3Kα with siRNA significantly inhibited RV1B-induced IL-6, CXCL8, CXCL5 
and CXCL10 mRNA expression, suggesting that it is required for their induction. The 
pan-PI3K Class 1 (PI3Kα, β, δ and λ) chemical inhibitors Wortmannin and LY294002 
also significantly inhibited RV1B-induced IL-6, CXCL8 and CXCL5 mRNA, and 
Wortmannin inhibited CXCL10 mRNA. A small but non-significant reduction in RV1B-
induced CXCL10 mRNA was observed with LY294002 used at 10µM. A possible 
explanation for the differing extent of RV1B-induced pro-inflammatory cytokine inhibition 
using Wortmannin versus LY294002 is the higher potency of Wortmannin [380]. 
Consistent with our finding, a role for PI3K in RV-induced CXCL8 expression has been 
demonstrated using LY294002 [291]. As studies have shown NF-κB to be required for 
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RV-induced IL-6, CXCL8 and CXCL10 [95] [82] [91], our observed reduction in RV1B-
induced IL-6, CXCL8 and CXCL10 mRNA upon PI3Kα inhibition may be due to 
decreased NF-κB activation. This possibility is supported by a study reporting RV-
induced NF-κB dependent reporter activation to be inhibited by PI3K chemical inhibition 
[291]. PI3Kα siRNA inhibited RV1B-induced CXCL10 to a lesser extent than IL-6, 
CXCL8 and CXCL5, which may reflect the requirement for IRF transcription factors in 
addition to NF-κB in the regulation of CXCL10 [91].  
Targeting PI3Kα with siRNA did not significantly inhibit RV1B-induced CCL5, IFN-β, 
IFN-λ1 or IFN-λ2/3 mRNA expression, suggesting that is it not required for their 
induction. In contrast to these findings, inhibition of PI3K with Wortmannin and 
LY294002 significantly inhibited RV1B-induced CCL5, IFN-β and IFN-λ1, and 
Wortmannin significantly inhibited and LY294002 non-significantly reduced RV1B-
induced IFN-λ2/3 mRNA. Our conflicting PI3Kα siRNA and Wortmannin results may 
possibly be explained in the following way. Wortmannin has been demonstrated to affect 
endocytic trafficking pathways, including the retention of receptors and viruses in early 
endosomes, preventing receptor recycling to the plasma membrane or transport of 
receptor or virus to lysosomes [381] [382] [383]. RV enters the host cell through the 
endosome and is transported to late endosomes, where a sufficiently low pH (<5.6) is 
present to allow RV un-coating [75]. In keeping with this mechanism of RV entry into 
host cells a recent study has demonstrated Wortmannin to retain RV in the early 
endosome [384]. It is therefore possible that prevention of transport of RV into the late 
endosome negatively affects RV recognition by TLR3, with studies reporting TLR3-
ligand interaction to require acidic pH [385] [233], and binding affinity to be increased by 
lowering pH, to within the late endosome pH range [385]. RV1B triggered TLR3-
mediated induction of IFN and pro-inflammatory cytokine expression in the presence of 
Wortmannin may therefore be decreased in this present study. Our differing PI3Kα 
siRNA and LY294002 results may also possibly be explained by the lack of specificity of 
LY294002, with studies demonstrating LY294002 to non-specifically bind proteins 
unrelated to PI3K [386], to inhibit kinases other than PI3K [380]. Furthmore, LY294002 
has been shown to inhibit RV internalisation into 16HBE cells [291], suggesting that 
LY294002 may act to prevent TLR3-mediated recognition of RV1B and subsequently 
TLR3-induced IFN and pro-inflammatory cytokine expression. For the above reasons we 
believed that the results obtained with PI3Kα specific siRNA in this current study are 
therefore more reliable.           
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The inability of PI3Kα specific siRNA to inhibit RV1B-induced CCL5, IFN-β, IFN-λ1 and 
IFN-λ2/3 mRNA expression, is not supported by a study reporting a requirement for 
PI3Kα in TLR3-mediated IRF3 activation [286], and in turn studies demonstrating a 
requirement for IRF3 in CCL5 [154] [155], IFN-β [151] [139], IFN-λ1 and IFN-λ2/3 [202] 
[203] induction. Our findings could therefore possibly be explained by incomplete 
inhibition of PI3Kα protein expression by PI3Kα specific siRNA, with sufficient PI3Kα 
remaining to enable IRF3 activation. Alternatively, no interactions between PI3Kα and 
members of the RIG-I/MDA5 pathway have been reported, and studies have suggested 
RIG-I induced IRF3 activation not to require PI3K [286] [292]. Continued IRF3 activation 
by the RIG-I/MDA5 pathway, in the presence of PI3Kα specific siRNA, could also 
explain our observed non-inhibition of RV1B-induced CCL5, IFN-β, IFN-λ1 and IFN-λ2/3 
mRNA. Furthermore, the non-impairment of RV1B-induced CCL5, IFN-β, IFN-λ1 or IFN-
λ2/3 by PI3Kα siRNA, despite the presence of NF-κB binding sites in their promoters, 
suggests these genes to have a greater dependence upon IRF3 than NF-κB for their 
transcription. 
These PI3Kα specific siRNA results suggest PI3Kα to be a potential therapeutic target 
for virus-induced asthma exacerbations, with inhibition of PI3Kα resulting in decreased 
pro-inflammatory cytokine and chemokine production, but not inhibiting IFN production 
in asthmatic BEC. 
5.10.8 Summary 
This study of adaptor proteins and signalling kinases is crucial in better understanding 
the signalling mechanisms of how RV1B-induced IFN-β, IFN-λ and pro-inflammatory 
cytokine expression occurs in HBEC. Deficient expression or function of any of our 
identified adaptor proteins or signalling intermediates involved in induction of IFN-β and 
IFN-λ, could potentially explain the deficient IFN-β and IFN-λ production in asthmatic 
bronchial epithelial cells. We have determined both TRAF6 and JNK2 specific siRNA not 
to inhibit RV1B-induced IFN-β and IFN-λ expression, not to affect CCL5 and CXCL10 
expression, and to inhibit CXCL8, IL-6 and CXCL5 expression. We have also 
determined PI3Kα specific siRNA not to inhibit RV1B-induced IFN-β, IFN-λ or CCL5 
expression, and to inhibit CXCL8, IL-6, CXCL5 and CXCL10 expression. These findings 
also suggest that TRAF6, JNK2 and PI3Kα represent potential therapeutic targets for 
virus-induced exacerbations of asthma, the inhibition of which may help to prevent 
CXCL8, IL-6 and CXCL5 expression, and additionally CXCL10 expression by targeting 
PI3Kα, without affecting IFN expression. 
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Figure 6.1 Signalling pathways implicated in IFN-β and Pro-inflammatory cytokine 
production. Transcription factors investigated in this chapter, for their role in RV1B-induced IFN 
and pro-inflammatory cytokine expression in HBEC are shaded.  
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6.1 Introduction 
During a viral infection, type I IFN-α/β and type III IFN-λs are induced rapidly and 
transiently at the transcriptional level. Transcriptional regulation of IFN-β is well studied 
in cell types other than HBEC, with viruses other than RV used to induce IFN-β 
transcription. The IFN-β promoter contains four positive regulatory domains (PRDs) 
termed PRDI-PRDIV, which lie within a region of DNA termed the enhancer region and 
are required for activation of the promoter. The transcription factors NF-κB, ATF-2/c-
Jun, IRF1, IRF3 and IRF7 have been identified to bind to the IFN-β promoter (NF-κB to 
PRDII, IRF1 and IRF3/7 to PRDIII-I, ATF2/c-Jun to PRDIV) and induce transcription 
[186] [187] [189] [190] [144]. Transcriptional activation of the IFN-β gene requires the 
assembly of an enhanceosome, containing the above mentioned transcription factors 
and its’ binding to the IFN-β enhancer. The architectural high mobility group protein 
(HMG 1(Y)) facilitates the formation of the enhanceosome by altering the conformation 
of the DNA helix to enable co-ordinated transcription factor binding to the IFN-β 
enhancer. The co-activator proteins CREB-binding protein (CBP) and p300 interact with 
each of the transcription factors, thus mediating interactions between them, and 
facilitating further interactions with the basal transcriptional machinery required to initiate 
IFN-β transcription.  
The co-induction of transcription factors into their active forms upon viral infection, their 
interaction with PRDs and interactions with each other, have been shown to be required 
for maximal induction of the IFN-β promoter [190] [144] [187] [387] [198] [147]. Mutation 
of PRDI [191], PRDII [185] [191] or the PRDIV [189] binding site in the IFN-β promoter 
has been shown to reduce specific transcription factor binding and the level of virus 
induction. An essential requirement for IRF1 in virus-induced IFN-β expression has been 
questioned, with no impairment of type I IFN-α/β induction shown in IRF1 deficient 
MEFs [143]. MEFs deficient in JNK2 show reduced virus-induction of IFN-β expression 
indirectly supporting the role of ATF-2/c-Jun in type I IFN production [167]. The 
importance of NF-κB in IFN-β expression has been further suggested using IKK-β 
deficient cells, and preventing virus-induced IFN-β expression [167]. An essential role 
for NF-κB in virus-induced IFN-β expression has recently been challenged, with an NF-
κB p65 knockout mouse study showing no significant reduction in virus-induced type I 
IFN-α/β expression [169]. Dominant negative IRF3 [144] [147] and IRF7 [144] have 
been shown to reduce virus-induced IFN-β promoter activation. The importance of IRF3 
and IRF7 is further highlighted in knockout mouse studies, as cells deficient in both IRF-
3 and IRF7 do not show virus-induced IFN-β expression [151] [139]. IRF7 requires type I 
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IFN for its expression, and thus has been proposed to be primarily involved in mediating 
late phase IFN-β induction following virus infection. IRF3 is constitutively expressed and 
therefore suggested to mediate initial IFN-β induction following virus infection.  
IFN-λ transcription is less well studied, and has also been studied in cell types other 
than HBEC, and using viruses other than RV. IFN-λ transcription is believed to be 
regulated in a similar fashion to IFN-β, with IRF and NF-κB binding sites identified in the 
IFN-λ1 and IFN-λ2/3 promoters [202] [203] and shown to be required for their 
transcriptional activation by virus [202].  
The transcription factors necessary for induction of IFN-β and IFN-λ expression in HBEC 
upon RV infection are unknown and are investigated in this chapter. The requirement for 
NF-κB in RV-induced pro-inflammatory cytokine (CCL5, CXCL10, CXCL8, IL-6, CXCL5) 
expression in HBEC was also investigated. Studies have previously shown NF-κB to be 
required for RV induced CXCL8, IL-6 and CXCL10 expression in airway epithelial cell 
lines [95] [82] [91], and a role for NF-κB in RV-induced CCL5 and CXCL5 has not 
previously been investigated. Studies of asthmatic individuals have additionally shown 
increased p65 protein expression in peripheral blood mononuclear cells (PBMCs) [165] 
and increased NF-κB DNA-binding in cells extracted from sputum and bronchial 
biopsies [166]. NF-κB activation is therefore suggested to be increased in asthmatic 
individuals, and so confirmation of its requirement in RV1B-induced pro-inflammatory 
cytokine expression in HBEC was performed.  
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6.2  Effect of mutant PRD regions on the inducibility of 
the IFN-β promoter in HBEC 
Mutated constructs of the wild-type IFN-β promoter reporter construct were made, by 
site directed mutagenesis of each of the four positive regulatory domains (PRDI-IV) 
within the promoter. Using a wild-type IFN-β promoter reporter construct and four new 
IFN-β promoter reporter constructs, each containing a mutated PRD region (PRDI-IV), 
the relative cis-acting sites important for IFN-β promoter induction, by RV1B, in HBEC 
were investigated. In addition, which transcription factors are required by RV1B, to 
activate the IFN-β promoter in HBEC, could be postulated from an understanding of the 
required PRD regions. 
6.2.1  RV1B-induced IFN-β promoter activation in HBEC requires 
each of PRDs I-IV  
HBEC were transfected with a wild-type IFN-β promoter reporter construct, or one of 
four IFN-β promoter activation constructs, each containing a different mutated PRD 
region (PRDI, PRDII, PRDIII, PRDIV) and β-galactosidase vector (pCMVSPORT-βgal) to 
control for transfection efficiency. Transfected cells were cultured for 24h before 
infection with RV1B (MOI of 1) or treating with BEBM alone. Total cell lysates were 
harvested 24h post-infection/treatment with BEBM alone, and IFN-β promoter activation 
measured by Luciferase assay. RV1B significantly induced activation of the wild-type 
IFN-β promoter (p<0.001), versus un-infected wild-type IFN-β promoter transfected cells 
(Fig 6.2). A mutation in any one of the four PRD regions (PRDI-IV) significantly reduced 
IFN-β promoter activation relative to infected wild-type IFN-β promoter transfected cells 
(all p<0.001).  
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Figure 6.2 Effect of PRD mutations on IFN-β promoter activation by RV1B in HBEC. HBEC 
were transiently transfected with reporter constructs containing mutated PRDs or the wild-type 
IFN-β promoter together with β-galactosidase vector. At 24h post-transfection, HBEC were 
infected with RV1B (MOI of 1) or treated with infection medium. Total cell lysates were collected 
24h post-infection and Luciferase measured. Mutation of any PRD region reduced RV1B-induced 
IFN-β promoter activation, compared to wild-type IFN-β promoter (all p<0.001). Data are the 
mean ± SEM of 6 separate experiments. Data are presented as fold-induction of normalised 
luciferase levels relative to medium treated cells. 
6.2.2  ∆RIG-I- and ∆TRIF- induced IFN-β promoter activation in 
HBEC requires PRDI-IV  
HBEC were transfected with either constitutively active RIG-I (∆RIG-I), constitutively 
active TRIF (∆TRIF), pEFBOS control vector or pUNO1 control vector, and either wild-
type IFN-β, or IFN-β promoter reporter constructs with mutated PRDI-IV, and a β-
galactosidase expressing construct (pCMVSPORT-βgal) to control for transfection 
efficiency. ∆RIG-I and ∆TRIF significantly induced the activation of wild-type IFN-β- 
promoter (both p<0.001) (Fig. 6.3A, B), versus control vector (pEFBOS/pUNO1 
respectively). A mutation in PRDI, PRDII, PRDIII (all p<0.01) or PRDIV (p<0.05) 
significantly reduced ∆RIG-I induced activation of the IFN-β promoter relative to wild-
type IFN-β promoter transfected cells (Fig. 6.3A). A mutation in any one of the four PRD 
regions (PRDI-IV) also significantly reduced ∆TRIF IFN-β promoter activation relative to 
wild-type IFN-β promoter transfected cells (PRDI, PRDIV both p<0.01, PRDII, PRDIII 
both p<0.001) (Fig. 6.3B).  
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Figure 6.3 Effect of PRD mutations on IFN-β promoter activation by ∆RIG-I and ∆TRIF in 
HBEC. HBEC were transfected with either constitutively active RIG-I (∆RIG-I), constitutively 
active TRIF (∆TRIF), pEFBOS control vector or pUNO1 control vector, and either wild-type IFN-β, 
or one of four mutant PRD region IFN-β promoter reporter constructs together with β-
galactosidase vector. At 24h post-transfection, total cell lysates were collected and Luciferase 
measured. Mutant PRDI, PRDII, PRDIII (all p<0.01) and PRDIV (p<0.05) reduced ∆RIG-I 
activation of the IFN-β promoter, compared to wild-type IFN-β promoter activation. Mutant PRDI 
(p<0.01) PRDII, PRDIII (both p<0.001) and PRDIV (p<0.01) reduced ∆TRIF activation of the IFN-
β promoter, compared to wild-type IFN-β promoter activation. Data are the mean ± SEM of 5 (A) 
and 6 (B) separate experiments. Data are presented as fold-induction of normalised luciferase 
levels relative to control vector transfected cells.  
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6.3 Effect of IRF1, IRF3 and IRF7 inhibition on RV1B 
infected HBEC  
Having demonstrated which PRDs within the IFN-β promoter are required by RV1B to 
induce activation of the promoter, and with knowledge of which transcription factors bind 
to the specific PRD regions (PRDI-IV) within the promoter, confirmation of the required 
PRD regions to initiate RV1B-induced IFN-β gene transcription was performed by 
investigating the requirement of the PRD-binding transcription factors NF-κB p65 
(PRDII), ATF-2/c-Jun (PRDIV), IRF1, IRF3 and IRF7 (PRDI/III) in RV1B-induced IFN-β 
gene transcription, using siRNA specifically targeting each transcription factor.  
6.3.1  Inhibition of IRF1, IRF3 and IRF7 mRNA and protein by 
IRF1, IRF3 and IRF7 specific siRNA 
HBEC were transfected with IRF1, IRF3, IRF7, a non-targeting control siRNA or were 
untransfected, and then cultured for 24h before incubating with RV1B (MOI of 1), or 
treating with BEBM alone, for 1h with shaking, and culturing for a further 24h. Cells were 
harvested for total RNA or protein, and IRF1, IRF3 and IRF7 mRNA levels analysed by 
TaqMan RT-PCR or IRF1, IRF3 and IRF7 protein by western blot analysis. Following 
RV1B infection, IRF1, IRF3 and IRF7 siRNA reduced IRF1, IRF3 and IRF7 mRNA 
respectively to 28%, 14% and 23% (all p<0.001: Figures 6.4A, C, E), of expression 
levels obtained with non-targeting control siRNA. IRF7 protein was not detected by 
western blot at this 24h time-point post RV1B infection. IRF1 and IRF3 proteins were 
detected in medium treated alone cells (Figure 6.4B, D). In uninfected non-targeting 
control siRNA transfected cells, IRF1 and IRF3 proteins were detected but their 
expression not enhanced compared to medium treated alone cells (Figure 6.4B, D). 
IRF1 and IRF3 targeting siRNA reduced IRF1 and IRF3 protein expression respectively, 
compared to non-targeting control siRNA in the absence of RV1B infection (Figure 6.4B, 
D). RV1B infection did not increase IRF1 or IRF3 protein expression compared to 
medium treated alone cells (Figure 6.4B, D). siRNA targeting IRF1 or IRF3 in the 
presence of RV1B infection, reduced IRF1, and reduced IRF3 protein respectively, 
compared to RV1B infected non-targeting control siRNA transfected cells (Figure 6.4B, 
D). The structural protein β-actin was used as a control to assess protein loading in each 
blot. 
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Figure 6.4 Reduction of IRF1, IRF3 and IRF7 mRNA and protein by IRF1, IRF3 and IRF7 
specific siRNA in HBEC. HBEC were transiently transfected with IRF1, IRF3, IRF7 or non-
targeting control siRNA (100nM) or untransfected. 24h post-transfection, cells were infected with 
RV1B (MOI 1) or treated with infection medium alone. At 24h post-infection, cells were harvested 
for total RNA or protein and IRF1 (A), IRF3 (C) and IRF7 (E) mRNA measured by TaqMan RT-
PCR, or IRF1 (B) and IRF3 (D) protein measured by western blot. IRF1, IRF3 and IRF7 mRNA 
expression was inhibited by IRF1, IRF3 and IRF7 siRNA respectively (all p<0.001), versus non-
targeting control siRNA. Data are the mean ± SEM of 4 (A), 5 (C) and 5 (E) separate experiments 
and expressed as % of control siRNA transfected cells =100%, (***p<0.001, **p<0.01, *p<0.05 
versus non-targeting control siRNA). Western blots are representative of 2-3 experiments. 
A B
D
E
C
0
25
50
75
100
RV1B      +          +
Control      +           -
IRF1       -          +
***
IR
F1
 
m
R
N
A
e
xp
re
ss
io
n
 
re
la
tiv
e
 
to
co
n
tro
l (%
)
RV1B      +       +       +          - - -
Control       - +        - - +       -
IRF1      +        - - +       - -
IRF1
β-actin
0
25
50
75
100
***
RV1B      +          +
Control      +           -
IRF3       -          +
IR
F3
 
m
R
N
A
e
xp
re
ss
io
n
 
re
la
tiv
e
 
to
co
n
tro
l (%
)
RV1B      +       +       +          - - -
Control       - +        - - +       -
IRF3      +        - - +       - -
IRF3
β-actin
0
25
50
75
100
RV1B      +          +
Control      +           -
IRF7       -          +
***IR
F7
 
m
R
N
A
e
xp
re
ss
io
n
 
re
la
tiv
e
 
to
co
n
tro
l (%
)
IRF7 protein not detected
                                                                                                                             Chapter 6: Results 
 
213 
6.3.2 IRF3 siRNA, but not IRF7 siRNA, inhibited RV1B-induced 
IFN-β, IFN-λ1 and IFN-λ2/3; IRF1 siRNA inhibited RV1B-
induced IFN-β but not IFN-λ1 or IFN-λ2/3    
HBEC were transfected with IRF1, IRF3, IRF7 siRNA, a non-targeting control siRNA or 
were untransfected, and then cultured for 24h before incubating with RV1B (MOI of 1) or 
treating with BEBM alone, for 1h with shaking and culturing for a further 24h. Cells were 
harvested for total RNA and IFN-β, IFN-λ1 and IFN-λ2/3 mRNA analysed by TaqMan 
RT-PCR. IRF1 siRNA significantly inhibited RV1B-induced IFN-β (p<0.01), but not IFN-
λ1 or IFN-λ2/3 (both p>0.05), compared to RV1B infected non-targeting control siRNA 
transfected cells (Fig. 6.5A, B, C). siRNA targeting IRF3 significantly inhibited RV1B-
induced IFN-β (p<0.001), IFN-λ1 (p<0.001) and IFN-λ2/3 (p<0.01), and IRF7 siRNA did 
not affect RV1B induction of IFN-β, IFN-λ1 and IFN-λ2/3 mRNA (all p>0.05), compared 
to RV1B infected non-targeting control siRNA transfected cells (Fig. 6.5A, B, C). No 
significant difference between uninfected untransfected cells and uninfected non-
targeting control siRNA transfected cells was observed (all p>0.05), indicating that 
control siRNA alone did not induce IFN-β, IFN-λ1 or IFN-λ2/3 mRNA.   
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Figure 6.5 Effect of IRF1, IRF3 and IRF7 siRNA on RV1B induced IFN-β, IFN-λ1 and IFN-
λ2/3 mRNA expression in HBEC. HBEC were transiently transfected with IRF1, IRF3, IRF7, 
non-targeting control siRNA, or untransfected. 24h post-transfection, cells were infected with 
RV1B (MOI 1), or treated with infection medium alone. At 24h post-infection, cells were harvested 
for total RNA and IFN-β, IFN-λ1 and IFN-λ2/3 mRNA measured by TaqMan RT-PCR. IRF1 
siRNA inhibited RV1B induced IFN-β (A) (p<0.01) but not IFN-λ1 (B) or IFN-λ2/3 (C) (both 
p>0.05) mRNA expression, IRF3 siRNA inhibited RV1B induced IFN-β (A) and IFN-λ1 (B) (both 
p<0.001), and IFN-λ2/3 (C) (p<0.01) mRNA expression, and IRF7 siRNA did not affect RV1B-
induced IFN-β, IFN-λ1 or IFN-λ2/3 (all p>0.05), compared to cells infected and transfected with 
non-targeting control siRNA. Data are the mean ± SEM of 4 (using IRF1 siRNA), and 5 (using 
IRF3 and IRF7 siRNA) separate experiments and expressed as % of infected control =100%, 
(***p<0.001, **p<0.01, *p<0.05 versus non-targeting control siRNA), ### versus untransfected, 
uninfected control.   
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6.4 Effect of NF-κB p65 inhibition on RV1B infected 
HBEC  
The hetero-dimeric transcription factor NF-κB p65/p50 has been reported in studies 
using viruses other than RV and cells other than HBEC to be the principal NF-κB 
species involved in virus activation of the human IFN-β promoter [186] [192] [144], and 
recently an NF-κB binding site has been identified in, and shown to be required for the 
activation of IFN-λ1 and IFN-λ2/3 promoters [202] [203]. The role of NF-κB p65 in IFN-β 
production upon RV1B infection of HBEC was investigated and would support the data 
showing that PRDII is required for IFN-β promoter activation by RV. The requirement for 
NF-κB p65 in RV1B-induced IFN-λ-1, IFN-λ2/3 and pro-inflammatory cytokine (CCL5, 
CXCL10, CXCL5, IL-6, CXCL8) production in HBEC was additionally investigated, with 
studies using siRNA specific to the NF-κB p65 sub-unit. 
6.4.1 Inhibition of NF-κB p65 mRNA and protein by NF-κB p65 
targeting siRNA 
HBEC were transfected with NF-κB p65 specific siRNA, a non-targeting control siRNA 
or were untransfected, and then cultured for 24h before incubating with RV1B (MOI of 
1), or treating with BEBM alone, and culturing for a further 24h. Cells were harvested for 
total RNA or protein and reduction in NF-κB p65 mRNA analysed by TaqMan RT-PCR, 
or reduction in NF-κB p65 protein by western blot analysis. Following RV1B infection, 
NF-κB p65 siRNA reduced NF-κB p65 mRNA expression to 9% (p<0.001), of 
expression levels obtained with non-targeting control siRNA (Fig. 6.6A). NF-κB p65 
protein was detected in medium treated alone cells (Fig.6.6B). In uninfected non-
targeting control siRNA transfected cells NF-κB p65 protein was detected, but its 
expression not enhanced compared to medium treated alone cells (Fig.6.6B). NF-κB 
p65 targeting siRNA reduced NF-κB p65 protein expression compared to non-targeting 
control siRNA in the absence of RV1B infection (Fig.6.6B). RV1B did not induce NF-κB 
p65 protein expression compared to medium treated alone cells (Fig.6.6B). siRNA 
targeting NF-κB p65 reduced NF-κB p65 protein expression compared to non-targeting 
control siRNA in the presence of RV1B infection (Fig.6.6B). The structural protein β-
actin was used as a control for protein loading. 
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Figure 6.6 Reduction of NF-κB p65 mRNA and protein by NF-κB p65 specific siRNA in 
HBEC. HBEC were transiently transfected with NF-κB p65 siRNA, non-targeting control siRNA 
(100nM) or untransfected, cells cultured for 24h and infected with RV1B (MOI 1) or treated with 
infection medium alone. At 24h post-infection, cells were harvested for total RNA or protein, and 
NF-κB p65 mRNA measured by TaqMan RT-PCR (A), or protein measured by western blot (B). 
NF-κB p65 siRNA inhibited NF-κB p65 mRNA (p<0.001) versus non-targeting control siRNA. 
Data are the mean ± SEM of 9 (A) separate experiments and expressed as % of control siRNA 
transfected cells =100%, (***p<0.001, **p<0.01, *p<0.05 versus non-targeting control siRNA).  
Western blot is representative of 2-3 experiments. 
6.4.2  Inhibition of NF-κB p65 does not affect RV1B-induced IFN-
β, IFN-λ1 or IFN-λ2/3 gene expression   
HBEC were transfected with NF-κB p65 specific siRNA, a non-targeting control siRNA 
or were untransfected, and then cultured for 24h before incubating with RV1B (MOI of 
1), or treating with BEBM alone, and culturing for a further 24h. Cells were harvested for 
total RNA and IFN-β, IFN-λ1 and IFN-λ2/3 mRNA analysed by TaqMan RT-PCR. NF-κB 
p65 siRNA did not affect RV1B-induced IFN-β, IFN-λ1 or IFN-λ2/3 (all p>0.05) 
compared to RV1B infected non-targeting control siRNA transfected cells (Fig.6.7A-C). 
No significant difference between uninfected untransfected cells and uninfected non-
targeting control siRNA transfected cells was observed (all p>0.05), indicating that 
control siRNA alone did not induce IFN-β, IFN-λ1 or IFN-λ2/3 mRNA.   
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Figure 6.7 Effect of NF-κB p65 siRNA on RV1B induced IFN-β, IFN-λ1 and IFN-λ2/3 mRNA 
expression in HBEC. HBEC were transiently transfected with NF-κB p65 siRNA, non-targeting 
control siRNA, or untransfected. 24h post-transfection, cells were infected with RV1B (MOI 1), or 
treated with infection medium alone. 24h post-infection, cells were harvested for total RNA and 
IFN-β, IFN-λ1 and IFN-λ2/3 mRNA measured by TaqMan RT-PCR. NF-κB p65 siRNA did not 
inhibit RV1B-induced IFN-β (A), IFN-λ1 (B) or IFN-λ2/3 (C) (all p>0.05), compared to cells 
infected and transfected with non-targeting control siRNA. Data are the mean ± SEM of 9 
separate experiments and expressed as % of infected control =100%, (***p<0.001, **p<0.01, 
*p<0.05 versus non-targeting control siRNA), ### versus untransfected, uninfected control.   
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6.4.3  NF-κB p65 siRNA inhibits RV1B-induced pro-inflammatory 
cytokine gene expression 
In identical experiments to those produced in section 6.4.2, NF-κB p65 siRNA 
significantly inhibited RV1B-induced CCL5, CXCL10, IL-6, CXCL8 and CXCL5 (Fig. 
6.8A-E) (all p<0.001), compared to RV1B infected non-targeting control siRNA 
transfected cells. No significant difference between uninfected untransfected cells and 
uninfected non-targeting control siRNA transfected cells was observed (all p>0.05) 
indicating that control siRNA alone did not induce pro-inflammatory cytokine mRNA.   
 
 
 
 
 
Figure 6.8 Effect of NF-κB p65 siRNA on RV1B induced pro-inflammatory cytokine mRNA 
expression in HBEC. HBEC were transiently transfected with NF-κB p65 siRNA or non-targeting 
control siRNA, or untransfected. 24h post-transfection, cells were infected with RV1B (MOI of 1), 
or treated with infection medium alone. 24h post-infection, cells were harvested for total RNA and 
pro-inflammatory cytokines measured by TaqMan RT-PCR. NF-κB p65 siRNA inhibited RV1B 
induced CCL5 (A), CXCL10 (B), IL-6 (C), CXCL8 (D) and CXCL5 (E) (all p<0.001) mRNA 
expression compared to cells infected and transfected with non-targeting control siRNA. Data are 
the mean ± SEM of 9 separate experiments and expressed as % of infected control =100%, 
(***p<0.001, **p<0.01, *p<0.05 versus non-targeting control siRNA), ### versus untransfected, 
uninfected control.   
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6.5 Effect of ATF-2 and c-Jun inhibition on RV1B 
infected HBEC 
Having demonstrated the requirement for PRDIV within the IFN-β promoter for RV1B-
induced activation of the promoter, a role for the PRDIV binding heterodimeric 
transcription factor ATF-2/c-Jun in RV1B-induction of IFN-β was investigated, in order to 
support PRDIV mutant IFN-β promoter results. A role ATF-2 and c-Jun in RV1B-induced 
IFN-λ-1 and IFN-λ2/3 was also investigated, using siRNA specifically targeting ATF-2 or 
c-Jun.  
6.5.1  Inhibition of ATF-2 and c-Jun mRNA and protein by ATF-2 
and c-Jun specific siRNA 
HBEC were transfected with ATF-2 or c-Jun specific siRNA, a non-targeting control 
siRNA or were untransfected, and then cultured for 24h before incubating with RV1B 
(MOI of 1), or treating with BEBM alone, and culturing for a further 24h. Cells were 
harvested for total RNA, or protein, and reduction in ATF-2 and c-Jun mRNA analysed 
by TaqMan RT-PCR, or ATF-2 and c-Jun protein by western blot analysis. Following 
RV1B infection, ATF-2 and c-Jun siRNA reduced ATF-2 and c-Jun mRNA levels 
respectively to 18% and 19% (both p<0.001), of expression levels obtained with non-
targeting control siRNA (Fig. 6.9A, C). ATF-2 and c-Jun proteins were detected in 
medium treated alone cells (Fig. 6.9B, D). In uninfected non-targeting control siRNA 
transfected cells ATF-2 and c-Jun proteins were detected, and their expression not 
enhanced compared to medium treated alone cells (Fig. 6.9B, D). ATF-2 and c-Jun 
specific targeting siRNA reduced ATF-2 protein and c-Jun protein expression 
respectively, compared to non-targeting control siRNA in the absence of RV1B infection 
(Fig. 6.9B, D). RV1B did not induce ATF-2 or c-Jun protein expression compared to 
medium treated alone cells (Fig. 6.9B, D). siRNA targeting ATF-2 and c-Jun reduced 
ATF-2 and c-Jun protein expression respectively, compared to non-targeting control 
siRNA in the presence of RV1B infection (Fig. 6.9B, D). The structural protein β-actin 
was used as a control for protein loading.  
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Figure 6.9 Reduction of ATF-2 and c-Jun mRNA and protein by ATF-2 and c-Jun specific 
siRNA in HBEC. HBEC were transiently transfected with ATF-2, c-Jun or non-targeting control 
siRNA (100nM) or untransfected, cells cultured for 24h and infected with RV1B (MOI 1) or treated 
with infection medium alone. At 24h post-infection, cells were harvested for total RNA or protein 
and ATF-2 (A) and c-Jun (C) mRNA measured by TaqMan RT-PCR, or ATF-2 (B) and c-Jun (D) 
protein measured by western blot. ATF-2 and c-Jun mRNA was inhibited by ATF-2 and c-Jun 
siRNA respectively (p<0.001), versus non-targeting control siRNA. Data are the mean ± SEM of 
7 separate experiments and expressed as % of control siRNA transfected cells =100%, 
(***p<0.001, **p<0.01, *p<0.05 versus non-targeting control siRNA). Western blots are 
representative of 2-3 experiments.  
6.5.2  ATF2 and c-Jun siRNA inhibited RV1B-induced IFN-β, ATF-
2 siRNA did not affect, and c-Jun siRNA enhanced RV1B-
induced IFN-λ1 and IFN-λ2/3  
HBEC were transfected with ATF-2 or c-Jun specific siRNA, a non-targeting control 
siRNA or were untransfected, and then cultured for 24h before incubating with RV1B 
(MOI of 1), or treating with BEBM alone, and culturing for a further 24h. Cells were 
harvested for total RNA and IFN-β, IFN-λ1 and IFN-λ2/3 mRNA analysed by TaqMan 
RT-PCR. ATF-2 siRNA significantly inhibited RV1B-induced IFN-β (p<0.001) but did not 
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affect RV1B-induced IFN-λ1 or IFN-λ2/3 mRNA (both p>0.05) compared to RV1B 
infected non-targeting control siRNA transfected cells (Fig. 6.10A, B, C). siRNA targeting 
c-Jun significantly inhibited RV1B-induced IFN-β (p<0.001), did not affect RV1B-
induction of IFN-λ1 (p<0.05) and enhanced induction of IFN-λ2/3 (p<0.01), compared to 
RV1B infected non-targeting control siRNA transfected cells. No significant difference 
between uninfected untransfected cells and uninfected nontargeting control siRNA 
transfected cells was observed (all p>0.05), indicating that control siRNA alone did not 
induce IFN-β, IFN-λ1 or IFN-λ2/3 mRNA.  
 
Figure 6.10 Effect of ATF-2 and c-Jun siRNA on RV1B induced IFN-β, IFN-λ1 and IFN-λ2/3 
mRNA expression in HBEC. HBEC were transiently transfected with ATF-2, c-Jun or non-
targeting control siRNA, or untransfected. 24h post-transfection, cells were infected with RV1B 
(MOI 1), or treated with infection medium alone. 24h post-infection, cells were harvested for total 
RNA and IFN-β, IFN-λ1 and IFN-λ2/3 mRNA measured by TaqMan RT-PCR. ATF-2 siRNA 
inhibited RV1B induced IFN-β (A) (p<0.001) but not IFN-λ1 (B) or IFN-λ2/3 (C) (both p>0.05) 
mRNA expression, and c-Jun siRNA inhibited RV1B induced IFN-β (A) (p<0.001) but not IFN-λ1 
(B) (p>0.05) and enhanced IFN-λ2/3 (C) (p<0.01) mRNA expression, compared to cells infected 
and transfected with non-targeting control siRNA. Data are the mean ± SEM of 7 separate 
experiments and expressed as % of infected control =100%, (***p<0.001, **p<0.01, *p<0.05 
versus non-targeting control siRNA), ### versus untransfected, uninfected control.   
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6.6 Effect of transcription factor targeting siRNA on IFN 
and pro-inflammatory cytokine expression in HBEC 
To ensure, that all of the transcription factor targeting siRNA used in this study did not 
significantly induce interferon or the production of pro-inflammatory cytokine mRNA, the 
effect of each siRNA on interferon and pro-inflammatory cytokine gene expression, in 
the absence of RV infection, was assessed in parallel experiments and compared to 
untransfected cells. Non-specific, dsDNA oligonucleotide was used as a transfection 
control.  
6.6.1 IRF1, IRF3, IRF7, NF-κB p65, ATF-2 and c-Jun siRNA do not 
induce IFNs in HBEC  
HBEC were transfected with IRF1, IRF3, IRF7, NF-κB p65, ATF-2, c-Jun specific siRNA 
or dsDNA, then cultured for 24h before replacing culture medium with fresh BEBM, and 
culturing for a further 24h. Cells were harvested for total RNA and IFN-β, IFN-λ1 and 
IFN-λ2/3 mRNA analysed by TaqMan RT-PCR (Table 6.1). IRF1, IRF3, c-Jun and ATF-
2 siRNA transfection did not induce IFN-β, or IFN-λ2/3 mRNA and non-significantly 
induced IFN-λ1 mRNA, compared to untransfected control cells (all p>0.05). 
Transfection with IRF7 siRNA did not induce IFN-β, IFN-λ1 or IFN-λ2/3 mRNA (all 
p>0.05), compared to untransfected control cells. NF-κB p65 targeting siRNA non-
significantly induced IFN-β (p>0.05), and did not induce IFN-λ1 or IFN-λ2/3 mRNA 
(p>0.05), compared to untransfected control cells. IFN-β, IFN-λ1 and IFN-λ2/3 mRNA 
copies in dsDNA transfected cells were non-significantly increased compared to their 
respective IFN-β, IFN-λ1 and IFN-λ2/3 mRNA copies in untransfected control cells (all 
p>0.05). No-significant difference in IFN-β, IFN-λ1 or IFN-λ2/3 mRNA (all p>0.05) was 
observed between IRF1, IRF3, IRF7, NF-κB p65, ATF-2 or c-Jun siRNA transfected 
cells and dsDNA transfected cells. 
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 IFN-β IFN-λ1 IFN-λ2/3 
Un-transfected    
Mean copies ± SEM 2.0x104 ± 7.6x103 6.7x102 ± 4.8x102 1.2x103 ± 6.2x102 
dsDNA    
Mean copies ± SEM 3.1x104 ± 1.3x104 NS 2.2x103 ± 1.5x103 NS 1.9x103 ± 1.0x103 NS 
IRF1 siRNA    
Mean copies ± SEM 7.2x103 ± 2.0x103 NS/NS 1.3x103 ± 1.3x103 NS/NS 3.2x102 ± 1.4x102 NS/NS 
IRF3 siRNA    
Mean copies ± SEM 1.1x104 ± 3.2x104 NS/NS 2.2x103 ± 1.6x103 NS/NS 2.1x102 ± 1.0x102 NS/NS 
IRF7 siRNA    
Mean copies ± SEM 9.4x103 ± 2.1x103 NS/NS 4.0x102 ± 2.7x102 NS/NS 1.7x102 ± 5.8x101 NS/NS 
NF-κB p65 siRNA    
Mean copies ± SEM 3.5x104 ± 1.1x104 NS/NS 6.1x102 ± 3.7x102 NS/NS 6.0x102 ± 2.5x102 NS/NS 
c-Jun siRNA    
Mean copies ± SEM 8.2x103 ± 4.6x103 NS/NS 1.2x103 ± 1.1x103 NS/NS 4.6x102 ± 1.7x102 NS/NS 
ATF-2 siRNA    
Mean copies ± SEM 1.7x104 ± 7.5x103 NS/NS 4.1x103 ± 3.5x103 NS/NS 4.1x102 ± 2.1x102 NS/NS 
 
Figure 6.1 Effect of IRF1, IRF3, IRF7, p65, c-Jun and ATF-2 siRNA or dsDNA transfection 
on IFN-β, IFN-λ1 and IFN-λ2/3 mRNA expression in HBEC. HBEC were transiently transfected 
with IRF1, IRF3, IRF7, p65, c-Jun, ATF-2 siRNA or dsDNA. 24h post-transfection, medium was 
replaced and cells cultured in fresh infection medium for 24h. Total cell RNA was harvested for 
analysis at 48h post-transfection and IFN-β, IFN-λ1 and IFN-λ2/3 measured by TaqMan RT-
PCR. IRF1, IRF3, IRF7, p65, c-Jun, ATF-2 siRNA or dsDNA transfection did not significantly 
induce IFN-β, IFN-λ1 or IFN-λ2/3 mRNA expression compared to un-transfected control cells (all 
p>0.05). Data are the mean mRNA copy number per 2x105 cells ± SEM of 5 separate 
experiments. Statistics are shown as dsDNA versus untransfected cells (NS), and IRF1, IRF3, 
IRF7, p65, c-Jun, ATF-2 targeting siRNA versus dsDNA/untransfected cells respectively (NS/NS). 
6.6.2  NF-κB p65 siRNA does not induce pro-inflammatory 
cytokines in HBEC  
HBEC were transfected with NF-κB p65 specific siRNA or dsDNA, then cultured for 24h 
before replacing culture medium with fresh BEBM and culturing for a further 24h. Cells 
were harvested for total RNA and CCL5, CXCL10, CXCL5, IL-6, and CXCL8 mRNA 
analysed by TaqMan RT-PCR (Table 6.2). NF-κB p65 siRNA transfection did not induce 
CCL5, CXCL10, CXCL8 or CXCL5 mRNA (all p>0.05), and non-significantly induced IL-
6 mRNA (p>0.05) compared to untransfected control cells. CCL5, CXCL10, CXCL5, IL-6 
and CXCL8 mRNA copies in dsDNA transfected cells were non-significantly increased 
compared to their respective mRNA copies in untransfected control cells (all p>0.05). 
No-significant difference in CCL5, CXCL8, CXCL5 or IL-6 mRNA (all p>0.05) was 
observed between NF-κB p65 siRNA transfected cells and dsDNA transfected cells, and 
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CXCL10 mRNA (p<0.05) was reduced in NF-κB p65 siRNA transfected cells compared 
to dsDNA transfected cells.   
 
 CCL5 CXCL10 CXCL5 IL-6 CXCL8 
Un-transfected      
Mean copies 5.0x105 1.1x106 4.8x105 9.0x103 3.3x106 
± SEM ± 1.6x105 ± 1.9x105 ± 1.2x105 ± 3.4x103 ± 1.2x106 
dsDNA      
Mean copies 1.0x106 NS 2.5x106 NS 7.8x105 NS 1.7x104 NS 3.9x106 NS 
± SEM ± 4.0x105 ± 9.1x105 ± 2.1x105 ± 9.5x103 ± 1.0x106 
NF-κB p65 siRNA      
Mean copies 1.1x105 NS/NS 2.0x105 */NS 2.9x105 NS/NS 1.1x104 NS/NS 9.3x105 NS/NS 
± SEM ± 4.9x104 ± 5.3x104 ± 1.0x105 ± 4.7x103 ± 3.0x105 
 
Figure 6.2 Effect of NF-κB siRNA or dsDNA transfection on CCL5, CXCL10, CXCL5, IL-6 
and CXCL8 mRNA expression in HBEC. HBEC were transiently transfected with NF-κB siRNA 
or dsDNA. 24h post-transfection, medium was replaced and cells cultured for a further 24h. Total 
cell RNA was harvested for analysis at 48h post-transfection and pro-inflammatory cytokines 
measured by TaqMan RT-PCR. NF-κB siRNA or dsDNA transfection did not significantly induce 
CCL5, CXCL10, CXCL5, IL-6 or CXCL8 mRNA expression compared to un-transfected cells (all 
p>0.05). Data are the mean mRNA copy number per 2x105 cells ± SEM of 5 separate 
experiments. Statistics are shown as dsDNA versus untransfected cells (NS), and NF-κB p65 
targeting siRNA versus dsDNA/untransfected cells respectively (e.g. NS/NS).  
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6.7 Chapter 6: Discussion 
6.7.1 PRDs I-IV are all required for RV1B, ∆RIG-I and ∆TRIF-
induced IFN-β transcription 
RV1B significantly induced the activation of wild-type IFN-β promoter, compared to un-
infected cells. The induction level was small (~3.5 fold) and may reflect the difficulty of 
plasmid delivery to HBEC, coupled with the observation that transfected cells show a 
decreased susceptibility to RV infection, possibly partially explained by cell death 
induced by plasmid transfection. The four positive regulatory domain (PRD) regions 
(PRDI-IV) within the promoter were all required by RV1B for significant induction of IFN-
β promoter reporter construct activation in HBEC. The transcription factors identified in 
the literature to bind to PRDs in the IFN-β promoter, and recently identified in the crystal 
structure of the IFN-β enhanceosome [201], are therefore implicated as being activated 
upon RV1B infection of HBEC, and to bind to, and induce activation of the IFN-β 
promoter. Consistent with our finding, mutation of PRDI, PRDII [185] [191] and PRDIV 
[189] has previously been reported to reduce IFN-β promoter reporter construct 
activation in cells other than HBEC and using viruses other than RV.  
Constitutive activation of the RIG-I and TLR3 pathways also significantly induced wild-
type IFN-β promoter reporter construct activation, compared to empty control vector. 
Reflective of the constitutive and therefore enhanced activation of these pathways, 
activation of the wild-type IFN-β promoter was greater than that observed with RV1B 
infection. Consistent with our finding other studies using constitutively active RIG-I [245] 
and over-expressing TRIF [219] [214] [216] [221] have shown IFN-β promoter reporter 
construct activation in cells other than HBEC. The transcription factors known to bind the 
PRD regions are therefore implicated as being activated following RIG-I and TLR3 
mediated signalling. This is supported by our previous observation of NF-κB and IRF3 
dependent reporter activation, by expression of ∆RIG-I and ∆TRIF (Chapter 3 Fig.3.14 
and 3.16). Mutation of any of the four PRD regions significantly inhibited ∆RIG-I and 
∆TRIF-induced IFN-β transcription, suggesting that like RV1B, all four PRD regions are 
required by the RIG-I and TLR3 pathways to mediate activation of the IFN-β promoter in 
HBEC. Despite mutation of any PRD region significantly reducing both RIG-I and TLR3 
pathway mediated induction of IFN-β promoter activation, the promoter was still weakly 
activated by ∆RIG-I and ∆TRIF. This finding was not observed with RV1B infection, and 
is therefore due to the constitutive activation of RIG-I and TLR3 signalling pathways. 
Studies have shown weak activation of wild-type IFN-β promoter reporter constructs by 
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expression of large doses of individual transcription factors [186] [187] or dual 
combinations of transcription factors [186] [187] [192]. Residual weak activation of 
mutated IFN-β promoter reporter constructs, by ∆RIG-I and ∆TRIF, may therefore be 
due to the induction of large amounts of activated transcription factors, and their 
activation of the IFN-β promoter, by specific transcription factor binding to the three 
remaining non-mutated PRD regions. This possibility would be supported by the study of 
dual PRD region mutations within the IFN-β promoter and the observation of further 
reduced IFN-β promoter reporter construct activation by ∆RIG-I and ∆TRIF.  
6.7.2 IRF1 is required for RV1B-induced IFN-β, but not IFN-λ 
expression in HBEC 
IRF1 siRNA significantly inhibited RV1B-induced IFN-β, but not IFN-λ1 or IFN-λ2/3 
mRNA, suggesting that IRF1 is required by RV1B for IFN-β induction, but not IFN-λ1 or 
IFN-λ2/3 in HBEC. The level of RV1B-induced IFN-β inhibition by IRF1 siRNA was not 
comparable to the degree of IRF1 mRNA inhibition by IRF1 targeting siRNA. This may 
be due to the incomplete inhibition of RV1B-induced IRF1 protein expression by IRF1 
siRNA. Alternatively, IRF1 may be functionally redundant with another IRF, and this may 
explain only a modest reduction in RV1B-induced IFN-β gene expression by IRF1 
siRNA. Studies have shown a role for IRF1 in polyIC-induced IFN-β expression [143] 
[142] and expression of IRF1 to induce endogenous [140] [141] [135] and exogenous 
type I IFNs [141] [135]. However, in contrast to our findings, a role for IRF1 in virus-
induced IFN-β has been questioned, with IRF1 not required for NDV-induced IFN-β 
expression [143], and IRF1 binding to the endogenous IFN-β promoter not detected 
following SV infection [144]. However, these studies used viruses other than RV and cell 
types other than HBEC; therefore IRF1 may be required in this study for RV1B-induced 
IFN-β expression in HBEC. A study has shown IRF1 binding to the IFN-λ1 and IFN-λ2/3 
promoters upon SV infection and expression of IRF1 to enhance virus-induced IFN-λ 
promoter activation [203]. Although inconsistent with our finding of no role for IRF1 in 
RV1B-induced IFN-λ1 and IFN-λ2/3, a cell type and stimuli specific role for IRF1 in IFN-
λ expression may exist. In addition, this study is the first to use a functional inhibition 
technique to examine a role for IRF1 in virus-induced IFN-λ expression, and it can be 
argued that functional inhibition is a more definitive way than over-expression, of 
assessing the requirement of IRF1 in IFN-λ induction.  
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6.7.3 IRF7 is not required for RV1B-induced IFN-β or IFN-λ 
expression in HBEC 
IRF7 siRNA did not significantly inhibit RV1B-induced IFN-β, IFN-λ1 or IFN-λ2/3 mRNA, 
suggesting that IRF7 is not required for RV1B-induced IFN-β/IFN-λ expression in HBEC. 
Type I IFN production is required prior to the induction of IRF7 expression [137] [138]. 
The rapid first phase induction of IFN-β is therefore proposed not to be dependent on 
IRF7, but instead on IRF3, which is constitutively expressed and activated upon virus 
infection. However, in contrast to our finding, studies have shown a role for IRF7 in the 
second phase of IFN-β production [137] [138]. Some studies have also implicated a 
possible role for IRF7 in the early induction of IFN-β [139] [151], believed to be due to 
spontaneous type I IFN induction in cells, and thus a low level of IRF7 could be 
constitutively expressed. However, these studies did not use HBEC and so an early role 
for IRF7 may be cell type dependent. We could not detect IRF7 protein in RV1B infected 
HBEC, suggesting that HBEC do not express IRF7 protein and supporting our finding of 
no role for IRF7 in RV1B-induced IFN-β, IFN-λ1 and IFN-λ2/3 expression. However, 
IRF7 has a short half-life (~0.5-1h) [151], due to its ubiquitin dependent degradation 
[388] and at the time of sample collection (24h post-infection), IRF7 protein expression 
may have not been present, and therefore undetectable by western blot. We therefore 
cannot rule out the possibility that IRF7 protein is produced in HBEC upon RV1B 
infection, and that our result may be due to incomplete inhibition of IRF7 protein 
expression by siRNA, with sufficient IRF7 protein remaining to enable RV1B-induction of 
IFN mRNA. The presence of IRF7 protein could have been indirectly assessed by 
examining IFN-α knockdown by IRF7 siRNA, because IFN-α genes (with the exception 
of IFN-α4) generally require IRF7 for their induction [137]. In contrast to our findings, an 
over-expression study has implicated IRF7 to have a role in IFN-λ1 and IFN-λ2/3 
transcription [203]. However, IRF7 over-expression does not definitely prove that IRF7 is 
essential for IFN-λ1 and IFN-λ2/3 expression, and this study is the first to functionally 
inhibit IRF7 to investigate its role in virus-induced IFN-λ expression.  
6.7.4 IRF3 is required for RV1B-induced IFN-β and IFN-λ 
expression in HBEC 
IRF3 siRNA significantly inhibited RV1B-induced IFN-β, IFN-λ1 or IFN-λ2/3 mRNA, 
suggesting IRF3 to be essential for RV1B-induced IFN-β and IFN-λ expression in HBEC. 
The incomplete inhibition of RV1B-induced IFN-β, IFN-λ1 and IFN-λ2/3 mRNA, by IRF3 
siRNA, may be due to incomplete IRF3 mRNA/protein inhibition. This finding is 
consistent with studies in IRF3 deficient mice, which show significant reduction in virus-
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induced IFN-β expression [151] [139]. However, residual virus-induced IFN-β expression 
was shown in these studies and this was only removed with additional knockout of the 
IRF7 gene, suggesting that both IRF3 and IRF7 are required for maximal IFN-β 
expression. Despite this, expression of IRF3 or IRF7 alone is sufficient to restore NDV-
induced endogenous and exogenous IFN-β expression, in IRF3/IRF7 double deficient 
MEFs [151]. Wathelet et al [144] showed IRF3/IRF7 hetero-dimers, and not homo-
dimers, to form when expressing IRF3 and IRF7 together in the absence or presence of 
virus. It is therefore possible that IRF3/IRF7 hetero-dimers are formed upon virus 
infection, and homo-dimer formation is driven by the abundance ratio of the two IRFs. In 
turn, their abundance ratio could feasibly be governed by the timing and level of 
inducible IRF7 expression, their identified competition for transportation from the 
cytoplasm to the nucleus [389] and their rates of degradation (half-life). The abundance 
of IRF3 and IRF7 in turn may represent their relative contribution to IFN-β induction, 
including their relative contribution to RV1B-induced IFN-β expression in HBEC. In 
support of this we detected IRF3 protein in RV1B infected HBEC but no IRF7 protein at 
the equivalent time-point. This result supports our finding of a role for IRF3 in RV1B-
induced IFN-β expression, and the possibility that IRF7 may not be essential. In 
contrast, IRF7, which is constitutively produced in pDC, is implicated in both the early 
and late IFN response in these cells, as virus-induced IFN expression is only inhibited in 
IRF7 deficient, but not IRF3 deficient pDC [139]. Therefore the contribution of IRF7 to 
type I IFN induction depends upon its expression level, and supports the suggestion that 
IRF3 alone can mediate RV1B-induced IFN-β expression in HBEC.  
6.7.5 ATF-2/c-Jun is required for RV1B-induced IFN-β, but not 
IFN-λ expression in HBEC  
ATF-2 and c-Jun siRNA significantly inhibited RV1B-induced IFN-β, but not IFN-λ1 or 
IFN-λ2/3 mRNA, suggesting that the ATF-2/c-Jun hetero-dimeric transcription factor is 
required by RV1B for IFN-β induction, but not IFN-λ1 or IFN-λ2/3 in HBEC. Consistent 
with our finding, studies have shown ATF-2/c-Jun to bind to the endogenous IFN-β 
promoter upon viral infection [144] and inhibition of ATF-2 and c-Jun to reduce virus-
induced IFN-β transcription [190]. A binding site for ATF-2/c-Jun has not been reported 
in the promoter of IFN-λ1 and IFN-λ2/3 genes, and this is the first study to investigate a 
role for ATF-2 and c-Jun in virus-induced IFN-λ expression, and to suggest that they are 
not required. A reason for our observed increase in RV1B-induced IFN-λ2/3 expression 
upon c-Jun inhibition is unclear, although c-Jun inhibition has been correlated with 
decreased apoptosis [169], thus decreased RV-induced apoptosis in c-Jun siRNA 
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transfected HBEC may account for the increased IFN-λ2/3 expression observed 
compared to RV infected control siRNA transfected HBEC. Alternatively enhanced 
RV1B-induced IFN-λ2/3 expression upon c-Jun specific siRNA transfection may reflect 
an as yet unknown mechanism in the regulation of the IFN-λ2/3 gene.  
6.7.6 NF-κB p65 is not required for RV1B-induced IFN-β or IFN-λ 
expression in HBEC  
Of the NF-κB family members, a predominance of NF-κB p65/p50 hetero-dimers has 
been shown in viral infection [186]. NF-κB p65/p50 has also been reported to bind to the 
endogenous IFN-β promoter following viral infection [144]. Our study of NF-κB therefore 
focussed on NF-κB p65, as studies have shown the p50 sub-unit to have little or no 
ability to trans-activate PRDII [186] [192] [390]. Furthermore, a hetero-dimer of inactive 
p65 with wild-type p50 has been shown not to induce PRDII activation [192] and 
increasing mounts of p50 have also been shown to inhibit p65/p50 activation of PRDII 
[186] [390]. NF-κB p65 is therefore suggested to be responsible for trans-activation of 
PRDII, and p50 to compete for the PRDII site binding and to possibly function in post-
induction repression of IFN-β transcription. The observed synergism between p50 and 
p65 in activation of a PRDII-dependent reporter, and of the intact IFN-β promoter (with 
the additional presence of ATF-2/c-Jun and IRF1) is proposed to be due to p50 
conferring increased p65/p50 binding affinity [186]. 
NF-κB p65 siRNA did not significantly inhibit RV1B-induced IFN-β mRNA expression, 
suggesting that NF-κB p65 is not required for the induction of IFN-β in HBEC by RV1B. 
This finding is not consistent with our identified requirement for PRDII in RV1B-induced 
IFN-β transcription. There could be several explanations for this conflicting result. Firstly, 
we have used a synthetic IFN-β promoter construct to determine PRD region 
requirement, and this may not necessarily reflect the PRD region requirement in the 
endogenous IFN-β promoter. Alternatively, and in keeping with our observed 
requirement for PRDII in RV1B-induced IFN-β transcription, we cannot rule out the 
possibility that NF-κB p65 is required for RV1B-induced IFN-β expression and that the 
level of NF-κB p65 protein required is low and remains following NF-κB p65 inhibition by 
siRNA. Thirdly, as all of the NF-κB sub-units are able to bind to the PRDII region within 
the IFN-β promoter this result could be considered as a reflection of functional 
redundancy between NF-κB subunits. However, studies identifying the predominance of 
NF-κB p65/p50 hetero-dimers in viral infection [186], the requirement for NF-κB p65/p50 
to confer virus-inducibility on an IFN-β promoter reporter [186] and the binding of NF-κB 
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p65/p50 to the endogenous IFN-β promoter upon viral infection [144], suggest that NF-
κB lacking a p65 sub-unit is unlikely to activate the IFN-β promoter. Furthermore, the 
recently reported crystal structure of the IFN-β enhanceosome determined NF-κB 
p65/p50 to bind to PRDII [201]. However, functional redundancy cannot be ruled out and 
may be cell type dependent. It must also be considered that, with exception of p65/p50 
binding to the endogenous IFN-β promoter upon virus infection [144], these studies are 
strongly suggestive, but do not definitely prove NF-κB p65/p50 is essential for IFN-β 
expression. A definitive, NF-κB sub-unit gene knockout study has recently been 
performed, and supports our finding of a non-essential role for NF-κB p65 in virus-
induced IFN-β expression, with SV or NDV-induced IFN-β expression slightly reduced, 
but still abundant, in NF-κB p65 deficient MEFs [169]. The use of a chromatin 
immunoprecipitation technique to assess binding of NF-κB p65 to the endogenous IFN-β 
promoter in RV1B infected HBEC, may help support a possible non-requirement for NF-
κB p65 in RV1B-induced IFN-β transcription in HBEC. 
NF-κB p65 siRNA also did not significantly inhibit RV1B-induced IFN-λ1 or IFN-λ2/3 
mRNA expression, suggesting that NF-κB p65 is not required their induction in HBEC by 
RV1B. This finding is not consistent with reports identifying the NF-κB binding site in the 
IFN-λ1 and IFN-λ2/3 promoters to bind NF-κB p65 [203], and showing the NF-κB 
binding site to be required for virus-inducibility of an IFN-λ1 promoter reporter [202]. 
However these reports do not provide definitive proof that IFN-λ expression essentially 
requires NF-κB p65 for its induction, and our study is the first to investigate the 
requirement for NF-κB p65 in virus-induced IFN-λ expression using a functional 
inhibition technique, which we argue is a more definitive method of assessing gene 
function. It is therefore possible that NF-κB p65 is not essential for virus-induced IFN-λ 
expression, or alternatively that a cell type and/or stimulus specific requirement for NF-
κB p65 in IFN-λ expression exits. Other possible explanations for our finding include the 
presence of a small amount of remaining NF-κB p65 protein after NF-κB p65 inhibition 
by siRNA, which is sufficient to enable the induction of IFN-λ gene expression, or 
functional redundancy between NF-κB sub-units for RV-induced IFN-λ expression.  
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6.7.7 NF-κB p65 is required for RV1B-induced pro-inflammatory 
cytokine expression in HBEC 
In contrast to IFN induction, NF-κB p65 siRNA significantly inhibited RV1B-induced 
CCL5, CXCL10, IL-6, CXCL8 and CXCL5 up-regulation in HBEC. The degree of NF-κB 
p65 mRNA/protein inhibition by NF-κB p65 siRNA in this study is therefore functionally 
sufficient with respect to inhibiting RV1B-induced pro-inflammatory gene expression. 
Studies have shown NF-κB to be required for RV induced CXCL8, IL-6 and CXCL10 
expression in airway epithelial cell lines [95] [82] [91], and a role for NF-κB in CCL5 
[155] [391] and CXCL5 expression [173] [174], supporting our findings. The incomplete 
inhibition of RV1B-induced pro-inflammatory cytokine gene expression may reflect 
residual NF-κB p65 protein presence and/or the additional role of other transcription 
factors such as IRF3, in regulating the transcription of some genes particularly CCL5 
and CXCL10 [155] [391] [91].  
6.7.9 Summary 
The key findings from this study of the transcription factors required for RV1B-induced 
IFN-β and IFN-λ expression in HBEC is that IRF3 is commonly required for IFN 
induction. Therefore a quantitative or qualitative IRF3 deficiency may contribute to the 
asthmatic phenotype of deficient IFN-β and IFN-λ production observed in asthmatic 
cells. In turn this deficiency may be due to a quantitative or qualitative deficiency in one 
or more signalling intermediates that lead to IRF3 activation. The requirement for NF-κB 
p65 for RV1B-induced pro-inflammatory cytokine expression but not IFN expression, 
suggests NF-κB p65 to be a potential therapeutic target for viral induced exacerbations 
of asthma, with NF-κB p65 functional inhibition reducing inflammatory cell recruitment 
into the lung, without affecting IFN production.  
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This section will summarise the key findings of this study and discuss the key findings 
and their relevance with respect to the potential development of future therapeutic 
targets for virus-induced asthma exacerbations. The future work required to confirm and 
progress the findings of this study toward therapeutic target identification will also be 
discussed. 
7.1 Key study findings to support Hypotheses 
The pattern recognition receptors, signalling intermediates and transcription factors 
required by RV to induce IFN and pro-inflammatory cytokine expression in HBEC were 
investigated by functional inhibition using siRNA and either studies using constitutive 
activation of a signalling molecule or over-expression of a signalling molecule. These 
experiments have identified the pattern recognition receptors (RIG-I, MDA5, TLR3), their 
downstream signalling adaptor proteins (TRIF, Cardif, TRAF3, TRAF6), kinases (TBK-
1/IKKε, IKK-β, JNK2), and transcription factors (ATF/c-Jun, NF-κB, IRF-3/7) to be 
required for RV-induced IFN expression and/or pro-inflammatory cytokine expression, 
supporting our first hypothesis. Additionally, this is the first report of a role for RIG-I in 
the control of a picornavirus infection. 
Whilst having common signalling intermediates, this study has identified TRAF6 and 
JNK2 not to be required for RV-induced IFN-β/λ expression, and not to affect CCL5 and 
CXCL10 expression, but to be required for CXCL8, IL-6 and CXCL5 expression. PI3Kα 
was also identified not to be required for RV1B-induced IFN-β/λ or CCL5 expression, but 
to be required for CXCL8, IL-6, CXCL5 and CXCL10 expression. This study has also 
identified NF-κB p65 not be required for RV-induced expression of IFN-β/λs, but to be 
required for all of the pro-inflammatory cytokines measured (CCL5, CXCL10, CXCL8, IL-
6, CXCL5). Further, IRF3 was identified to be commonly required for RV-induced 
expression of IFN-β/λs. These findings support the hypothesis that the induction of IFN-
β/λ and pro-inflammatory cytokines/chemokines, by RV, requires one or more distinct 
signalling molecules, and/or transcription factors. A summary of the pattern recognition 
receptors, adaptors, kinases and transcription factors identified to be required for RV-
induced IFN-β, IFN-λ1 and IFN-λ2/3 expression is shown in figure 7.1. The significance 
of these key findings with respect to the identification of potential future therapeutic 
targets for virus-induced asthma exacerbations, and the future work required to progress 
this possibility is discussed in the next sections.  
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7.1.1 A role for RIG-I in the innate immune response to RV 
infection  
This study has determined that the inhibition of RIG-I, using siRNA, to significantly inhibit 
RV-induced expression of IFN-β, IL-6, CXCL8, CXCL5, CCL5 and CXCL10 in HBEC. 
Further, inhibition of RIG-I resulted in enhanced RV1B and to a lesser extent RV16 
replication/release from HBEC. This is the first suggestion that RIG-I can have a role in 
the innate immune response to a picornavirus infection. A previous in vivo study, using 
the picornavirus EMCV, determined RIG-I to be dispensable for IFN-β production [259], 
and is supported by studies showing RIG-I to recognise 5’-triphosphate containing RNA 
[249] [250], which picornaviruses do not possess [350]. However, there is evidence that 
RIG-I binds [245] [246] [247] [326] and responds to polyIC [245], suggesting that it may 
recognise viral dsRNA replication intermediates, and that the role of RIG-I in the innate 
immune response to virus may not be solely dependent upon recognition of 5’-
triphosphate containing RNA. The findings of this study support this notion, and further 
our understanding of the host innate immune response to viral infection. It could be 
suggested, from the findings of previous studies and the findings of this study, that 
although preferential recognition of viruses can occur through specific pattern 
recognition receptors (PRRs), viral PRRs can work together to provide a rapid and 
efficient response to viral infection. This is supported by our identified role for the three 
PRRs, TLR3, RIG-I and MDA5 in the innate immune response to RV infection, and a 
role for TLR3 in the up-regulation of RIG-I and MDA5 expression upon RV infection. In 
turn, which PRRs work together will depend upon which are expressed by the host cell, 
and may additionally depend upon the route of virus entry into the host cell. In this 
respect, RV enters the host cell through the endosome [74] [75], where it will encounter 
TLR3, and replicates in the cytoplasm where RIG-I and MDA5 are present, indirectly 
supporting our finding that all three PRRs encounter RV nucleic acid during the infection 
cycle of HBECs.       
In future experiments, a definitive role for RIG-I in the innate immune response to RV 
infection of HBEC can be shown by demonstrating RIG-I to bind to RV dsRNA 
replication intermediates. This interaction may be identified by gel shift assay, with full-
length RIG-I binding to RV replication products visualised within a polyacrylamide gel. 
Additionally, the ATPase activity of RNA helicases is dsRNA dependent [392], enabling 
measurement RIG-I ATPase activity to indicate binding between full-length RIG-I and 
RV replication products. These two techniques have recently been demonstrated by 
Marques et al [341] to show the interaction of RIG-I with dsRNA. Furthermore, with the 
recent development of a mouse model of RV infection in our lab [393], the investigation 
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of an in vivo role for RIG-I in the innate immune response to RV, using RIG-I knockout 
mice, will further define a role for RIG-I in the response to RV infection.   
Further, to increase our understanding of how TLR3 and RIG-I/MDA5 pathways co-
operate to initiate the anti-viral response to RV, the mechanism by which TLR3 
regulates RIG-I and MDA5 expression upon RV infection requires further investigation. 
In this respect, whether TLR3-mediated RIG-I and/or MDA5 expression is IFN 
dependent or IFN independent will be determined, as a recent finding in our lab using 
IFNAR1 knockout mice, suggests that initial RV-induction of RIG-I and MDA5 is IFN-
independent (N. Bartlett; M. Edwards; unpublished observations). TLR3 may therefore 
be the initial sensor of RV infection upon endosome cell entry, and mediate initial (early) 
RIG-I and MDA5 induction in an IFN-independent manner.  
7.1.2 IRF3 and TRIF are common to both RV1B-induced IFN-β 
and IFN-λ in HBEC 
Of the transcription factors identified in the literature to bind to the IFN-β promoter, and 
to the promoters of the IFN-λ genes, IRF3 was the only transcription factor identified in 
this study to be commonly required by RV1B to induce the expression of IFN-β and IFN-
λ in HBEC. It may therefore be argued that the deficiency in asthmatics to express IFN-
β/λ may include IRF3, or a signalling molecule upstream of IRF3 which we have 
identified in this study to be required for both RV1B-induced IFN-β and IFN-λ 
expression. In this respect, these molecules include the signalling kinases TBK-1 and 
IKKε, the adaptor proteins TRIF (and possibly Cardif), and the pattern recognition 
receptors TLR3 and MDA5, which initiate signalling to IRF3 activation. However, this 
study has identified TBK-1, IKKε, Cardif, TRIF, MDA5 and TLR3 to additionally be 
required for RV1B-induced pro-inflammatory cytokine expression, and signalling to pro-
inflammatory cytokine induction is intact in asthmatics. Therefore a deficiency in these 
up-stream signalling molecules may be considered to be an unlikely cause of IFN-β/λ 
deficiency in asthmatics. These findings would suggest that the most likely candidate for 
the deficiency in asthmatics to express IFN-β/λ is IRF3 itself. In support of this 
possibility, IRF3 is within the TLR4 signalling pathway and Contoli et al [126] not only 
identified a deficiency in IFN-λ production in asthmatic BEC infected with RV, but also in 
asthmatic macrophages stimulated with lipopolysaccharide (LPS), which is a ligand for 
TLR4. Another signalling molecule that is in the TLR4 pathway and that was additionally 
identified in this present study to be required for both RV1B-induced IFN-β and IFN-λ 
expression is TRIF. As mentioned earlier, a deficiency in TRIF in asthmatics in unlikely 
as TRIF was identified in this present study to have a role in pro-inflammatory cytokine 
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expression, however, it is possible that a deficiency in TRIF function rather than 
abundance exists in asthmatics. In this respect a functionally deficient TRIF that fails to 
interact with the downstream kinase complex TANK/TBK-1/IKKε may prevent 
continuation of signalling from TLR3 (and TLR4) to IRF3, upon RV infection (and LPS 
stimulation).  
Future work will include an investigation of the TRIF and IRF3 expression levels (using 
TaqMan RT-PCR and western blot) in BEC from asthmatic and normal individuals with 
and without RV infection. This will enable us to determine whether there is a deficiency 
in the expression of TRIF or IRF3 in asthmatic individuals, as compared to normal 
individuals. Although our findings suggest that a deficiency in TRIF abundance may be 
unlikely, this investigation will help to rule out this possibility. An assessment of IRF3 
activation upon RV infection of asthmatic and normal BECs can also be performed to 
determine whether a deficiency in IRF3 activation exists in asthmatics, by measuring 
IRF3 phosphorylation, observing IRF3 dimerisation or translocation to the nucleus, using 
techniques such as western blotting and confocal microscopy respectively. Additionally, 
an investigation into which proteins TRIF is interacting with upon RV infection of normal 
and asthmatic bronchial epithelial cells (BEC) can be made, and determination of 
whether any distinctions between asthmatic and normal BECs can be found. This may 
be achieved by using techniques such as co-immunoprecipitation or confocal 
microscopy, and will enable us to determine whether there is a deficiency in TRIF 
function in asthmatic individuals, as compared to normal individuals. All of this work will 
initially require the collection of BEC from asthmatic and normal individuals, and their 
successful growth in vitro. The screening of asthmatic cells using techniques such as 
TaqMan RT-PCR, virus titration assays and ELISA, will be required to confirm their 
deficiency in IFN-β/λ expression and increased RV replication, compared with BEC from 
normal individuals. These studies are currently planned in our laboratory. 
If these future studies identify TRIF and/or IRF3 to be deficient in abundance or function 
upon RV infection in asthmatic BEC, this molecule may represent a potential therapeutic 
target for virus-induced asthma exacerbations, and the modulation of which may act to 
enhance IFN production. In turn, this will enable a more effective anti-viral response in 
asthmatic BEC, with IFN activation of the JAK-STAT signalling pathway mediating the 
induction of multiple anti-viral genes and the elimination of virus infection more rapidly. 
In could be considered that the administration of type I IFN or type III IFN themselves 
may be an approach to treat or prevent virus-induced asthma exacerbations. In the 
1980s type I IFN-α and IFN-β were extensively investigated for their potential in the 
prevention and treatment of clinical colds. Studies showed high doses of IFN-α2 given 
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prior to experimental RV infection to be effective in reducing RV infection and colds, but 
to cause significant side effects including blood and increased mucus in nasal discharge 
and damage to the nasal mucosa [394] [395]. The findings of one study, giving IFN-α2 
after experimental RV inoculation, showed it to have little effect on reducing nasal 
symptom scores [396], and another giving IFN-α2 prior to natural RV infection to have 
promise in reducing infection frequency, but again to cause unwanted side effects [397]. 
An initial study administrating the recombinant IFN-β, IFN-β Ser, prior to RV 
experimental infection showed significant reduction in clinical scores and nasal 
secretions [398]. However, later investigation of IFN-β Ser efficacy showed it only to be 
effective at reducing RV experimentally induced colds at high doses, and high doses to 
coincide with significant side effects including mucosal bleeding and sub-epithelial 
lymphocytes in nasal biopsy specimens [399]. Furthermore, a study of natural RV 
infection showed giving IFN-β Ser to offer no significant benefit in reducing occurrence 
of RV colds even when used at higher doses, nor was the number of days of illness in 
patients who developed colds reduced by IFN-β Ser [400]. The results of these studies 
led to a halt in the development of IFN therapy for the prevention and treatment of RV 
colds. Although the use of IFN therapy has not been investigated in virus-induced 
asthma exacerbations, the findings of the above studies suggest that local inflammation 
occurs following intranasal delivery of IFN. In consideration of this, even if IFN could be 
delivered to the lower airways of asthmatics in a sufficient dose to be beneficial in 
preventing/treating RV infection and thus asthma exacerbation, the risk of IFN 
administration causing enhanced inflammation in the already inflamed asthmatic airways 
is a substantial caveat to this therapeutic approach.   
7.1.3 NF-κB p65 is a potential therapeutic target for RV-induced 
asthma exacerbations 
NF-κB is believed to play an essential role in generating the chronic inflammation 
observed in the lungs of asthmatic patients, due to its requirement in the transcription of 
many inflammatory mediators. This is supported by studies suggesting NF-κB activation 
to be enhanced in the tissues of asthmatic individuals. Adult uncontrolled, moderate and 
severe asthmatic subjects have been shown to have elevated IKK-β protein, 
phosphorylated IκBα and nuclear NF-κB p65, in peripheral blood mononuclear cells 
(PBMCs) compared to normal individuals [165]. Children with moderate asthma have 
also been reported to have higher NF-κB p65 and phosphorylated IκBα levels in 
PBMCs, compared to normal controls [401]. Further, subjects with stable untreated 
asthma show increased NF-κB DNA-binding in cells extracted from sputum and 
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bronchial biopsies [166] [402], and increased NF-κB p65 activation in cultured bronchial 
epithelial cells [402]. NF-κB is therefore recognised as an attractive target to reduce 
existing inflammation in asthmatic airways, and for asthma exacerbations to help 
prevent enhanced expression of pro-inflammatory mediators and enhanced 
inflammation. 
This study has shown that the inhibition of NF-κB p65, using siRNA, to significantly 
inhibit RV-induced expression of IL-6, CXCL8, CXCL5, CCL5 and CXCL10 in HBEC. 
Previous in vitro models of RV infection of airway epithelial cells have shown RV to 
induce NF-κB activation [95], and to up-regulate the expression of many inflammatory 
mediators that require NF-κB for their induction, including GM-CSF [80], IL-6 [95], 
CXCL8 [82], CXCL10 [91], ICAM-1 [101] and VCAM-1 [102]. Additionally, this study is 
the first to report a requirement for NF-κB in RV-induced CCL5 and CXCL5 expression. 
NF-κB p65 is therefore an attractive therapeutic target for RV-induced asthma 
exacerbations that will inhibit inflammatory mediator production but will not further inhibit 
the already diminished anti-viral response in asthmatic BEC. Neutrophilia is observed in 
RV infected airways [88] [110], thus the inhibition of the neutrophil chemo-attractants 
CXCL8 and CXCL5 would reduce their influx into the lung, and subsequent neutrophil 
release of neutrophilic proteases, which has been correlated with severity of virus-
induced asthma exacerbations [61]. Increased numbers of eosinophils and lymphocytes 
are also observed in RV infected airways [111] and increased markers of eosinophil 
activation [87]. Inhibition of the eosinophil chemo-attractant CCL5, and lymphocyte 
chemo-attractants CCL5 and CXCL10 would therefore reduce the influx of these cells in 
the asthmatic lung. Consequently, this would reduce potential lung damage from 
eosinophil release of an array of toxic oxygen species, histamine, leukotrienes and 
highly basic proteins, and the release of Th2 cytokines (IL-4, IL-5, IL-13) from Th2 
lymphocytes, that act to further increase lung inflammation by their attraction of 
eosinophils and basophils [403] [404] [109], enhancement of mucin production [405] and 
VCAM-1 expression [406]. Inhibition of NF-κB-induced ICAM-1 and VCAM-1 up-
regulation would also impair their established roles in inflammatory cell recruitment [105] 
[106] [109] and further RV cell entry through binding to ICAM-1. Targeting of NF-κB is 
therefore advantageous in the treatment of RV-induced asthma exacerbations to impair 
enhancement of existing lower airway inflammation, and resultant impaired lung 
function, increased bronchial hyper-responsiveness and exacerbation of asthma 
symptoms.  
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In contrast to pro-inflammatory cytokine/chemokine inhibition, this study has determined 
the inhibition of NF-κB p65, using siRNA, not to affect RV-induced expression of IFN-β/λ 
in HBEC. This finding supports the targeting NF-κB p65 as a therapy for RV-induced 
asthma exacerbations that will not further inhibit the already diminished anti-viral 
response to RV in asthmatic BEC. Contrary to our findings, previous studies have 
suggested NF-κB p65 to be required for virus induced IFN-β expression [186] [144]. 
However, with exception of NF-κB p65/p50 binding to the endogenous IFN-β promoter 
[144], these studies are strongly suggestive, but do not definitely prove NF-κB p65/p50 
is essential for virus-induced IFN-β expression. Additionally, a study in p65-/- MEFs has 
recently been performed [169], and supports our finding of a non-essential role for NF-
κB p65 in virus-induced IFN-β expression.  
Immediate future work will include the confirmation of our current suggestion that NF-κB 
p65 is not required for RV-induced IFN-β/λ expression in normal HBEC. This may be 
achieved with the use of chromatin immuno-precipitation and PCR, to investigate 
whether NF-κB p65 is binding to the endogenous IFN-β/IFN-λ promoters in HBEC, upon 
RV infection. A confirmation of NF-κB p65 binding to the promoters of pro-inflammatory 
genes upon RV infection of HBEC can also be made. An in vivo investigation of the 
requirement for NF-κB p65 in IFN-β/λ expression will also be made with the use of RV 
infection in NF-κB p65 deficient mice. Recently, a murine model of RV infection has 
been established [393] and this will allow the use of p65 deficient mice. Our investigation 
of the positive regulatory domains (PRDs) required by RV to induce IFN-β promoter 
reporter activation in HBEC, determined NF-κB binding region (PRDII) to be required. A 
possible explanation for this is that NF-κB p65 may be required in a small quantity to 
mediate RV-induced IFN-β/λ production in HBEC. If the former suggestion is true then 
RV-induced IFN-β/λ expression should be absent from NF-κB p65 deficient mice, and 
increasing doses of an NF-κB p65 can be investigated in NF-κB p65 deficient MEFs, for 
their restoration of RV-induced IFN-β/λ expression.    
Due to an established role for NF-κB in the transcription of many inflammatory 
mediators, and evidence indicating that corticosteroids which are the most effective 
treatment currently available to prevent inflammation in asthma, act at least in part 
through NF-κB inhibition [407], recent years have seen a focus of drug discovery and 
development efforts in the area of NF-κB and the NF-κB signalling pathway. These 
efforts have particularly focused on the development of small molecule inhibitors 
targeting the NF-κB activating kinase IKK-β, as IKK-β is widely implicated in NF-κB 
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mediated inflammation. Further, other NF-κB inhibition strategies include the use of 26S 
proteasome inhibitors, NF-κB binding site (κB) decoy oligos and NF-κB nuclear 
localisation signal blockers and dimerisation inhibitors [408].  
With respect to small molecule inhibitors of IKK-β, a number are currently in 
development [408] and in vitro have been demonstrated to reduce pro-inflammatory 
cytokine/chemokine, and/or adhesion molecule expression in respiratory cells, in 
response to NF-κB activating stimuli [409] [410] [411], including RV infection [209] [37]. 
Their testing in small animal models of asthma has additionally been successful in 
reducing lung inflammation, airway hyper-responsiveness, pro-inflammatory mediator 
expression and mucus hyper-secretion, in response to allergen challenge [411] [412] 
[413]. Collectively, these studies support the use of IKK-β inhibition to treat inflammatory 
disease; however inhibitors of this type have not yet been tested in human models of 
asthma or any model of virus-induced asthma. However, despite these promising 
findings, this thesis has identified a requirement for IKK-β in IFN-β/λ expression upon 
RV infection of HBEC. This finding suggests that targeting IKK-β to treat RV-induced 
asthma exacerbations may result in the further reduction of the deficient IFN-β/λ levels 
reported in RV-infected asthmatic patients [125] [126]. To investigate this possibility, 
future work will include the use of asthmatic BEC, confirmation of their reduced IFN-β/λ 
levels (versus normal BEC) upon RV infection, and examination of the effect of 
treatment with a small molecule inhibitor of IKK-β on IFN-β/λ levels.  
Depending upon our findings, therapeutic strategies that directly inhibit NF-κB, rather 
than IKK-β, may be a better approach for the treatment of RV-induced asthma 
exacerbations. These approaches would include the use of NF-κB decoy oligos, which 
have recently been shown in a murine AHR model to reduce levels of inflammatory cells 
and cytokines in BAL and AHR [414]. Future work will therefore include the testing of 
NF-κB p65 decoy oligos for their ability to impair pro-inflammatory cytokine/chemokine 
expression (and not affect IFN expression) in HBEC. Anti-sense oligos specifically 
targeting NF-κB are another potential strategy, and in an allergic mouse model of 
asthma have shown inhibition of inflammatory cell influx into the lung, cytokine detection 
in BAL and airway hyper-responsiveness [415]. There is also potential to use siRNA 
specifically targeting NF-κB as a therapeutic. Although siRNA degradation, and 
therefore bioavailability, is likely to be a limitation to its use, siRNA duplexes with greater 
stability are in development. Alternatively, the stable expression of short hairpin RNA 
from plasmid or viral vectors, which is then cleaved into siRNA, would enable a 
continuous level of target gene inhibition. Both of these approaches will be limited by the 
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ability to deliver siRNA or shRNA expressing plasmid into bronchial epithelium in vivo. 
However, approaches have been developed to improve cellular delivery of siRNA and 
shRNA [416] [417] [418], and following the recent success of in vivo mouse studies 
using nasally administered RSV targeting siRNA, in both preventing and treating RSV 
infection [419] [420], RSV targeting siRNA have now entered Phase II clinical trials [416] 
[417]. Other limitations to the use of siRNA include its potential to be recognised by 
pattern recognition receptors (PRRs) and trigger an innate immune response, and the 
possibility of off-target silencing effects. These issues of siRNA stability, delivery to cells, 
innate immune response triggering and off-target effects must therefore be thoroughly 
addressed before siRNA can become a new therapeutic strategy.  
A caveat to the targeting of NF-κB for therapeutic benefit in RV-induced asthma 
exacerbations, is that is has a crucial role in both innate and adaptive immune 
responses, and is required for the transcriptional regulation of a large number of proteins 
involved in normal cellular physiology including cell growth, differentiation and 
proliferation. In this respect, NF-κB p65 gene deficiency in mice is embryonic lethal due 
to massive TNFα-induced liver apoptosis [421]. The global inhibition of NF-κB is 
therefore likely to result in many additional, unwanted effects, and in humans and mice, 
defective NF-κB activation has been shown to result in their high susceptibility to 
bacterial infection [422] [423] [424]. To avoid this, it may be possible to develop NF-κB 
targeting drugs that can be used transiently during RV-induced asthma exacerbation. 
The seasonal behaviour of RV in the community, and also the identification of the 
september epidemic in school-aged children as vectors of RV infection [425], suggest 
that transient therapy may be suitable for asthma exacerbations. Alternatively, unwanted 
side effects may be minimised by linking small molecule inhibitors, decoy oligos, anti-
sense or siRNA to a cell type specific delivery system. However, how to deliver a drug in 
a cell-specific or organ specific manner is as yet unsolved. Ways in which this may be 
achieved may involve a method of delivery that encompasses the use of markers or 
molecules that recognise specific cells. If this is achieved, a thorough understanding of 
the role of NF-κB in the transcription of genes that are beneficial for the normal 
physiology and in response to infection of the targeted cell type will be required before 
NF-κB intervention can become a serious therapeutic option.     
7.1.4 TRAF6 is a potential therapeutic target for RV-induced 
asthma exacerbations 
This study has determined that inhibition of TRAF6, using siRNA, to significantly inhibit 
RV-induced expression of IL-6, CXCL8 and CXCL5, and not to affect RV-induced CCL5, 
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CXCL10 or IFN-β/λ expression. This study also reports TRAF6 over-expression to 
induce NF-κB-dependent, but not IRF3-dependent, or IFN-β/λ promoter reporter 
construct activation in HBEC, supporting our TRAF6 targeting siRNA findings.  
TRAF6 represents an attractive therapeutic target for RV-induced asthma 
exacerbations, inhibiting pro-inflammatory cytokine/chemokine production, but not 
inhibiting IFN production in asthmatic BEC. Targeting of TRAF6 to reduce RV-induced 
CXCL8 and CXCL5 expression in asthmatic BEC will help to reduce the influx of 
neutrophils into the airway. Although TRAF6 inhibition did not reduce RV-induced 
CXCL10 or CCL5 expression, indicating TRAF6 inhibition not to reduce eosinophil and 
lymphocyte influx into the lungs of asthmatic patients, eosinophils are believed to play a 
predominant role in non virus-induced asthma exacerbations [61], and rapid onset fatal 
asthma is frequently associated with a neutrophil infiltrate [115]. A therapy that acts to 
help inhibit neutrophil influx into the airway is therefore highly advantageous for the 
treatment of RV-induced asthma exacerbations.  
Immediate future work with respect to TRAF6 includes confirmation of the requirement 
for TRAF6 in RV-induced IL-6, CXCL8 and CXCL5, but not IFN expression in HBEC, 
using an alternative method of TRAF6 inhibition such as a TRAF6 dominant negative 
mutant.  Additionally, TRAF6 inhibition can be used to determine whether TRAF6 is also 
important for RV-induced pro-inflammatory cytokine production in other resident lung 
cells, such as airway smooth muscle (ASM) and macrophages. If so, this may expand 
the therapeutic benefit of targeting TRAF6 for the treatment of virus-induced asthma 
exacerbations. To confirm that TRAF6 is not required for IRF3 activation, and 
additionally support its non-requirement in IFN production, IRF3 phosphorylation/nuclear 
translocation could be investigated following TRAF6 over-expression. To confirm that 
TRAF6 has a role in NF-κB activation, and that this may be through IKK-complex 
activation, the effect of TRAF6 inhibition on the phosphorylation and/or degradation of 
the NF-κB inhibitory protein IκBα can be investigated. Additionally, the mechanism by 
which TRAF6 leads to transcription factor activation can be investigated, using co-
immunoprecipitation to determine the proteins that TRAF6 interacts with upon RV 
infection.  
Studies have shown the MAPKKK TAK1 to be recruited to poly-ubiquitinated TRAF6 via 
TAB2, which preferentially binds to lysine-63-linked poly-ubiquitin chains [297]. In turn, 
TRAF6 activates TAK1 kinase activity by an unknown mechanism, and activated TAK1 
activates IKK-β and MAPKKs by phosphorylation [296], leading to NF-κB and AP-1 
activation respectively. Future work may therefore also include the inhibition of TAK1 
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and TAB2 functioning with siRNA to determine whether these molecules are also 
required for RV-induced IL-6, CXCL8 and CXCL5 expression. This exploration will 
provide a better understand of the signalling mechanism by which RV induces pro-
inflammatory cytokines/chemokines, and further identification of where potential future 
therapeutic targeting strategies could be employed.  
The use of TRAF6, TAK1 or TAB2 deficient mice, and the observation of decreased pro-
inflammatory chemokine production, and neutrophil influx into the lungs, will help to 
validate TRAF6 (or its down-stream signalling intermediates) as a drug target. With this 
in vivo confirmation, TRAF6 could be progressed further as a therapeutic target for RV-
induced asthma exacerbations, with the investigation of potential therapeutic strategies 
for TRAF6 inhibition. This may include the determination of the region of TRAF6 protein 
required for binding to the TLR3 adaptor protein TRIF and the RIG-I/MDA5 adaptor 
protein Cardif. In turn, this may enable the development of TRAF6 inhibitory peptides to 
prevent TRAF6 functioning in these pathways upon RV infection. The validity of this 
strategy to inhibit TRAF6 function in vitro has recently been demonstrated [426]. Further, 
testing of TRAF6 inhibitory peptides in the recently developed mouse model of RV 
infection in our lab [393] will help validate the inhibitory peptide approach as a 
therapeutic strategy.   
TRAF6 deficiency has not yet been investigated in small animal models for a potential 
role in asthma pathogenesis. The in vivo investigation of TRAF6 to date has 
predominantly focused on investigating its role in the TNF and IL-1 receptor family 
signalling pathways, and TLR4 signalling. With respect to its role in TNF family 
functions, TRAF6 is required for CD40-mediated antibody affinity maturation and B-cell 
differentiation [427] [428], RANK-mediated differentiation and activation of osteoclasts 
[429] [430] and EDAR-mediated development of hair follicles, sweat and sebaceous 
glands [431]. IL-1 stimulated NF-κB and JNK activation is deficient in TRAF6 deficient 
cells [432], and in TLR4 signalling TRAF6 deficiency results in impaired responses to 
LPS stimulation [432]. These findings suggest that if the targeting of TRAF6 cannot be 
achieved specifically in the TLR3 and RIG-I/MDA5 signalling pathways, TRAF6 targeting 
may result in unwanted effects. For example the death of TRAF6 mice at an early age 
has been attributed to bone abnormalities due to a defect in osteoclastogenesis [432], 
and diminishing the cellular response to bacterial infections, through TLR4 signalling, 
could result in opportunistic bacterial infections in patients. However, it must also be 
considered that targeting TRAF6 to inhibit IL-1 and TLR pathways may be 
advantageous in RV-induced asthma exacerbations as this multi-pronged approach to 
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inhibiting NF-κB activation by these pathways, may be beneficial in reducing the 
inflammatory response. 
7.1.5 Other potential therapeutic targets for RV-induced asthma 
exacerbations: JNK2 and PI3Kα 
This study has determined that inhibition of JNK2, using siRNA, to significantly inhibit 
RV-induced expression of IL-6, CXCL8 and CXCL5, and not to affect RV-induced CCL5, 
CXCL10 or IFN-β/λ expression. Previous studies have implicated JNK2 in IL-6 and 
CXCL8 induction [167] [372], and this is the first study to report a requirement for JNK2 
in RV-induced IL-6, CXCL8 and CXCL5 expression. JNK2 is therefore a therapeutic 
target for RV-induced asthma exacerbations that will inhibit inflammatory mediator 
production but will not further inhibit the already diminished anti-viral response in 
asthmatic BEC.  
The potential of targeting JNKs for therapeutic benefit in asthma has been shown in rat 
and mouse allergic asthma models, using the JNK small molecule inhibitor SP600125, 
which inhibits all three isoforms of JNK (JNK1-3). In the rat asthma models SP600125 
inhibited ovalbumin-induced c-Jun phosphorylation in the lungs, reduced eosinophil, T-
cell and neutrophil numbers in BAL fluid [433] [434] and proliferation of airway smooth 
muscle and epithelial cells [433]. In the mouse ovalbumin-challenged asthma model, 
SP600125 also reduced eosinophil and T-cell numbers in BAL, reduced eosinophil 
inflammation in bronchial submucosa, goblet cell hyperplasia and airway 
hyperresponsiveness [435]. Despite these promising findings, inhibition of all JNK 
isoforms by SP600125 and subsequently the inhibition of c-Jun phosphorylation may 
result in inhibition of IFN-β expression, as this present study has identified a requirement 
for c-Jun in RV1B-induced IFN-β expression. An investigation into the effect of 
SP600125 on IFN-β induction has not yet been performed, but the findings of this 
present study would suggest that small molecule inhibitors that specifically target JNK2, 
rather than all JNK isoforms, will enable c-Jun activation and therefore may be beneficial 
in avoiding inhibition of IFN-β expression in asthmatic BEC. However, whether the 
specific targeting of JNK2 would still offer the beneficial effects demonstrated in rat and 
mouse allergic asthma models with SP600125 is unknown.   
Future work with respect to JNK2 includes the confirmation of our current findings in 
normal HBEC. An alternative method of JNK2 inhibition such as a JNK2 dominant 
negative mutant can be used to confirm the requirement of JNK2 in RV-induced IL-6, 
CXCL8 and CXCL5, but not IFN expression in HBEC. The effect of JNK2 specific siRNA 
or JNK1 specific siRNA, or a combination of these two, on RV1B-induced c-Jun 
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activation can be determined by measuring the phosphorylation state of c-Jun. 
Additionally, whether dual inhibition of JNK2 and JNK1 together would inhibit RV1B-
induced IFN-β expression can be investigated, to determine whether small molecule 
inhibitors targeting both JNK isoforms, as potential therapies for virus-induced asthma 
exacerbations would potentially be detrimental to IFN-β induction in asthmatic cells.    
This study has also shown that inhibition of PI3Kα, using siRNA, to significantly inhibit 
RV-induced expression of IL-6, CXCL8, CXCL5 and CXCL10, and not to affect RV-
induced CCL5 or IFN-β/λ expression, additionally implicating PI3Kα as a potential 
therapeutic target for RV-induced asthma exacerbations. The PI3K family is currently an 
area of considerable interest for therapeutic targeting in many diseases due to their 
roles in cellular signalling events controlling cell metabolism, growth, proliferation, 
differentiation, motility and survival [436]. To date, little attention has been given to the 
potential of targeting PI3Kα in asthma, but instead has focused on its amplified 
expression or mutation in a variety of cancers [437], and drugs targeting PI3Kα for 
cancer treatment have shown promise in human tumour xenograft mouse models [438]. 
In contrast, PI3Kδ and PI3Kγ whose expression is restricted to haematopoietic cells are 
receiving considerable interest as potential inflammation and allergy drug targets, due to 
results of genetic targeting of PI3Kδ or PI3Kγ in mice. Neutrophils and macrophages 
from PI3Kγ knockout mice show greatly reduced chemotaxis in response to a variety of 
chemoattractants [439] [440]. Reduced human neutrophil chemotaxis in response to N-
formyl-Met-Leu-Phe has also been demonstrated using the PI3Kδ selective inhibitor 
IC87114 [441]. The potential of targeting PI3Kδ in asthma (using inhibitor IC87114) has 
also been shown in mouse models of allergic asthma, with IC87114 reducing ovalbumin-
induced inflammatory cell influx into the lungs, mucus production, Th2 cytokines, CCL5, 
eotaxin, ICAM-1 and VCAM-1 expression levels, vascular permeability and airway 
hyperresponsiveness [442] [443].   
Despite a focus on PI3Kδ or PI3Kγ as potential therapeutic targets in haematopoietic 
cells, the findings of this study additionally suggest PI3Kα to be a potential target by 
which to inhibit pro-inflammatory cytokine production by resident lung cells. Future work 
with respect to PI3Kα includes the confirmation of our current findings in normal HBEC, 
and investigation of the effect of PI3Kα specific siRNA on RV-induced mediators from 
other lung cells such as airway smooth muscle cells and macrophages. Targeting the 
PI3Kα downstream kinase Akt with siRNA can be used to indirectly confirm the 
requirement for PI3Kα signalling in RV-induced pro-inflammatory cytokine expression 
but not IFN expression. Co-immunoprecipitation studies can be used to determine 
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whether PI3Kα acts within the TLR3 and/or RIG-I pathway in HBEC, and the effect of 
PI3Kα specific siRNA on IRF3 and NF-κB activation can be investigated. With respect to 
the later investigation, our current PI3Kα specific siRNA findings suggest that PI3Kα 
does not inhibit IRF3 activation, but does inhibit NF-κB activation.  
7.2 Conclusion 
Specific and effective treatments for virus-induced asthma exacerbations still represent 
an unmet clinical need. This thesis has investigated and produced a better 
understanding of the mechanism by which RV induces IFN-β/λ, that are deficient in 
asthmatic BEC, and pro-inflammatory cytokines/chemokines, that have intact expression 
in asthmatic BEC. In doing so, this study has identified signalling molecules (TRIF and 
IRF3) that may be deficient in asthmatic BEC signalling to IFN expression. Additionally, 
signalling molecules have been identified that are required for RV-induced pro-
inflammatory cytokine expression, but not IFN expression (NF-κB p65, TRAF6, JNK2 
and PI3Kα) and these represent potential new therapeutic targets for virus-induced 
asthma exacerbations.  
 
 
 
 
 
                                                                                                                                        References 
 
248 
References 
 
1. Wilson, D.H., R.J. Adams, G. Tucker, S. Appleton, A.W. Taylor, and R.E. Ruffin, 
Trends in asthma prevalence and population changes in South Australia, 1990-
2003. Med J Aust, 2006. 184(5): p. 226-9. 
2. Pearce, N. and J. Douwes, The global epidemiology of asthma in children. Int J 
Tuberc Lung Dis, 2006. 10(2): p. 125-32. 
3. Upton, M.N., A. McConnachie, C. McSharry, C.L. Hart, G.D. Smith, C.R. Gillis, 
and G.C. Watt, Intergenerational 20 year trends in the prevalence of asthma and 
hay fever in adults: the Midspan family study surveys of parents and offspring. 
BMJ, 2000. 321(7253): p. 88-92. 
4. Masoli, M., D. Fabian, S. Holt, and R. Beasley, The global burden of asthma: 
executive summary of the GINA Dissemination Committee report. Allergy, 2004. 
59(5): p. 469-78. 
5. Worldwide variation in prevalence of symptoms of asthma, allergic 
rhinoconjunctivitis, and atopic eczema: ISAAC. The International Study of 
Asthma and Allergies in Childhood (ISAAC) Steering Committee. Lancet, 1998. 
351(9111): p. 1225-32. 
6. van den Akker-van Marle, M.E., J. Bruil, and S.B. Detmar, Evaluation of cost of 
disease: assessing the burden to society of asthma in children in the European 
Union. Allergy, 2005. 60(2): p. 140-9. 
7. Asthma UK, Asthma Risk for Young Children, Audit 1999/2000, Retrived Dec. 
2007, from www.asthma.org.uk 
8. Godard, P., P. Chanez, L. Siraudin, N. Nicoloyannis, and G. Duru, Costs of 
asthma are correlated with severity: a 1-yr prospective study. Eur Respir J, 2002. 
19(1): p. 61-7. 
9. GINA report, Global Strategy for Asthma Management and Prevention 2006. 
Retrived Dec. 2007 from www.ginasthma.org 
10. Pizzichini, M.M., T.A. Popov, A. Efthimiadis, P. Hussack, S. Evans, E. Pizzichini, 
J. Dolovich, and F.E. Hargreave, Spontaneous and induced sputum to measure 
indices of airway inflammation in asthma. Am J Respir Crit Care Med, 1996. 
154(4 Pt 1): p. 866-9. 
11. Kharitonov, S., K. Alving, and P.J. Barnes, Exhaled and nasal nitric oxide 
measurements: recommendations. The European Respiratory Society Task 
Force. Eur Respir J, 1997. 10(7): p. 1683-93. 
12. Horvath, I. and P.J. Barnes, Exhaled monoxides in asymptomatic atopic 
subjects. Clin Exp Allergy, 1999. 29(9): p. 1276-80. 
13. Duse, M., F. Donato, V. Porteri, F. Pirali, V. Spinoni, C. Tosoni, M. Vettore, and 
C. Lombardi, High prevalence of atopy, but not of asthma, among children in an 
industrialized area in North Italy: the role of familial and environmental factors--a 
population-based study. Pediatr Allergy Immunol, 2007. 18(3): p. 201-8. 
14. Custovic, A., S.C. Taggart, H.C. Francis, M.D. Chapman, and A. Woodcock, 
Exposure to house dust mite allergens and the clinical activity of asthma. J 
Allergy Clin Immunol, 1996. 98(1): p. 64-72. 
15. Gelber, L.E., L.H. Seltzer, J.K. Bouzoukis, S.M. Pollart, M.D. Chapman, and T.A. 
Platts-Mills, Sensitization and exposure to indoor allergens as risk factors for 
asthma among patients presenting to hospital. Am Rev Respir Dis, 1993. 147(3): 
p. 573-8. 
                                                                                                                                        References 
 
249 
16. Djukanovic, R., I. Feather, C. Gratziou, A. Walls, D. Peroni, P. Bradding, M. 
Judd, P.H. Howarth, and S.T. Holgate, Effect of natural allergen exposure during 
the grass pollen season on airways inflammatory cells and asthma symptoms. 
Thorax, 1996. 51(6): p. 575-81. 
17. van der Zee, S., G. Hoek, H.M. Boezen, J.P. Schouten, J.H. van Wijnen, and B. 
Brunekreef, Acute effects of urban air pollution on respiratory health of children 
with and without chronic respiratory symptoms. Occup Environ Med, 1999. 
56(12): p. 802-12. 
18. Kesten, S., J. Szalai, and B. Dzyngel, Air quality and the frequency of emergency 
room visits for asthma. Ann Allergy Asthma Immunol, 1995. 74(3): p. 269-73. 
19. Chilmonczyk, B.A., L.M. Salmun, K.N. Megathlin, L.M. Neveux, G.E. Palomaki, 
G.J. Knight, A.J. Pulkkinen, and J.E. Haddow, Association between exposure to 
environmental tobacco smoke and exacerbations of asthma in children. N Engl J 
Med, 1993. 328(23): p. 1665-9. 
20. Mapp, C.E., P. Boschetto, P. Maestrelli, and L.M. Fabbri, Occupational asthma. 
Am J Respir Crit Care Med, 2005. 172(3): p. 280-305. 
21. Suman, O.E., K.C. Beck, M.A. Babcock, D.F. Pegelow, and A.W. Reddan, 
Airway obstruction during exercise and isocapnic hyperventilation in asthmatic 
subjects. J Appl Physiol, 1999. 87(3): p. 1107-13. 
22. Szczeklik, A. and D.D. Stevenson, Aspirin-induced asthma: advances in 
pathogenesis and management. J Allergy Clin Immunol, 1999. 104(1): p. 5-13. 
23. Lieberman, D., S. Printz, M. Ben-Yaakov, Z. Lazarovich, B. Ohana, M.G. 
Friedman, B. Dvoskin, M. Leinonen, and I. Boldur, Atypical pathogen infection in 
adults with acute exacerbation of bronchial asthma. Am J Respir Crit Care Med, 
2003. 167(3): p. 406-10. 
24. Cunningham, A.F., S.L. Johnston, S.A. Julious, F.C. Lampe, and M.E. Ward, 
Chronic Chlamydia pneumoniae infection and asthma exacerbations in children. 
Eur Respir J, 1998. 11(2): p. 345-9. 
25. Freymuth, F., A. Vabret, J. Brouard, F. Toutain, R. Verdon, J. Petitjean, S. 
Gouarin, J.F. Duhamel, and B. Guillois, Detection of viral, Chlamydia 
pneumoniae and Mycoplasma pneumoniae infections in exacerbations of asthma 
in children. J Clin Virol, 1999. 13(3): p. 131-9. 
26. Atmar, R.L., E. Guy, K.K. Guntupalli, J.L. Zimmerman, V.D. Bandi, B.D. Baxter, 
and S.B. Greenberg, Respiratory tract viral infections in inner-city asthmatic 
adults. Arch Intern Med, 1998. 158(22): p. 2453-9. 
27. Green, R.M., A. Custovic, G. Sanderson, J. Hunter, S.L. Johnston, and A. 
Woodcock, Synergism between allergens and viruses and risk of hospital 
admission with asthma: case-control study. BMJ, 2002. 324(7340): p. 763. 
28. Murray, C.S., G. Poletti, T. Kebadze, J. Morris, A. Woodcock, S.L. Johnston, and 
A. Custovic, A study of modifiable risk factors for asthma exacerbations: virus 
infection and allergen exposure synergistically increase risk of asthma 
hospitalization in children. Thorax, 2005: p. in press. 
29. Chauhan, A.J., H.M. Inskip, C.H. Linaker, S. Smith, J. Schreiber, S.L. Johnston, 
and S.T. Holgate, Personal exposure to nitrogen dioxide (NO2) and the severity 
of virus-induced asthma in children. Lancet, 2003. 361(9373): p. 1939-44. 
30. Higham, J., K. Venables, E. Kupek, and M. Bajekal, Asthma and thunderstorms: 
description of an epidemic in general practice in Britain using data from a 
doctors' deputising service in the UK. J Epidemiol Community Health, 1997. 
51(3): p. 233-8. 
                                                                                                                                        References 
 
250 
31. Nicholson, K.G., J. Kent, and D.C. Ireland, Respiratory viruses and 
exacerbations of asthma in adults. Bmj, 1993. 307(6910): p. 982-6. 
32. Johnston, S.L., P.K. Pattemore, G. Sanderson, S. Smith, F. Lampe, L. Josephs, 
P. Symington, S. O'Toole, S.H. Myint, D.A. Tyrrell, and S.T. Holgate, Community 
study of role of viral infections in exacerbations of asthma in 9-11 year old 
children. Bmj, 1995. 310(6989): p. 1225-9. 
33. Adcock, I.M., Molecular mechanisms of glucocorticosteroid actions. Pulm 
Pharmacol Ther, 2000. 13(3): p. 115-26. 
34. Wang, J., Z. Zhu, R. Nolfo, and J.A. Elias, Dexamethasone regulation of lung 
epithelial cell and fibroblast interleukin-11 production. Am J Physiol, 1999. 276(1 
Pt 1): p. L175-85. 
35. Papi, A., N.G. Papadopoulos, K. Degitz, S.T. Holgate, and S.L. Johnston, 
Corticosteroids inhibit rhinovirus-induced intercellular adhesion molecule-1 up-
regulation and promoter activation on respiratory epithelial cells. J Allergy Clin 
Immunol, 2000. 105(2 Pt 1): p. 318-26. 
36. Edwards, M.R., M.W. Johnson, and S.L. Johnston, Combination Therapy: 
Synergistic Suppression of Virus Induced Chemokines in Airway Epithelial Cells. 
Am J Respir Cell Mol Biol, 2006. 34: p. 616-624. 
37. Edwards, M.R., J. Haas, R.A. Panettieri, Jr., M. Johnson, and S.L. Johnston, 
Corticosteroids and beta2 agonists differentially regulate rhinovirus-induced 
interleukin-6 via distinct Cis-acting elements. J Biol Chem, 2007. 282(21): p. 
15366-75. 
38. Grunberg, K., R.F. Sharon, J.K. Sont, J.C. In 't Veen, W.A. Van Schadewijk, E.P. 
De Klerk, C.R. Dick, J.H. Van Krieken, and P.J. Sterk, Rhinovirus-induced airway 
inflammation in asthma: effect of treatment with inhaled corticosteroids before 
and during experimental infection. Am J Respir Crit Care Med, 2001. 164(10 Pt 
1): p. 1816-22. 
39. Pauwels, R.A., S. Pedersen, W.W. Busse, W.C. Tan, Y.Z. Chen, S.V. Ohlsson, 
A. Ullman, C.J. Lamm, and P.M. O'Byrne, Early intervention with budesonide in 
mild persistent asthma: a randomised, double-blind trial. Lancet, 2003. 
361(9363): p. 1071-6. 
40. Harrison, T.W., J. Oborne, S. Newton, and A.E. Tattersfield, Doubling the dose 
of inhaled corticosteroid to prevent asthma exacerbations: randomised controlled 
trial. Lancet, 2004. 363(9405): p. 271-5. 
41. Johnston, N.W., S.L. Johnston, J.M. Duncan, J.M. Greene, T. Kebadze, P.K. 
Keith, M. Roy, S. Waserman, and M.R. Sears, The September epidemic of 
asthma exacerbations in children: a search for etiology. J Allergy Clin Immunol, 
2005. 115(1): p. 132-8. 
42. Murray, C.S., G. Poletti, T. Kebadze, J. Morris, A. Woodcock, S.L. Johnston, and 
A. Custovic, Study of modifiable risk factors for asthma exacerbations: virus 
infection and allergen exposure increase the risk of asthma hospital admissions 
in children. Thorax, 2006. 61(5): p. 376-82. 
43. McKean, M. and F. Ducharme. Inhaled steroids for episodic viral wheeze of 
childhood. Chochrane Database of Systematic Reviews, 2000. 
44. Wilson, N., K. Sloper, and M. Silverman, Effect of continuous treatment with 
topical corticosteroid on episodic viral wheeze in preschool children. Arch Dis 
Child, 1995. 72(4): p. 317-20. 
45. Doull, I.J., F.C. Lampe, S. Smith, J. Schreiber, N.J. Freezer, and S.T. Holgate, 
Effect of inhaled corticosteroids on episodes of wheezing associated with viral 
                                                                                                                                        References 
 
251 
infection in school age children: randomised double blind placebo controlled trial. 
Bmj, 1997. 315(7112): p. 858-62. 
46. Spoelstra, F.M., D.S. Postma, H. Hovenga, J.A. Noordhoek, and H.F. Kauffman, 
Additive anti-inflammatory effect of formoterol and budesonide on human lung 
fibroblasts. Thorax, 2002. 57(3): p. 237-41. 
47. Korn, S.H., A. Jerre, and R. Brattsand, Effects of formoterol and budesonide on 
GM-CSF and IL-8 secretion by triggered human bronchial epithelial cells. Eur 
Respir J, 2001. 17(6): p. 1070-7. 
48. Pauwels, R.A., C.G. Lofdahl, D.S. Postma, A.E. Tattersfield, P. O'Byrne, P.J. 
Barnes, and A. Ullman, Effect of inhaled formoterol and budesonide on 
exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy 
(FACET) International Study Group. N Engl J Med, 1997. 337(20): p. 1405-11. 
49. O'Byrne, P.M., H. Bisgaard, P.P. Godard, M. Pistolesi, M. Palmqvist, Y. Zhu, T. 
Ekstrom, and E.D. Bateman, Budesonide/formoterol combination therapy as both 
maintenance and reliever medication in asthma. Am J Respir Crit Care Med, 
2005. 171(2): p. 129-36. 
50. Lundborg, M., S. Wille, L. Bjermer, B. Tilling, M. Lundgren, G. Telg, T. Ekstrom, 
and O. Selroos, Maintenance plus reliever budesonide/formoterol compared with 
a higher maintenance dose of budesonide/formoterol plus formoterol as reliever 
in asthma: an efficacy and cost-effectiveness study. Curr Med Res Opin, 2006. 
22(5): p. 809-21. 
51. Corne, J.M., C. Marshall, S. Smith, J. Schreiber, G. Sanderson, S.T. Holgate, 
and S.L. Johnston, Frequency, severity, and duration of rhinovirus infections in 
asthmatic and non-asthmatic individuals: a longitudinal cohort study. Lancet, 
2002. 359(9309): p. 831-4. 
52. Beasley, R., E.D. Coleman, Y. Hermon, P.E. Holst, T.V. O'Donnell, and M. 
Tobias, Viral respiratory tract infection and exacerbations of asthma in adult 
patients. Thorax, 1988. 43(9): p. 679-83. 
53. Grissell, T.V., H. Powell, D.R. Shafren, M.J. Boyle, M.J. Hensley, P.D. Jones, 
B.F. Whitehead, and P.G. Gibson, Interleukin-10 gene expression in acute virus-
induced asthma. Am J Respir Crit Care Med, 2005. 172(4): p. 433-9. 
54. Kling, S., H. Donninger, Z. Williams, J. Vermeulen, E. Weinberg, K. Latiff, R. 
Ghildyal, and P. Bardin, Persistence of rhinovirus RNA after asthma 
exacerbation in children. Clin Exp Allergy, 2005. 35(5): p. 672-8. 
55. Heymann, P.W., H.T. Carper, D.D. Murphy, T.A. Platts-Mills, J. Patrie, A.P. 
McLaughlin, E.A. Erwin, M.S. Shaker, M. Hellems, J. Peerzada, F.G. Hayden, 
T.K. Hatley, and R. Chamberlain, Viral infections in relation to age, atopy, and 
season of admission among children hospitalized for wheezing. J Allergy Clin 
Immunol, 2004. 114(2): p. 239-47. 
56. Rakes, G.P., E. Arruda, J.M. Ingram, G.E. Hoover, J.C. Zambrano, F.G. Hayden, 
T.A. Platts-Mills, and P.W. Heymann, Rhinovirus and respiratory syncytial virus 
in wheezing children requiring emergency care. IgE and eosinophil analyses. Am 
J Respir Crit Care Med, 1999. 159(3): p. 785-90. 
57. Freymuth, F., A. Vabret, F. Galateau-Salle, J. Ferey, G. Eugene, J. Petitjean, E. 
Gennetay, J. Brouard, M. Jokik, J.F. Duhamel, and B. Guillois, Detection of 
respiratory syncytial virus, parainfluenzavirus 3, adenovirus and rhinovirus 
sequences in respiratory tract of infants by polymerase chain reaction and 
hybridization. Clin Diagn Virol, 1997. 8(1): p. 31-40. 
58. Weigl, J.A., W. Puppe, B. Grondahl, and H.J. Schmitt, Epidemiological 
investigation of nine respiratory pathogens in hospitalized children in Germany 
                                                                                                                                        References 
 
252 
using multiplex reverse-transcriptase polymerase chain reaction. Eur J Clin 
Microbiol Infect Dis, 2000. 19(5): p. 336-43. 
59. Legg, J.P., J.A. Warner, S.L. Johnston, and J.O. Warner, Frequency of detection 
of picornaviruses and seven other respiratory pathogens in infants. Pediatr Infect 
Dis J, 2005. 24(7): p. 611-6. 
60. Kusel, M.M., N.H. de Klerk, P.G. Holt, T. Kebadze, S.L. Johnston, and P.D. Sly, 
Role of respiratory viruses in acute upper and lower respiratory tract illness in the 
first year of life: a birth cohort study. Pediatr Infect Dis J, 2006. 25(8): p. 680-6. 
61. Wark, P.A., S.L. Johnston, I. Moric, J.L. Simpson, M.J. Hensley, and P.G. 
Gibson, Neutrophil degranulation and cell lysis is associated with clinical severity 
in virus-induced asthma. Eur Respir J, 2002. 19(1): p. 68-75. 
62. Monto, A.S., The seasonality of rhinovirus infections and its implications for 
clinical recognition. Clin Ther, 2002. 24(12): p. 1987-97. 
63. Arruda, E., A. Pitkaranta, T.J. Witek, Jr., C.A. Doyle, and F.G. Hayden, 
Frequency and natural history of rhinovirus infections in adults during autumn. J 
Clin Microbiol, 1997. 35(11): p. 2864-8. 
64. Rossmann, M.G., E. Arnold, J.W. Erickson, E.A. Frankenberger, J.P. Griffith, 
H.J. Hecht, J.E. Johnson, G. Kamer, M. Luo, A.G. Mosser, and et al., Structure 
of a human common cold virus and functional relationship to other 
picornaviruses. Nature, 1985. 317(6033): p. 145-53. 
65. Rossmann, M.G. and A.C. Palmenberg, Conservation of the putative receptor 
attachment site in picornaviruses. Virology, 1988. 164(2): p. 373-82. 
66. Rossmann, M.G., The canyon hypothesis. Viral Immunol, 1989. 2(3): p. 143-61. 
67. Colonno, R.J., J.H. Condra, S. Mizutani, P.L. Callahan, M.E. Davies, and M.A. 
Murcko, Evidence for the direct involvement of the rhinovirus canyon in receptor 
binding. Proc Natl Acad Sci U S A, 1988. 85(15): p. 5449-53. 
68. Johnston, S.L., P.G. Bardin, and P.K. Pattemore, Viruses as precipitants of 
asthma symptoms. III. Rhinoviruses: molecular biology and prospects for future 
intervention. Clin Exp Allergy, 1993. 23(4): p. 237-46. 
69. Belsham, G.J. and N. Sonenberg, RNA-protein interactions in regulation of 
picornavirus RNA translation. Microbiol Rev, 1996. 60(3): p. 499-511. 
70. Greve, J.M., G. Davis, A.M. Meyer, C.P. Forte, S.C. Yost, C.W. Marlor, M.E. 
Kamarck, and A. McClelland, The major human rhinovirus receptor is ICAM-1. 
Cell, 1989. 56(5): p. 839-47. 
71. Staunton, D.E., V.J. Merluzzi, R. Rothlein, R. Barton, S.D. Marlin, and T.A. 
Springer, A cell adhesion molecule, ICAM-1, is the major surface receptor for 
rhinoviruses. Cell, 1989. 56(5): p. 849-53. 
72. Marlovits, T.C., T. Zechmeister, H. Schwihla, B. Ronacher, and D. Blaas, 
Recombinant soluble low-density lipoprotein receptor fragment inhibits common 
cold infection. J Mol Recognit, 1998. 11(1-6): p. 49-51. 
73. Marlovits, T.C., C. Abrahamsberg, and D. Blaas, Very-low-density lipoprotein 
receptor fragment shed from HeLa cells inhibits human rhinovirus infection. J 
Virol, 1998. 72(12): p. 10246-50. 
74. Nurani, G., B. Lindqvist, and J.M. Casasnovas, Receptor priming of major group 
human rhinoviruses for uncoating and entry at mild low-pH environments. J Virol, 
2003. 77(22): p. 11985-91. 
75. Bayer, N., D. Schober, E. Prchla, R.F. Murphy, D. Blaas, and R. Fuchs, Effect of 
bafilomycin A1 and nocodazole on endocytic transport in HeLa cells: implications 
for viral uncoating and infection. J Virol, 1998. 72(12): p. 9645-55. 
                                                                                                                                        References 
 
253 
76. Suzuki, T., M. Yamaya, K. Sekizawa, M. Hosoda, N. Yamada, S. Ishizuka, K. 
Nakayama, M. Yanai, Y. Numazaki, and H. Sasaki, Bafilomycin A(1) inhibits 
rhinovirus infection in human airway epithelium: effects on endosome and ICAM-
1. Am J Physiol Lung Cell Mol Physiol, 2001. 280(6): p. L1115-27. 
77. Kim, J., S.P. Sanders, E.S. Siekierski, V. Casolaro, and D. Proud, Role of NF-
kappa B in cytokine production induced from human airway epithelial cells by 
rhinovirus infection. J Immunol, 2000. 165(6): p. 3384-92. 
78. Subauste, M.C., D.B. Jacoby, S.M. Richards, and D. Proud, Infection of a human 
respiratory epithelial cell line with rhinovirus. Induction of cytokine release and 
modulation of susceptibility to infection by cytokine exposure. J Clin Invest, 1995. 
96(1): p. 549-57. 
79. Papadopoulos, N.G., A. Papi, J. Meyer, L.A. Stanciu, S. Salvi, S.T. Holgate, and 
S.L. Johnston, Rhinovirus infection up-regulates eotaxin and eotaxin-2 
expression in bronchial epithelial cells. Clin Exp Allergy, 2001. 31(7): p. 1060-6. 
80. Griego, S.D., C.B. Weston, J.L. Adams, R. Tal-Singer, and S.B. Dillon, Role of 
p38 mitogen-activated protein kinase in rhinovirus-induced cytokine production 
by bronchial epithelial cells. J Immunol, 2000. 165(9): p. 5211-20. 
81. Johnston, S.L., A. Papi, P.J. Bates, J.G. Mastronarde, M.M. Monick, and G.W. 
Hunninghake, Low grade rhinovirus infection induces a prolonged release of IL-8 
in pulmonary epithelium. J Immunol, 1998. 160(12): p. 6172-81. 
82. Zhu, Z., W. Tang, J.M. Gwaltney, Jr., Y. Wu, and J.A. Elias, Rhinovirus 
stimulation of interleukin-8 in vivo and in vitro: role of NF-kappaB. Am J Physiol, 
1997. 273(4 Pt 1): p. L814-24. 
83. Schroth, M.K., E. Grimm, P. Frindt, D.M. Galagan, S.I. Konno, R. Love, and J.E. 
Gern, Rhinovirus replication causes RANTES production in primary bronchial 
epithelial cells. Am J Respir Cell Mol Biol, 1999. 20(6): p. 1220-8. 
84. Donninger, H., R. Glashoff, H.M. Haitchi, J.A. Syce, R. Ghildyal, E. van 
Rensburg, and P.G. Bardin, Rhinovirus induction of the CXC chemokine 
epithelial-neutrophil activating peptide-78 in bronchial epithelium. J Infect Dis, 
2003. 187(11): p. 1809-17. 
85. de Kluijver, J., K. Grunberg, D. Pons, E.P. de Klerk, C.R. Dick, P.J. Sterk, and 
P.S. Hiemstra, Interleukin-1beta and interleukin-1ra levels in nasal lavages 
during experimental rhinovirus infection in asthmatic and non-asthmatic subjects. 
Clin Exp Allergy, 2003. 33(10): p. 1415-8. 
86. Fleming, H.E., F.F. Little, D. Schnurr, P.C. Avila, H. Wong, J. Liu, S. Yagi, and 
H.A. Boushey, Rhinovirus-16 colds in healthy and in asthmatic subjects: similar 
changes in upper and lower airways. Am J Respir Crit Care Med, 1999. 160(1): 
p. 100-8. 
87. Grunberg, K., H.H. Smits, M.C. Timmers, E.P. de Klerk, R.J. Dolhain, E.C. Dick, 
P.S. Hiemstra, and P.J. Sterk, Experimental rhinovirus 16 infection. Effects on 
cell differentials and soluble markers in sputum in asthmatic subjects. Am J 
Respir Crit Care Med, 1997. 156(2 Pt 1): p. 609-16. 
88. Pizzichini, M.M., E. Pizzichini, A. Efthimiadis, A.J. Chauhan, S.L. Johnston, P. 
Hussack, J. Mahony, J. Dolovich, and F.E. Hargreave, Asthma and natural colds. 
Inflammatory indices in induced sputum: a feasibility study. Am J Respir Crit 
Care Med, 1998. 158(4): p. 1178-84. 
89. Norzila, M.Z., K. Fakes, R.L. Henry, J. Simpson, and P.G. Gibson, Interleukin-8 
secretion and neutrophil recruitment accompanies induced sputum eosinophil 
activation in children with acute asthma. Am J Respir Crit Care Med, 2000. 161(3 
Pt 1): p. 769-74. 
                                                                                                                                        References 
 
254 
90. Turner, R.B., K.W. Weingand, C.H. Yeh, and D.W. Leedy, Association between 
interleukin-8 concentration in nasal secretions and severity of symptoms of 
experimental rhinovirus colds. Clin Infect Dis, 1998. 26(4): p. 840-6. 
91. Spurrell, J.C., S. Wiehler, R.S. Zaheer, S.P. Sanders, and D. Proud, Human 
Airway Epithelial Cells Produce Ip-10 (Cxcl10) in Vitro and in Vivo Upon 
Rhinovirus Infection. Am J Physiol Lung Cell Mol Physiol, 2005. 289: p. 85-95. 
92. Teran, L.M., M.C. Seminario, J.K. Shute, A. Papi, S.J. Compton, J.L. Low, G.J. 
Gleich, and S.L. Johnston, RANTES, macrophage-inhibitory protein 1alpha, and 
the eosinophil product major basic protein are released into upper respiratory 
secretions during virus-induced asthma exacerbations in children. J Infect Dis, 
1999. 179(3): p. 677-81. 
93. Wark, P.A., F. Bucchieri, S.L. Johnston, P.G. Gibson, L. Hamilton, J. Mimica, G. 
Zummo, S.T. Holgate, J. Attia, A. Thakkinstian, and D.E. Davies, IFN-gamma-
induced protein 10 is a novel biomarker of rhinovirus-induced asthma 
exacerbations. J Allergy Clin Immunol, 2007. 120(3): p. 586-93. 
94. Gabay, C., Interleukin-6 and chronic inflammation. Arthritis Res Ther, 2006. 8 
Suppl 2: p. S3. 
95. Zhu, Z., W. Tang, A. Ray, Y. Wu, O. Einarsson, M.L. Landry, J. Gwaltney, Jr., 
and J.A. Elias, Rhinovirus stimulation of interleukin-6 in vivo and in vitro. 
Evidence for nuclear factor kappa B-dependent transcriptional activation. J Clin 
Invest, 1996. 97(2): p. 421-30. 
96. Einarsson, O., G.P. Geba, Z. Zhu, M. Landry, and J.A. Elias, Interleukin-11: 
stimulation in vivo and in vitro by respiratory viruses and induction of airways 
hyperresponsiveness. J Clin Invest, 1996. 97(4): p. 915-24. 
97. Yin, T.G., P. Schendel, and Y.C. Yang, Enhancement of in vitro and in vivo 
antigen-specific antibody responses by interleukin 11. J Exp Med, 1992. 175(1): 
p. 211-6. 
98. Volonaki, E., S. Psarras, P. Xepapadaki, D. Psomali, D. Gourgiotis, and N.G. 
Papadopoulos, Synergistic effects of fluticasone propionate and salmeterol on 
inhibiting rhinovirus-induced epithelial production of remodelling-associated 
growth factors. Clin Exp Allergy, 2006. 36(10): p. 1268-73. 
99. He, S.H., J. Zheng, and M.K. Duan, Induction of mucin secretion from human 
bronchial tissue and epithelial cells by rhinovirus and lipopolysaccharide. Acta 
Pharmacol Sin, 2004. 25(9): p. 1176-81. 
100. Inoue, D., M. Yamaya, H. Kubo, T. Sasaki, M. Hosoda, M. Numasaki, Y. 
Tomioka, H. Yasuda, K. Sekizawa, H. Nishimura, and H. Sasaki, Mechanisms of 
mucin production by rhinovirus infection in cultured human airway epithelial cells. 
Respir Physiol Neurobiol, 2006. 154(3): p. 484-99. 
101. Papi, A. and S.L. Johnston, Rhinovirus infection induces expression of its own 
receptor intercellular adhesion molecule 1 (ICAM-1) via increased NF-kappaB-
mediated transcription. J Biol Chem, 1999. 274(14): p. 9707-20. 
102. Papi, A. and S.L. Johnston, Respiratory epithelial cell expression of vascular cell 
adhesion molecule-1 and its up-regulation by rhinovirus infection via NF-kappaB 
and GATA transcription factors. J Biol Chem, 1999. 274(42): p. 30041-51. 
103. Winther, B., E. Arruda, T.J. Witek, S.D. Marlin, M.M. Tsianco, D.J. Innes, and 
F.G. Hayden, Expression of ICAM-1 in nasal epithelium and levels of soluble 
ICAM-1 in nasal lavage fluid during human experimental rhinovirus infection. 
Arch Otolaryngol Head Neck Surg, 2002. 128(2): p. 131-6. 
104. Grunberg, K., R.F. Sharon, T.J. Hiltermann, J.J. Brahim, E.C. Dick, P.J. Sterk, 
and J.H. Van Krieken, Experimental rhinovirus 16 infection increases intercellular 
                                                                                                                                        References 
 
255 
adhesion molecule-1 expression in bronchial epithelium of asthmatics regardless 
of inhaled steroid treatment. Clin Exp Allergy, 2000. 30(7): p. 1015-23. 
105. Broide, D.H., S. Sullivan, T. Gifford, and P. Sriramarao, Inhibition of pulmonary 
eosinophilia in P-selectin- and ICAM-1-deficient mice. Am J Respir Cell Mol Biol, 
1998. 18(2): p. 218-25. 
106. Chin, J.E., G.E. Winterrowd, C.A. Hatfield, J.R. Brashler, R.L. Griffin, S.L. 
Vonderfecht, K.P. Kolbasa, S.F. Fidler, K.L. Shull, R.F. Krzesicki, K.A. Ready, 
C.J. Dunn, L.M. Sly, N.D. Staite, and I.M. Richards, Involvement of intercellular 
adhesion molecule-1 in the antigen-induced infiltration of eosinophils and 
lymphocytes into the airways in a murine model of pulmonary inflammation. Am J 
Respir Cell Mol Biol, 1998. 18(2): p. 158-67. 
107. Humlicek, A.L., L. Pang, and D.C. Look, Modulation of airway inflammation and 
bacterial clearance by epithelial cell ICAM-1. Am J Physiol Lung Cell Mol 
Physiol, 2004. 287(3): p. L598-607. 
108. Elices, M.J., L. Osborn, Y. Takada, C. Crouse, S. Luhowskyj, M.E. Hemler, and 
R.R. Lobb, VCAM-1 on activated endothelium interacts with the leukocyte 
integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site. Cell, 
1990. 60(4): p. 577-84. 
109. Schleimer, R.P., S.A. Sterbinsky, J. Kaiser, C.A. Bickel, D.A. Klunk, K. Tomioka, 
W. Newman, F.W. Luscinskas, M.A. Gimbrone, Jr., B.W. McIntyre, and et al., IL-
4 induces adherence of human eosinophils and basophils but not neutrophils to 
endothelium. Association with expression of VCAM-1. J Immunol, 1992. 148(4): 
p. 1086-92. 
110. Jarjour, N.N., J.E. Gern, E.A. Kelly, C.A. Swenson, C.R. Dick, and W.W. Busse, 
The effect of an experimental rhinovirus 16 infection on bronchial lavage 
neutrophils. J Allergy Clin Immunol, 2000. 105(6 Pt 1): p. 1169-77. 
111. Fraenkel, D.J., P.G. Bardin, G. Sanderson, F. Lampe, S.L. Johnston, and S.T. 
Holgate, Lower airways inflammation during rhinovirus colds in normal and in 
asthmatic subjects. Am J Respir Crit Care Med, 1995. 151(3 Pt 1): p. 879-86. 
112. Teran, L.M., S.L. Johnston, J.M. Schroder, M.K. Church, and S.T. Holgate, Role 
of nasal interleukin-8 in neutrophil recruitment and activation in children with 
virus-induced asthma. Am J Respir Crit Care Med, 1997. 155(4): p. 1362-6. 
113. Qiu, Y., J. Zhu, V. Bandi, K.K. Guntupalli, and P.K. Jeffery, Bronchial mucosal 
inflammation and upregulation of CXC chemoattractants and receptors in severe 
exacerbations of asthma. Thorax, 2007. 62(6): p. 475-82. 
114. Shaw, D.E., M.A. Berry, B. Hargadon, S. McKenna, M.J. Shelley, R.H. Green, 
C.E. Brightling, A.J. Wardlaw, and I.D. Pavord, Association between neutrophilic 
airway inflammation and airflow limitation in adults with asthma. Chest, 2007. 
132(6): p. 1871-5. 
115. Carroll, N., S. Carello, C. Cooke, and A. James, Airway structure and 
inflammatory cells in fatal attacks of asthma. Eur Respir J, 1996. 9(4): p. 709-15. 
116. Sur, S., T.B. Crotty, G.M. Kephart, B.A. Hyma, T.V. Colby, C.E. Reed, L.W. Hunt, 
and G.J. Gleich, Sudden-onset fatal asthma. A distinct entity with few eosinophils 
and relatively more neutrophils in the airway submucosa? Am Rev Respir Dis, 
1993. 148(3): p. 713-9. 
117. Levy, D.E. and A. Garcia-Sastre, The virus battles: IFN induction of the antiviral 
state and mechanisms of viral evasion. Cytokine Growth Factor Rev, 2001. 12(2-
3): p. 143-56. 
118. Samuel, C.E., Antiviral actions of interferons. Clin Microbiol Rev, 2001. 14(4): p. 
778-809, table of contents. 
                                                                                                                                        References 
 
256 
119. Maher, S.G., A.L. Romero-Weaver, A.J. Scarzello, and A.M. Gamero, Interferon: 
cellular executioner or white knight? Curr Med Chem, 2007. 14(12): p. 1279-89. 
120. Haller, O., P. Staeheli, and G. Kochs, Interferon-induced Mx proteins in antiviral 
host defense. Biochimie, 2007. 89(6-7): p. 812-8. 
121. Chin, K.C. and P. Cresswell, Viperin (cig5), an IFN-inducible antiviral protein 
directly induced by human cytomegalovirus. Proc Natl Acad Sci U S A, 2001. 
98(26): p. 15125-30. 
122. Boehm, U., T. Klamp, M. Groot, and J.C. Howard, Cellular responses to 
interferon-gamma. Annu Rev Immunol, 1997. 15: p. 749-95. 
123. Sheppard, P., W. Kindsvogel, W. Xu, K. Henderson, S. Schlutsmeyer, T.E. 
Whitmore, R. Kuestner, U. Garrigues, C. Birks, J. Roraback, C. Ostrander, D. 
Dong, J. Shin, S. Presnell, B. Fox, B. Haldeman, E. Cooper, D. Taft, T. Gilbert, 
F.J. Grant, M. Tackett, W. Krivan, G. McKnight, C. Clegg, D. Foster, and K.M. 
Klucher, IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol, 
2003. 4(1): p. 63-8. 
124. Kotenko, S.V., G. Gallagher, V.V. Baurin, A. Lewis-Antes, M. Shen, N.K. Shah, 
J.A. Langer, F. Sheikh, H. Dickensheets, and R.P. Donnelly, IFN-lambdas 
mediate antiviral protection through a distinct class II cytokine receptor complex. 
Nat Immunol, 2003. 4(1): p. 69-77. 
125. Wark, P.A., S.L. Johnston, F. Bucchieri, R. Powell, S. Puddicombe, V. Laza-
Stanca, S.T. Holgate, and D.E. Davies, Asthmatic bronchial epithelial cells have 
a deficient innate immune response to infection with rhinovirus. J Exp Med, 
2005. 201(6): p. 937-47. 
126. Contoli, M., S.D. Message, V. Laza-Stanca, M.R. Edwards, P.A. Wark, N.W. 
Bartlett, T. Kebadze, P. Mallia, L.A. Stanciu, H.L. Parker, L. Slater, A. Lewis-
Antes, O.M. Kon, S.T. Holgate, D.E. Davies, S.V. Kotenko, A. Papi, and S.L. 
Johnston, Role of deficient type III interferon-lambda production in asthma 
exacerbations. Nat Med, 2006. 12(9): p. 1023-1026. 
127. M. Xatzipsalti, R.H., A. Ribbene, J.L. Sones, D. Bagmane, P.A. Wark, S.T. 
Holgate, D.E. Davies, Deficient Interferon Production Following Rhinovirus 
Infection of Differentiated Bronchial Epithelial Cells from Asthmatic Subjects, in 
American Thoracic Society. 2007: San Francisco. 
128. Bufe, A., K. Gehlhar, E. Grage-Griebenow, and M. Ernst, Atopic phenotype in 
children is associated with decreased virus-induced interferon-alpha release. Int 
Arch Allergy Immunol, 2002. 127(1): p. 82-8. 
129. Gehlhar, K., C. Bilitewski, K. Reinitz-Rademacher, G. Rohde, and A. Bufe, 
Impaired virus-induced interferon-alpha2 release in adult asthmatic patients. Clin 
Exp Allergy, 2006. 36(3): p. 331-7. 
130. Fujii, Y., T. Shimizu, M. Kusumoto, Y. Kyogoku, T. Taniguchi, and T. Hakoshima, 
Crystal structure of an IRF-DNA complex reveals novel DNA recognition and 
cooperative binding to a tandem repeat of core sequences. EMBO J, 1999. 
18(18): p. 5028-41. 
131. Paun, A. and P.M. Pitha, The IRF family, revisited. Biochimie, 2007. 89(6-7): p. 
744-53. 
132. Barnes, B.J., P.A. Moore, and P.M. Pitha, Virus-specific activation of a novel 
interferon regulatory factor, IRF-5, results in the induction of distinct interferon 
alpha genes. J Biol Chem, 2001. 276(26): p. 23382-90. 
133. Fujita, T., L.F. Reis, N. Watanabe, Y. Kimura, T. Taniguchi, and J. Vilcek, 
Induction of the transcription factor IRF-1 and interferon-beta mRNAs by 
                                                                                                                                        References 
 
257 
cytokines and activators of second-messenger pathways. Proc Natl Acad Sci U 
S A, 1989. 86(24): p. 9936-40. 
134. Miyamoto, M., T. Fujita, Y. Kimura, M. Maruyama, H. Harada, Y. Sudo, T. 
Miyata, and T. Taniguchi, Regulated expression of a gene encoding a nuclear 
factor, IRF-1, that specifically binds to IFN-beta gene regulatory elements. Cell, 
1988. 54(6): p. 903-13. 
135. Harada, H., T. Fujita, M. Miyamoto, Y. Kimura, M. Maruyama, A. Furia, T. Miyata, 
and T. Taniguchi, Structurally similar but functionally distinct factors, IRF-1 and 
IRF-2, bind to the same regulatory elements of IFN and IFN-inducible genes. 
Cell, 1989. 58(4): p. 729-39. 
136. Au, W.C., P.A. Moore, W. Lowther, Y.T. Juang, and P.M. Pitha, Identification of a 
member of the interferon regulatory factor family that binds to the interferon-
stimulated response element and activates expression of interferon-induced 
genes. Proc Natl Acad Sci U S A, 1995. 92(25): p. 11657-61. 
137. Marie, I., J.E. Durbin, and D.E. Levy, Differential viral induction of distinct 
interferon-alpha genes by positive feedback through interferon regulatory factor-
7. EMBO J, 1998. 17(22): p. 6660-9. 
138. Sato, M., N. Hata, M. Asagiri, T. Nakaya, T. Taniguchi, and N. Tanaka, Positive 
feedback regulation of type I IFN genes by the IFN-inducible transcription factor 
IRF-7. FEBS Lett, 1998. 441(1): p. 106-10. 
139. Honda, K., H. Yanai, H. Negishi, M. Asagiri, M. Sato, T. Mizutani, N. Shimada, Y. 
Ohba, A. Takaoka, N. Yoshida, and T. Taniguchi, IRF-7 is the master regulator 
of type-I interferon-dependent immune responses. Nature, 2005. 434(7034): p. 
772-7. 
140. Fujita, T., Y. Kimura, M. Miyamoto, E.L. Barsoumian, and T. Taniguchi, Induction 
of endogenous IFN-alpha and IFN-beta genes by a regulatory transcription 
factor, IRF-1. Nature, 1989. 337(6204): p. 270-2. 
141. Harada, H., K. Willison, J. Sakakibara, M. Miyamoto, T. Fujita, and T. Taniguchi, 
Absence of the type I IFN system in EC cells: transcriptional activator (IRF-1) 
and repressor (IRF-2) genes are developmentally regulated. Cell, 1990. 63(2): p. 
303-12. 
142. Reis, L.F., H. Harada, J.D. Wolchok, T. Taniguchi, and J. Vilcek, Critical role of a 
common transcription factor, IRF-1, in the regulation of IFN-beta and IFN-
inducible genes. EMBO J, 1992. 11(1): p. 185-93. 
143. Matsuyama, T., T. Kimura, M. Kitagawa, K. Pfeffer, T. Kawakami, N. Watanabe, 
T.M. Kundig, R. Amakawa, K. Kishihara, A. Wakeham, and et al., Targeted 
disruption of IRF-1 or IRF-2 results in abnormal type I IFN gene induction and 
aberrant lymphocyte development. Cell, 1993. 75(1): p. 83-97. 
144. Wathelet, M.G., C.H. Lin, B.S. Parekh, L.V. Ronco, P.M. Howley, and T. 
Maniatis, Virus infection induces the assembly of coordinately activated 
transcription factors on the IFN-beta enhancer in vivo. Mol Cell, 1998. 1(4): p. 
507-18. 
145. Lin, R., C. Heylbroeck, P.M. Pitha, and J. Hiscott, Virus-dependent 
phosphorylation of the IRF-3 transcription factor regulates nuclear translocation, 
transactivation potential, and proteasome-mediated degradation. Mol Cell Biol, 
1998. 18(5): p. 2986-96. 
146. Sato, M., N. Tanaka, N. Hata, E. Oda, and T. Taniguchi, Involvement of the IRF 
family transcription factor IRF-3 in virus-induced activation of the IFN-beta gene. 
FEBS Lett, 1998. 425(1): p. 112-6. 
                                                                                                                                        References 
 
258 
147. Yoneyama, M., W. Suhara, Y. Fukuhara, M. Fukuda, E. Nishida, and T. Fujita, 
Direct triggering of the type I interferon system by virus infection: activation of a 
transcription factor complex containing IRF-3 and CBP/p300. Embo J, 1998. 
17(4): p. 1087-95. 
148. Servant, M.J., N. Grandvaux, B.R. tenOever, D. Duguay, R. Lin, and J. Hiscott, 
Identification of the minimal phosphoacceptor site required for in vivo activation 
of interferon regulatory factor 3 in response to virus and double-stranded RNA. J 
Biol Chem, 2003. 278(11): p. 9441-7. 
149. Mori, M., M. Yoneyama, T. Ito, K. Takahashi, F. Inagaki, and T. Fujita, 
Identification of Ser-386 of interferon regulatory factor 3 as critical target for 
inducible phosphorylation that determines activation. J Biol Chem, 2004. 
279(11): p. 9698-702. 
150. Takahasi, K., N.N. Suzuki, M. Horiuchi, M. Mori, W. Suhara, Y. Okabe, Y. 
Fukuhara, H. Terasawa, S. Akira, T. Fujita, and F. Inagaki, X-ray crystal structure 
of IRF-3 and its functional implications. Nat Struct Biol, 2003. 10(11): p. 922-7. 
151. Sato, M., H. Suemori, N. Hata, M. Asagiri, K. Ogasawara, K. Nakao, T. Nakaya, 
M. Katsuki, S. Noguchi, N. Tanaka, and T. Taniguchi, Distinct and essential roles 
of transcription factors IRF-3 and IRF-7 in response to viruses for IFN-alpha/beta 
gene induction. Immunity, 2000. 13(4): p. 539-48. 
152. Juang, Y.T., W. Lowther, M. Kellum, W.C. Au, R. Lin, J. Hiscott, and P.M. Pitha, 
Primary activation of interferon A and interferon B gene transcription by 
interferon regulatory factor 3. Proc Natl Acad Sci U S A, 1998. 95(17): p. 9837-
42. 
153. Sharma, S., B.R. tenOever, N. Grandvaux, G.P. Zhou, R. Lin, and J. Hiscott, 
Triggering the interferon antiviral response through an IKK-related pathway. 
Science, 2003. 300(5622): p. 1148-51. 
154. Lin, R., C. Heylbroeck, P. Genin, P.M. Pitha, and J. Hiscott, Essential role of 
interferon regulatory factor 3 in direct activation of RANTES chemokine 
transcription. Mol Cell Biol, 1999. 19(2): p. 959-66. 
155. Ieki, K., S. Matsukura, F. Kokubu, T. Kimura, H. Kuga, M. Kawaguchi, M. Odaka, 
S. Suzuki, S. Watanabe, H. Takeuchi, R.P. Schleimer, and M. Adachi, Double-
stranded RNA activates RANTES gene transcription through co-operation of 
nuclear factor-kappaB and interferon regulatory factors in human airway 
epithelial cells. Clin Exp Allergy, 2004. 34(5): p. 745-52. 
156. Nakaya, T., M. Sato, N. Hata, M. Asagiri, H. Suemori, S. Noguchi, N. Tanaka, 
and T. Taniguchi, Gene induction pathways mediated by distinct IRFs during 
viral infection. Biochem Biophys Res Commun, 2001. 283(5): p. 1150-6. 
157. Grandvaux, N., M.J. Servant, B. tenOever, G.C. Sen, S. Balachandran, G.N. 
Barber, R. Lin, and J. Hiscott, Transcriptional profiling of interferon regulatory 
factor 3 target genes: direct involvement in the regulation of interferon-stimulated 
genes. J Virol, 2002. 76(11): p. 5532-9. 
158. Talon, J., C.M. Horvath, R. Polley, C.F. Basler, T. Muster, P. Palese, and A. 
Garcia-Sastre, Activation of interferon regulatory factor 3 is inhibited by the 
influenza A virus NS1 protein. J Virol, 2000. 74(17): p. 7989-96. 
159. Erlandsson, L., R. Blumenthal, M.L. Eloranta, H. Engel, G. Alm, S. Weiss, and T. 
Leanderson, Interferon-beta is required for interferon-alpha production in mouse 
fibroblasts. Curr Biol, 1998. 8(4): p. 223-6. 
160. Lin, R., Y. Mamane, and J. Hiscott, Multiple regulatory domains control IRF-7 
activity in response to virus infection. Journal of Biological Chemistry, 2000. 
275(44): p. 34320-7. 
                                                                                                                                        References 
 
259 
161. Zhang, L. and J.S. Pagano, Structure and function of IRF-7. J Interferon 
Cytokine Res, 2002. 22(1): p. 95-101. 
162. May, M.J. and S. Ghosh, Signal transduction through NF-kappa B. Immunol 
Today, 1998. 19(2): p. 80-8. 
163. Barnes, P.J. and M. Karin, Nuclear factor-kappaB: a pivotal transcription factor in 
chronic inflammatory diseases. N Engl J Med, 1997. 336(15): p. 1066-71. 
164. Xiao, G., A.B. Rabson, W. Young, G. Qing, and Z. Qu, Alternative pathways of 
NF-kappaB activation: a double-edged sword in health and disease. Cytokine 
Growth Factor Rev, 2006. 17(4): p. 281-93. 
165. Gagliardo, R., P. Chanez, M. Mathieu, A. Bruno, G. Costanzo, C. Gougat, I. 
Vachier, J. Bousquet, G. Bonsignore, and A.M. Vignola, Persistent activation of 
nuclear factor-kappaB signaling pathway in severe uncontrolled asthma. Am J 
Respir Crit Care Med, 2003. 168(10): p. 1190-8. 
166. Hart, L.A., V.L. Krishnan, I.M. Adcock, P.J. Barnes, and K.F. Chung, Activation 
and localization of transcription factor, nuclear factor-kappaB, in asthma. Am J 
Respir Crit Care Med, 1998. 158(5 Pt 1): p. 1585-92. 
167. Chu, W.M., D. Ostertag, Z.W. Li, L. Chang, Y. Chen, Y. Hu, B. Williams, J. 
Perrault, and M. Karin, JNK2 and IKKbeta are required for activating the innate 
response to viral infection. Immunity, 1999. 11(6): p. 721-31. 
168. Algarte, M., H. Nguyen, C. Heylbroeck, R. Lin, and J. Hiscott, IkappaB-mediated 
inhibition of virus-induced beta interferon transcription. J Virol, 1999. 73(4): p. 
2694-702. 
169. Wang, X., S. Hussain, E.J. Wang, M.O. Li, A. Garcia-Sastre, and A.A. Beg, Lack 
of essential role of NF-kappa B p50, RelA, and cRel subunits in virus-induced 
type 1 IFN expression. J Immunol, 2007. 178(11): p. 6770-6. 
170. Neznanov, N., K.M. Chumakov, L. Neznanova, A. Almasan, A.K. Banerjee, and 
A.V. Gudkov, Proteolytic cleavage of the p65-RelA subunit of NF-kappaB during 
poliovirus infection. J Biol Chem, 2005. 280(25): p. 24153-8. 
171. Wang, X., M. Li, H. Zheng, T. Muster, P. Palese, A.A. Beg, and A. Garcia-Sastre, 
Influenza A virus NS1 protein prevents activation of NF-kappaB and induction of 
alpha/beta interferon. J Virol, 2000. 74(24): p. 11566-73. 
172. Nelson, P.J., H.T. Kim, W.C. Manning, T.J. Goralski, and A.M. Krensky, Genomic 
organization and transcriptional regulation of the RANTES chemokine gene. J 
Immunol, 1993. 151(5): p. 2601-12. 
173. Chang, M.S., J. McNinch, R. Basu, and S. Simonet, Cloning and characterization 
of the human neutrophil-activating peptide (ENA-78) gene. J Biol Chem, 1994. 
269(41): p. 25277-82. 
174. Keates, A.C., S. Keates, J.H. Kwon, K.O. Arseneau, D.J. Law, L. Bai, J.L. 
Merchant, T.C. Wang, and C.P. Kelly, ZBP-89, Sp1, and nuclear factor-kappa B 
regulate epithelial neutrophil-activating peptide-78 gene expression in Caco-2 
human colonic epithelial cells. J Biol Chem, 2001. 276(47): p. 43713-22. 
175. Angel, P. and M. Karin, The role of Jun, Fos and the AP-1 complex in cell-
proliferation and transformation. Biochim Biophys Acta, 1991. 1072(2-3): p. 129-
57. 
176. Karin, M., The regulation of AP-1 activity by mitogen-activated protein kinases. J 
Biol Chem, 1995. 270(28): p. 16483-6. 
177. Hai, T. and T. Curran, Cross-family dimerization of transcription factors Fos/Jun 
and ATF/CREB alters DNA binding specificity. Proc Natl Acad Sci U S A, 1991. 
88(9): p. 3720-4. 
                                                                                                                                        References 
 
260 
178. Whitmarsh, A.J. and R.J. Davis, Transcription factor AP-1 regulation by mitogen-
activated protein kinase signal transduction pathways. J Mol Med, 1996. 74(10): 
p. 589-607. 
179. Ono, K. and J. Han, The p38 signal transduction pathway: activation and 
function. Cell Signal, 2000. 12(1): p. 1-13. 
180. Davis, R.J., Signal transduction by the JNK group of MAP kinases. Cell, 2000. 
103(2): p. 239-52. 
181. Ludwig, S., C. Ehrhardt, E.R. Neumeier, M. Kracht, U.R. Rapp, and S. Pleschka, 
Influenza virus-induced AP-1-dependent gene expression requires activation of 
the JNK signaling pathway. J Biol Chem, 2001. 276(24): p. 10990-8. 
182. Hoffmann, E., O. Dittrich-Breiholz, H. Holtmann, and M. Kracht, Multiple control 
of interleukin-8 gene expression. J Leukoc Biol, 2002. 72(5): p. 847-55. 
183. Hiura, T.S., S.J. Kempiak, and A.E. Nel, Activation of the human RANTES gene 
promoter in a macrophage cell line by lipopolysaccharide is dependent on stress-
activated protein kinases and the IkappaB kinase cascade: implications for 
exacerbation of allergic inflammation by environmental pollutants. Clin Immunol, 
1999. 90(3): p. 287-301. 
184. Casola, A., R.P. Garofalo, H. Haeberle, T.F. Elliott, R. Lin, M. Jamaluddin, and 
A.R. Brasier, Multiple cis regulatory elements control RANTES promoter activity 
in alveolar epithelial cells infected with respiratory syncytial virus. J Virol, 2001. 
75(14): p. 6428-39. 
185. Thanos, D. and T. Maniatis, The high mobility group protein HMG I(Y) is required 
for NF-kappa B-dependent virus induction of the human IFN-beta gene. Cell, 
1992. 71(5): p. 777-89. 
186. Thanos, D. and T. Maniatis, Identification of the rel family members required for 
virus induction of the human beta interferon gene. Mol Cell Biol, 1995. 15(1): p. 
152-64. 
187. Thanos, D. and T. Maniatis, Virus induction of human IFN beta gene expression 
requires the assembly of an enhanceosome. Cell, 1995. 83(7): p. 1091-100. 
188. Schafer, S.L., R. Lin, P.A. Moore, J. Hiscott, and P.M. Pitha, Regulation of type I 
interferon gene expression by interferon regulatory factor-3. J Biol Chem, 1998. 
273(5): p. 2714-20. 
189. Du, W. and T. Maniatis, An ATF/CREB binding site is required for virus induction 
of the human interferon beta gene [corrected]. Proc Natl Acad Sci U S A, 1992. 
89(6): p. 2150-4. 
190. Du, W., D. Thanos, and T. Maniatis, Mechanisms of transcriptional synergism 
between distinct virus-inducible enhancer elements. Cell, 1993. 74(5): p. 887-98. 
191. Goodbourn, S. and T. Maniatis, Overlapping positive and negative regulatory 
domains of the human beta-interferon gene. Proc Natl Acad Sci U S A, 1988. 
85(5): p. 1447-51. 
192. Garoufalis, E., I. Kwan, R. Lin, A. Mustafa, N. Pepin, A. Roulston, J. Lacoste, 
and J. Hiscott, Viral induction of the human beta interferon promoter: modulation 
of transcription by NF-kappa B/rel proteins and interferon regulatory factors. J 
Virol, 1994. 68(8): p. 4707-15. 
193. Yang, H., G. Ma, C.H. Lin, M. Orr, and M.G. Wathelet, Mechanism for 
transcriptional synergy between interferon regulatory factor (IRF)-3 and IRF-7 in 
activation of the interferon-beta gene promoter. European Journal of 
Biochemistry, 2004. 271(18): p. 3693-703. 
                                                                                                                                        References 
 
261 
194. Neish, A.S., M.A. Read, D. Thanos, R. Pine, T. Maniatis, and T. Collins, 
Endothelial interferon regulatory factor 1 cooperates with NF-kappa B as a 
transcriptional activator of vascular cell adhesion molecule 1. Mol Cell Biol, 1995. 
15(5): p. 2558-69. 
195. Lehn, D.A., T.S. Elton, K.R. Johnson, and R. Reeves, A conformational study of 
the sequence specific binding of HMG-I (Y) with the bovine interleukin-2 cDNA. 
Biochemistry International, 1988. 16(5): p. 963-71. 
196. Qin, B.Y., C. Liu, H. Srinath, S.S. Lam, J.J. Correia, R. Derynck, and K. Lin, 
Crystal structure of IRF-3 in complex with CBP.[see comment]. Structure, 2005. 
13(9): p. 1269-77. 
197. Perkins, N.D., L.K. Felzien, J.C. Betts, K. Leung, D.H. Beach, and G.J. Nabel, 
Regulation of NF-kappaB by cyclin-dependent kinases associated with the p300 
coactivator. Science, 1997. 275(5299): p. 523-7. 
198. Merika, M., A.J. Williams, G. Chen, T. Collins, and D. Thanos, Recruitment of 
CBP/p300 by the IFN beta enhanceosome is required for synergistic activation of 
transcription. Mol Cell, 1998. 1(2): p. 277-87. 
199. Bannister, A.J., T. Oehler, D. Wilhelm, P. Angel, and T. Kouzarides, Stimulation 
of c-Jun activity by CBP: c-Jun residues Ser63/73 are required for CBP induced 
stimulation in vivo and CBP binding in vitro. Oncogene, 1995. 11(12): p. 2509-
14. 
200. Kawasaki, H., J. Song, R. Eckner, H. Ugai, R. Chiu, K. Taira, Y. Shi, N. Jones, 
and K.K. Yokoyama, p300 and ATF-2 are components of the DRF complex, 
which regulates retinoic acid- and E1A-mediated transcription of the c-jun gene 
in F9 cells. Genes & Development, 1998. 12(2): p. 233-45. 
201. Panne, D., T. Maniatis, and S.C. Harrison, An atomic model of the interferon-
beta enhanceosome. Cell, 2007. 129(6): p. 1111-23. 
202. Onoguchi, K., M. Yoneyama, A. Takemura, S. Akira, T. Taniguchi, H. Namiki, 
and T. Fujita, Viral infections activate types I and III interferon genes through a 
common mechanism. J Biol Chem, 2007. 282(10): p. 7576-81. 
203. Osterlund, P.I., T.E. Pietila, V. Veckman, S.V. Kotenko, and I. Julkunen, IFN 
regulatory factor family members differentially regulate the expression of type III 
IFN (IFN-lambda) genes. J Immunol, 2007. 179(6): p. 3434-42. 
204. Kumar, A., J. Haque, J. Lacoste, J. Hiscott, and B.R. Williams, Double-stranded 
RNA-dependent protein kinase activates transcription factor NF-kappa B by 
phosphorylating I kappa B. Proc Natl Acad Sci U S A, 1994. 91(14): p. 6288-92. 
205. Zamanian-Daryoush, M., T.H. Mogensen, J.A. DiDonato, and B.R. Williams, NF-
kappaB activation by double-stranded-RNA-activated protein kinase (PKR) is 
mediated through NF-kappaB-inducing kinase and IkappaB kinase. Mol Cell Biol, 
2000. 20(4): p. 1278-90. 
206. Balachandran, S., P.C. Roberts, L.E. Brown, H. Truong, A.K. Pattnaik, D.R. 
Archer, and G.N. Barber, Essential role for the dsRNA-dependent protein kinase 
PKR in innate immunity to viral infection. Immunity, 2000. 13(1): p. 129-41. 
207. Yang, Y.L., L.F. Reis, J. Pavlovic, A. Aguzzi, R. Schafer, A. Kumar, B.R. 
Williams, M. Aguet, and C. Weissmann, Deficient signaling in mice devoid of 
double-stranded RNA-dependent protein kinase. Embo J, 1995. 14(24): p. 6095-
106. 
208. Posti, K., S. Leinonen, S. Tetri, S. Kottari, P. Viitala, O. Pelkonen, and H. Raunio, 
Modulation of murine phenobarbital-inducible CYP2A5, CYP2B10 and CYP1A 
enzymes by inhibitors of protein kinases and phosphatases. Eur J Biochem, 
1999. 264(1): p. 19-26. 
                                                                                                                                        References 
 
262 
209. Edwards, M.R., C.A. Hewson, V. Laza-Stanca, H.T. Lau, N. Mukaida, M.B. 
Hershenson, and S.L. Johnston, Protein kinase R, IkappaB kinase-beta and NF-
kappaB are required for human rhinovirus induced pro-inflammatory cytokine 
production in bronchial epithelial cells. Mol Immunol, 2006. 
210. Gern, J.E., D.A. French, K.A. Grindle, R.A. Brockman-Schneider, S. Konno, and 
W.W. Busse, Double-stranded RNA induces the synthesis of specific 
chemokines by bronchial epithelial cells. Am J Respir Cell Mol Biol, 2003. 28(6): 
p. 731-7. 
211. O'Neill, L.A. and A.G. Bowie, The family of five: TIR-domain-containing adaptors 
in Toll-like receptor signalling. Nat Rev Immunol, 2007. 7(5): p. 353-64. 
212. Guillot, L., R. Le Goffic, S. Bloch, N. Escriou, S. Akira, M. Chignard, and M. Si-
Tahar, Involvement of toll-like receptor 3 in the immune response of lung 
epithelial cells to double-stranded RNA and influenza A virus. J Biol Chem, 2005. 
280(7): p. 5571-80. 
213. Matsumoto, M., S. Kikkawa, M. Kohase, K. Miyake, and T. Seya, Establishment 
of a monoclonal antibody against human Toll-like receptor 3 that blocks double-
stranded RNA-mediated signaling. Biochem Biophys Res Commun, 2002. 
293(5): p. 1364-9. 
214. Oshiumi, H., M. Matsumoto, K. Funami, T. Akazawa, and T. Seya, TICAM-1, an 
adaptor molecule that participates in Toll-like receptor 3-mediated interferon-beta 
induction. Nat Immunol, 2003. 4(2): p. 161-7. 
215. Alexopoulou, L., A.C. Holt, R. Medzhitov, and R.A. Flavell, Recognition of 
double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. 
Nature, 2001. 413(6857): p. 732-8. 
216. Fitzgerald, K.A., S.M. McWhirter, K.L. Faia, D.C. Rowe, E. Latz, D.T. Golenbock, 
A.J. Coyle, S.M. Liao, and T. Maniatis, IKKepsilon and TBK1 are essential 
components of the IRF3 signaling pathway. Nat Immunol, 2003. 4(5): p. 491-6. 
217. Duffy, K.E., R.J. Lamb, L.R. San Mateo, J.L. Jordan, G. Canziani, M. Brigham-
Burke, J. Korteweg, M. Cunningham, H.S. Beck, J. Carton, J. Giles-Komar, C. 
Duchala, R.T. Sarisky, and M.L. Mbow, Down modulation of human TLR3 
function by a monoclonal antibody. Cell Immunol, 2007. 248(2): p. 103-14. 
218. Yamamoto, M., S. Sato, H. Hemmi, K. Hoshino, T. Kaisho, H. Sanjo, O. 
Takeuchi, M. Sugiyama, M. Okabe, K. Takeda, and S. Akira, Role of adaptor 
TRIF in the MyD88-independent toll-like receptor signaling pathway. Science, 
2003. 301(5633): p. 640-3. 
219. Yamamoto, M., S. Sato, K. Mori, K. Hoshino, O. Takeuchi, K. Takeda, and S. 
Akira, Cutting edge: a novel Toll/IL-1 receptor domain-containing adapter that 
preferentially activates the IFN-beta promoter in the Toll-like receptor signaling. J 
Immunol, 2002. 169(12): p. 6668-72. 
220. Hoebe, K., X. Du, P. Georgel, E. Janssen, K. Tabeta, S.O. Kim, J. Goode, P. Lin, 
N. Mann, S. Mudd, K. Crozat, S. Sovath, J. Han, and B. Beutler, Identification of 
Lps2 as a key transducer of MyD88-independent TIR signalling. Nature, 2003. 
424(6950): p. 743-8. 
221. Sato, S., M. Sugiyama, M. Yamamoto, Y. Watanabe, T. Kawai, K. Takeda, and 
S. Akira, Toll/IL-1 receptor domain-containing adaptor inducing IFN-beta (TRIF) 
associates with TNF receptor-associated factor 6 and TANK-binding kinase 1, 
and activates two distinct transcription factors, NF-kappa B and IFN-regulatory 
factor-3, in the Toll-like receptor signaling. J Immunol, 2003. 171(8): p. 4304-10. 
                                                                                                                                        References 
 
263 
222. Jiang, Z., T.W. Mak, G. Sen, and X. Li, Toll-like receptor 3-mediated activation of 
NF-kappaB and IRF3 diverges at Toll-IL-1 receptor domain-containing adapter 
inducing IFN-beta. Proc Natl Acad Sci U S A, 2004. 101(10): p. 3533-8. 
223. Han, K.J., X. Su, L.G. Xu, L.H. Bin, J. Zhang, and H.B. Shu, Mechanisms of the 
TRIF-induced interferon-stimulated response element and NF-kappaB activation 
and apoptosis pathways. J Biol Chem, 2004. 279(15): p. 15652-61. 
224. Stack, J., I.R. Haga, M. Schroder, N.W. Bartlett, G. Maloney, P.C. Reading, K.A. 
Fitzgerald, G.L. Smith, and A.G. Bowie, Vaccinia virus protein A46R targets 
multiple Toll-like-interleukin-1 receptor adaptors and contributes to virulence. J 
Exp Med, 2005. 201(6): p. 1007-18. 
225. Harte, M.T., I.R. Haga, G. Maloney, P. Gray, P.C. Reading, N.W. Bartlett, G.L. 
Smith, A. Bowie, and L.A. O'Neill, The poxvirus protein A52R targets Toll-like 
receptor signaling complexes to suppress host defense. J Exp Med, 2003. 
197(3): p. 343-51. 
226. Ferreon, J.C., A.C. Ferreon, K. Li, and S.M. Lemon, Molecular determinants of 
TRIF proteolysis mediated by the hepatitis C virus NS3/4A protease. J Biol 
Chem, 2005. 280(21): p. 20483-92. 
227. Li, K., E. Foy, J.C. Ferreon, M. Nakamura, A.C. Ferreon, M. Ikeda, S.C. Ray, M. 
Gale, Jr., and S.M. Lemon, Immune evasion by hepatitis C virus NS3/4A 
protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. 
Proc Natl Acad Sci U S A, 2005. 102(8): p. 2992-7. 
228. Meylan, E., J. Curran, K. Hofmann, D. Moradpour, M. Binder, R. Bartenschlager, 
and J. Tschopp, Cardif is an adaptor protein in the RIG-I antiviral pathway and is 
targeted by hepatitis C virus. Nature, 2005. 437(7062): p. 1167-72. 
229. Lund, J.M., L. Alexopoulou, A. Sato, M. Karow, N.C. Adams, N.W. Gale, A. 
Iwasaki, and R.A. Flavell, Recognition of single-stranded RNA viruses by Toll-
like receptor 7. Proc Natl Acad Sci U S A, 2004. 101(15): p. 5598-603. 
230. Vollmer, J., R. Weeratna, P. Payette, M. Jurk, C. Schetter, M. Laucht, T. Wader, 
S. Tluk, M. Liu, H.L. Davis, and A.M. Krieg, Characterization of three CpG 
oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur J 
Immunol, 2004. 34(1): p. 251-62. 
231. Lee, J., T.H. Chuang, V. Redecke, L. She, P.M. Pitha, D.A. Carson, E. Raz, and 
H.B. Cottam, Molecular basis for the immunostimulatory activity of guanine 
nucleoside analogs: activation of Toll-like receptor 7. Proc Natl Acad Sci U S A, 
2003. 100(11): p. 6646-51. 
232. Diebold, S.S., T. Kaisho, H. Hemmi, S. Akira, and C. Reis e Sousa, Innate 
antiviral responses by means of TLR7-mediated recognition of single-stranded 
RNA. Science, 2004. 303(5663): p. 1529-31. 
233. de Bouteiller, O., E. Merck, U.A. Hasan, S. Hubac, B. Benguigui, G. Trinchieri, 
E.E. Bates, and C. Caux, Recognition of double-stranded RNA by human toll-like 
receptor 3 and downstream receptor signaling requires multimerization and an 
acidic pH. J Biol Chem, 2005. 280(46): p. 38133-45. 
234. Nishimura, M. and S. Naito, Tissue-specific mRNA expression profiles of human 
toll-like receptors and related genes. Biol Pharm Bull, 2005. 28(5): p. 886-92. 
235. Chuang, T.H. and R.J. Ulevitch, Cloning and characterization of a sub-family of 
human toll-like receptors: hTLR7, hTLR8 and hTLR9. Eur Cytokine Netw, 2000. 
11(3): p. 372-8. 
236. Hornung, V., S. Rothenfusser, S. Britsch, A. Krug, B. Jahrsdorfer, T. Giese, S. 
Endres, and G. Hartmann, Quantitative expression of toll-like receptor 1-10 
                                                                                                                                        References 
 
264 
mRNA in cellular subsets of human peripheral blood mononuclear cells and 
sensitivity to CpG oligodeoxynucleotides. J Immunol, 2002. 168(9): p. 4531-7. 
237. Kadowaki, N., S. Ho, S. Antonenko, R.W. Malefyt, R.A. Kastelein, F. Bazan, and 
Y.J. Liu, Subsets of human dendritic cell precursors express different toll-like 
receptors and respond to different microbial antigens. J Exp Med, 2001. 194(6): 
p. 863-9. 
238. An, H., H. Xu, Y. Yu, M. Zhang, R. Qi, X. Yan, S. Liu, W. Wang, Z. Guo, Z. Qin, 
and X. Cao, Up-regulation of TLR9 gene expression by LPS in mouse 
macrophages via activation of NF-kappaB, ERK and p38 MAPK signal pathways. 
Immunol Lett, 2002. 81(3): p. 165-9. 
239. Sha, Q., A.Q. Truong-Tran, J.R. Plitt, L.A. Beck, and R.P. Schleimer, Activation 
of airway epithelial cells by toll-like receptor agonists. Am J Respir Cell Mol Biol, 
2004. 31(3): p. 358-64. 
240. Lin, C.F., C.H. Tsai, C.H. Cheng, Y.S. Chen, F. Tournier, and T.H. Yeh, 
Expression of Toll-like receptors in cultured nasal epithelial cells. Acta 
Otolaryngol, 2007. 127(4): p. 395-402. 
241. Ritter, M., D. Mennerich, A. Weith, and P. Seither, Characterization of Toll-like 
receptors in primary lung epithelial cells: strong impact of the TLR3 ligand 
poly(I:C) on the regulation of Toll-like receptors, adaptor proteins and 
inflammatory response. J Inflamm (Lond), 2005. 2: p. 16. 
242. Homma, T., A. Kato, N. Hashimoto, J. Batchelor, M. Yoshikawa, S. Imai, H. 
Wakiguchi, H. Saito, and K. Matsumoto, Corticosteroid and cytokines 
synergistically enhance toll-like receptor 2 expression in respiratory epithelial 
cells. Am J Respir Cell Mol Biol, 2004. 31(4): p. 463-9. 
243. Lund, J., A. Sato, S. Akira, R. Medzhitov, and A. Iwasaki, Toll-like receptor 9-
mediated recognition of Herpes simplex virus-2 by plasmacytoid dendritic cells. J 
Exp Med, 2003. 198(3): p. 513-20. 
244. Krug, A., G.D. Luker, W. Barchet, D.A. Leib, S. Akira, and M. Colonna, Herpes 
simplex virus type 1 activates murine natural interferon-producing cells through 
toll-like receptor 9. Blood, 2004. 103(4): p. 1433-7. 
245. Yoneyama, M., M. Kikuchi, T. Natsukawa, N. Shinobu, T. Imaizumi, M. 
Miyagishi, K. Taira, S. Akira, and T. Fujita, The RNA helicase RIG-I has an 
essential function in double-stranded RNA-induced innate antiviral responses. 
Nat Immunol, 2004. 5(7): p. 730-7. 
246. Yoneyama, M., M. Kikuchi, K. Matsumoto, T. Imaizumi, M. Miyagishi, K. Taira, E. 
Foy, Y.M. Loo, M. Gale, Jr., S. Akira, S. Yonehara, A. Kato, and T. Fujita, Shared 
and Unique Functions of the DExD/H-Box Helicases RIG-I, MDA5, and LGP2 in 
Antiviral Innate Immunity. J Immunol, 2005. 175(5): p. 2851-8. 
247. Rothenfusser, S., N. Goutagny, G. DiPerna, M. Gong, B.G. Monks, A. 
Schoenemeyer, M. Yamamoto, S. Akira, and K.A. Fitzgerald, The RNA helicase 
Lgp2 inhibits TLR-independent sensing of viral replication by retinoic acid-
inducible gene-I. J Immunol, 2005. 175(8): p. 5260-8. 
248. Saito, T., R. Hirai, Y.M. Loo, D. Owen, C.L. Johnson, S.C. Sinha, S. Akira, T. 
Fujita, and M. Gale, Jr., Regulation of innate antiviral defenses through a shared 
repressor domain in RIG-I and LGP2. Proc Natl Acad Sci U S A, 2007. 104(2): p. 
582-7. 
249. Hornung, V., J. Ellegast, S. Kim, K. Brzozka, A. Jung, H. Kato, H. Poeck, S. 
Akira, K.K. Conzelmann, M. Schlee, S. Endres, and G. Hartmann, 5'-
Triphosphate RNA is the ligand for RIG-I. Science, 2006. 314(5801): p. 994-7. 
                                                                                                                                        References 
 
265 
250. Pichlmair, A., O. Schulz, C.P. Tan, T.I. Naslund, P. Liljestrom, F. Weber, and C. 
Reis e Sousa, RIG-I-mediated antiviral responses to single-stranded RNA 
bearing 5'-phosphates. Science, 2006. 314(5801): p. 997-1001. 
251. Kang, D.C., R.V. Gopalkrishnan, Q. Wu, E. Jankowsky, A.M. Pyle, and P.B. 
Fisher, mda-5: An interferon-inducible putative RNA helicase with double-
stranded RNA-dependent ATPase activity and melanoma growth-suppressive 
properties. Proc Natl Acad Sci U S A, 2002. 99(2): p. 637-42. 
252. Siren, J., T. Imaizumi, D. Sarkar, T. Pietila, D.L. Noah, R. Lin, J. Hiscott, R.M. 
Krug, P.B. Fisher, I. Julkunen, and S. Matikainen, Retinoic acid inducible gene-I 
and mda-5 are involved in influenza A virus-induced expression of antiviral 
cytokines. Microbes Infect, 2006. 8: p. 2013-20. 
253. Sumpter, R., Jr., Y.M. Loo, E. Foy, K. Li, M. Yoneyama, T. Fujita, S.M. Lemon, 
and M. Gale, Jr., Regulating intracellular antiviral defense and permissiveness to 
hepatitis C virus RNA replication through a cellular RNA helicase, RIG-I. J Virol, 
2005. 79(5): p. 2689-99. 
254. Seth, R.B., L. Sun, C.K. Ea, and Z.J. Chen, Identification and Characterization of 
MAVS, a Mitochondrial Antiviral Signaling Protein that Activates NF-kappaB and 
IRF3. Cell, 2005. 122(5): p. 669-82. 
255. Kawai, T., K. Takahashi, S. Sato, C. Coban, H. Kumar, H. Kato, K.J. Ishii, O. 
Takeuchi, and S. Akira, IPS-1, an adaptor triggering RIG-I- and Mda5-mediated 
type I interferon induction. Nat Immunol, 2005. 6(10): p. 981-8. 
256. Xu, L.G., Y.Y. Wang, K.J. Han, L.Y. Li, Z. Zhai, and H.B. Shu, VISA Is an 
Adapter Protein Required for Virus-Triggered IFN-beta Signaling. Mol Cell, 2005. 
19(6): p. 727-40. 
257. Foy, E., K. Li, R. Sumpter, Jr., Y.M. Loo, C.L. Johnson, C. Wang, P.M. Fish, M. 
Yoneyama, T. Fujita, S.M. Lemon, and M. Gale, Jr., Control of antiviral defenses 
through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling. 
Proc Natl Acad Sci U S A, 2005. 102(8): p. 2986-91. 
258. Kato, H., S. Sato, M. Yoneyama, M. Yamamoto, S. Uematsu, K. Matsui, T. 
Tsujimura, K. Takeda, T. Fujita, O. Takeuchi, and S. Akira, Cell type-specific 
involvement of RIG-I in antiviral response. Immunity, 2005. 23(1): p. 19-28. 
259. Kato, H., O. Takeuchi, S. Sato, M. Yoneyama, M. Yamamoto, K. Matsui, S. 
Uematsu, A. Jung, T. Kawai, K.J. Ishii, O. Yamaguchi, K. Otsu, T. Tsujimura, 
C.S. Koh, C. Reis e Sousa, Y. Matsuura, T. Fujita, and S. Akira, Differential roles 
of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature, 2006. 
441(7089): p. 101-5. 
260. Kumar, H., T. Kawai, H. Kato, S. Sato, K. Takahashi, C. Coban, M. Yamamoto, 
S. Uematsu, K.J. Ishii, O. Takeuchi, and S. Akira, Essential role of IPS-1 in 
innate immune responses against RNA viruses. J Exp Med, 2006. 203(7): p. 
1795-803. 
261. Sun, Q., L. Sun, H.H. Liu, X. Chen, R.B. Seth, J. Forman, and Z.J. Chen, The 
specific and essential role of MAVS in antiviral innate immune responses. 
Immunity, 2006. 24(5): p. 633-42. 
262. DiDonato, J.A., M. Hayakawa, D.M. Rothwarf, E. Zandi, and M. Karin, A 
cytokine-responsive IkappaB kinase that activates the transcription factor NF-
kappaB. Nature, 1997. 388(6642): p. 548-54. 
263. Delhase, M., M. Hayakawa, Y. Chen, and M. Karin, Positive and negative 
regulation of IkappaB kinase activity through IKKbeta subunit phosphorylation. 
Science, 1999. 284(5412): p. 309-13. 
                                                                                                                                        References 
 
266 
264. Ling, L., Z. Cao, and D.V. Goeddel, NF-kappaB-inducing kinase activates IKK-
alpha by phosphorylation of Ser-176. Proc Natl Acad Sci U S A, 1998. 95(7): p. 
3792-7. 
265. Lee, F.S., R.T. Peters, L.C. Dang, and T. Maniatis, MEKK1 activates both 
IkappaB kinase alpha and IkappaB kinase beta. Proc Natl Acad Sci U S A, 1998. 
95(16): p. 9319-24. 
266. Zhao, Q. and F.S. Lee, Mitogen-activated protein kinase/ERK kinase kinases 2 
and 3 activate nuclear factor-kappaB through IkappaB kinase-alpha and IkappaB 
kinase-beta. J Biol Chem, 1999. 274(13): p. 8355-8. 
267. Sakurai, H., H. Miyoshi, W. Toriumi, and T. Sugita, Functional interactions of 
transforming growth factor beta-activated kinase 1 with IkappaB kinases to 
stimulate NF-kappaB activation. J Biol Chem, 1999. 274(15): p. 10641-8. 
268. Zandi, E., D.M. Rothwarf, M. Delhase, M. Hayakawa, and M. Karin, The IkappaB 
kinase complex (IKK) contains two kinase subunits, IKKalpha and IKKbeta, 
necessary for IkappaB phosphorylation and NF-kappaB activation. Cell, 1997. 
91(2): p. 243-52. 
269. Zandi, E., Y. Chen, and M. Karin, Direct phosphorylation of IkappaB by IKKalpha 
and IKKbeta: discrimination between free and NF-kappaB-bound substrate. 
Science, 1998. 281(5381): p. 1360-3. 
270. Pomerantz, J.L. and D. Baltimore, NF-kappaB activation by a signaling complex 
containing TRAF2, TANK and TBK1, a novel IKK-related kinase. EMBO J, 1999. 
18(23): p. 6694-704. 
271. Nomura, F., T. Kawai, K. Nakanishi, and S. Akira, NF-kappaB activation through 
IKK-i-dependent I-TRAF/TANK phosphorylation. Genes Cells, 2000. 5(3): p. 191-
202. 
272. McWhirter, S.M., K.A. Fitzgerald, J. Rosains, D.C. Rowe, D.T. Golenbock, and T. 
Maniatis, IFN-regulatory factor 3-dependent gene expression is defective in 
Tbk1-deficient mouse embryonic fibroblasts. Proc Natl Acad Sci U S A, 2004. 
101(1): p. 233-8. 
273. Hemmi, H., O. Takeuchi, S. Sato, M. Yamamoto, T. Kaisho, H. Sanjo, T. Kawai, 
K. Hoshino, K. Takeda, and S. Akira, The roles of two IkappaB kinase-related 
kinases in lipopolysaccharide and double stranded RNA signaling and viral 
infection. J Exp Med, 2004. 199(12): p. 1641-50. 
274. Ikeda, F., C.M. Hecker, A. Rozenknop, R.D. Nordmeier, V. Rogov, K. Hofmann, 
S. Akira, V. Dotsch, and I. Dikic, Involvement of the ubiquitin-like domain of 
TBK1/IKK-i kinases in regulation of IFN-inducible genes. EMBO J, 2007. 26(14): 
p. 3451-62. 
275. Derijard, B., J. Raingeaud, T. Barrett, I.H. Wu, J. Han, R.J. Ulevitch, and R.J. 
Davis, Independent human MAP-kinase signal transduction pathways defined by 
MEK and MKK isoforms. Science, 1995. 267(5198): p. 682-5. 
276. Sanchez, I., R.T. Hughes, B.J. Mayer, K. Yee, J.R. Woodgett, J. Avruch, J.M. 
Kyriakis, and L.I. Zon, Role of SAPK/ERK kinase-1 in the stress-activated 
pathway regulating transcription factor c-Jun. Nature, 1994. 372(6508): p. 794-8. 
277. Yao, Z., K. Diener, X.S. Wang, M. Zukowski, G. Matsumoto, G. Zhou, R. Mo, T. 
Sasaki, H. Nishina, C.C. Hui, T.H. Tan, J.P. Woodgett, and J.M. Penninger, 
Activation of stress-activated protein kinases/c-Jun N-terminal protein kinases 
(SAPKs/JNKs) by a novel mitogen-activated protein kinase kinase. J Biol Chem, 
1997. 272(51): p. 32378-83. 
                                                                                                                                        References 
 
267 
278. Tournier, C., C. Dong, T.K. Turner, S.N. Jones, R.A. Flavell, and R.J. Davis, 
MKK7 is an essential component of the JNK signal transduction pathway 
activated by proinflammatory cytokines. Genes Dev, 2001. 15(11): p. 1419-26. 
279. Gupta, S., D. Campbell, B. Derijard, and R.J. Davis, Transcription factor ATF2 
regulation by the JNK signal transduction pathway. Science, 1995. 267(5196): p. 
389-93. 
280. Livingstone, C., G. Patel, and N. Jones, ATF-2 contains a phosphorylation-
dependent transcriptional activation domain. EMBO J, 1995. 14(8): p. 1785-97. 
281. Hibi, M., A. Lin, T. Smeal, A. Minden, and M. Karin, Identification of an 
oncoprotein- and UV-responsive protein kinase that binds and potentiates the c-
Jun activation domain. Genes Dev, 1993. 7(11): p. 2135-48. 
282. Kallunki, T., B. Su, I. Tsigelny, H.K. Sluss, B. Derijard, G. Moore, R. Davis, and 
M. Karin, JNK2 contains a specificity-determining region responsible for efficient 
c-Jun binding and phosphorylation. Genes Dev, 1994. 8(24): p. 2996-3007. 
283. Smeal, T., B. Binetruy, D.A. Mercola, M. Birrer, and M. Karin, Oncogenic and 
transcriptional cooperation with Ha-Ras requires phosphorylation of c-Jun on 
serines 63 and 73. Nature, 1991. 354(6353): p. 494-6. 
284. Pulverer, B.J., J.M. Kyriakis, J. Avruch, E. Nikolakaki, and J.R. Woodgett, 
Phosphorylation of c-jun mediated by MAP kinases. Nature, 1991. 353(6345): p. 
670-4. 
285. Gupta, S., T. Barrett, A.J. Whitmarsh, J. Cavanagh, H.K. Sluss, B. Derijard, and 
R.J. Davis, Selective interaction of JNK protein kinase isoforms with transcription 
factors. EMBO J, 1996. 15(11): p. 2760-70. 
286. Sarkar, S.N., K.L. Peters, C.P. Elco, S. Sakamoto, S. Pal, and G.C. Sen, Novel 
roles of TLR3 tyrosine phosphorylation and PI3 kinase in double-stranded RNA 
signaling. Nat Struct Mol Biol, 2004. 11(11): p. 1060-7. 
287. Sarkar, S.N., H.L. Smith, T.M. Rowe, and G.C. Sen, Double-stranded RNA 
signaling by Toll-like receptor 3 requires specific tyrosine residues in its 
cytoplasmic domain. J Biol Chem, 2003. 278(7): p. 4393-6. 
288. Sarkar, S.N., C.P. Elco, K.L. Peters, S. Chattopadhyay, and G.C. Sen, Two 
tyrosine residues of Toll-like receptor 3 trigger different steps of NF-kappa B 
activation. J Biol Chem, 2007. 282(6): p. 3423-7. 
289. Aksoy, E., W. Vanden Berghe, S. Detienne, Z. Amraoui, K.A. Fitzgerald, G. 
Haegeman, M. Goldman, and F. Willems, Inhibition of phosphoinositide 3-kinase 
enhances TRIF-dependent NF-kappa B activation and IFN-beta synthesis 
downstream of Toll-like receptor 3 and 4. Eur J Immunol, 2005. 35(7): p. 2200-9. 
290. Thomas, K.W., M.M. Monick, J.M. Staber, T. Yarovinsky, A.B. Carter, and G.W. 
Hunninghake, Respiratory syncytial virus inhibits apoptosis and induces NF-
kappa B activity through a phosphatidylinositol 3-kinase-dependent pathway. J 
Biol Chem, 2002. 277(1): p. 492-501. 
291. Newcomb, D.C., U. Sajjan, S. Nanua, Y. Jia, A.M. Goldsmith, J.K. Bentley, and 
M.B. Hershenson, Phosphatidylinositol 3-kinase is required for rhinovirus-
induced airway epithelial cell interleukin-8 expression. J Biol Chem, 2005. 
280(44): p. 36952-61. 
292. Chang, T.H., C.L. Liao, and Y.L. Lin, Flavivirus induces interferon-beta gene 
expression through a pathway involving RIG-I-dependent IRF-3 and PI3K-
dependent NF-kappaB activation. Microbes Infect, 2006. 8(1): p. 157-71. 
                                                                                                                                        References 
 
268 
293. Lad, S.P., G. Yang, D.A. Scott, T.H. Chao, S. Correia Jda, J.C. de la Torre, and 
E. Li, Identification of MAVS splicing variants that interfere with RIGI/MAVS 
pathway signaling. Mol Immunol, 2008. 45(8): p. 2277-87. 
294. Baud, V., Z.G. Liu, B. Bennett, N. Suzuki, Y. Xia, and M. Karin, Signaling by 
proinflammatory cytokines: oligomerization of TRAF2 and TRAF6 is sufficient for 
JNK and IKK activation and target gene induction via an amino-terminal effector 
domain. Genes Dev, 1999. 13(10): p. 1297-308. 
295. Deng, L., C. Wang, E. Spencer, L. Yang, A. Braun, J. You, C. Slaughter, C. 
Pickart, and Z.J. Chen, Activation of the IkappaB kinase complex by TRAF6 
requires a dimeric ubiquitin-conjugating enzyme complex and a unique 
polyubiquitin chain. Cell, 2000. 103(2): p. 351-61. 
296. Wang, C., L. Deng, M. Hong, G.R. Akkaraju, J. Inoue, and Z.J. Chen, TAK1 is a 
ubiquitin-dependent kinase of MKK and IKK. Nature, 2001. 412(6844): p. 346-51. 
297. Kanayama, A., R.B. Seth, L. Sun, C.K. Ea, M. Hong, A. Shaito, Y.H. Chiu, L. 
Deng, and Z.J. Chen, TAB2 and TAB3 activate the NF-kappaB pathway through 
binding to polyubiquitin chains. Mol Cell, 2004. 15(4): p. 535-48. 
298. Lamothe, B., A. Besse, A.D. Campos, W.K. Webster, H. Wu, and B.G. Darnay, 
Site-specific Lys-63-linked tumor necrosis factor receptor-associated factor 6 
auto-ubiquitination is a critical determinant of I kappa B kinase activation. J Biol 
Chem, 2007. 282(6): p. 4102-12. 
299. Wu, C.J., D.B. Conze, T. Li, S.M. Srinivasula, and J.D. Ashwell, Sensing of Lys 
63-linked polyubiquitination by NEMO is a key event in NF-kappaB activation 
[corrected]. Nat Cell Biol, 2006. 8(4): p. 398-406. 
300. Thiefes, A., S. Wolter, J.F. Mushinski, E. Hoffmann, O. Dittrich-Breiholz, N. 
Graue, A. Dorrie, H. Schneider, D. Wirth, B. Luckow, K. Resch, and M. Kracht, 
Simultaneous blockade of NFkappaB, JNK, and p38 MAPK by a kinase-inactive 
mutant of the protein kinase TAK1 sensitizes cells to apoptosis and affects a 
distinct spectrum of tumor necrosis factor [corrected] target genes. J Biol Chem, 
2005. 280(30): p. 27728-41. 
301. Meylan, E., K. Burns, K. Hofmann, V. Blancheteau, F. Martinon, M. Kelliher, and 
J. Tschopp, RIP1 is an essential mediator of Toll-like receptor 3-induced NF-
kappa B activation. Nat Immunol, 2004. 5(5): p. 503-7. 
302. Cusson-Hermance, N., S. Khurana, T.H. Lee, K.A. Fitzgerald, and M.A. Kelliher, 
Rip1 mediates the Trif-dependent toll-like receptor 3- and 4-induced NF-
{kappa}B activation but does not contribute to interferon regulatory factor 3 
activation. J Biol Chem, 2005. 280(44): p. 36560-6. 
303. Jiang, Z., M. Zamanian-Daryoush, H. Nie, A.M. Silva, B.R. Williams, and X. Li, 
Poly(I-C)-induced Toll-like receptor 3 (TLR3)-mediated activation of NFkappa B 
and MAP kinase is through an interleukin-1 receptor-associated kinase (IRAK)-
independent pathway employing the signaling components TLR3-TRAF6-TAK1-
TAB2-PKR. J Biol Chem, 2003. 278(19): p. 16713-9. 
304. Holtmann, H., J. Enninga, S. Kalble, A. Thiefes, A. Dorrie, M. Broemer, R. 
Winzen, A. Wilhelm, J. Ninomiya-Tsuji, K. Matsumoto, K. Resch, and M. Kracht, 
The MAPK kinase kinase TAK1 plays a central role in coupling the interleukin-1 
receptor to both transcriptional and RNA-targeted mechanisms of gene 
regulation. J Biol Chem, 2001. 276(5): p. 3508-16. 
305. Rothe, M., J. Xiong, H.B. Shu, K. Williamson, A. Goddard, and D.V. Goeddel, I-
TRAF is a novel TRAF-interacting protein that regulates TRAF-mediated signal 
transduction. Proc Natl Acad Sci U S A, 1996. 93(16): p. 8241-6. 
                                                                                                                                        References 
 
269 
306. Guo, B. and G. Cheng, Modulation of the interferon antiviral response by the 
TBK1/IKKi adaptor protein TANK. J Biol Chem, 2007. 282(16): p. 11817-26. 
307. Hacker, H., V. Redecke, B. Blagoev, I. Kratchmarova, L.C. Hsu, G.G. Wang, 
M.P. Kamps, E. Raz, H. Wagner, G. Hacker, M. Mann, and M. Karin, Specificity 
in Toll-like receptor signalling through distinct effector functions of TRAF3 and 
TRAF6. Nature, 2006. 439(7073): p. 204-7. 
308. Oganesyan, G., S.K. Saha, B. Guo, J.Q. He, A. Shahangian, B. Zarnegar, A. 
Perry, and G. Cheng, Critical role of TRAF3 in the Toll-like receptor-dependent 
and -independent antiviral response. Nature, 2006. 439(7073): p. 208-11. 
309. Saha, S.K., E.M. Pietras, J.Q. He, J.R. Kang, S.Y. Liu, G. Oganesyan, A. 
Shahangian, B. Zarnegar, T.L. Shiba, Y. Wang, and G. Cheng, Regulation of 
antiviral responses by a direct and specific interaction between TRAF3 and 
Cardif. EMBO J, 2006. 25(14): p. 3257-63. 
310. Fujita, F., Y. Taniguchi, T. Kato, Y. Narita, A. Furuya, T. Ogawa, H. Sakurai, T. 
Joh, M. Itoh, M. Delhase, M. Karin, and M. Nakanishi, Identification of NAP1, a 
regulatory subunit of IkappaB kinase-related kinases that potentiates NF-kappaB 
signaling. Mol Cell Biol, 2003. 23(21): p. 7780-93. 
311. Sasai, M., H. Oshiumi, M. Matsumoto, N. Inoue, F. Fujita, M. Nakanishi, and T. 
Seya, Cutting Edge: NF-kappaB-activating kinase-associated protein 1 
participates in TLR3/Toll-IL-1 homology domain-containing adapter molecule-1-
mediated IFN regulatory factor 3 activation. J Immunol, 2005. 174(1): p. 27-30. 
312. Sasai, M., M. Shingai, K. Funami, M. Yoneyama, T. Fujita, M. Matsumoto, and T. 
Seya, NAK-associated protein 1 participates in both the TLR3 and the 
cytoplasmic pathways in type I IFN induction. J Immunol, 2006. 177(12): p. 8676-
83. 
313. Shimada, T., T. Kawai, K. Takeda, M. Matsumoto, J. Inoue, Y. Tatsumi, A. 
Kanamaru, and S. Akira, IKK-i, a novel lipopolysaccharide-inducible kinase that 
is related to IkappaB kinases. Int Immunol, 1999. 11(8): p. 1357-62. 
314. Tojima, Y., A. Fujimoto, M. Delhase, Y. Chen, S. Hatakeyama, K. Nakayama, Y. 
Kaneko, Y. Nimura, N. Motoyama, K. Ikeda, M. Karin, and M. Nakanishi, NAK is 
an IkappaB kinase-activating kinase. Nature, 2000. 404(6779): p. 778-82. 
315. Bonnard, M., C. Mirtsos, S. Suzuki, K. Graham, J. Huang, M. Ng, A. Itie, A. 
Wakeham, A. Shahinian, W.J. Henzel, A.J. Elia, W. Shillinglaw, T.W. Mak, Z. 
Cao, and W.C. Yeh, Deficiency of T2K leads to apoptotic liver degeneration and 
impaired NF-kappaB-dependent gene transcription. Embo J, 2000. 19(18): p. 
4976-85. 
316. An, H., J. Hou, J. Zhou, W. Zhao, H. Xu, Y. Zheng, Y. Yu, S. Liu, and X. Cao, 
Phosphatase SHP-1 promotes TLR- and RIG-I-activated production of type I 
interferon by inhibiting the kinase IRAK1. Nat Immunol, 2008. 9(5): p. 542-50. 
317. Johnston S.L., T.D.A., Rhinoviruses, in Diagnostic procedures for viral, rickettsial 
and chlamydial infections., S.N.J. Lennette E.H., Editor. 1995, American public 
health association: Washington D.C. p. 253-263. 
318. Whiteside, S.T., K.V. Visvanathan, and S. Goodbourn, Identification of novel 
factors that bind to the PRD I region of the human beta-interferon promoter. 
Nucleic Acids Res, 1992. 20(7): p. 1531-8. 
319. Kirchhoff, S., D. Wilhelm, P. Angel, and H. Hauser, NFkappaB activation is 
required for interferon regulatory factor-1-mediated interferon beta induction. Eur 
J Biochem, 1999. 261(2): p. 546-54. 
                                                                                                                                        References 
 
270 
320. Hewson, C.A., A. Jardine, M.R. Edwards, V. Laza-Stanca, and S.L. Johnston, 
Toll-like receptor 3 is induced by and mediates antiviral activity against rhinovirus 
infection of human bronchial epithelial cells. J Virol, 2005. 79(19): p. 12273-9. 
321. Le Goffic, R., J. Pothlichet, D. Vitour, T. Fujita, E. Meurs, M. Chignard, and M. Si-
Tahar, Cutting Edge: Influenza A virus activates TLR3-dependent inflammatory 
and RIG-I-dependent antiviral responses in human lung epithelial cells. J 
Immunol, 2007. 178(6): p. 3368-72. 
322. Rudd, B.D., E. Burstein, C.S. Duckett, X. Li, and N.W. Lukacs, Differential role 
for TLR3 in respiratory syncytial virus-induced chemokine expression. J Virol, 
2005. 79(6): p. 3350-7. 
323. Tabeta, K., P. Georgel, E. Janssen, X. Du, K. Hoebe, K. Crozat, S. Mudd, L. 
Shamel, S. Sovath, J. Goode, L. Alexopoulou, R.A. Flavell, and B. Beutler, Toll-
like receptors 9 and 3 as essential components of innate immune defense 
against mouse cytomegalovirus infection. Proc Natl Acad Sci U S A, 2004. 
101(10): p. 3516-21. 
324. Wang, T., T. Town, L. Alexopoulou, J.F. Anderson, E. Fikrig, and R.A. Flavell, 
Toll-like receptor 3 mediates West Nile virus entry into the brain causing lethal 
encephalitis. Nat Med, 2004. 10(12): p. 1366-73. 
325. Isogawa, M., M.D. Robek, Y. Furuichi, and F.V. Chisari, Toll-like receptor 
signaling inhibits hepatitis B virus replication in vivo. J Virol, 2005. 79(11): p. 
7269-72. 
326. Takahasi, K., M. Yoneyama, T. Nishihori, R. Hirai, H. Kumeta, R. Narita, M. Gale, 
Jr., F. Inagaki, and T. Fujita, Nonself RNA-sensing mechanism of RIG-I helicase 
and activation of antiviral immune responses. Mol Cell, 2008. 29(4): p. 428-40. 
327. Reynolds, A., E.M. Anderson, A. Vermeulen, Y. Fedorov, K. Robinson, D. Leake, 
J. Karpilow, W.S. Marshall, and A. Khvorova, Induction of the interferon 
response by siRNA is cell type- and duplex length-dependent. RNA, 2006. 12(6): 
p. 988-93. 
328. Persengiev, S.P., X. Zhu, and M.R. Green, Nonspecific, concentration-
dependent stimulation and repression of mammalian gene expression by small 
interfering RNAs (siRNAs). RNA, 2004. 10(1): p. 12-8. 
329. Matsukura, S., F. Kokubu, M. Kurokawa, M. Kawaguchi, K. Ieki, H. Kuga, M. 
Odaka, S. Suzuki, S. Watanabe, H. Takeuchi, T. Kasama, and M. Adachi, 
Synthetic double-stranded RNA induces multiple genes related to inflammation 
through Toll-like receptor 3 depending on NF-kappaB and/or IRF-3 in airway 
epithelial cells. Clin Exp Allergy, 2006. 36(8): p. 1049-62. 
330. Han, J., Y. Lee, K.H. Yeom, Y.K. Kim, H. Jin, and V.N. Kim, The Drosha-DGCR8 
complex in primary microRNA processing. Genes Dev, 2004. 18(24): p. 3016-27. 
331. Bartel, D.P., MicroRNAs: genomics, biogenesis, mechanism, and function. Cell, 
2004. 116(2): p. 281-97. 
332. Yi, R., Y. Qin, I.G. Macara, and B.R. Cullen, Exportin-5 mediates the nuclear 
export of pre-microRNAs and short hairpin RNAs. Genes Dev, 2003. 17(24): p. 
3011-6. 
333. Chendrimada, T.P., R.I. Gregory, E. Kumaraswamy, J. Norman, N. Cooch, K. 
Nishikura, and R. Shiekhattar, TRBP recruits the Dicer complex to Ago2 for 
microRNA processing and gene silencing. Nature, 2005. 436(7051): p. 740-4. 
334. Hammond, S.M., E. Bernstein, D. Beach, and G.J. Hannon, An RNA-directed 
nuclease mediates post-transcriptional gene silencing in Drosophila cells. 
Nature, 2000. 404(6775): p. 293-6. 
                                                                                                                                        References 
 
271 
335. Hammond, S.M., S. Boettcher, A.A. Caudy, R. Kobayashi, and G.J. Hannon, 
Argonaute2, a link between genetic and biochemical analyses of RNAi. Science, 
2001. 293(5532): p. 1146-50. 
336. Schwarz, D.S., G. Hutvagner, B. Haley, and P.D. Zamore, Evidence that siRNAs 
function as guides, not primers, in the Drosophila and human RNAi pathways. 
Molecular Cell, 2002. 10(3): p. 537-48. 
337. Cullen, B.R., Is RNA interference involved in intrinsic antiviral immunity in 
mammals? Nat Immunol, 2006. 7(6): p. 563-7. 
338. Gitlin, L. and R. Andino, Nucleic acid-based immune system: the antiviral 
potential of mammalian RNA silencing. J Virol, 2003. 77(13): p. 7159-65. 
339. Sledz, C.A., M. Holko, M.J. de Veer, R.H. Silverman, and B.R. Williams, 
Activation of the interferon system by short-interfering RNAs. Nat Cell Biol, 2003. 
5(9): p. 834-9. 
340. Kariko, K., P. Bhuyan, J. Capodici, and D. Weissman, Small interfering RNAs 
mediate sequence-independent gene suppression and induce immune activation 
by signaling through toll-like receptor 3. J Immunol, 2004. 172(11): p. 6545-9. 
341. Marques, J.T., T. Devosse, D. Wang, M. Zamanian-Daryoush, P. Serbinowski, 
R. Hartmann, T. Fujita, M.A. Behlke, and B.R. Williams, A structural basis for 
discriminating between self and nonself double-stranded RNAs in mammalian 
cells. Nat Biotechnol, 2006. 24(5): p. 559-65. 
342. Judge, A.D., V. Sood, J.R. Shaw, D. Fang, K. McClintock, and I. MacLachlan, 
Sequence-dependent stimulation of the mammalian innate immune response by 
synthetic siRNA. Nat Biotechnol, 2005. 23(4): p. 457-62. 
343. Jackson, A.L., S.R. Bartz, J. Schelter, S.V. Kobayashi, J. Burchard, M. Mao, B. 
Li, G. Cavet, and P.S. Linsley, Expression profiling reveals off-target gene 
regulation by RNAi. Nat Biotechnol, 2003. 21(6): p. 635-7. 
344. Semizarov, D., L. Frost, A. Sarthy, P. Kroeger, D.N. Halbert, and S.W. Fesik, 
Specificity of short interfering RNA determined through gene expression 
signatures. Proc Natl Acad Sci U S A, 2003. 100(11): p. 6347-52. 
345. Lin, X., X. Ruan, M.G. Anderson, J.A. McDowell, P.E. Kroeger, S.W. Fesik, and 
Y. Shen, siRNA-mediated off-target gene silencing triggered by a 7 nt 
complementation. Nucleic Acids Res, 2005. 33(14): p. 4527-35. 
346. Jackson, A.L., J. Burchard, J. Schelter, B.N. Chau, M. Cleary, L. Lim, and P.S. 
Linsley, Widespread siRNA "off-target" transcript silencing mediated by seed 
region sequence complementarity. RNA, 2006. 12(7): p. 1179-87. 
347. Jackson, A.L., J. Burchard, D. Leake, A. Reynolds, J. Schelter, J. Guo, J.M. 
Johnson, L. Lim, J. Karpilow, K. Nichols, W. Marshall, A. Khvorova, and P.S. 
Linsley, Position-specific chemical modification of siRNAs reduces "off-target" 
transcript silencing. RNA, 2006. 12(7): p. 1197-205. 
348. Product Literature, Technical Notes. Retrived Dec. 2007.   [cited; Available from: 
www.dharmacon.com/prodinfo. 
349. Gitlin, L., W. Barchet, S. Gilfillan, M. Cella, B. Beutler, R.A. Flavell, M.S. 
Diamond, and M. Colonna, Essential role of mda-5 in type I IFN responses to 
polyriboinosinic:polyribocytidylic acid and encephalomyocarditis picornavirus. 
Proc Natl Acad Sci U S A, 2006. 103(22): p. 8459-64. 
350. Lee, Y.F., A. Nomoto, B.M. Detjen, and E. Wimmer, A protein covalently linked to 
poliovirus genome RNA. Proc Natl Acad Sci U S A, 1977. 74(1): p. 59-63. 
                                                                                                                                        References 
 
272 
351. Childs, K., N. Stock, C. Ross, J. Andrejeva, L. Hilton, M. Skinner, R. Randall, and 
S. Goodbourn, mda-5, but not RIG-I, is a common target for paramyxovirus V 
proteins. Virology, 2007. 359(1): p. 190-200. 
352. Liu, P., M. Jamaluddin, K. Li, R.P. Garofalo, A. Casola, and A.R. Brasier, 
Retinoic acid-inducible gene I mediates early antiviral response and Toll-like 
receptor 3 expression in respiratory syncytial virus-infected airway epithelial 
cells. J Virol, 2007. 81(3): p. 1401-11. 
353. Livengood, A.J., C.C. Wu, and D.A. Carson, Opposing roles of RNA receptors 
TLR3 and RIG-I in the inflammatory response to double-stranded RNA in a 
Kaposi's sarcoma cell line. Cell Immunol, 2007. 249(2): p. 55-62. 
354. Wagoner, J., M. Austin, J. Green, T. Imaizumi, A. Casola, A. Brasier, K.S. 
Khabar, T. Wakita, M. Gale, Jr., and S.J. Polyak, Regulation of CXCL-8 
(interleukin-8) induction by double-stranded RNA signaling pathways during 
hepatitis C virus infection. J Virol, 2007. 81(1): p. 309-18. 
355. Kubota, K., H. Sakaki, T. Imaizumi, H. Nakagawa, A. Kusumi, W. Kobayashi, K. 
Satoh, and H. Kimura, Retinoic acid-inducible gene-I is induced in gingival 
fibroblasts by lipopolysaccharide or poly IC: possible roles in interleukin-1beta, -6 
and -8 expression. Oral Microbiol Immunol, 2006. 21(6): p. 399-406. 
356. Tanabe, M., M. Kurita-Taniguchi, K. Takeuchi, M. Takeda, M. Ayata, H. Ogura, 
M. Matsumoto, and T. Seya, Mechanism of up-regulation of human Toll-like 
receptor 3 secondary to infection of measles virus-attenuated strains. Biochem 
Biophys Res Commun, 2003. 311(1): p. 39-48. 
357. Miettinen, M., T. Sareneva, I. Julkunen, and S. Matikainen, IFNs activate toll-like 
receptor gene expression in viral infections. Genes Immun, 2001. 2(6): p. 349-
55. 
358. Heinz, S., V. Haehnel, M. Karaghiosoff, L. Schwarzfischer, M. Muller, S.W. 
Krause, and M. Rehli, Species-specific regulation of Toll-like receptor 3 genes in 
men and mice. J Biol Chem, 2003. 278(24): p. 21502-9. 
359. Gerosa, F., A. Gobbi, P. Zorzi, S. Burg, F. Briere, G. Carra, and G. Trinchieri, 
The reciprocal interaction of NK cells with plasmacytoid or myeloid dendritic cells 
profoundly affects innate resistance functions. J Immunol, 2005. 174(2): p. 727-
34. 
360. Dalod, M., T. Hamilton, R. Salomon, T.P. Salazar-Mather, S.C. Henry, J.D. 
Hamilton, and C.A. Biron, Dendritic cell responses to early murine 
cytomegalovirus infection: subset functional specialization and differential 
regulation by interferon alpha/beta. J Exp Med, 2003. 197(7): p. 885-98. 
361. Taniguchi, T. and A. Takaoka, A weak signal for strong responses: interferon-
alpha/beta revisited. Nat Rev Mol Cell Biol, 2001. 2(5): p. 378-86. 
362. Gresser, I., Biologic effects of interferons. Journal of Investigative Dermatology, 
1990. 95(6 Suppl): p. 66S-71S. 
363. Tovey, M.G., M. Streuli, I. Gresser, J. Gugenheim, B. Blanchard, J. Guymarho, 
F. Vignaux, and M. Gigou, Interferon messenger RNA is produced constitutively 
in the organs of normal individuals. Proceedings of the National Academy of 
Sciences of the United States of America, 1987. 84(14): p. 5038-42. 
364. Yount, J.S., T.M. Moran, and C.B. Lopez, Cytokine-independent upregulation of 
MDA5 in viral infection.[erratum appears in J Virol. 2007 Sep;81(17):9609]. 
Journal of Virology, 2007. 81(13): p. 7316-9. 
365. Kaiser, W.J. and M.K. Offermann, Apoptosis induced by the toll-like receptor 
adaptor TRIF is dependent on its receptor interacting protein homotypic 
interaction motif. Journal of Immunology, 2005. 174(8): p. 4942-52. 
                                                                                                                                        References 
 
273 
366. Libermann, T.A. and D. Baltimore, Activation of interleukin-6 gene expression 
through the NF-kappa B transcription factor. Mol Cell Biol, 1990. 10(5): p. 2327-
34. 
367. Ray, A., S.B. Tatter, L.T. May, and P.B. Sehgal, Activation of the human "beta 2-
interferon/hepatocyte-stimulating factor/interleukin 6" promoter by cytokines, 
viruses, and second messenger agonists. Proc Natl Acad Sci U S A, 1988. 
85(18): p. 6701-5. 
368. Mukaida, N., M. Shiroo, and K. Matsushima, Genomic structure of the human 
monocyte-derived neutrophil chemotactic factor IL-8. J Immunol, 1989. 143(4): p. 
1366-71. 
369. Mukaida, N., Y. Mahe, and K. Matsushima, Cooperative interaction of nuclear 
factor-kappa B- and cis-regulatory enhancer binding protein-like factor binding 
elements in activating the interleukin-8 gene by pro-inflammatory cytokines. J 
Biol Chem, 1990. 265(34): p. 21128-33. 
370. Cao, Z., J. Xiong, M. Takeuchi, T. Kurama, and D.V. Goeddel, TRAF6 is a signal 
transducer for interleukin-1. Nature, 1996. 383(6599): p. 443-6. 
371. Song, H.Y., C.H. Regnier, C.J. Kirschning, D.V. Goeddel, and M. Rothe, Tumor 
necrosis factor (TNF)-mediated kinase cascades: bifurcation of nuclear factor-
kappaB and c-jun N-terminal kinase (JNK/SAPK) pathways at TNF receptor-
associated factor 2. Proceedings of the National Academy of Sciences of the 
United States of America, 1997. 94(18): p. 9792-6. 
372. Oltmanns, U., R. Issa, M.B. Sukkar, M. John, and K.F. Chung, Role of c-jun N-
terminal kinase in the induced release of GM-CSF, RANTES and IL-8 from 
human airway smooth muscle cells. Br J Pharmacol, 2003. 139(6): p. 1228-34. 
373. Bohmann, D., T.J. Bos, A. Admon, T. Nishimura, P.K. Vogt, and R. Tjian, Human 
proto-oncogene c-jun encodes a DNA binding protein with structural and 
functional properties of transcription factor AP-1. Science, 1987. 238(4832): p. 
1386-92. 
374. Angel, P., E.A. Allegretto, S.T. Okino, K. Hattori, W.J. Boyle, T. Hunter, and M. 
Karin, Oncogene jun encodes a sequence-specific trans-activator similar to AP-
1. Nature, 1988. 332(6160): p. 166-71. 
375. Yang, J. and A. Richmond, Constitutive IkappaB kinase activity correlates with 
nuclear factor-kappaB activation in human melanoma cells. Cancer Res, 2001. 
61(12): p. 4901-9. 
376. Raingeaud, J., S. Gupta, J.S. Rogers, M. Dickens, J. Han, R.J. Ulevitch, and R.J. 
Davis, Pro-inflammatory cytokines and environmental stress cause p38 mitogen-
activated protein kinase activation by dual phosphorylation on tyrosine and 
threonine. Journal of Biological Chemistry, 1995. 270(13): p. 7420-6. 
377. Raingeaud, J., A.J. Whitmarsh, T. Barrett, B. Derijard, and R.J. Davis, MKK3- 
and MKK6-regulated gene expression is mediated by the p38 mitogen-activated 
protein kinase signal transduction pathway. Molecular & Cellular Biology, 1996. 
16(3): p. 1247-55. 
378. Kujime, K., S. Hashimoto, Y. Gon, K. Shimizu, and T. Horie, p38 mitogen-
activated protein kinase and c-jun-NH2-terminal kinase regulate RANTES 
production by influenza virus-infected human bronchial epithelial cells. Journal of 
Immunology, 2000. 164(6): p. 3222-8. 
379. Park, C., S. Lee, I.H. Cho, H.K. Lee, D. Kim, S.Y. Choi, S.B. Oh, K. Park, J.S. 
Kim, and S.J. Lee, TLR3-mediated signal induces proinflammatory cytokine and 
chemokine gene expression in astrocytes: differential signaling mechanisms of 
TLR3-induced IP-10 and IL-8 gene expression. GLIA, 2006. 53(3): p. 248-56. 
                                                                                                                                        References 
 
274 
380. Davies, S.P., H. Reddy, M. Caivano, and P. Cohen, Specificity and mechanism 
of action of some commonly used protein kinase inhibitors. Biochemical Journal, 
2000. 351(Pt 1): p. 95-105. 
381. Martys, J.L., C. Wjasow, D.M. Gangi, M.C. Kielian, T.E. McGraw, and J.M. 
Backer, Wortmannin-sensitive trafficking pathways in Chinese hamster ovary 
cells. Differential effects on endocytosis and lysosomal sorting. Journal of 
Biological Chemistry, 1996. 271(18): p. 10953-62. 
382. Shpetner, H., M. Joly, D. Hartley, and S. Corvera, Potential sites of PI-3 kinase 
function in the endocytic pathway revealed by the PI-3 kinase inhibitor, 
wortmannin. Journal of Cell Biology, 1996. 132(4): p. 595-605. 
383. Spiro, D.J., W. Boll, T. Kirchhausen, and M. Wessling-Resnick, Wortmannin 
alters the transferrin receptor endocytic pathway in vivo and in vitro. Molecular 
Biology of the Cell, 1996. 7(3): p. 355-67. 
384. Brabec, M., D. Blaas, and R. Fuchs, Wortmannin delays transfer of human 
rhinovirus serotype 2 to late endocytic compartments. Biochemical & Biophysical 
Research Communications, 2006. 348(2): p. 741-9. 
385. Leonard, J.N., R. Ghirlando, J. Askins, J.K. Bell, D.H. Margulies, D.R. Davies, 
and D.M. Segal, The TLR3 signaling complex forms by cooperative receptor 
dimerization. Proceedings of the National Academy of Sciences of the United 
States of America, 2008. 105(1): p. 258-63. 
386. Gharbi, S.I., M.J. Zvelebil, S.J. Shuttleworth, T. Hancox, N. Saghir, J.F. Timms, 
and M.D. Waterfield, Exploring the specificity of the PI3K family inhibitor 
LY294002. Biochemical Journal, 2007. 404(1): p. 15-21. 
387. Yie, J., M. Merika, N. Munshi, G. Chen, and D. Thanos, The role of HMG I(Y) in 
the assembly and function of the IFN-beta enhanceosome. Embo J, 1999. 
18(11): p. 3074-89. 
388. Yu, Y., S.E. Wang, and G.S. Hayward, The KSHV immediate-early transcription 
factor RTA encodes ubiquitin E3 ligase activity that targets IRF7 for proteosome-
mediated degradation. Immunity, 2005. 22(1): p. 59-70. 
389. Au, W.C., P.A. Moore, D.W. LaFleur, B. Tombal, and P.M. Pitha, 
Characterization of the interferon regulatory factor-7 and its potential role in the 
transcription activation of interferon A genes. J Biol Chem, 1998. 273(44): p. 
29210-7. 
390. Schmitz, M.L. and P.A. Baeuerle, The p65 subunit is responsible for the strong 
transcription activating potential of NF-kappa B. EMBO Journal, 1991. 10(12): p. 
3805-17. 
391. Genin, P., M. Algarte, P. Roof, R. Lin, and J. Hiscott, Regulation of RANTES 
chemokine gene expression requires cooperativity between NF-kappa B and 
IFN-regulatory factor transcription factors. J Immunol, 2000. 164(10): p. 5352-61. 
392. Tanner, N.K. and P. Linder, DExD/H box RNA helicases: from generic motors to 
specific dissociation functions. Molecular Cell, 2001. 8(2): p. 251-62. 
393. Bartlett, N.W., R.P. Walton, M.R. Edwards, J. Aniscenko, G. Caramori, J. Zhu, N. 
Glanville, K.J. Choy, P. Jourdan, J. Burnet, T.J. Tuthill, M.S. Pedrick, M.J. Hurle, 
C. Plumpton, N.A. Sharp, J.N. Bussell, D.M. Swallow, J. Schwarze, B. Guy, J.W. 
Almond, P.K. Jeffery, C.M. Lloyd, A. Papi, R.A. Killington, D.J. Rowlands, E.D. 
Blair, N.J. Clarke, and S.L. Johnston, Mouse models of rhinovirus-induced 
disease and exacerbation of allergic airway inflammation. Nat Med, 2008. 14(2): 
p. 199-204. 
                                                                                                                                        References 
 
275 
394. Samo, T.C., S.B. Greenberg, R.B. Couch, J. Quarles, P.E. Johnson, S. Hook, 
and M.W. Harmon, Efficacy and tolerance of intranasally applied recombinant 
leukocyte A interferon in normal volunteers. J Infect Dis, 1983. 148(3): p. 535-42. 
395. Hayden, F.G. and J.M. Gwaltney, Jr., Intranasal interferon alpha 2 for prevention 
of rhinovirus infection and illness. J Infect Dis, 1983. 148(3): p. 543-50. 
396. Hayden, F.G. and J.M. Gwaltney, Jr., Intranasal interferon-alpha 2 treatment of 
experimental rhinoviral colds. J Infect Dis, 1984. 150(2): p. 174-80. 
397. Monto, A.S., T.C. Shope, S.A. Schwartz, and J.K. Albrecht, Intranasal interferon-
alpha 2b for seasonal prophylaxis of respiratory infection. J Infect Dis, 1986. 
154(1): p. 128-33. 
398. Higgins, P.G., W. Al-Nakib, J. Willman, and D.A. Tyrrell, Interferon-beta ser as 
prophylaxis against experimental rhinovirus infection in volunteers. J Interferon 
Res, 1986. 6(2): p. 153-9. 
399. Sperber, S.J., P.A. Levine, D.J. Innes, S.E. Mills, and F.G. Hayden, Tolerance 
and efficacy of intranasal administration of recombinant beta serine interferon in 
healthy adults. J Infect Dis, 1988. 158(1): p. 166-75. 
400. Sperber, S.J., P.A. Levine, J.V. Sorrentino, D.K. Riker, and F.G. Hayden, 
Ineffectiveness of recombinant interferon-beta serine nasal drops for prophylaxis 
of natural colds. J Infect Dis, 1989. 160(4): p. 700-5. 
401. La Grutta, S., R. Gagliardo, F. Mirabella, G.B. Pajno, G. Bonsignore, J. 
Bousquet, V. Bellia, and A.M. Vignola, Clinical and biological heterogeneity in 
children with moderate asthma. Am J Respir Crit Care Med, 2003. 167(11): p. 
1490-5. 
402. Zhao, S., Y. Qi, X. Liu, Q. Jiang, S. Liu, Y. Jiang, and Z. Jiang, Activation of NF-
kappa B in bronchial epithelial cells from children with asthma. Chin Med J 
(Engl), 2001. 114(9): p. 909-11. 
403. Moser, R., J. Fehr, and P.L. Bruijnzeel, IL-4 controls the selective endothelium-
driven transmigration of eosinophils from allergic individuals. Journal of 
Immunology, 1992. 149(4): p. 1432-8. 
404. Resnick, M.B. and P.F. Weller, Mechanisms of eosinophil recruitment. American 
Journal of Respiratory Cell & Molecular Biology, 1993. 8(4): p. 349-55. 
405. Dabbagh, K., K. Takeyama, H.M. Lee, I.F. Ueki, J.A. Lausier, and J.A. Nadel, IL-
4 induces mucin gene expression and goblet cell metaplasia in vitro and in vivo. 
Journal of Immunology, 1999. 162(10): p. 6233-7. 
406. Doucet, C., D. Brouty-Boye, C. Pottin-Clemenceau, C. Jasmin, G.W. Canonica, 
and B. Azzarone, IL-4 and IL-13 specifically increase adhesion molecule and 
inflammatory cytokine expression in human lung fibroblasts. International 
Immunology, 1998. 10(10): p. 1421-33. 
407. Barnes, P.J. and I.M. Adcock, How do corticosteroids work in asthma? Ann 
Intern Med, 2003. 139(5 Pt 1): p. 359-70. 
408. Karin, M., Y. Yamamoto, and Q.M. Wang, The IKK NF-kappa B system: a 
treasure trove for drug development. Nat Rev Drug Discov, 2004. 3(1): p. 17-26. 
409. Newton, R., N.S. Holden, M.C. Catley, W. Oyelusi, R. Leigh, D. Proud, and P.J. 
Barnes, Repression of inflammatory gene expression in human pulmonary 
epithelial cells by small-molecule IkappaB kinase inhibitors. J Pharmacol Exp 
Ther, 2007. 321(2): p. 734-42. 
410. Catley, M.C., M.B. Sukkar, K.F. Chung, B. Jaffee, S.M. Liao, A.J. Coyle, B. 
Haddad el, P.J. Barnes, and R. Newton, Validation of the anti-inflammatory 
properties of small-molecule IkappaB Kinase (IKK)-2 inhibitors by comparison 
                                                                                                                                        References 
 
276 
with adenoviral-mediated delivery of dominant-negative IKK1 and IKK2 in human 
airways smooth muscle. Mol Pharmacol, 2006. 70(2): p. 697-705. 
411. Birrell, M.A., E. Hardaker, S. Wong, K. McCluskie, M. Catley, J. De Alba, R. 
Newton, S. Haj-Yahia, K.T. Pun, C.J. Watts, R.J. Shaw, T.J. Savage, and M.G. 
Belvisi, Ikappa-B kinase-2 inhibitor blocks inflammation in human airway smooth 
muscle and a rat model of asthma. Am J Respir Crit Care Med, 2005. 172(8): p. 
962-71. 
412. Henderson, W.R., Jr., E.Y. Chi, J.L. Teo, C. Nguyen, and M. Kahn, A small 
molecule inhibitor of redox-regulated NF-kappa B and activator protein-1 
transcription blocks allergic airway inflammation in a mouse asthma model. J 
Immunol, 2002. 169(9): p. 5294-9. 
413. Ziegelbauer, K., F. Gantner, N.W. Lukacs, A. Berlin, K. Fuchikami, T. Niki, K. 
Sakai, H. Inbe, K. Takeshita, M. Ishimori, H. Komura, T. Murata, T. Lowinger, 
and K.B. Bacon, A selective novel low-molecular-weight inhibitor of IkappaB 
kinase-beta (IKK-beta) prevents pulmonary inflammation and shows broad anti-
inflammatory activity. Br J Pharmacol, 2005. 145(2): p. 178-92. 
414. Desmet, C., P. Gosset, B. Pajak, D. Cataldo, M. Bentires-Alj, P. Lekeux, and F. 
Bureau, Selective blockade of NF-kappa B activity in airway immune cells 
inhibits the effector phase of experimental asthma. J Immunol, 2004. 173(9): p. 
5766-75. 
415. Choi, I.W., D.K. Kim, H.M. Ko, and H.K. Lee, Administration of antisense 
phosphorothioate oligonucleotide to the p65 subunit of NF-kappaB inhibits 
established asthmatic reaction in mice. International Immunopharmacology, 
2004. 4(14): p. 1817-28. 
416. Novobrantseva, T.I., A. Akinc, A. Borodovsky, and A. de Fougerolles, Delivering 
silence: advancements in developing siRNA therapeutics. Current Opinion in 
Drug Discovery & Development, 2008. 11(2): p. 217-24. 
417. de Fougerolles, A., H.P. Vornlocher, J. Maraganore, and J. Lieberman, 
Interfering with disease: a progress report on siRNA-based therapeutics. Nature 
Reviews. Drug Discovery, 2007. 6(6): p. 443-53. 
418. Patrick Y. Lu, M.C.W., Delivering Small Interfering RNA for Novel Therapeutics 
in Methods in Molecular Biology: Drug Delivery Systems, K.K. Jain, Editor. 2008, 
Humana Press. p. 93-107. 
419. Bitko, V., A. Musiyenko, O. Shulyayeva, and S. Barik, Inhibition of respiratory 
viruses by nasally administered siRNA. Nature Medicine, 2005. 11(1): p. 50-5. 
420. Zhang, W., H. Yang, X. Kong, S. Mohapatra, H. San Juan-Vergara, G. 
Hellermann, S. Behera, R. Singam, R.F. Lockey, and S.S. Mohapatra, Inhibition 
of respiratory syncytial virus infection with intranasal siRNA nanoparticles 
targeting the viral NS1 gene.[erratum appears in Nat Med. 2005 Feb;11(2):233]. 
Nature Medicine, 2005. 11(1): p. 56-62. 
421. Beg, A.A., W.C. Sha, R.T. Bronson, S. Ghosh, and D. Baltimore, Embryonic 
lethality and liver degeneration in mice lacking the RelA component of NF-kappa 
B. Nature, 1995. 376(6536): p. 167-70. 
422. Quinton, L.J., M.R. Jones, B.T. Simms, M.S. Kogan, B.E. Robson, S.J. Skerrett, 
and J.P. Mizgerd, Functions and regulation of NF-kappaB RelA during 
pneumococcal pneumonia. J Immunol, 2007. 178(3): p. 1896-903. 
423. Sadikot, R.T., H. Zeng, M. Joo, M.B. Everhart, T.P. Sherrill, B. Li, D.S. Cheng, 
F.E. Yull, J.W. Christman, and T.S. Blackwell, Targeted immunomodulation of 
the NF-kappaB pathway in airway epithelium impacts host defense against 
Pseudomonas aeruginosa. J Immunol, 2006. 176(8): p. 4923-30. 
                                                                                                                                        References 
 
277 
424. Doffinger, R., S. Patel, and D.S. Kumararatne, Human immunodeficiencies that 
predispose to intracellular bacterial infections. Current Opinion in Rheumatology, 
2005. 17(4): p. 440-6. 
425. Johnston, N.W., S.L. Johnston, G.R. Norman, J. Dai, and M.R. Sears, The 
September epidemic of asthma hospitalization: school children as disease 
vectors.[erratum appears in J Allergy Clin Immunol. 2007 Jul;120(1):47]. Journal 
of Allergy & Clinical Immunology, 2006. 117(3): p. 557-62. 
426. Poblenz, A.T., J.J. Jacoby, S. Singh, and B.G. Darnay, Inhibition of RANKL-
mediated osteoclast differentiation by selective TRAF6 decoy peptides. 
Biochemical & Biophysical Research Communications, 2007. 359(3): p. 510-5. 
427. Ahonen, C., E. Manning, L.D. Erickson, B. O'Connor, E.F. Lind, S.S. Pullen, M.R. 
Kehry, and R.J. Noelle, The CD40-TRAF6 axis controls affinity maturation and 
the generation of long-lived plasma cells. Nat Immunol, 2002. 3(5): p. 451-6. 
428. Yasui, T., M. Muraoka, Y. Takaoka-Shichijo, I. Ishida, N. Takegahara, J. Uchida, 
A. Kumanogoh, S. Suematsu, M. Suzuki, and H. Kikutani, Dissection of B cell 
differentiation during primary immune responses in mice with altered CD40 
signals. Int Immunol, 2002. 14(3): p. 319-29. 
429. Hsu, H., D.L. Lacey, C.R. Dunstan, I. Solovyev, A. Colombero, E. Timms, H.L. 
Tan, G. Elliott, M.J. Kelley, I. Sarosi, L. Wang, X.Z. Xia, R. Elliott, L. Chiu, T. 
Black, S. Scully, C. Capparelli, S. Morony, G. Shimamoto, M.B. Bass, and W.J. 
Boyle, Tumor necrosis factor receptor family member RANK mediates osteoclast 
differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad 
Sci U S A, 1999. 96(7): p. 3540-5. 
430. Gravallese, E.M., D.L. Galson, S.R. Goldring, and P.E. Auron, The role of TNF-
receptor family members and other TRAF-dependent receptors in bone 
resorption. Arthritis Res, 2001. 3(1): p. 6-12. 
431. Naito, A., H. Yoshida, E. Nishioka, M. Satoh, S. Azuma, T. Yamamoto, S. 
Nishikawa, and J. Inoue, TRAF6-deficient mice display hypohidrotic ectodermal 
dysplasia. Proc Natl Acad Sci U S A, 2002. 99(13): p. 8766-71. 
432. Lomaga, M.A., W.C. Yeh, I. Sarosi, G.S. Duncan, C. Furlonger, A. Ho, S. 
Morony, C. Capparelli, G. Van, S. Kaufman, A. van der Heiden, A. Itie, A. 
Wakeham, W. Khoo, T. Sasaki, Z. Cao, J.M. Penninger, C.J. Paige, D.L. Lacey, 
C.R. Dunstan, W.J. Boyle, D.V. Goeddel, and T.W. Mak, TRAF6 deficiency 
results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. 
Genes Dev, 1999. 13(8): p. 1015-24. 
433. Eynott, P.R., P. Nath, S.Y. Leung, I.M. Adcock, B.L. Bennett, and K.F. Chung, 
Allergen-induced inflammation and airway epithelial and smooth muscle cell 
proliferation: role of Jun N-terminal kinase. Br J Pharmacol, 2003. 140(8): p. 
1373-80. 
434. Eynott, P.R., L. Xu, B.L. Bennett, A. Noble, S.Y. Leung, P. Nath, D.A. 
Groneberg, I.M. Adcock, and K.F. Chung, Effect of an inhibitor of Jun N-terminal 
protein kinase, SP600125, in single allergen challenge in sensitized rats. 
Immunology, 2004. 112(3): p. 446-53. 
435. Nath, P., P. Eynott, S.Y. Leung, I.M. Adcock, B.L. Bennett, and K.F. Chung, 
Potential role of c-Jun NH2-terminal kinase in allergic airway inflammation and 
remodelling: effects of SP600125. Eur J Pharmacol, 2005. 506(3): p. 273-83. 
436. Marone, R., V. Cmiljanovic, B. Giese, and M.P. Wymann, Targeting 
phosphoinositide 3-kinase: moving towards therapy. Biochim Biophys Acta, 
2008. 1784(1): p. 159-85. 
                                                                                                                                        References 
 
278 
437. Samuels, Y. and K. Ericson, Oncogenic PI3K and its role in cancer. Curr Opin 
Oncol, 2006. 18(1): p. 77-82. 
438. Raynaud, F.I., S. Eccles, P.A. Clarke, A. Hayes, B. Nutley, S. Alix, A. Henley, F. 
Di-Stefano, Z. Ahmad, S. Guillard, L.M. Bjerke, L. Kelland, M. Valenti, L. 
Patterson, S. Gowan, A. de Haven Brandon, M. Hayakawa, H. Kaizawa, T. 
Koizumi, T. Ohishi, S. Patel, N. Saghir, P. Parker, M. Waterfield, and P. 
Workman, Pharmacologic characterization of a potent inhibitor of class I 
phosphatidylinositide 3-kinases. Cancer Res, 2007. 67(12): p. 5840-50. 
439. Thomas, M.J., A. Smith, D.H. Head, L. Milne, A. Nicholls, W. Pearce, B. 
Vanhaesebroeck, M.P. Wymann, E. Hirsch, A. Trifilieff, C. Walker, P. Finan, and 
J. Westwick, Airway inflammation: chemokine-induced neutrophilia and the class 
I phosphoinositide 3-kinases. Eur J Immunol, 2005. 35(4): p. 1283-91. 
440. Hirsch, E., V.L. Katanaev, C. Garlanda, O. Azzolino, L. Pirola, L. Silengo, S. 
Sozzani, A. Mantovani, F. Altruda, and M.P. Wymann, Central role for G protein-
coupled phosphoinositide 3-kinase gamma in inflammation. Science, 2000. 
287(5455): p. 1049-53. 
441. Sadhu, C., B. Masinovsky, K. Dick, C.G. Sowell, and D.E. Staunton, Essential 
role of phosphoinositide 3-kinase delta in neutrophil directional movement. J 
Immunol, 2003. 170(5): p. 2647-54. 
442. Lee, K.S., H.K. Lee, J.S. Hayflick, Y.C. Lee, and K.D. Puri, Inhibition of 
phosphoinositide 3-kinase delta attenuates allergic airway inflammation and 
hyperresponsiveness in murine asthma model. FASEB J, 2006. 20(3): p. 455-65. 
443. Lee, K.S., S.J. Park, S.R. Kim, K.H. Min, S.M. Jin, K.D. Puri, and Y.C. Lee, 
Phosphoinositide 3-kinase-delta inhibitor reduces vascular permeability in a 
murine model of asthma. J Allergy Clin Immunol, 2006. 118(2): p. 403-9. 
 
 
